0001428336-24-000016.txt : 20240322 0001428336-24-000016.hdr.sgml : 20240322 20240322160119 ACCESSION NUMBER: 0001428336-24-000016 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 24775114 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 10-K 1 hqy-20240131.htm 10-K hqy-20240131
00014283362024FYFALSE25223600014283362023-02-012024-01-3100014283362023-07-31iso4217:USD00014283362024-03-13xbrli:shares00014283362024-01-3100014283362023-01-31iso4217:USDxbrli:shares0001428336us-gaap:ServiceMember2023-02-012024-01-310001428336us-gaap:ServiceMember2022-02-012023-01-310001428336us-gaap:ServiceMember2021-02-012022-01-310001428336us-gaap:FinancialServiceOtherMember2023-02-012024-01-310001428336us-gaap:FinancialServiceOtherMember2022-02-012023-01-310001428336us-gaap:FinancialServiceOtherMember2021-02-012022-01-310001428336us-gaap:CreditAndDebitCardMember2023-02-012024-01-310001428336us-gaap:CreditAndDebitCardMember2022-02-012023-01-310001428336us-gaap:CreditAndDebitCardMember2021-02-012022-01-3100014283362022-02-012023-01-3100014283362021-02-012022-01-310001428336us-gaap:CommonStockMember2021-01-310001428336us-gaap:AdditionalPaidInCapitalMember2021-01-310001428336us-gaap:RetainedEarningsMember2021-01-3100014283362021-01-310001428336us-gaap:CommonStockMember2021-02-012022-01-310001428336us-gaap:AdditionalPaidInCapitalMember2021-02-012022-01-310001428336us-gaap:RetainedEarningsMember2021-02-012022-01-310001428336us-gaap:CommonStockMember2022-01-310001428336us-gaap:AdditionalPaidInCapitalMember2022-01-310001428336us-gaap:RetainedEarningsMember2022-01-3100014283362022-01-310001428336us-gaap:CommonStockMember2022-02-012023-01-310001428336us-gaap:AdditionalPaidInCapitalMember2022-02-012023-01-310001428336us-gaap:RetainedEarningsMember2022-02-012023-01-310001428336us-gaap:CommonStockMember2023-01-310001428336us-gaap:AdditionalPaidInCapitalMember2023-01-310001428336us-gaap:RetainedEarningsMember2023-01-310001428336us-gaap:CommonStockMember2023-02-012024-01-310001428336us-gaap:AdditionalPaidInCapitalMember2023-02-012024-01-310001428336us-gaap:RetainedEarningsMember2023-02-012024-01-310001428336us-gaap:CommonStockMember2024-01-310001428336us-gaap:AdditionalPaidInCapitalMember2024-01-310001428336us-gaap:RetainedEarningsMember2024-01-310001428336us-gaap:ComputerSoftwareIntangibleAssetMember2023-02-012024-01-310001428336us-gaap:ComputerSoftwareIntangibleAssetMember2022-02-012023-01-310001428336us-gaap:ComputerSoftwareIntangibleAssetMember2021-02-012022-01-310001428336hqy:AcquiredHSAIntangibleAssetsMember2023-02-012024-01-310001428336hqy:AcquiredHSAIntangibleAssetsMember2022-02-012023-01-310001428336hqy:AcquiredHSAIntangibleAssetsMember2021-02-012022-01-310001428336hqy:PassiveCustodialFundsMember2024-01-31xbrli:pure0001428336hqy:NonPassiveCustodialFundsMember2024-01-310001428336srt:RestatementAdjustmentMemberus-gaap:ServiceMember2023-02-012024-01-310001428336srt:RestatementAdjustmentMemberus-gaap:FinancialServiceOtherMember2023-02-012024-01-310001428336srt:RestatementAdjustmentMemberus-gaap:ServiceMember2022-02-012023-01-310001428336srt:RestatementAdjustmentMemberus-gaap:FinancialServiceOtherMember2022-02-012023-01-310001428336srt:RestatementAdjustmentMemberus-gaap:FinancialServiceOtherMember2021-02-012022-01-310001428336srt:RestatementAdjustmentMemberus-gaap:ServiceMember2021-02-012022-01-31hqy:segment0001428336us-gaap:LeaseholdImprovementsMembersrt:MinimumMember2024-01-310001428336us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2024-01-310001428336srt:MinimumMemberus-gaap:ComputerEquipmentMember2024-01-310001428336srt:MaximumMemberus-gaap:ComputerEquipmentMember2024-01-310001428336us-gaap:FurnitureAndFixturesMember2024-01-310001428336hqy:ComputerSoftwareAndCapitalizedSoftwareDevelopmentCostsMember2024-01-310001428336srt:MinimumMemberhqy:A401kCustomerRelationshipsMember2024-01-310001428336srt:MaximumMemberhqy:A401kCustomerRelationshipsMember2024-01-310001428336us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2024-01-310001428336us-gaap:DevelopedTechnologyRightsMembersrt:MaximumMember2024-01-310001428336us-gaap:TrademarksAndTradeNamesMember2024-01-310001428336hqy:AcquiredHSAIntangibleAssetsMember2024-01-310001428336hqy:HSAMember2024-01-310001428336hqy:RACustomerRelationshipMember2024-01-310001428336hqy:LuumAcquisitionMember2021-03-080001428336hqy:LuumAcquisitionMember2021-03-082021-03-080001428336hqy:LuumAcquisitionMember2022-04-300001428336hqy:LuumAcquisitionMember2021-03-092022-04-300001428336hqy:FurtherAcquisitionMember2021-11-012021-11-010001428336hqy:FurtherAcquisitionMember2021-11-010001428336hqy:FurtherAcquisitionMember2021-11-022023-01-310001428336hqy:FurtherAcquisitionMember2023-01-310001428336us-gaap:LeaseholdImprovementsMember2024-01-310001428336us-gaap:LeaseholdImprovementsMember2023-01-310001428336us-gaap:FurnitureAndFixturesMember2023-01-310001428336us-gaap:ComputerEquipmentMember2024-01-310001428336us-gaap:ComputerEquipmentMember2023-01-3100014283362024-02-012024-01-310001428336srt:MinimumMember2024-01-310001428336srt:MaximumMember2024-01-31hqy:extension0001428336hqy:WageWorksIncMember2022-01-310001428336hqy:WageWorksIncMember2021-02-012022-01-3100014283362022-03-242022-03-240001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-01-310001428336us-gaap:CustomerRelationshipsMember2024-01-310001428336us-gaap:DevelopedTechnologyRightsMember2024-01-310001428336us-gaap:TradeNamesMember2024-01-310001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-01-310001428336hqy:AcquiredHSAIntangibleAssetsMember2023-01-310001428336us-gaap:CustomerRelationshipsMember2023-01-310001428336us-gaap:DevelopedTechnologyRightsMember2023-01-310001428336us-gaap:TradeNamesMember2023-01-310001428336hqy:LuumAndFurtherMember2022-02-012023-01-310001428336hqy:A4500SeniorNotesDue2029Member2024-01-310001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMember2024-01-310001428336hqy:HSAPortfolioMember2024-01-310001428336hqy:CreditAgreementMember2024-01-310001428336hqy:HSAPortfolioMember2023-09-012023-09-300001428336hqy:WageWorksInc.Member2021-04-300001428336hqy:UnionMesaMemberhqy:WageWorksInc.Member2021-11-052021-11-050001428336hqy:UnionMesaMemberhqy:WageWorksInc.Member2021-11-240001428336hqy:UnionMesaMemberhqy:WageWorksInc.Member2023-12-290001428336hqy:UnionMesaMemberus-gaap:PrimeRateMemberhqy:WageWorksInc.Member2023-12-292023-12-290001428336hqy:A4500SeniorNotesDue2029Member2023-01-310001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMember2023-01-310001428336us-gaap:RevolvingCreditFacilityMember2024-01-310001428336us-gaap:RevolvingCreditFacilityMember2023-01-310001428336hqy:A4500SeniorNotesDue2029Memberus-gaap:SeniorNotesMember2021-10-080001428336hqy:A4500SeniorNotesDue2029Memberus-gaap:SeniorNotesMember2024-01-310001428336hqy:A4500SeniorNotesDue2029Memberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2021-10-082021-10-080001428336hqy:A4500SeniorNotesDue2029Memberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2021-10-082021-10-080001428336hqy:A4500SeniorNotesDue2029Memberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:SeniorNotesMember2021-10-082021-10-080001428336hqy:A4500SeniorNotesDue2029Memberus-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:SeniorNotesMember2021-10-082021-10-080001428336hqy:A4500SeniorNotesDue2029Memberus-gaap:DebtInstrumentRedemptionPeriodFiveMemberus-gaap:SeniorNotesMember2021-10-082021-10-080001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMemberus-gaap:SecuredDebtMember2021-10-082021-10-080001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMemberus-gaap:SecuredDebtMember2021-10-080001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-10-082021-10-080001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-10-080001428336us-gaap:LetterOfCreditMemberhqy:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-10-080001428336hqy:CreditAgreementMember2021-10-080001428336hqy:CreditAgreementMembersrt:MinimumMemberhqy:LondonInterbankOfferedRateMember2023-05-312023-05-310001428336hqy:CreditAgreementMembersrt:MaximumMemberhqy:LondonInterbankOfferedRateMember2023-05-312023-05-310001428336us-gaap:BaseRateMemberhqy:CreditAgreementMembersrt:MinimumMember2023-05-312023-05-310001428336us-gaap:BaseRateMemberhqy:CreditAgreementMembersrt:MaximumMember2023-05-312023-05-310001428336hqy:SecuredOvernightFinancingRateSOFRMemberhqy:CreditAgreementMember2023-06-012023-06-010001428336hqy:SecuredOvernightFinancingRateSOFRMemberhqy:CreditAgreementMembersrt:MinimumMember2023-06-012023-06-010001428336hqy:SecuredOvernightFinancingRateSOFRMemberhqy:CreditAgreementMembersrt:MaximumMember2023-06-012023-06-010001428336us-gaap:BaseRateMemberhqy:CreditAgreementMembersrt:MinimumMember2023-06-012023-06-010001428336us-gaap:BaseRateMemberhqy:CreditAgreementMembersrt:MaximumMember2023-06-012023-06-010001428336us-gaap:LineOfCreditMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2023-02-012024-01-310001428336us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2023-02-012024-01-310001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberhqy:TermLoanFacilityMemberhqy:DebtInstrumentAmortizationPeriodOneMember2024-01-310001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberhqy:DebtInstrumentAmortizationPeriodTwoAndThreePeriodMemberhqy:TermLoanFacilityMember2024-01-310001428336hqy:DebtInstrumentAmortizationPeriodFourMemberus-gaap:LineOfCreditMemberhqy:CreditAgreementMemberhqy:TermLoanFacilityMember2024-01-310001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberhqy:TermLoanFacilityMemberhqy:DebtInstrumentAmortizationPeriodFiveMember2024-01-310001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberhqy:TermLoanFacilityMember2024-01-310001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberhqy:TermLoanFacilityMember2023-02-012024-01-310001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberhqy:TermLoanFacilityMember2023-04-012023-04-300001428336us-gaap:StateAndLocalJurisdictionMember2024-01-310001428336us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2024-01-310001428336us-gaap:CostOfSalesMember2023-02-012024-01-310001428336us-gaap:CostOfSalesMember2022-02-012023-01-310001428336us-gaap:CostOfSalesMember2021-02-012022-01-310001428336hqy:SalesandMarketingMember2023-02-012024-01-310001428336hqy:SalesandMarketingMember2022-02-012023-01-310001428336hqy:SalesandMarketingMember2021-02-012022-01-310001428336hqy:TechnologyandDevelopmentMember2023-02-012024-01-310001428336hqy:TechnologyandDevelopmentMember2022-02-012023-01-310001428336hqy:TechnologyandDevelopmentMember2021-02-012022-01-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2023-02-012024-01-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2022-02-012023-01-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2021-02-012022-01-310001428336us-gaap:OtherNonoperatingIncomeExpenseMember2023-02-012024-01-310001428336us-gaap:OtherNonoperatingIncomeExpenseMember2022-02-012023-01-310001428336us-gaap:OtherNonoperatingIncomeExpenseMember2021-02-012022-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2023-02-012024-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2022-02-012023-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2021-02-012022-01-310001428336hqy:PerformanceRestrictedStockUnitsMember2023-02-012024-01-310001428336hqy:PerformanceRestrictedStockUnitsMember2022-02-012023-01-310001428336hqy:PerformanceRestrictedStockUnitsMember2021-02-012022-01-310001428336us-gaap:EmployeeStockOptionMember2023-02-012024-01-310001428336us-gaap:EmployeeStockOptionMember2022-02-012023-01-310001428336us-gaap:EmployeeStockOptionMember2021-02-012022-01-310001428336us-gaap:RestrictedStockMember2023-02-012024-01-310001428336us-gaap:RestrictedStockMember2022-02-012023-01-310001428336us-gaap:RestrictedStockMember2021-02-012022-01-310001428336hqy:PerformanceRestrictedStockAwardsMember2023-02-012024-01-310001428336hqy:PerformanceRestrictedStockAwardsMember2022-02-012023-01-310001428336hqy:PerformanceRestrictedStockAwardsMember2021-02-012022-01-310001428336hqy:TotalNonCashShareBasedPaymentArrangementExpenseMember2023-02-012024-01-310001428336hqy:TotalNonCashShareBasedPaymentArrangementExpenseMember2022-02-012023-01-310001428336hqy:TotalNonCashShareBasedPaymentArrangementExpenseMember2021-02-012022-01-310001428336hqy:EquityAwardsExchangedForCashInBusinessCombinationMember2023-02-012024-01-310001428336hqy:EquityAwardsExchangedForCashInBusinessCombinationMember2022-02-012023-01-310001428336hqy:EquityAwardsExchangedForCashInBusinessCombinationMember2021-02-012022-01-310001428336hqy:IncentivePlanMember2024-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2022-03-012022-03-310001428336hqy:PerformanceRestrictedStockUnitsMember2022-01-310001428336srt:MinimumMemberhqy:PerformanceRestrictedStockUnitsMember2021-02-012022-01-310001428336hqy:PerformanceRestrictedStockUnitsMembersrt:MaximumMember2021-02-012022-01-310001428336hqy:PerformanceRestrictedStockUnitsMember2023-01-310001428336srt:MinimumMemberhqy:PerformanceRestrictedStockUnitsMember2022-02-012023-01-310001428336hqy:PerformanceRestrictedStockUnitsMembersrt:MaximumMember2022-02-012023-01-310001428336hqy:PerformanceRestrictedStockUnitsMember2024-01-310001428336srt:MinimumMemberhqy:PerformanceRestrictedStockUnitsMember2023-02-012024-01-310001428336hqy:PerformanceRestrictedStockUnitsMembersrt:MaximumMember2023-02-012024-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2023-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2024-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2022-01-310001428336us-gaap:RestrictedStockMember2024-01-310001428336hqy:A4500SeniorNotesDue2029Memberus-gaap:FairValueInputsLevel2Member2024-01-310001428336hqy:A401kMemberus-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember2023-02-012024-01-310001428336hqy:A401kMemberus-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember2022-02-012023-01-310001428336hqy:A401kMemberus-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember2021-02-012022-01-310001428336hqy:EmployeeRelatedLiabilitiesCurrentMember2024-01-310001428336hqy:EmployeeRelatedLiabilitiesCurrentMember2023-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2023-11-012024-01-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2023-11-012024-01-310001428336us-gaap:ServiceMember2023-11-012024-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2023-11-012024-01-310001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-11-012024-01-310001428336us-gaap:FinancialServiceOtherMember2023-11-012024-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2023-11-012024-01-310001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-11-012024-01-310001428336us-gaap:CreditAndDebitCardMember2023-11-012024-01-310001428336srt:ScenarioPreviouslyReportedMember2023-11-012024-01-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-11-012024-01-3100014283362023-11-012024-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2023-08-012023-10-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2023-08-012023-10-310001428336us-gaap:ServiceMember2023-08-012023-10-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2023-08-012023-10-310001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-08-012023-10-310001428336us-gaap:FinancialServiceOtherMember2023-08-012023-10-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2023-08-012023-10-310001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-08-012023-10-310001428336us-gaap:CreditAndDebitCardMember2023-08-012023-10-310001428336srt:ScenarioPreviouslyReportedMember2023-08-012023-10-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-08-012023-10-3100014283362023-08-012023-10-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2023-05-012023-07-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2023-05-012023-07-310001428336us-gaap:ServiceMember2023-05-012023-07-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2023-05-012023-07-310001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-05-012023-07-310001428336us-gaap:FinancialServiceOtherMember2023-05-012023-07-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2023-05-012023-07-310001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-05-012023-07-310001428336us-gaap:CreditAndDebitCardMember2023-05-012023-07-310001428336srt:ScenarioPreviouslyReportedMember2023-05-012023-07-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-05-012023-07-3100014283362023-05-012023-07-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2023-02-012023-04-300001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2023-02-012023-04-300001428336us-gaap:ServiceMember2023-02-012023-04-300001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2023-02-012023-04-300001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-02-012023-04-300001428336us-gaap:FinancialServiceOtherMember2023-02-012023-04-300001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2023-02-012023-04-300001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-02-012023-04-300001428336us-gaap:CreditAndDebitCardMember2023-02-012023-04-300001428336srt:ScenarioPreviouslyReportedMember2023-02-012023-04-300001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-02-012023-04-3000014283362023-02-012023-04-300001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2022-11-012023-01-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2022-11-012023-01-310001428336us-gaap:ServiceMember2022-11-012023-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2022-11-012023-01-310001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-11-012023-01-310001428336us-gaap:FinancialServiceOtherMember2022-11-012023-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2022-11-012023-01-310001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-11-012023-01-310001428336us-gaap:CreditAndDebitCardMember2022-11-012023-01-310001428336srt:ScenarioPreviouslyReportedMember2022-11-012023-01-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-11-012023-01-3100014283362022-11-012023-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2022-08-012022-10-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2022-08-012022-10-310001428336us-gaap:ServiceMember2022-08-012022-10-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2022-08-012022-10-310001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-08-012022-10-310001428336us-gaap:FinancialServiceOtherMember2022-08-012022-10-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2022-08-012022-10-310001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-08-012022-10-310001428336us-gaap:CreditAndDebitCardMember2022-08-012022-10-310001428336srt:ScenarioPreviouslyReportedMember2022-08-012022-10-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-08-012022-10-3100014283362022-08-012022-10-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2022-05-012022-07-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2022-05-012022-07-310001428336us-gaap:ServiceMember2022-05-012022-07-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2022-05-012022-07-310001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-05-012022-07-310001428336us-gaap:FinancialServiceOtherMember2022-05-012022-07-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2022-05-012022-07-310001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-05-012022-07-310001428336us-gaap:CreditAndDebitCardMember2022-05-012022-07-310001428336srt:ScenarioPreviouslyReportedMember2022-05-012022-07-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-05-012022-07-3100014283362022-05-012022-07-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2022-02-012022-04-300001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2022-02-012022-04-300001428336us-gaap:ServiceMember2022-02-012022-04-300001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2022-02-012022-04-300001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-02-012022-04-300001428336us-gaap:FinancialServiceOtherMember2022-02-012022-04-300001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2022-02-012022-04-300001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-02-012022-04-300001428336us-gaap:CreditAndDebitCardMember2022-02-012022-04-300001428336srt:ScenarioPreviouslyReportedMember2022-02-012022-04-300001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-02-012022-04-3000014283362022-02-012022-04-300001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2021-11-012022-01-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2021-11-012022-01-310001428336us-gaap:ServiceMember2021-11-012022-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2021-11-012022-01-310001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-11-012022-01-310001428336us-gaap:FinancialServiceOtherMember2021-11-012022-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2021-11-012022-01-310001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-11-012022-01-310001428336us-gaap:CreditAndDebitCardMember2021-11-012022-01-310001428336srt:ScenarioPreviouslyReportedMember2021-11-012022-01-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-11-012022-01-3100014283362021-11-012022-01-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2021-08-012021-10-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2021-08-012021-10-310001428336us-gaap:ServiceMember2021-08-012021-10-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2021-08-012021-10-310001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-08-012021-10-310001428336us-gaap:FinancialServiceOtherMember2021-08-012021-10-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2021-08-012021-10-310001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-08-012021-10-310001428336us-gaap:CreditAndDebitCardMember2021-08-012021-10-310001428336srt:ScenarioPreviouslyReportedMember2021-08-012021-10-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-08-012021-10-3100014283362021-08-012021-10-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2021-05-012021-07-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2021-05-012021-07-310001428336us-gaap:ServiceMember2021-05-012021-07-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2021-05-012021-07-310001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-05-012021-07-310001428336us-gaap:FinancialServiceOtherMember2021-05-012021-07-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2021-05-012021-07-310001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-05-012021-07-310001428336us-gaap:CreditAndDebitCardMember2021-05-012021-07-310001428336srt:ScenarioPreviouslyReportedMember2021-05-012021-07-310001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-05-012021-07-3100014283362021-05-012021-07-310001428336srt:ScenarioPreviouslyReportedMemberus-gaap:ServiceMember2021-02-012021-04-300001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:ServiceMember2021-02-012021-04-300001428336us-gaap:ServiceMember2021-02-012021-04-300001428336srt:ScenarioPreviouslyReportedMemberus-gaap:FinancialServiceOtherMember2021-02-012021-04-300001428336us-gaap:FinancialServiceOtherMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-02-012021-04-300001428336us-gaap:FinancialServiceOtherMember2021-02-012021-04-300001428336srt:ScenarioPreviouslyReportedMemberus-gaap:CreditAndDebitCardMember2021-02-012021-04-300001428336us-gaap:CreditAndDebitCardMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-02-012021-04-300001428336us-gaap:CreditAndDebitCardMember2021-02-012021-04-300001428336srt:ScenarioPreviouslyReportedMember2021-02-012021-04-300001428336srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-02-012021-04-3000014283362021-02-012021-04-300001428336us-gaap:SubsequentEventMemberhqy:HSAPortfolioMember2024-03-072024-03-07hqy:transferhqy:account0001428336us-gaap:SubsequentEventMemberhqy:HSAPortfolioMember2024-03-070001428336hqy:DelanoLaddMember2023-02-012024-01-310001428336hqy:DelanoLaddMember2023-11-012024-01-310001428336hqy:DelanoLaddMember2024-01-310001428336hqy:StephenNeelemanMember2023-02-012024-01-310001428336hqy:StephenNeelemanMember2023-11-012024-01-310001428336hqy:StephenNeelemanMember2024-01-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended January 31, 2024
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to            
Commission File Number: 001-36568
HEALTHEQUITY, INC.
(Exact name of registrant as specified in its charter)
Delaware52-2383166
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(801) 727-1000
(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:
None
.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ¨

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
The aggregate market value of voting and non-voting common equity held by non-affiliates of the registrant on July 31, 2023, based on the closing price of $67.94 for shares of the registrant’s common stock as reported by the NASDAQ Global Select Market was approximately $5.1 billion. For purposes of determining whether a stockholder was an affiliate of the registrant at July 31, 2023, the registrant assumed that a stockholder was an affiliate of the registrant at July 31, 2023 if such stockholder (i) beneficially owned 10% or more of the registrant’s capital stock, as determined based on public filings, and/or (ii) was an executive officer or director, or was affiliated with an executive officer or director of the registrant, at July 31, 2023. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of March 13, 2024, there were 86,158,631 shares of the registrant's common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant's definitive proxy statement related to its 2024 annual meeting of stockholders (the "2024 Proxy Statement") are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2024 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.




HealthEquity, Inc. and subsidiaries
Form 10-K annual report

Table of contents
Page
Part I.
Item 1.
Item 1A.
Item 1B.
Item 1C.
Item 2.
Item 3.
Item 4.
Part II.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 9C.
Part III.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Part IV.
Item 15.
Item 16.





SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K includes forward-looking statements that involve risks and uncertainties, including in the sections entitled “Business,” “Risk factors,” and “Management’s discussion and analysis of financial condition and results of operations.” Statements that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements include, without limitation, statements regarding our industry, business strategy, plans, goals, and expectations concerning our markets and market position, future operations, expenses and other results of operations, margins, profitability, tax rates, capital expenditures, liquidity and capital resources, and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future,” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this report.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties, and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, the risks identified in Item 1A. Risk factors.
Unless the context otherwise indicates or requires, the terms “we,” “our,” “us,” “HealthEquity,” and the “Company,” as used in this Annual Report on Form 10-K, refer to HealthEquity, Inc. and its subsidiaries as a combined entity, except where otherwise stated or where it is clear that the terms mean only HealthEquity, Inc. exclusive of its subsidiaries.


-1-

Part I
Item 1. Business
Company overview
We are a leader and an innovator in providing technology-enabled services that empower consumers to make healthcare saving and spending decisions. We use our innovative technology to manage consumers' tax-advantaged health savings accounts (“HSAs”) and other consumer-directed benefits (“CDBs”) offered by employers, including flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”), and to administer Consolidated Omnibus Budget Reconciliation Act (“COBRA”), commuter and other benefits. As part of our services, we provide consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. We believe the shift to greater consumer responsibility for healthcare costs will require a significant portion of consumers under the age of 65 with private health insurance in the United States to use offerings such as ours.
The core of our offerings is the HSA, a financial account through which consumers spend and save long-term for healthcare expenses on a tax-advantaged basis. As of January 31, 2024, we administered 8.7 million HSAs, with balances totaling $25.2 billion, which we call HSA Assets, as well as 7.0 million complementary CDBs. We refer to the aggregate number of HSAs and other CDBs that we administer as Total Accounts, of which we had 15.7 million as of January 31, 2024.
We reach consumers primarily through relationships with their employers, which we call Clients. We reach Clients primarily through relationships with benefits brokers and advisors, integrated partnerships with a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan recordkeepers, which we call Network Partners, and a sales force that calls on Clients directly. As of January 31, 2024, our platforms were integrated with more than 200 Network Partners.
We have increased our share of the growing HSA market from 4% in December 2010 to 20% as of June 2023, measured by HSA Assets. According to Devenir, as of June 2023, we were the largest HSA provider by both accounts and HSA Assets. In addition, we believe we are the largest provider of other CDBs. We seek to differentiate ourselves through our service-driven culture, product breadth, ecosystem connectivity, and proprietary technology. Our proprietary technology allows us to help consumers optimize the value of their HSAs and other CDBs and gain confidence and skills in managing their healthcare costs as part of their financial security.
Our ability to assist consumers is enhanced by our capacity to securely share data in both directions with others in the health, benefits, and retirement ecosystems. Our commuter benefits offering also leverages connectivity to an ecosystem of mass transit, ride hailing, and parking providers.
Our business model provides strong visibility into our future operating performance, with the vast majority of our accounts opened before the start of our fiscal year.
We earn revenue primarily from three sources: service, custodial, and interchange. We earn service revenue mainly from fees paid by our Network Partners, Clients, and members for the administration services we provide in connection with the HSAs and other CDBs we offer. We earn custodial revenue primarily from HSA cash held by our federally insured bank and credit union partners, which we collectively call our Depository Partners, HSA cash held by our insurance company partners, and Client-held funds deposited with our Depository Partners. We earn interchange revenue mainly from fees paid by merchants on payments that our members make using our physical payment cards and on our virtual payment system. See “Key components of our results of operations” for additional information on our sources of revenue.
Recent acquisitions
Luum acquisition. In March 2021, we bolstered our commuter offering by acquiring 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition"). The aggregate purchase price for the acquisition consisted of $56.2 million in cash. Luum provides employers with various commuter services, including access to real-time commute data, to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits.
Fifth Third Bank HSA portfolio acquisition. In September 2021, we acquired the Fifth Third Bank, National Association ("Fifth Third") HSA portfolio, which consisted of $490.0 million of HSA Assets held in approximately 160,000 HSAs in exchange for a purchase price of $60.8 million in cash.
-2-

Further acquisition. In November 2021, we acquired the Further business (other than Further's voluntary employee beneficiary association business), a leading provider of HSA and other CDB administration services, with approximately 580,000 HSAs and $1.9 billion of HSA Assets, for $455 million in cash (the "Further Acquisition").
HealthSavings HSA portfolio acquisition. In March 2022, we acquired the Health Savings Administrators, L.L.C. (“HealthSavings”) HSA portfolio, which consisted of $1.3 billion of HSA Assets held in approximately 87,000 HSAs in exchange for a purchase price of $60 million in cash.
BenefitWallet HSA portfolio acquisition. In September 2023, we entered into an agreement to acquire the BenefitWallet HSA portfolio from Conduent Business Services, LLC, for a purchase price of $425.0 million and reimbursement of up to $20.0 million of Conduent's transfer-related expenses. In addition, we expect to incur approximately $7.0 million of transaction costs associated with the acquisition. The agreement contemplates a transfer of approximately 665,000 customer accounts and their approximately $2.8 billion of HSA Assets and includes a mechanism to adjust the purchase price based on the amount of HSA Assets actually transferred. The transfer is expected to close in multiple tranches during the first half of fiscal 2025, subject to the satisfaction of certain customary closing conditions. We expect to pay approximately 50% of the purchase price and associated costs using cash on hand, with the remainder paid using our revolving credit facility with the actual percentages to be determined in connection with the payment for each tranche. On March 7, 2024, the first of the three HSA Asset transfers occurred, with approximately 266,000 HSAs and $1.1 billion of HSA Assets transferring to HealthEquity’s custody. In connection with this transfer, HealthEquity paid the applicable purchase price of $163.9 million using cash on hand.
Our products and services
Health savings accounts. The Medicare Modernization Act of 2003 created HSAs, a tax-exempt trust or custodial account managed by a custodian that is a bank, an insurance company, or a non-bank custodian specifically authorized by the Internal Revenue Service, or IRS, as meeting certain ownership, capitalization, expertise, and governance requirements. We are an IRS-approved non-bank custodian of our members' HSAs, designated to serve as both a passive and non-passive non-bank custodian of HSAs.
To be eligible to contribute to an HSA, an individual must be covered under a high deductible healthcare plan, or HDHP, have no additional health coverage, not be enrolled in Medicare, and not be claimed as a dependent on someone else’s tax return. HSAs have several tax-advantaged benefits, which we call the "triple tax savings": (1) individuals can claim a tax deduction for contributions they make to their HSAs, and contributions that their employers make to their HSAs may be excluded from their gross income for purposes of federal and most state income and employment tax; (2) the interest or earnings on the assets in the account, including reinvestment, accumulate without being subject to tax; and (3) distributions may be tax free if they are used to pay qualified medical expenses. There is no requirement to provide receipts to us to substantiate HSA distributions to members, whether made through our payment card or directly from our online HSA platform. Additionally, taxable distributions other than for qualified medical expenses are permitted without penalty (although subject to income tax) after age 65. Balances remain in the account until used, i.e., there is no “use or lose” requirement. An HSA is owned by the account holder; it remains the account holder’s property upon a change of employment, health plan or retirement.
Investment platform and advisory services. We offer an investment platform and access to an online-only automated investment advisory service to all of our members whose account balances exceed a stated threshold. These services are entirely elective to the member. The advisory service is delivered through a web-based tool, Advisor, which is offered and managed by HealthEquity Advisors, LLC, our SEC-registered investment adviser subsidiary. HealthEquity Advisors, LLC provides investment advice to its clients exclusively through the Advisor tool on an interactive website. Members who utilize our investment platform or subscribe for Advisor services pay asset-based fees, subject to a monthly fee cap, which include the cost of the advisory service and all other expenses associated with transactions made through these online tools.
Advisor provides investment education guidance and management, including maintaining HSA cash (liquidity) in amounts directed by the member, targeting risk appropriate portfolio diversification, and mutual fund selection.
We offer investors access to three levels of service:
Self-driven: For members who do not subscribe for Advisor, we provide an investment platform to invest HSA balances. Neither we nor Advisor provides advice to members in respect of investments among funds on the platform;
GPS powered by HealthEquity Advisors, LLC: Advisor provides guidance and advice, but the member makes the final investment decisions and implements portfolio allocation and investment advice through the HealthEquity platform; and
-3-

AutoPilot powered by HealthEquity Advisors, LLC: Advisor manages the account and implements portfolio allocation and investment advice automatically for the member.
Regardless of the level of service selected, members are responsible for their proportionate share of fees and expenses payable by the underlying mutual funds and other investment vehicles in which they invest.
Healthcare flexible spending accounts. Healthcare FSAs are employer-sponsored CDBs that enable employees to set aside pre-tax dollars to pay for eligible healthcare expenses that are not generally covered by insurance, such as co-pays, deductibles and over-the-counter medical products, as well as vision expenses, orthodontia, and medical devices. Healthcare FSAs can be customized by employers so they have the freedom to determine what eligible expenses may be reimbursed under these arrangements. Our employer Clients also realize payroll tax (i.e., FICA and Medicare) savings on the pre-tax contributions made by their employees.
The IRS imposes a limit, indexed to inflation, on pre-tax dollar employee contributions made to healthcare FSAs. The IRS also allows a carryover of up to 20% of the indexed contribution limit that does not count against or otherwise affect the indexed salary reduction limit applicable to each plan year. Employers are able to contribute additional amounts in excess of this statutory limit and may choose to do so in an effort to mitigate the impact of rising healthcare costs on their employees.
Dependent care flexible spending accounts. We also administer FSA programs for dependent care plans. These plans allow employees to set aside pre-tax dollars to pay for eligible dependent care expenses, which typically include child care or day care expenses but may also include expenses incurred from adult and elder care. Current laws and regulations impose a statutory limit on the amount of pre-tax dollars employees can contribute to dependent care FSAs with no carryover allowed. Like healthcare FSAs, employers can also contribute funds to employees’ dependent care FSAs; however, these are subject to the statutory annual limit on total contributions. As with healthcare FSAs, employers realize payroll tax savings on the pre-tax dependent care FSA contributions made by their employees.
HealthEquity administers the United States Office of Personnel Management's (“OPM”) Federal Flexible Spending Account Program (“FSAFEDS”). This relationship provides eligible federal government employees access to our advanced technology platforms and premium service capabilities.
Health reimbursement arrangements. Under HRAs, employers provide their employees with a specified amount of reimbursement funds that are available to help employees defray their out-of-pocket healthcare expenses, such as deductibles, co-insurance and co-payments. HRAs may only be funded by employers and there is no limitation on how much employers may contribute; however, similar to other CDBs that are funded with pre-tax dollars, employers are required to establish the programs in such a way as to prevent discrimination in favor of highly compensated employees. HRAs must either be considered an excepted benefit (for example, a dental-only HRA or a vision-only HRA), a retiree HRA or be integrated with another group health plan. HRAs can be customized by employers so employers have the freedom to determine what expenses are eligible for reimbursement under these arrangements. At the end of the plan year, employers have the option to allow all or a portion of the unused funds to roll over and accumulate year-to-year if not spent. All amounts paid by employers into HRAs are deductible for tax purposes by the employer and tax-free to the employee.
COBRA. We offer federal COBRA and state continuation services to employer clients to meet the employer’s obligation to make available continuation of coverage for participants who are no longer eligible for the employer’s COBRA covered benefits, which include medical, dental, vision, HRAs, and certain healthcare FSAs. COBRA requires employers to make health coverage available for qualified beneficiaries for a period of up to 36 months post-termination. As part of our COBRA program, we offer a direct billing service where former employee participants pay us directly as opposed to their employers for coverage they elect to continue. We handle the accounting and customer services for such terminated employees, as well as interfacing with the carrier regarding the employees’ eligibility for participation in the COBRA program.
Commuter programs. We administer pre-tax commuter benefit programs. Employers are permitted to provide employees with commuter benefits including qualified transit (which includes vanpooling) and parking. The maximum monthly federal (and sometimes state) tax free exclusion is indexed for inflation.
Our Luum technology platform provides employers with various commuter services, including access to real-time commute data, to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits.
-4-

Our competitive landscape
Our direct competitors are HSA custodians and other CDB providers. Many of these are state or federally chartered banks and other financial institutions for which we believe benefits administration services are not a core business. Some of our direct competitors (including healthcare service companies such as UnitedHealth Group's Optum, Webster Bank, and well-known retail investment companies, such as Fidelity Investments) are in a position to devote more resources to the development, sale and support of their products and services than we have at our disposal. Our CDB administration competitors include health insurance carriers, human resources consultants and outsourcers, payroll providers, national CDB specialists, regional third-party administrators, and commercial banks. In addition, numerous indirect competitors, including benefits administration service providers, partner with banks and other HSA custodians to compete with us. Our Network Partners and ecosystem partners may also choose to offer competitive services directly, as some health plans have done. Our success depends on our ability to predict and react quickly to these and other industry and competitive dynamics.
Our competitive strengths and strategy
We believe we are well-positioned to benefit from the transformation of the healthcare benefits market. Our technology platforms are aligned with a healthcare environment that rewards consumer engagement and fosters an integrated consumer experience.
Market leadership. We have established a leadership position in the HSA industry through our focus on innovation and differentiated capabilities. Our leadership position is evidenced by the increase in our market share (measured by HSA Assets), from 4% in December 2010 to 20% in June 2023, as reported in the June 2023 Devenir HSA Research Report, which indicates we are the largest HSA custodian measured by both accounts and HSA Assets.
Differentiated consumer experience. We have designed our solution and support services to deliver a differentiated consumer experience, which is a function of our culture and technology. We believe this provides an advantage relative to legacy competitors.
Culture:    We seek to provide remarkable experiences for our members, Clients and Network Partners through what we call our "Purple" service. We believe our Purple culture is a significant factor in our ability to attract and retain customers and to address opportunities in the rapidly changing healthcare sector.
Technology:    We believe our technology helps us drive member outcomes and deliver on our commitment to provide Purple service. We tailor the content of our technology platforms and the guidance of our experts to be timely, personal, and relevant to each member. For example, our technology generates health savings strategies that are delivered to our members when they interact with our platforms or contact us.
Customer service and education: As a key part of our strategy and commitment to provide Purple service, our team members work directly with our Network Partners, Clients, and members to engage with consumers, educating them about the benefits of our HSAs and our other products and providing personalized guidance. We employ individuals who provide real-time assistance to our members via telephone, email, or chat.
Bundled solution for HSAs and complementary CDBs. We are a market-share leader in each of the major categories of complementary CDBs, including FSAs and HRAs, COBRA and commuter benefits administration. Our Clients and their benefits advisors increasingly seek HSA providers that can deliver an integrated offering of HSAs and complementary CDBs. We believe that our ability to provide a combination of HSA and complementary CDB offerings significantly strengthens our value proposition to employers, health benefits brokers and consultants, and Network Partners as a leading single-source provider.
Large and diversified channel access. We believe our differentiated distribution platforms provide a competitive advantage by efficiently enabling us to reach a growing consumer market. Our solution is built on a business-to-business-to-consumer, or B2B2C, channel strategy, whereby we work with Network Partners and Clients to reach consumers in addition to marketing our services to these potential members directly. Reaching the consumer is critical in order for us to increase the number of our HSA members. Health plan Network Partners have been, and continue to be, a key channel through which we gain access to Clients and members.
We work directly with our Network Partners and Clients to reach the consumer in various ways. Our Network Partners collectively employ thousands of sales representatives and account managers who promote both the health plan and administrator partner’s health insurance products, such as HDHPs, and our products and services. Our Clients collectively employ thousands of human resources professionals who are tasked with explaining the benefits of our HSAs to their employees. Our sales and account management teams work with and train the sales
-5-

representatives and account management teams of our Network Partners and the human resource professionals of our Clients on the benefits of enrolling in, contributing to, and saving and spending through our HSAs, and our Network Partners and Clients then convey these benefits to prospective members. As a result of this collaboration, we develop relationships with each member who enrolls in an HSA with us. This personalized engagement with our members constitutes our B2B2C channel strategy.
Proprietary and integrated technology solution. We have a proprietary cloud-based technology solution, which we believe is differentiated in the marketplace for the key reasons described below. We are currently investing in a significant modernization of our proprietary technology platforms to support new opportunities and enhance security, privacy and platform infrastructure, while maintaining existing applications, features, and services.
Complete solution for managing consumer healthcare saving and spending: We believe our technology platforms drive member outcomes by enabling our members to use this technology based on their own needs and desires. For example, our members utilize our HSA platform to evaluate and pay healthcare bills through the member portal, which allows members to pay their healthcare providers, receive reimbursements and learn of savings opportunities for prescription drugs. Members also utilize the platform’s mobile app to view and pay claims on-the-go, including uploading medical and insurance documentation to the platform with their mobile phone cameras.
Purpose-built technology:    Our technology solution was designed specifically to serve the needs of our members, Network Partners, other ecosystem partners and our Clients. We believe our technology enables us to both provide remarkable experiences and drive member outcomes by providing greater functionality and flexibility than the technologies used by our competitors, many of which were originally developed for banking, benefits administration or retirement services. We believe we are one of few providers with a solution that encompasses all of the core functionality of healthcare saving and spending in one integrated, secure, and compliant system, including custodial administration of individual savings and investment accounts, card and electronic funds transaction processing, benefits enrollment and eligibility, electronic and paper medical claims processing, medical bill presentment, tax-advantaged reimbursement account and health incentive administration, HSA trust administration, online investment advice, and sophisticated analytics.
Data integration:    Our technology solution allows us to integrate data from disparate sources, which enables us to seamlessly incorporate personal health information and individually tailored strategies into the consumer experience. We utilize application programming interfaces (APIs) to integrate with health plans, pharmacy benefit managers, employers, and other benefits provider systems. A key part of our strategy is to integrate into our partners' ecosystems, rather than requiring them to conform to ours, as many of our partners’ systems rely on custom data models, non-standard formats, complex business rules, and security protocols that are difficult or expensive to change. We believe that this integration will enable us to deepen our partnerships with our Network Partners and other ecosystem partners.
Configurability:    Our flexible technology solution enables us to create a unique solution for each of our Network Partners. For example, a HealthEquity team member can configure product attributes, including integration with a partner’s chosen healthcare price transparency or wellness tools, single sign on, sales and broker support sites, branding, member communication, custom fulfillment and payment card, savings options and interest rates, fees, and investment choices.
Innovation:    We continue to invest in technology solutions to meet the evolving needs of our Network Partners, Clients and members. Our current innovation efforts include, among others, increasing member and client self-service capabilities, developing APIs, driving electronic communication rather than paper, increasing straight-through processing, improving overall process times utilizing both traditional robotic process automation, and increasingly through artificial intelligence ("AI") tools, leveraging stacked cards, and mobile wallet.
Scalable operating model. We believe that our model is scalable because our services are accessed primarily through our cloud-based technology platforms. After initial on-boarding and a period of education, our service costs for any given customer typically decline over time. Our opportunity to earn high-margin revenue from existing HSA members grows over time because as our HSA members’ balances grow, our custodial revenue and recordkeeping and advisory service revenues are increased without equivalent incremental cost to us.
Enhanced Rates. We partner with large, highly rated insurance company partners to hold, through group annuity contracts or other similar arrangements, HSA cash. We refer to this as our Enhanced Rates offering. Enhanced Rates is our default HSA cash offering, and a significant portion of new HSA cash is placed in Enhanced Rates. An increase in the percentage of HSA cash held in our Enhanced Rates offering positively impacts our custodial
-6-

revenue, as we generally receive a higher yield on HSA cash held by our insurance company partners compared to cash held by our Depository Partners. In addition, increased participation in our Enhances Rates offering reduces our exposure to short-term fluctuations in prevailing interest rates because contract repricing occurs gradually, at approximately 10% per year. The percentage of HSA cash held in our Enhanced Rates offering has increased, and we expect that it will continue to increase. Beginning in the fiscal year ending January 31, 2025, as our Basic Rates contracts expire, the HSA cash held in those Basic Rates contracts will transition to Enhanced Rates contracts, subject to our members retaining the right to keep their HSA cash in Basic Rates.
Strong retention rates. Retention of our HSA members has been strong over time. Individually owned trust accounts, including HSAs, have inherently high switching costs, as switching requires a certain amount of effort on the part of the account holder and may result in closure fees. We believe that our retention rates are also high due to our HSA platform’s integration with the broader healthcare system used by our HSA members and our customer engagement and focus on the consumer experience.
Selective acquisition strategy. We have historically acquired HSA portfolios and businesses that strengthen our service offerings. We expect to continue this growth strategy, including through the BenefitWallet HSA portfolio acquisition, and are regularly engaged in evaluating different opportunities. We have developed an internal capability to source, evaluate, and integrate acquisitions that have created value for stockholders. We believe the nature of our competitive landscape provides significant acquisition opportunities. Many of our competitors view their HSA businesses as non-core functions. We believe they may look to divest these assets and, in certain cases, be limited from making acquisitions due to depository capital requirements.
Our technology
Technology platforms. We provide multiple cloud-based platforms, accessed by our members online via a desktop or mobile device, through which our members can make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices. The platforms provide users with access to services we provide as well as services provided by third parties selected by us or by our Network Partners. Our delivery model for these platforms eliminates the need for our Clients to install and maintain hardware and software in order to support HSA and other CDB programs and enables us to rapidly implement product enhancements across our entire user base.
Among other features, our HSA platform includes the capability to present to users medical bills upon adjudication by a health plan, including details such as the amount paid by insurance, specific nature of the medical service provided, and diagnostic code. Users of our HSA platform can pay these bills from an account of ours or from any bank account, online, via a mobile device, or using our payment card. All users of our HSA platform gain access to our healthcare consumer specialists, available every hour of every day, via a toll-free telephone number or email. Our specialists can assist users with such tasks as optimizing the use of tax-advantaged accounts to reduce medical spending or selecting from among medical plans offered by an employer or health plan.
Our commuter platform provides Clients with various commuter services, including access to real-time commute data, to help Clients design and implement flexible return-to-office and hybrid-workplace strategies and benefits.
We are working to phase out a technology platform that we acquired in the Further Acquisition, which requires us to migrate the associated Clients to one of our other technology platforms.
For a description of our cybersecurity risk management framework for our technology platforms, see Item 1C. Cybersecurity.
Cloud-based solution. Our proprietary technology is deployed as a cloud-based solution that is accessible to customers online and through our mobile app. We utilize a multi-tenant architecture that allows changes made for one Network Partner to be extended to all others. This architecture provides operating leverage by reducing costs and improving efficiencies, enabling us to maximize the utilization of our infrastructure capacity with a reduction in required maintenance. We are increasing investment in our technology and communications systems to support new opportunities and enhance security, privacy, and platform infrastructure.
Our solution is delivered via cloud-based services and hosted in third-party data centers or on a virtual private cloud with an ability to scale on demand. This allows us to quickly support our current and projected growth. We utilize regional cloud failover and multiple redundant third-party data centers to ensure continuous access and data availability. The data centers are purpose-built facilities for hosting mission critical systems with multiple built-in redundancy layers to minimize service disruptions and meet industry-standard measures.
-7-

Government regulation
Our business is subject to extensive, complex, and rapidly changing federal and state laws and regulations.
IRS regulations
We are subject to applicable IRS regulations, which lay the foundation for tax savings and eligible expenses under the HSAs, HRAs, tax-advantaged commuter benefits, and FSAs we administer. The IRS issues guidance regarding these regulations regularly. In addition, we are subject to conflict of interest and other prohibited transaction rules that are enforced through excise taxes under the Internal Revenue Code. Although the excise taxes are enforced by the IRS, the underlying rules are promulgated by the Department of Labor.
In February 2006, HealthEquity, Inc. received designation by the U.S. Department of Treasury to act as a passive non-bank custodian, which allows HealthEquity, Inc. to custody HSA Assets for individual account holders. In July 2017, HealthEquity, Inc. received designation by the U.S. Department of Treasury to act as both a passive and non-passive non-bank custodian, which allows HealthEquity, Inc. to custody HSA Assets for individual account holders and use discretion to direct investment of such assets held. As a passive and non-passive non-bank custodian, the Company must maintain net worth (assets minus liabilities) greater than 2% of passive custodial funds held at each fiscal year-end and 4% of the non-passive custodial funds held at each fiscal year-end in order to take on additional custodial assets. As of January 31, 2024, the Company's year-end for trust and tax purposes, the net worth of the Company exceeded the required thresholds.
Privacy and data security regulations
In the provision of HSA custodial services and directed third-party administration services for FSAs and HRAs, we are subject to the Financial Services Modernization Act of 1999 (Gramm-Leach-Bliley Act or GLBA), the Health Insurance Portability and Accountability Act of 1996 (HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act), and similar state laws.
GLBA imposes financial privacy and security requirements on financial institutions that relate to the collection, storage, use, and disclosure of an account holder’s nonpublic personal information. Nonpublic personal information includes information that is collected or generated in the course of offering a financial product or service. For example, nonpublic personal information includes information submitted by a prospective account holder in an application, an account holder’s name and contact information, and transaction information. Because part of our business is the administration of financial products such as HSAs, we are required under the Consumer Financial Protection Bureau’s financial privacy rule under GLBA to send a notice of our privacy practices to account holders and to comply with restrictions on the disclosure of nonpublic personal information to non-affiliated third parties. We are also required under GLBA to establish reasonable administrative, technical, and physical safeguards to protect the security, confidentiality, and integrity of nonpublic personal information pursuant to the Federal Trade Commission’s safeguards rule. Violations of GLBA can result in civil and criminal penalties.
HIPAA covered entities and their business associates are required to adhere to HIPAA privacy and security standards. Covered entities include most healthcare providers, health plans, and healthcare clearinghouses. Because we perform services (such as FSA services) for covered entities that include processing protected health information, we are a business associate and subject to HIPAA. The two rules that most significantly affect our business are: (i) the Standards for Privacy of Individually Identifiable Health Information, or the Privacy Rule; and (ii) the Security Standards for the Protection of Electronic Protected Health Information, or the Security Rule. The Privacy Rule restricts the use and disclosure of protected health information and requires us to safeguard that information and provide certain rights to individuals with respect to that information. The Security Rule establishes requirements for safeguarding protected health information transmitted or stored electronically. Both civil and criminal penalties apply for violating HIPAA, which may be enforced by both the Department of Health and Human Services’ Office for Civil Rights and state attorneys general. Violations of HIPAA may also subject us to contractual remedies under the terms of business associate agreements with covered entities.
Various states also have laws and regulations that impose additional restrictions on our collection, storage, use, and disclosure of personal information. Privacy regulation in particular has become a priority issue in many states and with the Federal government. For example, the California Consumer Privacy Act (“CCPA”) protects certain privacy rights of California consumers and requires companies, such as ours, that process information on California residents, to make disclosures to consumers about their data collection, use, and sharing practices, and allows consumers to opt out of certain data sharing with third parties and provides a private right of action for data breaches. The CCPA does not generally apply to data subject to GLBA or HIPAA. We expect further privacy requirements to be applicable to us as a result of additional recently passed, and likely upcoming, state privacy laws similar to CCPA, which may expand consumers’ rights with respect to their personal information. Several of these
-8-

laws do not apply to entities or data subject to GLBA. The Federal government is also considering legislative and regulatory proposals concerning privacy, data protection, and cybersecurity, which may require us to implement and maintain additional operational or compliance measures.
ERISA
Our private-sector clients’ FSAs, HRAs, COBRA continuation insurance, and other account-based retirement plans are covered by the Employee Retirement Income Security Act of 1974, as amended, or ERISA, which governs “employee benefits plans.” Title I of ERISA does not generally apply to HSAs. ERISA generally imposes extensive reporting requirements on employers, as well as an obligation to provide various disclosures to covered employees and beneficiaries; and employers and third-party administrators that have authority or discretion over management, administration, or investment of plan assets are subject to fiduciary responsibility under ERISA. ERISA's requirements affect our FSAs, HRAs, and COBRA administration businesses. The Department of Labor can bring enforcement actions or assess penalties against employers, investment advisers, administrators, and other service providers for failing to comply with ERISA’s requirements. Participants and beneficiaries may also file lawsuits against employers, investment advisers, administrators, and other service providers under ERISA.
Department of Labor
The Department of Labor, or the DOL, regulates plans that are subject to ERISA, including health FSAs, HRAs, and 401(k) and other retirement plans, as well as COBRA administration. The DOL also issues guidance related to fiduciary responsibility and prohibited transactions under ERISA and the Internal Revenue Code that affect administration of HSAs (as well as health FSAs, HRAs, and retirement plans).
The DOL issues regulations, technical releases, and other guidance that apply to employee benefit plans, tax-favored savings arrangements (including HSAs) and COBRA administration, generally. In addition, in response to a request by an individual or an organization, the DOL’s Employee Benefits Security Administration may issue an advisory opinion that interprets and applies ERISA and/or corresponding prohibited transaction rules under the Internal Revenue Code to a specific situation, including issues related to consumer-centric healthcare accounts and retirement plans.
Healthcare reform
In March 2010, the federal government enacted significant reforms to healthcare benefits through the Affordable Care Act. The legislation amended various provisions in many federal laws, including the Internal Revenue Code and ERISA. The reforms included new excise taxes that incentivize employers to provide health benefits (including HSA-compatible benefits) to all full-time employees and new coverage mandates for health plans. The rules directly affect health FSAs and HRAs and have an indirect effect on HSAs. Further changes to the Affordable Care Act and related healthcare regulation remain under consideration, including "Medicare for all" plans.
Investment Advisers Act of 1940
Our subsidiary HealthEquity Advisors, LLC is an SEC-registered investment adviser that provides web-only automated investment advisory services to members. As an SEC-registered investment adviser, it must comply with the requirements of the Investment Advisers Act of 1940, or the Advisers Act, and related Securities and Exchange Commission, or SEC, regulations and is subject to periodic inspections by the SEC staff. Such requirements relate to, among other things, fiduciary duties to clients, disclosure obligations, recordkeeping and reporting requirements, marketing restrictions limitations on agency cross and principal transactions between the adviser and its clients, and general anti-fraud prohibitions. The SEC is authorized to institute proceedings and impose sanctions for violations of the Advisers Act, ranging from fines and censure to termination of an investment adviser’s registration. Investment advisers also are subject to certain state securities laws and regulations. Failure to comply with the Advisers Act or other federal and state securities and regulations could result in investigations, sanctions, profit disgorgement, fines or other similar consequences.
Intellectual property
Intellectual property is important to our success. We rely on trademarks and other forms of intellectual property rights and measures, including trade secrets, know-how and other unpatented proprietary processes, and nondisclosure agreements, to maintain and protect proprietary aspects of our products and technologies. We require our team members and consultants to execute confidentiality agreements in connection with their employment or consulting relationships with us. We also require our team members and consultants to disclose and assign to us all inventions conceived during the term of their employment or engagement while using our property or which relate to our business.
-9-

Geographic areas
Our sole geographic market is the U.S.
Human capital
HealthEquity is comprised of people dedicated to empowering consumers to spend, save, and invest for healthcare by delivering Purple service. We believe that our culture is a key differentiator that drives the success of our company through, among other things, attracting and retaining top talent.
Our board of directors and its committees provide oversight on certain human capital matters. The Talent, Compensation and Culture Committee of our board of directors acts on behalf of the board to review and determine executive compensation plans, policies, and programs; oversee the Company’s culture and related strategies, programs, and risks; and oversee the Company’s talent management, development, and retention efforts, including with respect to diversity and inclusion.
As of January 31, 2024, we had 3,126 full-time team members and 24 part-time team members. As of January 31, 2024, our team members had the following demographic characteristics:
Executive
Leadership Team (1)
All Other
People Leaders
All Other HealthEquity
Team Members (2)
Women31 %59 %66 %
Men69 %41 %33 %
Under age 30%%12 %
Between ages 30 and 5060 %67 %60 %
Over age 5040 %30 %28 %
People of color18 %26 %37 %
(1)Our executive leadership team includes people in VP-level positions and above.
(2)Gender was not specified by 1% of team members included in this column.
Diversity, equity, and inclusion ("DE&I")
To reach our goals, we seek to create an environment that attracts, sustains, and fulfills our team members. That starts with building and maintaining a diverse, equitable, and inclusive culture.
At HealthEquity, we embrace diversity as a strength. We recognize the power of diverse workplaces to produce innovative ideas and foster a productive work environment.
The Created Equal Council, our DE&I initiative, is comprised of HealthEquity team members who identify opportunities, guide solutions, and hold the Company accountable in the integration of DE&I practices. The Council is charged with researching, developing, and proposing mechanisms that will help create a supportive, positive, and inclusive work environment for all team members. The Council has representatives from key stakeholder teams, including People and Legal.
Talent acquisition and team member development
Our People team seeks to attract, hire, and develop qualified candidates and team members.
HealthEquity has taken, and continues to take, steps to strengthen our talent:
To improve the candidate experience and increase our focus on inclusive hiring practices, we created hiring committees within each department. These hiring committees have been trained on, and employ, a competency-based structured interviewing framework.
HealthEquity maintains its focus on DE&I across all departments and hierarchies by signing the Parity Pledge. We committed to interviewing a diverse candidate for every Director-level position and above.
We developed a Talent Partnership Program with our Employee Resource Groups (ERGs). Started in 2023, each ERG has a dedicated Talent partner who is responsible for sharing talent acquisition news and opportunities.
We continued an early career internship program, offering 22 positions across two key areas: corporate business functions and technology. To foster diversity and inclusion, we established partnerships with prominent schools classified as Historically Black Colleges and Universities (HBCUs) and Hispanic Serving Institutions (HSIs) in regions where our presence is strongest.
-10-

We built a library of resources for our “Grow Your Career” series with the Talent Partner and Talent Operations teams. This includes guides on how to write resumes, create a social media presence, and prepare for interviews to support team member development.
We run the Temporary On-Project Specialist (TOPS) program, which allows Member Service Specialists to experience working in other areas of the business. Selected individuals are able to support areas that need help while gaining experience that can assist with their personal and professional goals.
We are implementing a leadership development program to improve team member engagement and productivity.
Pay equity
Pay equity is a crucial metric in assessing diversity and equal opportunity at HealthEquity. We strive to provide a consistent and fair remuneration strategy for all team members through our Total Rewards package. This package includes:
Base salary
Incentive/bonus pay
Stock-based compensation
401(k) with company matching
Health benefits
The Total Rewards philosophy underlying this package is intended to promote fairness and simplicity so that team members and people leaders understand the goals and the outcomes. We strive to administer the Total Rewards package consistently, equitably, and free of discrimination as follows:
Maintaining competitive pay by reviewing market data annually
Rewarding team members based on their abilities, competencies, experience, and performance levels
Effectively communicating our Total Rewards policies and practices
Complying with all applicable federal, state, and local laws and requirements
Team member engagement
We also consider team member engagement an important metric of our organizational health. We regularly seek team member feedback and measure engagement, previously through the Net Promoter Score℠, or NPS®, survey, which was performed twice a year. As our Company continues to mature, we have shifted to measuring team member engagement three times per year through a survey which contains three engagement key performance indicators (KPIs) that we believe provide a comprehensive measure of team member engagement. The KPIs are designed to determine whether our team members recommend HealthEquity as a great place to work, whether their work gives them a sense of accomplishment, and whether they are motivated to go above and beyond in their work.
As of January 31, 2024, our team member engagement score was 80.7% favorable, 11.7% neutral, and 7.6% unfavorable, based on a participation rate of 89%. We believe that our team member engagement impacts our ability to retain our team members. For the year ended January 31, 2024, our total team member turnover was 14.4% and our voluntary turnover was 8.4%.
NPS® is a registered trademark of Bain & Company, Inc., Satmetrix Systems, Inc., and Fred Reichheld. Net Promoter Score℠ is a service mark of Bain & Company, Inc., Satmetrix Systems, Inc., and Fred Reichheld.
Corporate information
HealthEquity, Inc. was incorporated as a Delaware corporation on September 18, 2002. Our principal business office is located at 15 W. Scenic Pointe Dr., Ste. 100, Draper, Utah 84020. Our website address is www.healthequity.com. We do not incorporate the information contained on, or accessible through, our corporate website into this Annual Report on Form 10-K, and you should not consider it to be part of this report.
Where you can find additional information
Our website is located at www.healthequity.com, and our investor relations website is located at ir.healthequity.com. Information on our website is not incorporated into this report. Copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available, free of charge, on our investor relations website as soon as reasonably practicable after we file such material electronically with or furnish it to the
-11-

SEC. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.

-12-

Item 1A. Risk factors
You should carefully consider the risks described below together with the other information set forth in this Annual Report on Form 10-K. If any of the risks described below are realized, our business, financial condition, results of operations, and prospects could be materially and adversely affected. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and operating results.
Risks relating to our business and industry
Any diminution in, elimination of, or change in the availability of tax benefits for HSAs and other CDBs would materially adversely affect us.
Substantially all of our revenue is earned from tax-advantaged HSAs and other CDBs. The efforts of governmental and third-party payers to raise revenue or contain or reduce healthcare or other costs could include restructuring the tax benefits available through HSAs and other CDBs, which may adversely affect our business, operating results, and financial condition. For example, the federal government or states may seek to raise revenues by enacting tax laws that eliminate the tax deductions available to individuals who contribute to HSAs. We cannot predict if any new tax reforms will ultimately become law, or if enacted, what their terms or the regulations promulgated pursuant to such reforms will be. If the laws or regulations are changed to limit or eliminate the tax benefits available through these accounts, such a change would have a material adverse effect on our business.
Failure to adequately place and safeguard HSA cash and Client-held funds, or the failure of any of our depository or insurance company partners, could materially and adversely affect our business, financial condition and results of operations.
As a non-bank custodian, we rely on our federally insured custodial Depository Partners and our insurance company partners to hold HSA cash that we custody. The portion of HSA cash held by our insurance company partners is increasing with the increased adoption of our Enhanced Rates program. The HSA cash held through our insurance company partners is not federally insured, and our members bear the risk of loss with respect to either the failure of the insurance company partner holding their HSA cash or the breach by the insurance company partner of its obligations to guarantee principal or pay interest thereon. In addition, we deposit Client-held funds with our Depository Partners in interest-bearing demand deposit accounts, and for certain Clients these amounts exceed maximum federal deposit insurance levels.
If any material adverse event were to affect one of our Depository Partners or our insurance company partners, including a significant decline in its financial condition, a decline in the quality of its service, loss of deposits, its inability to comply with applicable banking, insurance or other regulatory requirements, systems failure or its inability to return principal or pay interest thereon, our business, financial condition and results of operations could be materially and adversely affected. In addition, in the event of such a failure of, or breach by, one of our insurance company partners, the HSA cash held through that insurance company partner would be at risk and no assurance can be given that our contractual arrangements with that insurance company partner would be sufficient for our members to fully recover their HSA cash, which would in turn result in reputational and financial harm to the Company.
In addition, certain of our insurance company partners have commitments to us with respect to the interest rates paid; however, some of these commitments are conditional upon certain market events and/or satisfaction of our obligations to the partner. A reduction of the interest rate payable, or a requirement that we post collateral in lieu of any such reduction, could have a material and adverse impact on our business, financial condition and results of operations.
Failure to adequately manage the liquidity of the custodial assets held by our Depository Partners and insurance company partners could materially and adversely affect our business, financial condition, and results of operations.
Certain of our arrangements with our depository and insurance company partners require that we keep a minimum amount of HSA cash with such partner. If we fail to comply with those minimum HSA cash requirements, including as a result of withdrawals by our members, we may be subject to penalties payable to our partners or a reduction in the interest payable. Such penalties or reductions, if imposed, could have a material and adverse impact on our business, financial condition and results of operations, and we may not have sufficient capital on hand to pay such penalties.

-13-

Integration of our acquisitions may not be successful, and we may not realize the synergies anticipated from our acquisitions.
The success of our acquisitions depends in part on our ability to realize the anticipated business opportunities from combining the operations of the acquired businesses with our business in an efficient and effective manner. Integration of our acquisitions could take longer and be more costly than anticipated, and it could result in the loss of key team members, the disruption of our ongoing business and the acquired business, tax costs or inefficiencies, or inconsistencies in standards, controls, information technology systems, procedures and policies, any of which could adversely affect our ability to maintain relationships with team members, Clients, Network Partners or other third parties, and could harm our financial performance. In addition, we may not realize the anticipated cost, revenue, and other synergies associated with successfully integrating our acquisitions.
Our management team and other team members continue to spend significant amounts of time on integration efforts relating to the Further Acquisition. Similar to the work completed to integrate the acquisition of WageWorks, as part of the Further Acquisition integration process we are working to migrate certain Clients and Network Partners to different technology platforms. In connection with the WageWorks technology platform migrations, we experienced the following challenges, all of which could also occur in connection with the Further technology platform migration:
we experienced Client and Network Partner attrition when we were unable to meet Client or Network Partner expectations or technical requirements;
certain Clients and Network Partners refused to cooperate with the platform migration process, resulting in delays to and additional costs associated with this process and the loss of certain of those Clients and Network Partners;
we experienced Client and Network Partner dissatisfaction, which may have impaired our long-term relationships with impacted Clients and Network Partners; and
we faced challenges in integrating the back-office systems and people associated with these technology platforms.
A decline in interest rate levels would reduce our ability to earn income on our HSA Assets and Client-held funds and to attract HSA contributions.
We partner with our depository and insurance company partners to hold our HSA Assets and other Client-held funds. We earn a significant portion of our consolidated revenue from fees we earn from our depository and insurance company partners, approximately 39%, 30%, and 25% during the fiscal years ended January 31, 2024, 2023, and 2022, respectively. A decline in prevailing interest rates has in the past and may again in the future negatively affect our business by reducing the yield we realize on our HSA Assets and other Client-held funds. In addition, if we do not offer competitive interest rates on HSA Assets, our members may choose another HSA custodian. Any such scenario could materially and adversely affect our business and results of operations.
A decline in the value of invested HSA Assets would adversely affect our results of operations.
If the value of the invested HSA Assets our members hold declines, whether due to market conditions or other factors, our fees, which are based on a percentage of the asset values, would be adversely affected, which would in turn negatively impact our results of operations.
If we are not successful in adapting to our rapidly evolving industry, our growth may be limited, and our business may be adversely affected.
The market for our products and services is subject to rapid and significant change and competition. The market for administration of HSAs and other CDBs is characterized by rapid technological change, new product and service introductions, evolving industry standards, changing customer needs, existing competition, and the entrance of non-traditional competitors. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of this market due in part to our rapidly evolving industry, industry consolidation, and the substantial resources available to our existing and potential competitors. In order to remain competitive, we are continually involved in a number of projects to develop new services or compete with these new market entrants. These projects carry risks, such as cost overruns, delays in delivery, performance problems, and lack of acceptance by our Clients, Network Partners and members.


-14-

Any diminution in the use of HSAs or other CDBs would materially adversely affect us.
We believe that many consumers are not familiar with, or do not fully appreciate, the tax-advantaged benefits of HSAs and other CDBs. Our success depends on the willingness of consumers to increase their use of HSAs and other CDBs, our ability to increase engagement, and our ability to demonstrate the value of our services to our existing and potential Clients, Network Partners and members.
If our members do not fully use their HSAs or CDBs, if employers reduce or cease to offer HSAs or other CDB programs, if the rate of adoption of these accounts decreases, if existing Clients, Network Partners and members do not recognize or acknowledge the benefits of our services or we do not drive engagement, then the market for our services might decline or develop more slowly than we expect, which could adversely affect our operating results.
We may be unable to compete effectively against our current and future competitors.
The market for our products and services is highly competitive. We view our competition in terms of direct and indirect competitors. Our direct HSA competitors are HSA custodians and administrators that include state or federally chartered banks, such as Webster Bank and Optum Bank, insurance companies, well-known retail investment companies, such as Fidelity Investments, and non-bank custodians approved by the U.S. Treasury. We also have numerous indirect HSA administration competitors, including benefits administrators and health plans, that license technology platforms and partner with other HSA custodians to provide "white label" HSA offerings. Our other CDB administration competitors include health insurance carriers, human resources consultants and outsourcers, payroll providers, national CDB specialists, regional third-party administrators, and commercial banks, and these competitors have entered, and others may also enter, the HSA market or expand existing HSA offerings to compete with us.
An increased focus on HSA-favorable healthcare regulatory reforms may create renewed interest and investment by our competitors in their HSA offerings and lead to greater competition, which could make it harder for us to maintain our growth trajectory. This risk would be compounded if legal requirements or administrative rules are interpreted in a way that makes compliance more onerous for us than for our competitors.
If one or more of our competitors were to merge or partner with another of our competitors, the change in the competitive landscape could materially adversely affect our ability to compete effectively. Our competitors have and may continue to establish or strengthen cooperative relationships with our current or future Network Partners or other strategic partners, thereby limiting our ability to promote our solution with these parties. We have seen an increase in Network Partners that have decided to offer HSAs or other CDBs directly to their customers, and a continuation of this trend would significantly reduce our channel partner opportunities and result in account attrition.
Well-known retail mutual fund companies, such as Fidelity Investments, have entered the HSA and CDB business and gained significant market share. Our market share could decline if Fidelity and other mutual fund companies continue expanding their presence in the market. These investment companies have significant advantages over us in terms of brand name recognition, years of experience managing tax-advantaged retirement accounts (e.g., 401(k) and IRA), highly developed recordkeeping, trust functions, and fund advisory and customer relations management, among others. If we are unable to compete effectively with these mutual fund company competitors, our results of operations, financial condition, business, and prospects could be materially adversely affected.
Many of our competitors, in particular banks, insurance companies, and other financial institutions, have longer operating histories and significantly greater financial, technical, marketing, and other resources than we have. As a result, some of these competitors are in a position to devote greater resources to the development, promotion, sale, and support of their products and services and have offered, or may in the future offer, a wider range of products and services that are increasingly desired by potential customers, and they have also used advertising and marketing strategies (including loss-leaders) that achieve broader brand recognition or acceptance.
Finally, our competitors may have the ability to devote more financial and operational resources than we can to developing new technologies and services, including services that provide improved operating functionality, and adding features to their existing service offerings. If successful, their development efforts could render our services less desirable, resulting in the loss of our existing customers or a reduction in the fees we earn from our products and services.




-15-

Developments in the rapidly changing healthcare industry could adversely affect our business.
Substantially all of our revenue is derived from healthcare-related saving and spending by consumers, which could be affected by changes affecting the broader healthcare industry, including decreased spending in the industry overall. General reductions in expenditures by healthcare industry participants could result from, among other things:
government regulation or private initiatives that affect the manner in which healthcare industry participants interact with consumers and the general public;
consolidation of healthcare industry participants;
reductions in governmental funding for healthcare; and
adverse changes in general business or economic conditions affecting healthcare industry participants.
Even if general expenditures by industry participants remain the same or increase, developments in the healthcare industry may result in reduced spending in some or all of the specific market segments that we serve now or in the future. The healthcare industry has changed significantly in recent years, and we expect that significant changes will continue to occur. However, the timing and impact of developments in the healthcare industry are difficult to predict. There is no assurance that the demand for our products and services will continue to exist at current levels or that we will have adequate technical, financial, and marketing resources to react to changes in the healthcare industry.
If our members do not continue to utilize our payment cards, our results of operations, business, and prospects would be materially adversely affected.
We derived 16%, 17%, and 17% of our total revenue during the fiscal years ended January 31, 2024, 2023, and 2022, respectively, from interchange fees that are paid to us when our customers utilize our payment cards. These fees represent a percentage of the expenses transacted on each card. For example, the COVID-19 pandemic had a materially adverse impact on the interchange fees generated due to decreased usage of our payment cards in our commuter product and in healthcare spending. If our customers do not use these payment cards at the rate we expect, if they elect to withdraw funds using a non-revenue generating mechanism such as direct reimbursement, if the impacts of societal changes arising out of the COVID-19 pandemic continue, or if other alternatives to these payment cards develop, our results of operations, business, and prospects would be materially adversely affected.
Failure to maintain effective internal control over financial reporting could have a material adverse effect on our reputation, results of operations and financial condition.
Effective internal control over financial reporting is necessary for us to provide reliable financial reports, prevent fraud and operate successfully as a public company. Any failure to execute on our internal controls and continue to maintain effective internal controls, to timely implement any necessary additional improvement to our internal controls or to effect remediation of any future material weakness or significant deficiency could, among other things, result in losses from fraud or error, harm our reputation or cause investors to lose confidence in our reported financial information, all of which could have a material adverse effect on our reputation, results of operations, or financial condition.
Management reviews and updates our systems of internal controls and procedures, as appropriate. Any system of controls is based in part on certain assumptions and can provide only reasonable, not absolute, assurances that the objectives of the system are met. Any failure or circumvention of our controls and procedures or failure to comply with regulations related to controls and procedures could have a material adverse effect on our reputation, results of operations and financial condition.
Data security, technological, and intellectual property risks
Cyber-attacks, including ransomware attacks, or other privacy or data security incidents could materially adversely impact our business.
Our proprietary technology platforms enable the exchange of, and access to, sensitive information, and, as a result, we are frequently the target of cyber-attacks or other privacy or data security incidents. As one of the largest providers of HSAs and other CDBs, we are an attractive target for cyber-attacks, including ransomware attacks, which means we must continue to secure and monitor each of our technology platforms, making sure these platforms are aligned to our industry benchmark security posture. In addition, geopolitical events, including the war between Russia and Ukraine, have resulted in, and may continue to result in, an increase in cyber-attacks.
Substantially all of our workforce works remotely. This remote work environment increases the risk of cybersecurity breaches and incidents, and the potential impact of these on our operations is also higher while our team members log in to our network remotely.
-16-

Our ability to ensure the security of our technology platforms and thus sensitive customer and partner information is critical to our operations. We rely on standard Internet and other security systems to provide the security and authentication necessary to effect secure transmission of data. Despite our security measures, our information technology and infrastructure are vulnerable to cybersecurity threats, including attacks by hackers and other malfeasance. Such security breaches could compromise our networks, or those of third-party service providers on which we rely, and result in the information stored or transmitted there to be accessed, modified or used in an unauthorized manner, publicly disclosed, lost, or stolen. Such access, use, disclosure, or other loss of information could result in regulatory scrutiny, legal claims or proceedings leading to liability, including under laws that protect the privacy of personal information, disrupt our operations and the services we provide to our Clients, damage our reputation, and cause a loss of confidence in our products and services, which could adversely affect our business, operations, and competitive position.
Security breaches, including a major breach of our network security and systems, could result in serious negative consequences for our business, including the loss of sensitive information, theft or loss of actual funds, litigation, indemnity obligations to our Clients, fines, penalties and other liabilities, including under laws that protect the privacy of personal information, disrupt our operations and the services we provide to our members, Clients and Network Partners. Such breaches could damage our reputation, and cause a loss of confidence in our products and services, reducing demand and resulting in an unwillingness of members, Clients, Network Partners and other data owners to provide us with their payment information or personal information, and otherwise harm our brand. Furthermore, if third parties improperly obtain and use the personal information of our members, we may be required to expend significant resources to resolve these problems. While we have security measures in place, we have experienced data privacy incidents in the past, including several incidents in 2018. As a result, or if our security measures are breached again or unauthorized access to data is otherwise obtained as a result of third-party action, team member error or otherwise, our reputation could be significantly damaged, our business may suffer and we could incur substantial liability, which could result in loss of sales, Clients and Network Partners.
Because techniques used to obtain unauthorized access to or sabotage systems change frequently and such novel techniques may not be identified until they are launched against a target, we may be unable to anticipate, or to implement adequate preventative measures to address, these techniques. Any or all of these issues could negatively impact our ability to attract new, or increase engagement by, members, Clients and Network Partners, and subject us to third-party lawsuits, regulatory fines, contractual liability, and other action or liability, thereby harming our operating results or financial condition.
Fraudulent and other illegal activity involving our products and services could lead to financial and reputational damage to us and reduce the use and acceptance of our products and services.
Criminals are using increasingly sophisticated methods to capture personal information in order to engage in illegal activities such as counterfeiting and identity theft. Even if we can secure our systems against these activities, we are vulnerable through third parties. We rely upon third parties for certain services, such as some transaction processing services and data feeds, which subjects us to risks related to the vulnerabilities of those third parties. For example, we are exposed to risks relating to the theft of payment card numbers housed in a merchant's point of sale systems if our members use our payment cards at a merchant whose systems are compromised. We may make our members whole for losses sustained when using our payment cards, even in instances where we are not directly responsible for the underlying cause of such loss. A single significant incident of fraud, or increases in the overall level of fraud, involving our payment cards, our custodial accounts or our reimbursement administration services, could result in financial and reputational damage to us, which could reduce the use and acceptance of our products and services, or cause our Clients, members and Network Partners to cease doing business with us.
We rely on software licensed from third parties that may be difficult to replace or that could cause errors or failures of our technology platforms that could lead to lost customers or harm to our reputation.
We rely on certain cloud-based software licensed from third parties to run our business. This software may experience outages, may not continue to be available to us on commercially reasonable terms and any loss of the right to use any of this software could result in, among others, delays in producing our financial statements, risks to our security environment, or the provisioning of our products and services until equivalent technology is either developed by us, or, if available, identified, obtained, and integrated into our systems and processes, which would likely take a significant amount of time and harm our business. In addition, we have service level agreements with certain of our Clients and Network Partners for which the availability of this software is critical. Any decrease in the availability of our service as a result of errors, defects, a disruption or failure of our licensed software may require us to provide significant fee credits or refunds to our customers. Our software licensed from third parties is also subject to change or upgrade, which may result in our incurring significant costs to implement such changes or upgrades.
-17-

Developing and implementing new and updated applications, features, and services for our technology platforms may be more difficult than expected, may take longer and cost more than expected, or may result in the platforms not operating as expected.
Attracting and retaining new Clients and Network Partners requires us to continue to improve the technology underlying our proprietary technology platforms and requires our technology to operate as expected. In addition, potential Clients and Network Partners are increasingly seeking a bundled solution, encompassing a wide range of features. We are currently investing in a significant modernization of our proprietary technology platforms to support new opportunities and enhance security, privacy and platform infrastructure, while maintaining existing applications, features, and services. If we are unable to do so on a timely basis or if we are unable to implement this modernization without disruption to our existing applications, features and services, or if we encounter technical obstacles that result in the technology not operating properly, we may lose potential and existing Clients and Network Partners. We rely on a combination of internal development, strategic relationships, licensing, and acquisitions to develop our content offerings, products and services. These efforts may:
cost more than expected;
take longer than originally expected to develop or implement;
require more testing than originally anticipated;
require significant cost to address or resolve technical defects or obstacles;
require additional advertising and marketing costs; and
require the acquisition of additional personnel and other resources.
The revenue opportunities earned from these efforts may fail to justify the effort or resources spent. In addition, material performance problems, defects or errors in our existing or new software may occur in the future, which may harm our operating results.
New products and services, including those incorporating or utilizing AI and machine learning may raise technological, security, legal and other risks and challenges related to, among other items, the use of personal information in such AI systems, flaws in our models or training datasets that may result in biased or inaccurate results or other unanticipated outcomes, ethical considerations regarding AI, potential infringement of third-party intellectual property rights, and our ability to safely deploy and implement governance and controls for AI systems. Realization of these risks could negatively impact our reputation, the demand for our products and services, our financial condition and results of operations, and otherwise draw adverse regulatory scrutiny.
Any disruption of service at our facilities, our third-party data centers, or our cloud service providers could interrupt or delay our customers’ access to our products and services.
The ability of our team members, members, Network Partners, and Clients to access our technology platforms is critical to our business. We cannot ensure that the measures we have taken to enable access to our technology platforms will be effective to prevent or minimize interruptions to our operations. Our technology platforms are hosted by third-party data centers, and we increasingly rely on third-party cloud service providers to support our technology platforms. Our facilities, our third-party data centers, and our cloud service providers are vulnerable to interruption or damage from a number of sources, many of which are beyond our control, including, without limitation:
extended power loss;
telecommunications failures from multiple telecommunications providers;
natural disaster or an act of terrorism;
software and hardware errors, or failures in our own systems or in other systems;
network environment disruptions such as computer viruses, hacking and similar problems in our own systems and in other systems;
theft and vandalism of equipment; and
actions or events caused by or related to third parties.
We attempt to mitigate these risks through various business continuity efforts, including redundant infrastructure, 24/7/365 system activity monitoring, backup and recovery procedures, use of a secure storage facility for backup media, separate production and test systems, and change management and system security measures, but our precautions may not protect against all potential problems. Our data recovery centers are equipped with physical space, power, storage and networking infrastructure and Internet connectivity to support our technology platforms in the event of the interruption of services at our data centers. Even with these data recovery centers, our operations would be interrupted during the transition process should our primary data center experience a failure. Disruptions at our data centers could cause disruptions to our technology platforms and data loss or corruption. We have experienced interruptions and delays in service and availability for data centers, and bandwidth and other
-18-

technology issues in the past. Frequent or persistent system failures that result in the unavailability of our technology platforms or slower response times could reduce our members', Clients' and Network Partners' ability to access our technology platforms, impair the delivery of our products and services, and harm the perception of our platforms as reliable, trustworthy, and consistent. Any future errors, failure, interruptions or delays experienced in connection with these third-party technologies could delay access to our products by members, Clients and Network Partners, which would harm our business. This could damage our reputation, subject us to potential liability or costs related to defending against claims or cause our members, Clients and Network Partners to cease doing business with us, any of which could negatively impact our financial results.
Our technology platforms may link to or utilize open source software, and any failure to comply with the terms of one or more of these open source licenses could negatively affect our business.
Our technology platforms may incorporate software covered by open source licenses. The terms of various open source licenses have not been interpreted by United States courts, and there is a risk that such licenses could be construed in a manner that imposes unfavorable conditions on us. For example, by the terms of certain open source licenses, we could be required to offer our technology platforms that incorporate the open source software for no cost, that we make publicly available source code for modifications or derivative works that we created based upon, incorporating or using the open source software, and/or that we license such modifications or derivative works under the terms of the particular open source license. If portions of our proprietary software are determined to be subject to an open source license, then the value of our technologies and services could be reduced.
In addition to risks related to license requirements, usage of open source software may be riskier than use of third-party commercial software, as open source licensors generally do not provide warranties or controls on the origin of the software. Many of the risks associated with usage of open source software cannot be eliminated and could negatively affect our business.
Legal and regulatory risks
The healthcare regulatory and political framework is uncertain and evolving, and we cannot predict the effect that further healthcare reform and other changes in government programs may have on our business, financial condition, or results of operations.
Healthcare laws and regulations are rapidly evolving and may change significantly in the future, which could adversely affect our financial condition and results of operations. In addition, proposals to implement a single payer or "Medicare for all" system in the U.S. or in individual states, if adopted, could have a material adverse effect on our business. The full impact of healthcare reform and other changes in the healthcare industry and in healthcare spending is unknown. Accordingly, we are unable to predict what effect healthcare reform measures will have on our business.
Changes in applicable federal and state laws relating to HSAs and other CDBs could materially adversely affect our business.
HSAs and other CDBs exist as a result of provisions in the Internal Revenue Code and other laws and regulations. Changes to the regulatory landscape impacting our products require substantial time and costs for us to ensure our products are compliant. For example, regulatory changes related to our FSA and COBRA products enacted in the wake of the COVID-19 pandemic created uncertainty and additional workload on our team members and resulted in additional costs. In addition, federal or state governments could impose laws that limit the eligibility requirements for our products, which could limit our ability to grow or cause us to lose existing members, or such governments could change the eligibility requirements we must meet to maintain the licenses we need to offer our products. We cannot predict if any new reforms will ultimately become law, or if enacted, what their terms or the regulations promulgated pursuant to such reforms will be, and such reforms could have a material adverse effect on our business.
We are subject to privacy regulations, including regarding the access, use, and disclosure of personally identifiable information. If we or any of our third-party service providers experience a privacy breach, it could result in substantial financial and reputational harm, including possible criminal and civil penalties.
State and federal laws and regulations govern the collection, dissemination, access, and use of personally identifiable information, including HIPAA and the Health Information Technology for Economic and Clinical Health Act ("HITECH"), which govern protected health information, and the Gramm-Leach-Bliley Act, which governs nonpublic personal information. In the provision of services, we and our third-party service providers collect, access, use, maintain, and transmit personally identifiable information in ways that are subject to these laws and regulations. Although we have implemented measures to comply with these privacy and data protection laws and regulations, we have experienced data privacy incidents in the past, though none have materially impacted our operations or financial condition. Any further unauthorized disclosure of personally identifiable information
-19-

experienced by us or our third-party service providers that process such information on our behalf could result in substantial financial and reputational harm to us, including possible criminal and civil penalties. In situations where we are subject to HIPAA and HITECH, in which we are a business associate providing services to covered entities, the covered entities direct HIPAA compliance matters in the event of a security breach, which complicates our ability to address harm caused by the breach. Additionally, as we have in connection with prior security incidents, we may be required to notify impacted individuals, plan sponsors, and regulatory authorities depending on the severity of the breach, our role, legal requirements, and contractual obligations.
Privacy and data protection regulation have become priority issues in many states, and as such the regulatory environment is continually changing. For example, the CCPA provides a private right of action for data breaches. Additional privacy requirements are expected as new state and federal privacy laws are enacted.
Continued compliance with current and potential new privacy and data protection laws and regulations, and meeting expectations with respect to the control of personal data in a rapidly changing technology environment, could result in higher compliance and technology costs for us, as well as costly penalties in the event we are deemed to not be in compliance with such laws and regulations.
Legislative, regulatory, and legal developments involving taxes could adversely affect our results of operations and cash flows.
We are subject to U.S. federal and state income, payroll, property, sales and use, and other types of taxes in numerous jurisdictions. Significant judgment is required in determining our provisions for income taxes. Changes in tax rates, enactments of new tax laws, revisions of tax regulations, and claims or litigation with taxing authorities could result in substantially higher taxes.
We do not collect sales and use taxes in all jurisdictions in which our customers are located, other than from sales of certain commuter services, based on our belief that such taxes are generally not applicable to our services. Sales and use tax laws and rates vary by jurisdiction and such laws are subject to interpretation. In those jurisdictions and in those cases where we do believe sales taxes are applicable, we collect and file timely sales tax returns. Currently, such sales taxes apply to certain commuter services, but otherwise are minimal to the rest of our services. Jurisdictions in which we do not collect sales and use taxes may assert that such taxes are applicable, which could result in the assessment of such taxes, interest, and penalties, and we could be required to collect such taxes in the future. Such additional sales and use tax liability could adversely affect the results of our operations.
Changes in laws and regulations relating to interchange fees on payment card transactions could adversely affect our revenue and results of operations.
Existing laws and regulations limit the fees or interchange rates that can be charged on payment card transactions. For example, the Federal Reserve Board has the power to regulate payment card interchange fees and has issued a rule setting a cap on the interchange fee an issuer can receive from a single payment card transaction. Our HSA-linked payment cards are exempt from this rule, although we are subject to a general requirement of reasonable compensation for services rendered. To the extent that our payment cards lose their exempt status, the interchange rates applicable to transactions involving our payment cards could be impacted, which could have a material adverse effect on our financial condition and results of operations.
Failure to comply with, or changes in, payment card industry, credit card association or other network rules or standards set by Visa or MasterCard, or changes in card association and debit network fees or products or interchange rates, could materially adversely affect us.
We, and the banks that issue our prepaid debit cards, are subject to Payment Card Industry Data Security Standards and Visa and MasterCard association rules that could subject us to a variety of fines or penalties that may be levied by the card associations or networks for acts or omissions by us or businesses that work with us, including card processors. Failure to comply with these rules and standards could result in significant fines, other penalties, or the termination of our interchange revenue agreements. The termination of the card association registrations held by us or any of the banks that issue our cards, or any changes in card association or other debit network rules or standards, including interpretation and implementation of existing rules, participants deciding to use PIN networks, standards or guidance that increase the cost of doing business or limit our ability to provide our products and services, or limit our ability to receive interchange fees, could have a material adverse effect on our results of operations, financial condition, business, and prospects. In addition, from time-to-time, card associations increase the organization or processing fees that they charge, which could increase our operating expenses, reduce our profit margin and materially adversely affect our results of operations, financial condition, business, and prospects.

-20-

We are subject to complex regulation, and any compliance failures or regulatory action could adversely affect our business.
Our business, including HSAs and many of the CDBs we administer and our investment adviser and trust company subsidiaries, is subject to extensive, complex, and frequently changing federal and state laws and regulations, including IRS, Health and Human Services (“HHS”), and Department of Labor (“DOL”) regulations; ERISA, HIPAA, HITECH, and other privacy and data security regulations; the Advisers Act; state banking laws; state third-party administrator laws; the Patient Protection and Affordable Care Act; and developing regulation regimes for the use of AI.
Our subsidiary HealthEquity Advisors, LLC is an SEC-registered investment adviser that provides automated web-only investment advisory services. As such, it must comply with the requirements of the Advisers Act and related SEC regulations and is subject to periodic inspections by the SEC staff. Such requirements relate to, among other things, fiduciary duties to clients, disclosure obligations, recordkeeping and reporting requirements, marketing restrictions, limitations on agency cross and principal transactions between the adviser and its clients, and general anti-fraud prohibitions. The SEC is authorized to institute proceedings and impose sanctions for violations of the Advisers Act, ranging from fines and censure to termination of an investment adviser’s registration. Investment advisers also are subject to certain state securities laws and regulations.
Our subsidiary HealthEquity Trust Company is a non-depository trust company and subject to regulation and supervision by the Wyoming Division of Banking.
As we continue to innovate and improve our products and services by leveraging automated decision making, machine learning and AI, our business model may be affected by global trends and laws that regulate the use of these developing technologies. Such laws or regulations may restrict or impose burdensome and costly requirements on our ability to use AI and machine learning and also may impact our ability to use certain data for developing our products and services.
Compliance with regulatory requirements requires resources and takes significant time and effort. Any claim of non-compliance, regardless of merit or ultimate outcome, could subject us to investigation by the HHS, the DOL, the SEC, the Wyoming Division of Banking, or other regulatory authorities. This in turn could result in additional claims or class action litigation brought on behalf of our members, Clients or Network Partners, any of which could result in substantial cost to us and divert management’s attention and other resources away from our operations. Furthermore, investor perceptions of us may suffer, and this could cause a decline in the market price of our common stock. Our compliance processes may not be sufficient to prevent assertions that we failed to comply with any applicable law, rule or regulation. In addition, all of our business is subject, to varying degrees, to fiduciary and other service provider obligations under ERISA, the Internal Revenue Code, and underlying regulations. A failure to comply could subject us to disgorgement of profits, excise taxes, civil penalties, private lawsuits, and other costs, including reputational harm.
If we are unable to meet or exceed the net worth test required by the IRS, we could be unable to maintain our non-bank custodian status.
As a non-bank custodian, we are required to comply with Treasury Regulations Section 1.408-2(e), including the net worth requirements set forth therein. If we should fail to comply with the Treasury Regulations’ non-bank custodian requirements, including the net worth requirements, such failure would materially and adversely affect our ability to maintain our current custodial accounts and grow by adding additional custodial accounts, and it could result in the institution of procedures for the revocation of our authorization to operate as a non-bank custodian.
Risks relating to our service and culture
Any failure to offer high-quality customer support services could adversely affect our relationships with our members, Clients, and Network Partners and our operating results.
Our customers depend on our support and customer education organizations to educate them about, and resolve technical issues relating to, our products and services. We may be unable to respond quickly enough to accommodate short-term increases in customer demand for education and support services. Increased customer demand for these services, without a corresponding increase in revenue, could increase costs and adversely affect our operating results. In addition, as substantially all of our team members in our support and customer education areas now work remotely, it is more difficult to train and manage these team members, which could adversely affect the service we provide.
Our sales process is highly dependent on the reputation of our products, services, and business and on positive recommendations from our existing customers. Further, we use third-party service providers for certain call centers
-21-

and COBRA claims and transaction processing, including certain offshore service providers for member chat service, which service providers may not provide the same quality of support services for our Clients and members. Any failure to maintain high-quality education and technical support, or a market perception that we do not maintain high-quality education support, could adversely affect our reputation, our ability to sell our products and services to existing and prospective customers and our business and operating results. We promote 24/7/365 education and support along with our proprietary technology platforms. Interruptions or delays that inhibit our ability to meet that standard have in the past hurt our reputation and ability to attract and retain customers, and such interruptions or delays in the future would likely also do so.
We rely on our management team and team members and our business could be harmed if we are unable to retain qualified personnel.
Our success depends, in part, on the skills, working relationships and continued services of our executive leadership team and other key personnel. While we have entered into employment agreements with our executive officers, all of our team members are “at-will” employees, and their employment can be terminated by us or them at any time, for any reason, and without notice, subject, in certain cases, to severance payment rights. In order to retain valuable team members, in addition to salary and cash incentives, we provide equity-based awards that vest over time or based on performance. The value to team members of these awards will be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract offers from other organizations. The departure of key personnel could adversely affect the conduct of our business. In such event, we would be required to hire other personnel to manage and operate our business, and there can be no assurance that we would be able to employ a suitable replacement for the departing individual, or that a replacement could be hired on terms that are favorable to us. Volatility or lack of performance in our stock price may affect our ability to attract replacements should key personnel depart.
Our success also depends on our ability to attract, retain, and motivate additional skilled management personnel and other team members. For example, competition for qualified personnel in our field is intense due to the limited number of individuals who possess the skills and experience required by our industry. New hires require significant training and, in most cases, take significant time before they achieve full productivity. New team members may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. If our retention efforts are not successful or our team member turnover rate increases in the future, our business, results of operations and financial condition could be materially and adversely affected.
If we cannot maintain our corporate culture as we grow, we could lose the innovation, teamwork, passion, and focus on execution that we believe contribute to our success.
We believe that a critical component to our success has been our corporate culture. We have invested substantial time and resources in building our team. As we continue to grow, including through the integration of team members joining us through our acquisitions, we have found it difficult to maintain these important aspects of our corporate culture. In addition, it is difficult to instill our culture in our now predominantly remote workforce. Any failure to preserve our culture could negatively affect our future success, including our ability to retain and recruit personnel and to effectively focus on and pursue our corporate objectives.
Risks relating to our partners and service providers
If our Network Partners choose to partner with other providers of, or otherwise reduce offering or cease to offer, our products and services, our business could be materially and adversely affected.
Our business increasingly depends on our Network Partners’ willingness to partner with us to offer their customers and/or employees our products and services. In particular, certain of our Network Partners enjoy significant market share in various geographic regions. In other geographies, we have multiple Network Partners that compete against each other for the same business, which at times results in our inability to bid for certain business or in us upsetting a Network Partner that we choose not to partner with in a certain bid or that expects us to bid exclusively with them. If these Network Partners choose to instead partner with our competitors, or otherwise reduce offering, or cease to offer, our products and services, our results of operations, business, and prospects could be materially adversely affected.
A change in relationship with any of our bank identification number sponsors, or the failure by these sponsors to comply with certain banking regulations, could materially and adversely affect our business.
We rely on a limited number of bank identification number ("BIN") sponsors in relation to the payment cards we issue. A BIN sponsor is a bank or credit union that provides the BIN that allows a prepaid card program to run on one of the major card brand networks (e.g., VISA, MasterCard, Discover or American Express). Our BIN sponsors enable us to link the payment cards that we offer our members to the VISA and Mastercard networks, thereby
-22-

allowing our members to use our payment cards to pay for expenses with a “swipe” of the card. If any material adverse event were to affect our BIN sponsors, including a significant decline in the financial condition of any of our BIN sponsors, a decline in the quality of service provided by our BIN sponsors, the inability of our BIN sponsors to comply with applicable banking and financial service regulatory requirements or industry standards, systems failure or the inability of our BIN sponsors to pay us fees, our business, financial condition, and results of operations could be materially and adversely affected because we may be forced to reduce the availability of, or eliminate entirely, our payment card offering, which would materially impact our interchange revenue. In addition, we do not have long-term contracts with our BIN sponsors, and our BIN sponsors may increase the fees charged to us or terminate our relationship. If we were required to change BIN sponsors, we could not accurately predict the success of such change or that the terms of our agreement with a new BIN sponsor would be as favorable to us, especially in light of the regulatory scrutiny of the payment card industry, which has rendered the market for BIN sponsor services less competitive.
Replacing our third-party service providers would be difficult and disruptive to our business.
We have entered into contracts with third-party service providers to provide critical services relating to our business, including the redesign of our technology platforms, fraud management and other customer verification services, transaction processing and settlement, telephony services, call centers and card production. In the past, certain of these service providers have failed to maintain adequate levels of support, did not provide high quality service to us and our members, increased the fees they charge us, discontinued their lines of business, terminated our contractual arrangements or ceased or reduce operations, and as a result, we suffered additional costs and were required to pursue new third-party relationships, which resulted in reputational harm, material disruption of our operations and our ability to provide our products and services, missed service-level agreements with Clients and Network Partners, and diverted management’s time and resources, and these events and consequences could happen with our current service providers moving forward. Transitioning to a new service provider often takes a significant amount of time and resources and, if we are unable to complete a transition to a new provider on a timely basis, or at all, we could be forced to temporarily or permanently discontinue certain services, such as our payment card services, which could disrupt services to our customers and adversely affect our business, financial condition, and results of operations. We may also be unable to establish comparable new third-party relationships on as favorable terms or at all, which could materially and adversely affect our business, financial condition, and results of operations.
Growth-related risks
Our acquisition strategy may not be successful.
We have in the past acquired, and, as a key part of our strategy, seek to acquire or invest in, assets, businesses, products, or technologies that we believe would complement or expand our products and services, enhance our technical capabilities, or otherwise offer growth opportunities. There is no assurance that we will be successful in consummating such acquisitions, or even if consummated, realize the anticipated benefits of these or any future acquisitions. The pursuit of potential acquisitions has in the past, and may in the future, divert the attention of management and cause us to incur various expenses related to identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated.
Acquisitions also increase the risk of unforeseen legal liability, including for potential violations of applicable law or industry rules and regulations, arising from prior or ongoing acts or omissions by the acquired businesses that are not discovered by due diligence during the acquisition process. Generally, if an acquisition fails to meet our expectations, our operating results, business, and financial condition may suffer. Certain of our past acquisitions also resulted in dilutive issuances of equity securities and the incurrence of additional debt, and future acquisitions could result in additional dilutive issuances of equity securities or the incurrence of additional debt, which could adversely affect our business, results of operations, or financial condition.
Failure to manage future growth effectively could have a material adverse effect on our business, financial condition, and results of operations.
The continued rapid expansion and development of our business has placed a significant strain upon our management and administrative, operational, and financial infrastructure. As of January 31, 2024, we had approximately 8.7 million HSAs and $25.2 billion in HSA Assets representing growth of 9% and 14%, respectively, from January 31, 2023. Our growth strategy contemplates further increasing the number of our HSAs, CDBs and our HSA Assets at relatively higher growth rates than industry averages. However, the rate at which we have been able to add new HSAs, CDBs and HSA Assets in the past may not be indicative of the rate at which we will be able to grow in the future.
-23-

Our success depends in part upon the ability of our executive officers to manage growth effectively. Our ability to grow also depends upon our ability to successfully hire, train, supervise, and manage new team members, obtain financing for our capital needs, expand our systems effectively, control increasing costs, allocate our human resources optimally, maintain clear lines of communication between our operational functions and our finance and accounting functions, and manage the pressures on our management and administrative, operational, and financial infrastructure. There can be no assurance that we will be able to accurately anticipate and respond to the changing demands we will face as we continue to expand our operations or that we will be able to manage growth effectively or to achieve further growth at all. If our business does not continue to grow or if we fail to effectively manage any future growth, our business, financial condition, and results of operations could be materially and adversely affected.
We may not accurately estimate the impact on our business of developing, introducing, and updating new and existing products and services.
We intend to continue to invest in technology and development to create new and enhanced products and services to offer our customers and to enhance the capabilities of our platforms. We may not be able to anticipate or manage new risks and obligations or legal, compliance, or other requirements that may arise in these areas. The anticipated benefits of such new and improved products and services may not outweigh the costs and resources associated with their development. Some new services may be received negatively by our existing and/or potential customers and strategic partners and have to be put on hold or canceled entirely.
Our ability to attract and retain new customer revenue from existing customers will depend in large part on our ability to enhance and improve our existing products and services and to introduce new products and services. The success of any enhancement or new product or service depends on several factors, including the timely completion, introduction, and market acceptance of the enhancement or new product or service. Any new product or service we develop or acquire may not be introduced in a timely or cost-effective manner and may not achieve the broad market acceptance necessary to earn significant revenue. If we are unable to successfully develop or acquire new products or services or enhance our existing products or services to meet member or network partner requirements, our results of operations, financial condition, business or prospects may be materially adversely affected.
We may need to record write-downs from future impairments of identified intangible assets and goodwill.
Our consolidated balance sheet includes significant intangible assets, including approximately $1.65 billion in goodwill and $835.9 million in intangible assets, together representing approximately 79% of our total assets as of January 31, 2024. The determination of related estimated useful lives and whether these assets are impaired involves significant judgments. We test our goodwill for impairment each fiscal year, but we also test goodwill and other intangible assets for impairment at any time when there is a change in circumstances that indicates that the carrying value of these assets may be impaired. This is particularly relevant to us given our recent acquisition history and the amount of goodwill and intangible assets on our balance sheet associated with those acquisitions. Any future determination that these assets are carried at greater than their fair value could result in substantial non-cash impairment charges, which could significantly impact our reported operating results.
Financing and related risks
Our substantial debt could limit our ability to fund operations, expose us to interest rate volatility, limit our ability to raise additional capital and have a material adverse effect on our ability to fulfill our obligations under our Credit Agreement and Indenture and to our Network Partners, Clients and members.
We are party to a credit agreement (the "Credit Agreement"), which consists of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $350 million (the "Term Loan Facility") and (ii) a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $1 billion. We have also issued $600 million of 4.50% unsecured Senior Notes due 2029 (the "Notes"). Under the Credit Agreement, we have the right to request additional commitments for new term loans and increases to then-existing term loans and revolving credit commitments in an amount up to the sum of (i) $300 million, plus (ii) an unlimited additional amount so long as the pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) does not exceed 3.85 to 1.00 (assuming any such new or increased revolving commitments are fully borrowed). We also have the right to incur additional debt from time to time, subject to the restrictions contained in the Credit Agreement and the indenture under which the Notes were issued (the "Indenture"). The substantial debt we have outstanding, combined with our other financial obligations and contractual commitments, has important consequences, including the following:
our level of debt may make it more difficult for us to satisfy our obligations with respect to our debt, and any failure to comply with the obligations under any of our debt instruments, including restrictive covenants,
-24-

could result in an event of default under the Credit Agreement or the Indenture and the agreements governing such other debt;
we use a portion of our cash flow from operations to pay principal and interest on our debt, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, strategic acquisitions, investments and alliances and other general corporate requirements;
our interest expense has increased substantially, and could continue to increase, if interest rates continue to increase, because any outstanding borrowings under our Credit Facilities are based on variable interest rates;
the interest rate on our Revolving Credit Facility will depend on the level of our specified financial ratios, and therefore could increase if such specified financial ratios increase;
such substantial debt could leave us vulnerable to general economic downturns and adverse competitive and industry conditions and could place us at a competitive disadvantage compared to those of our competitors that are less leveraged;
our debt service obligations could limit our flexibility to plan for, or react to, changes in our business and the industry in which we operate;
our level of debt may restrict us from raising additional financing on satisfactory terms to fund working capital, capital expenditures, strategic acquisitions, investments and joint ventures and other general corporate requirements;
our level of debt may prevent us from raising the funds necessary to repurchase all of the Notes tendered to us upon the occurrence of a change of control, which would constitute an event of default under the Indenture; and
a potential failure to comply with the financial and other restrictive covenants in any of our debt instruments, which, among other things, require us to maintain specified financial ratios, could, if not cured or waived, have a material adverse effect on our ability to fulfill our obligations under the Notes and on our business and prospects generally.
The Indenture and the Credit Agreement contain covenants that impose significant operational and financial restrictions on us, and the failure to comply with these covenants would result in an event of default under these instruments.
The Indenture and the Credit Agreement impose on us operating and other restrictions. These restrictions affect, and in many respects limit or prohibit, among other things, our ability to:
incur additional debt and issue certain capital stock;
create liens;
make investments or acquisitions;
enter into transactions with affiliates;
sell assets;
guarantee debt;
declare or pay dividends or other distributions to shareholders;
repurchase equity interests;
redeem debt that is subordinated in right of payment to certain debt instruments;
enter into agreements that restrict dividends or other payments from subsidiaries; and
consolidate, merge or transfer all or substantially all of our assets and the assets of our subsidiaries on a consolidated basis.
The terms of the Revolving Credit Facility in the Credit Agreement also require us to achieve and maintain compliance with specified financial ratios. The restrictions contained in the Credit Agreement:
limit our ability to plan for or react to market conditions or meet capital needs or otherwise restrict our activities or business plans; and
adversely affect our ability to finance our operations, strategic acquisitions, investments or alliances or other capital needs or to engage in other business activities that would be in our interest.
A breach of any of these restrictive covenants or our inability to comply with the required financial ratios would result in a default under some or all of the debt agreements. During the occurrence and continuance of a default, lenders under our Credit Facilities may elect to declare all outstanding borrowings, together with accrued interest and other fees, to be immediately due and payable, which would result in an event of default under the Indenture. The lenders will also have the right in these circumstances to terminate any commitments they have to provide further borrowings. Additionally, our Credit Agreement contains a cross-default provision, which generally causes a default or event of default under the Credit Agreement upon a qualifying default or event of default under any other debt instrument (including under the Indenture) and the Indenture contains a cross-acceleration provision. If we are
-25-

unable to repay outstanding borrowings when due, the lenders under our Credit Facilities will also have the right to proceed against the collateral granted to them to secure the debt. If lenders under the Credit Facilities accelerate the debt thereunder, then the obligations under the Notes would be accelerated. We cannot provide assurance that, if the indebtedness under our Credit Facilities or the Notes were to be accelerated, our assets would be sufficient to repay in full that indebtedness and our other indebtedness. If not cured or waived, such acceleration could have a material adverse effect on our business and our prospects.
General risk factors
Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable.
Certain provisions in our governing documents could make a merger, tender offer or proxy contest involving us difficult; even if such events would be beneficial to the interests of our stockholders. These provisions include the inability of our stockholders to act by written consent and certain advance notice procedures with respect to stockholder proposals and nominations for candidates for the election of directors. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law which, subject to certain exceptions, prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Accordingly, our board of directors could rely upon these or other provisions in our governing documents and Delaware law to prevent or delay a transaction involving a change in control of our company, even if doing so would benefit our stockholders.
The exclusive forum provision in our amended and restated certificate of incorporation could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or team members.
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim for breach of a fiduciary duty owed by any of our directors and officers to us or our stockholders, any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim governed by the internal affairs doctrine. The choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other team members, which may discourage such lawsuits against us and our directors, officers, and other team members. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.
Item 1B. Unresolved staff comments
None.
Item 1C. Cybersecurity
Overview
Cybersecurity risk is the risk of compromising the confidentiality, integrity, or availability of our technology platforms, data, and other systems, which could have an adverse impact on us, our members, Clients, and Network Partners. We take a strategic, risk-based approach to our cybersecurity program, which emphasizes continual improvement in an effort to protect and enable our business operations. Our enterprise cybersecurity program is designed to assess, identify, and manage cybersecurity threats through continuous monitoring of our information systems for potential vulnerabilities and through various controls and security tools designed to prevent, detect, escalate, investigate, resolve, and recover from identified and reasonably anticipated vulnerabilities, including any cybersecurity incidents, in a timely manner.
In the event a security risk is detected, or a breach occurs, we are prepared with response protocols based on National Institute of Standards & Technology ("NIST") guidelines. Our Security Incident Response Plan defines roles and responsibilities, incident severity levels, key contacts, post-incident steps, and guidelines for testing. Our procedures cover response steps for phishing attacks, ransomware, data breaches, and major vulnerabilities. In addition, we have an organic threat model that evaluates our security controls to help protect against attacker tactics, techniques, and procedures. See “Risk Factors” in Part I, Item 1A of this Form 10-K for further information about cybersecurity risk.
-26-

Risk management and strategy
We have implemented the Three Lines of Defense Model as the foundation of our risk management approach. Our information security team serves as a First Line, working with our Enterprise Risk Management & Compliance functions as a Second Line, and our Internal Audit function as the Third Line.
Cybersecurity is integrated into our operations, including through team member engagement, technology infrastructure, data fabric, and product development. Due to the sensitive nature of our customers’ data that we hold, we have a heightened focus on data security and protection. We maintain administrative, technical, and physical safeguards designed to protect confidential data. Our security team seeks to identify security risks by working with state and federal law enforcement, security information-sharing organizations, and 24/7 system surveillance through internal and external detection and response teams. Additionally, to help ensure our approach to customer privacy and security is effective and in line with industry standards, we publish Service and SOC 2 attestation reports on our risk management standards established by the Statement on Standards for Attestation Engagements 18 (SSAE-18).
We regularly engage external and internal assessors and auditors to evaluate and audit our cybersecurity policies, procedures, standards, and practices. Results from these assessments are shared with management for remediation and with the Cybersecurity and Technology Committee of our board of directors on a regular basis. We have obtained, or are working toward obtaining, industry certifications and attestations and have aligned our cybersecurity program with the NIST Cybersecurity Framework and related controls.
As part of our Partner Security Risk Management program, we perform initial risk assessments prior to engaging third-party service providers and ongoing risk assessments annually thereafter, which follow an established process designed to identify, assess, and periodically review our exposure to risk through our partners.
During the fiscal year ended January 31, 2024, no known cybersecurity threats materially affected, or we believe are reasonably likely to materially affect, our business, our business strategy, financial reporting, or results of operations.
Governance
The Cybersecurity and Technology Committee of our board of directors provides oversight of the Company’s cybersecurity threat landscape, risks and data security programs, and the Company’s management and mitigation of cybersecurity risks and potential breach incidents. The Audit and Risk Committee of our board of directors provides an additional layer of cybersecurity oversight, as it provides oversight of the Company’s enterprise risk management program, which includes management of cybersecurity risks and the potential fraud and privacy risks that could arise from a cybersecurity incident.
The Chief Security Officer (CSO) and his delegates meet with the Cybersecurity and Technology Committee at least quarterly to, among other items, review any cybersecurity incidents, review key risks and metrics on the Company’s cybersecurity program and related risk management programs, and discuss the Company’s cybersecurity programs and goals. The Cybersecurity and Technology Committee also participates in cybersecurity tabletop exercises with management and receives training on cybersecurity trends and developments. The Cybersecurity and Technology Committee updates the full board of directors at each quarterly board meeting, or more frequently if needed.
Our enterprise cybersecurity program is led by the CSO who oversees both information technology and information security functions. Our CSO brings more than 20 years of cybersecurity experience in various leadership positions, both in technology and finance industries. He holds a doctorate degree from the University of Michigan and holds over 100 US and global security-related patents. In order to assess and manage our material risks from cybersecurity threats, our CSO works with cross-functional teams, which are staffed with subject matter experts and leaders from each of the following areas:
Cybersecurity: We follow a defense-in-depth security model with a Joint Security Operations Center (JSOC), Attack Surface Management, and Data Protection team working with security architects and engineers deploying controls designed to prevent or limit the success of an attack.
Privacy and Governance: Our Data Privacy and Governance team helps our technology teams build a lasting roadmap to creating our products, services, and standards with privacy by design, and transparency at the forefront.
People Safety and Crisis Management: Led by federal law enforcement veterans, our People and Partner Safety team is responsible for ensuring the security of our team members across the US. We also conduct regular tabletop exercises to ensure we are ready to respond to crises, including cybersecurity incidents.
-27-

Fraud Prevention: Our Fraud Strategy and Prevention team leverages industry best practices of fraud prevention, identity and access management, and cybersecurity monitoring to protect the transactions of our members and Clients.
Item 2. Properties
We do not currently own any of our facilities. Our principal executive offices are located in Draper, Utah, and we lease additional office space in Texas. Since a majority of our workforce is now permanently working remotely, we no longer use portions of our office space and we have subleased, or are seeking opportunities to sublease, these offices.
Item 3. Legal proceedings
From time-to-time, we may be subject to various legal proceedings and claims that arise in the normal course of our business activities. Our wholly owned subsidiary, WageWorks, is party to certain pending material litigation. Except for such matters, as of the date of this Annual Report on Form 10-K, we were not a party to any litigation whereby the outcome of such litigation, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations, cash flows or financial position. For a description of these legal proceedings, see Note 7—Commitments and contingencies of the Notes to consolidated financial statements.
Item 4. Mine safety disclosures
Not applicable.
-28-

Part II.
Item 5. Market for registrant's common equity, related stockholder matters and issuer purchases of equity securities
Market information
Our common stock is listed on the NASDAQ Global Select Market under the symbol "HQY."
Holders
As of March 13, 2024, there were 23 holders of record of our common stock. This stockholder figure does not include a substantially greater number of holders whose shares are held of record by banks, brokers, and other financial institutions.
Dividend policy
We have no current plans to pay dividends on our common stock. Any decision to declare and pay dividends in the future will be made at the sole discretion of our board of directors and will depend on, among other things, our results of operations, cash requirements, financial condition, contractual restrictions, and other factors that our board of directors may deem relevant.
-29-

Performance graph
This performance graph shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
The following graph compares the cumulative total return of our common stock with the total return of the NASDAQ Composite Index (the "NASDAQ Composite"), the Russell 2000 Index (the "Russell 2000"), and the Russell 3000 Index (the "Russell 3000") from January 31, 2019 through January 31, 2024. Beginning with our Form 10-K for the fiscal year ended January 31, 2024, we changed one of our benchmark indexes from the Russell 3000 to the Russell 2000, as we believe that the Russell 2000 is more representative of our median peer group market capitalization. Data for the Russell 3000 is provided for comparison purposes only as we transition to use of the Russell 2000. The chart assumes $100 was invested on January 31, 2019 in the common stock of HealthEquity, Inc., the NASDAQ Composite, the Russell 2000, and the Russell 3000, and assumes reinvestment of any dividends. The stock price performance on the following graph is not necessarily indicative of future stock price performance.
1752
Unregistered sales of equity securities
None.
Purchases of equity securities by the issuer and affiliated purchasers
None.




-30-

Item 6. Reserved

Item 7. Management’s discussion and analysis of financial condition and results of operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those discussed in the section titled “Risk factors” included under Part I, Item 1A and elsewhere in this report. See “Special note regarding forward-looking statements” on page 1 of this Annual Report.
Overview
We are a leader and an innovator in providing technology-enabled services that empower consumers to make healthcare saving and spending decisions. We use our innovative technology to manage consumers' tax-advantaged HSAs and other CDBs offered by employers, including FSAs and HRAs, and to administer COBRA, commuter and other benefits. As part of our services, we provide consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings.
The core of our offerings is the HSA, a financial account through which consumers spend and save long-term for healthcare expenses on a tax-advantaged basis. As of January 31, 2024, we administered 8.7 million HSAs, with balances totaling $25.2 billion, which we call HSA Assets, as well as 7.0 million complementary CDBs. We refer to the aggregate number of HSAs and other CDBs that we administer as Total Accounts, of which we had 15.7 million as of January 31, 2024.
We reach consumers primarily through relationships with their employers, which we call Clients. We reach Clients primarily through relationships with benefits brokers and advisors, integrated partnerships with a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan recordkeepers, which we call Network Partners, and a sales force that calls on Clients directly. As of January 31, 2024, our platforms were integrated with more than 200 Network Partners.
We have increased our share of the growing HSA market from 4% in December 2010 to 20% as of June 2023, measured by HSA Assets. According to Devenir, as of June 2023, we were the largest HSA provider by both accounts and HSA Assets. In addition, we believe we are the largest provider of other CDBs. We seek to differentiate ourselves through our service-driven culture, product breadth, ecosystem connectivity, and proprietary technology. Our proprietary technology allows us to help consumers optimize the value of their HSAs and other CDBs and gain confidence and skills in managing their healthcare costs as part of their financial security.
Our ability to assist consumers is enhanced by our capacity to securely share data in both directions with others in the health, benefits, and retirement ecosystems. Our commuter benefits offering also leverages connectivity to an ecosystem of mass transit, ride hailing, and parking providers.
We earn revenue primarily from three sources: service, custodial, and interchange. We earn service revenue mainly from fees paid by our Network Partners, Clients, and members for the administration services we provide in connection with the HSAs and other CDBs we offer. We earn custodial revenue primarily from HSA cash held by our federally insured bank and credit union partners, which we collectively call our Depository Partners, HSA cash held by our insurance company partners, and Client-held funds deposited with our Depository Partners. We earn interchange revenue mainly from fees paid by merchants on payments that our members make using our physical payment cards and on our virtual payment system. See “Key components of our results of operations” for additional information on our sources of revenue.
Recent acquisitions
Luum acquisition. In March 2021, we bolstered our commuter offering by acquiring 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum. The aggregate purchase price for the acquisition consisted of $56.2 million in cash. Luum provides employers with various commuter services, including access to real-time commute data, to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits.
-31-

Fifth Third Bank HSA portfolio acquisition. In September 2021, we acquired the Fifth Third HSA portfolio, which consisted of $490.0 million of HSA Assets held in approximately 160,000 HSAs in exchange for a purchase price of $60.8 million in cash.
Further acquisition. In November 2021, we acquired the Further business (other than Further's voluntary employee beneficiary association business), a leading provider of HSA and other CDB administration services, with approximately 580,000 HSAs and $1.9 billion of HSA Assets, for $455 million in cash. We expect merger integration expenses attributable to the Further Acquisition totaling approximately $55 million to be incurred over a period of approximately five to six years from the acquisition date.
HealthSavings HSA portfolio acquisition. In March 2022, we acquired the HealthSavings HSA portfolio, which consisted of $1.3 billion of HSA Assets held in approximately 87,000 HSAs in exchange for a purchase price of $60 million in cash.
BenefitWallet HSA portfolio acquisition. In September 2023, we entered into an agreement to acquire the BenefitWallet HSA portfolio from Conduent Business Services, LLC, for a purchase price of $425.0 million and reimbursement of up to $20.0 million of Conduent's transfer-related expenses. In addition, we expect to incur approximately $7.0 million of transaction costs associated with the acquisition. The agreement contemplates a transfer of approximately 665,000 customer accounts and their approximately $2.8 billion of HSA Assets and includes a mechanism to adjust the purchase price based on the amount of HSA Assets actually transferred. The transfer is expected to close in multiple tranches during the first half of fiscal 2025, subject to the satisfaction of certain customary closing conditions. We expect to pay approximately 50% of the purchase price and associated costs using cash on hand, with the remainder paid using our revolving credit facility with the actual percentages to be determined in connection with the payment for each tranche. On March 7, 2024, the first of the three HSA Asset transfers occurred, with approximately 266,000 HSAs and $1.1 billion of HSA Assets transferring to HealthEquity’s custody. In connection with this transfer, HealthEquity paid the applicable purchase price of $163.9 million using cash on hand.
Key factors affecting our performance
We believe that our future performance will be driven by a number of factors, including those identified below. Each of these factors presents both significant opportunities and significant risks to our future performance. See also the section entitled “Risk factors” included in Part 1, Item 1A of this Annual Report on Form 10-K and our other reports filed with the SEC.
Our acquisition and integration strategy
We have historically acquired HSA portfolios and businesses that strengthen our service offerings. We plan to continue this growth strategy, including through the BenefitWallet HSA portfolio acquisition, and are regularly engaged in evaluating different opportunities. We have developed an internal capability to source, evaluate, and integrate acquired HSA portfolios. Our success depends in part on our ability to successfully integrate acquired businesses and HSA portfolios with our business in an efficient and effective manner.
Structural change in U.S. health insurance
We derive revenue primarily from healthcare-related saving and spending by consumers in the U.S., which are driven by changes in the broader healthcare industry, including the structure of health insurance. The average family premium for employer-sponsored health insurance has risen by 22% since 2018 and 47% since 2013, resulting in increased participation in HSA-qualified health plans and HSAs and increased consumer cost-sharing in health insurance more generally. We believe that continued growth in healthcare costs and related factors will spur continued growth in HSA-qualified health plans and HSAs and may encourage policy changes making HSAs or similar vehicles available to new populations such as individuals in Medicare. However, the timing and impact of these and other developments in U.S. healthcare are uncertain. Moreover, changes in healthcare policy, such as "Medicare for all" plans, could materially and adversely affect our business in ways that are difficult to predict.
Trends in U.S. tax law
Tax law has a profound impact on our business. Our offerings to members, Clients, and Network Partners consist primarily of services enabled, mandated, or advantaged by provisions of U.S. tax law and regulations. Changes in tax policy are speculative and may affect our business in ways that are difficult to predict.


-32-

Our client base
Our business model is based on a B2B2C distribution strategy, whereby we work with Network Partners and Clients to reach consumers to increase the number of our members with HSA accounts and complementary CDBs. We believe that there are significant opportunities to expand the scope of services that we provide to our current Clients.
Broad distribution footprint
We believe we have a diverse distribution footprint to attract new Clients and Network Partners. Our sales force calls on enterprise and regional employers in industries across the U.S., as well as potential Network Partners from among health plans, benefits administrators, and retirement plan record keepers. Our Network Partners are a key channel through which we gain access to Clients and members. Our Network Partners collectively employ thousands of sales representatives and account managers who promote both the Network Partners' products and our products and services. Our sales representatives and account management teams work with and train the sales representatives and account management teams of our Network Partners.
Product breadth
We are the largest custodian and administrator of HSAs, as well as a market-share leader in each of the major categories of complementary CDBs, including FSAs and HRAs, COBRA and commuter benefits administration. Our Clients and their benefits advisors increasingly seek HSA providers that can deliver an integrated offering of HSAs and complementary CDBs. With our CDB capabilities, we can provide employers with a single partner for both HSAs and complementary CDBs, which is preferred by the vast majority of employers, according to research conducted for us by Aite Group. We believe that the combination of HSA and complementary CDB offerings significantly strengthens our value proposition to employers, health benefits brokers and consultants, and Network Partners as a leading single-source provider.
Interest rates
As a non-bank custodian, our members’ custodial HSA cash assets are held by either our federally insured Depository Partners (our Basic Rates offering), pursuant to contractual arrangements we have with these Depository Partners, or by our insurance company partners through group annuity contracts or other similar arrangements (our Enhanced Rates offering). For the reasons described below, we have been taking steps to encourage our members to place more of their HSA cash in our Enhanced Rates offering. Beginning in the fiscal year ending January 31, 2025, as our Basic Rates contracts expire, the HSA cash held in those Basic Rates contracts will transition to Enhanced Rates contracts, subject to our members retaining the right to keep their HSA cash in Basic Rates.
The lengths of our agreements with Depository Partners typically range from three to five years and may have fixed or variable interest rate terms. The terms of new and renewing agreements with our Depository Partners are impacted by the then-prevailing interest rate environment, which in turn is driven by macroeconomic factors and government policies over which we have no control. Such factors, and the response of our competitors to them, also determine the amount of interest retained by our members.
HSA members who place their HSA cash into our Enhanced Rates offering retain a higher yield compared to our Basic Rates offering. An increase in the percentage of HSA cash held in our Enhanced Rates offering also positively impacts our custodial revenue, as we generally receive a higher yield on HSA cash held by our insurance company partners compared to cash held by our Depository Partners. As with our Depository Partners, yields paid by our insurance company partners are impacted by the prevailing interest rate environment, which in turn is driven by macroeconomic factors and government policies over which we have no control. Such factors, and the response of our competitors to them, also determine the amount of interest retained by our members.
We believe that increased participation in our Enhanced Rates offering, diversification of Depository Partners and insurance company partners, varied contract terms, and other factors reduce our exposure to short-term fluctuations in prevailing interest rates and mitigate the short-term impact of sustained increases or declines in prevailing interest rates on our custodial revenue. Over longer periods, sustained shifts in prevailing interest rates affect the amount of custodial revenue we can realize on custodial assets and the interest retained by our members.
Interest on our Term Loan Facility changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates. Recent interest rate increases have caused interest expense related to our Term Loan Facility to increase substantially.

-33-

Our proprietary technology
We believe that innovations incorporated in our technology differentiate us from our competitors and help drive our growth by enabling us to better assist consumers to make healthcare saving and spending decisions and maximize the value of their tax-advantaged benefits. Our full suite of CDB offerings complements our HSA solution and enhances our leadership position within the HSA sector. We are currently investing in a significant modernization of our proprietary technology platforms to support new opportunities and enhance security, privacy and platform infrastructure, while maintaining existing applications, features, and services. For example, we are making significant investments in the architecture and infrastructure of the technology that we use to provide our services to improve our transaction processing capabilities and support continued account and transaction growth, as well as in data-driven personalized engagement to help our members spend less, save more, and build wealth for retirement. In addition, we are investing in technology solutions to meet the evolving needs of our members, Clients and Network Partners. Our current innovation efforts include, among others, increasing member and client self-service capabilities, developing APIs, driving electronic communication rather than paper, increasing straight-through processing, improving overall process times utilizing both traditional robotic process automation, and increasingly through AI tools, leveraging stacked cards, and mobile wallet.
Our Purple culture
A successful healthcare consumer needs education and guidance delivered by people as well as by technology. The education and customer service we provide is driven by our Purple culture, which we believe is a significant factor in our ability to attract and retain customers and to address opportunities in the rapidly changing healthcare sector. We invest in and intend to continue to invest in human capital through technology-enabled training, career development, and advancement opportunities.
Our competition and industry
Our direct competitors are HSA custodians and other CDB providers. Many of these are state or federally chartered banks and other financial institutions for which we believe benefits administration services are not a core business. Some of our direct competitors (including healthcare service companies such as UnitedHealth Group's Optum, Webster Bank, and well-known retail investment companies, such as Fidelity Investments) are in a position to devote more resources to the development, sale, and support of their products and services than we have at our disposal. Our other CDB administration competitors include health insurance carriers, human resources consultants and outsourcers, payroll providers, national CDB specialists, regional third-party administrators, and commercial banks. In addition, numerous indirect competitors, including benefits administration service providers, partner with banks and other HSA custodians to compete with us. Our Network Partners and ecosystem partners may also choose to offer competitive services directly, as some health plans have done. Our success depends on our ability to predict and react quickly to these and other industry and competitive dynamics.
Regulatory environment
Federal law and regulations, including the Affordable Care Act, the Internal Revenue Code, the Employee Retirement Income Security Act and Department of Labor regulations, and public health regulations that govern the provision of health insurance and provide the tax advantages associated with our services, play a pivotal role in determining our market opportunity. Privacy and data security-related laws such as the Health Insurance Portability and Accountability Act, or HIPAA, and the Gramm-Leach-Bliley Act, laws governing the provision of investment advice to consumers, such as the Investment Advisers Act of 1940, or the Advisers Act, the USA PATRIOT Act, anti-money laundering laws, and the Federal Deposit Insurance Act, all play a similar role in determining our competitive landscape. In addition, state-level regulations also have significant implications for our business in some cases. For example, our subsidiary HealthEquity Trust Company is regulated by the Wyoming Division of Banking, and several states are considering, or have already passed, new privacy regulations that can affect our business. Various states also have laws and regulations that impose additional restrictions on our collection, storage, and use of personally identifiable information. Privacy regulation in particular has become a priority issue in many states, including, for example, the California Privacy Rights Act, which became effective on January 1, 2023. Our ability to predict and react quickly to relevant legal and regulatory trends and to correctly interpret their market and competitive implications is important to our success.
Key financial and operating metrics
We regularly review a number of key operating and financial metrics to evaluate our business, determine the allocation of our resources, make decisions regarding corporate strategies, and evaluate forward-looking projections and trends affecting our business. We discuss certain of these key financial metrics, including revenue, below in the
-34-

section entitled “Key components of our results of operations.” In addition, we utilize other key metrics as described below.
For a discussion related to key financial and operating metrics for fiscal year 2023 compared to fiscal year 2022, refer to Part II, Item 7. Management's discussion and analysis of financial condition and results of operations in our fiscal year 2023 Form 10-K, filed with the SEC on March 30, 2023.
Total Accounts
The following table sets forth our HSAs, CDBs, and Total Accounts as of and for the periods indicated:
(in thousands, except percentages)January 31, 2024January 31, 2023% Change
HSAs8,692 7,984 %
New HSAs from sales - Quarter-to-date497 445 12 %
New HSAs from sales - Year-to-date949 971 (2)%
New HSAs from acquisitions - Year-to-date— 90 (100)%
HSAs with investments610 541 13 %
CDBs7,006 6,933 %
Total Accounts15,698 14,917 %
Average Total Accounts - Quarter-to-date15,318 14,677 %
Average Total Accounts - Year-to-date15,105 14,531 %
The number of our HSAs and CDBs are key metrics because our revenue is driven by the amount we earn from them. The number of our HSAs increased by 0.7 million, or 9%, from January 31, 2023 to January 31, 2024, driven by new HSAs from sales. The number of our CDBs increased by 0.1 million, or 1%, from January 31, 2023 to January 31, 2024, primarily driven by an increase in HRA and commuter accounts, partially offset by a decrease in COBRA accounts.
HSA Assets
The following table sets forth HSA Assets as of and for the periods indicated:
(in millions, except percentages)January 31, 2024January 31, 2023% Change
HSA cash$15,006 $14,199 %
HSA investments10,208 7,947 28 %
Total HSA Assets25,214 22,146 14 %
Average daily HSA cash - Quarter-to-date14,210 13,375 %
Average daily HSA cash - Year-to-date$14,071 $13,049 %
HSA Assets includes our HSA members’ custodial assets, which consists of the following components: (i) HSA cash, which includes member cash held by our Depository Partners and our insurance company partners, and (ii) HSA investments, which includes member investments held by our custodial investment partners. Measuring HSA Assets is important because our custodial revenue is directly affected by average daily custodial balances for HSA Assets that are revenue generating.
HSA cash increased by $0.8 billion, or 6%, from January 31, 2023 to January 31, 2024, due to net HSA contributions from new and existing HSA members, partially offset by transfers to HSA investments.
HSA investments increased by $2.3 billion, or 28%, from January 31, 2023 to January 31, 2024, due to the increased market value of invested balances and transfers from HSA cash.
Total HSA Assets increased by $3.1 billion, or 14%, from January 31, 2023 to January 31, 2024, primarily due to net HSA contributions from new and existing HSA members and the increased market value of invested balances.





-35-

The following table summarizes the amount of HSA cash held by our Depository Partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of January 31, 2024:
Year ending January 31, (in billions, except percentages)HSA cash expected to repriceAverage annualized yield
2025$2.1 3.6 %
20263.5 1.6 %
20273.2 1.6 %
20281.9 3.8 %
Thereafter3.6 3.5 %
Total (1)$14.3 2.7 %
(1)Excludes $0.7 billion of HSA cash held in floating-rate contracts as of January 31, 2024. BenefitWallet HSA Assets and any subsequent growth in HSA cash are also excluded.
Client-held funds
(in millions, except percentages)January 31, 2024January 31, 2023% Change
Client-held funds$842 $901 (7)%
Average daily Client-held funds - Quarter-to-date791 809 (2)%
Average daily Client-held funds - Year-to-date845 827 %
Client-held funds are interest-earning deposits from which we generate custodial revenue. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of CDBs. We deposit the Client-held funds with our Depository Partners in interest-bearing demand deposit accounts that have a floating interest rate and no set term or duration. Client-held funds fluctuate depending on the timing of funding and spending of CDB balances and the number of CDBs we administer.
Adjusted EBITDA
We define Adjusted EBITDA, which is a non-GAAP financial metric, as earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items. We believe that Adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and our board of directors because it reflects operating profitability before consideration of non-operating expenses and non-cash expenses and serves as a basis for comparison against other companies in our industry.
The following table presents a reconciliation of net income (loss), the most comparable GAAP financial measure, to Adjusted EBITDA for the periods indicated:
Year ended January 31,
(in thousands)20242023
Net income (loss)$55,712 $(26,143)
Interest income(12,138)(1,763)
Interest expense55,455 48,424 
Income tax provision (benefit)19,328 (11,953)
Depreciation and amortization60,315 66,615 
Amortization of acquired intangible assets92,763 94,586 
Stock-based compensation expense77,151 62,614 
Merger integration expenses10,435 28,596 
Acquisition costs— 53 
Amortization of incremental costs to obtain a contract5,435 4,393 
Costs associated with unused office space4,179 4,958 
Other538 1,968 
Adjusted EBITDA$369,173 $272,348 
-36-

The following table sets forth our net income (loss) as a percentage of revenue:
Year ended January 31,
(in thousands, except percentages)20242023$ Change% Change
Net income (loss)$55,712 $(26,143)$81,855 *
As a percentage of revenue%(3)%
*Not meaningful
Our net income (loss) increased by $81.9 million, from net loss of $26.1 million for the fiscal year ended January 31, 2023 to net income of $55.7 million for the fiscal year ended January 31, 2024, due to an increase in gross profit and other income, net, partially offset by net increases in operating expenses and income tax provision, as described more fully in the section entitled "Results of operations."
The following table sets forth our Adjusted EBITDA as a percentage of revenue:
Year ended January 31,
(in thousands, except percentages)20242023$ Change% Change
Adjusted EBITDA$369,173 $272,348 $96,825 36 %
As a percentage of revenue37 %32 %
Our Adjusted EBITDA increased by $96.8 million, or 36%, from $272.3 million for the fiscal year ended January 31, 2023 to $369.2 million for the fiscal year ended January 31, 2024, primarily due to an increase in total revenue, partially offset by increases in personnel-related costs.
Our use of Adjusted EBITDA, including as a percentage of revenue, has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.
-37-

Non-GAAP net income
Non-GAAP net income is calculated by adding back to GAAP net income (loss) before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate. We believe that non-GAAP net income and non-GAAP net income per diluted share provide useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and our board of directors because these non-GAAP metrics reflect operating profitability before consideration of certain non-operating expenses and non-cash expenses and serve as a basis for comparison against other companies in our industry.
The following table presents a reconciliation of net income (loss), the most comparable GAAP financial measure, to non-GAAP net income for the periods indicated:
Year ended January 31,
(in thousands, except per share data)20242023
Net income (loss)$55,712 $(26,143)
Income tax provision (benefit)19,328 (11,953)
Income (loss) before income taxes - GAAP75,040 (38,096)
Non-GAAP adjustments:
Amortization of acquired intangible assets92,763 94,586 
Stock-based compensation expense77,151 62,614 
Merger integration expenses10,435 28,596 
Acquisition costs— 53 
Costs associated with unused office space4,179 4,958 
Loss on extinguishment of debt1,157 — 
Total adjustments to income (loss) before income taxes - GAAP185,685 190,807 
Income before income taxes - Non-GAAP260,725 152,711 
Income tax provision - Non-GAAP (1)65,180 38,178 
Non-GAAP net income195,545 114,533 
Diluted weighted-average shares86,957 84,442 
GAAP net income (loss) per diluted share$0.64 $(0.31)
Non-GAAP net income per diluted share$2.25 $1.36 
(1)The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
Our non-GAAP net income increased by $81.0 million, or 71%, from $114.5 million for the fiscal year ended January 31, 2023 to $195.5 million for the fiscal year ended January 31, 2024, primarily due to an increase in total revenue, partially offset by increases in personnel-related costs and interest expense.
Our use of non-GAAP net income has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.
Key components of our results of operations
Revenue
We generate revenue from three primary sources: service revenue, custodial revenue, and interchange revenue.
Service revenue.    We earn service revenue from the fees we charge our Network Partners, Clients, and members for the administration services we provide in connection with the HSAs and other CDBs we offer. With respect to our Network Partners and Clients, our fees are generally based on a fixed tiered structure for the duration of the relevant service agreement and are paid to us on a monthly basis. In addition, once a member’s HSA cash balance
-38-

reaches a certain threshold, the member is able to invest his or her HSA Assets through our investment partner from which we earn recordkeeping and advisory fees, calculated as a percentage of the member's HSA investments. We recognize revenue on a monthly basis as services are rendered to our members and Clients.
Custodial revenue.    We earn custodial revenue primarily from HSA cash held by our Depository Partners or our insurance company partners and Client-held funds held by our Depository Partners. HSA cash is held by our Depository Partners pursuant to contracts that (i) typically have terms ranging from three to five years, (ii) provide for a fixed or variable interest rate payable on the average daily cash balances held by the relevant Depository Partner, and (iii) have minimum and maximum required balances. HSA cash held by our insurance company partners is held in group annuity contracts or similar arrangements. Client-held funds held by our Depository Partners are held in interest-bearing demand deposit accounts that have a floating interest rate and no set term or duration. We earn custodial revenue on HSA cash and Client-held funds that is based on the interest rates offered to us by these Depository Partners and insurance company partners.
Interchange revenue.    We earn interchange revenue each time one of our members uses one of our physical payment cards or virtual platforms to make a purchase. This revenue is collected each time a member “swipes” our payment card to pay expenses. We recognize interchange revenue monthly based on reports received from third parties, namely, the card-issuing banks and card processors.
Cost of revenue
Service costs.    Service costs are comprised of costs related to servicing accounts, managing Client and Network Partner relationships and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations (such as office rent, supplies, and other overhead expenses), new member and participant supplies, and other operating costs related to servicing our members.
Custodial costs.    Custodial costs are comprised of interest retained by our HSA members on HSA cash and fees we pay to banking consultants whom we use to help secure agreements with our Depository Partners. Interest retained by HSA members is calculated on a tiered basis. The interest rates retained by HSA members can change based on a formula or upon required notice.
Interchange costs.    Interchange costs are comprised of costs we incur in connection with processing payment transactions initiated by our members. Due to the substantiation requirement on FSA/HRA-linked payment card transactions, payment card costs are higher for FSA/HRA card transactions. In addition to fixed per card fees, we are assessed additional transaction costs determined by the amount of the transaction.
Gross profit and gross margin
Our gross profit is our total revenue minus our total cost of revenue, and our gross margin is our gross profit expressed as a percentage of our total revenue. Our gross margin has been and will continue to be affected by a number of factors, including interest rates, the amount we charge our Network Partners, Clients, and members, the mix of our sources of revenue, how many services we deliver per account, and payment processing costs per account.
Operating expenses
Sales and marketing.    Sales and marketing expenses consist primarily of personnel and related expenses for our sales and marketing staff, including sales commissions for our direct sales force, external agent/broker commission expenses, marketing expenses, depreciation, amortization, stock-based compensation, and common expense allocations.
Technology and development.    Technology and development expenses include personnel and related expenses for software development and delivery, licensed software, information technology, data management, product, and security. Technology and development expenses also include software engineering services, the costs of operating our technology infrastructure, depreciation, amortization of capitalized software development costs, stock-based compensation, and common expense allocations.
General and administrative.    General and administrative expenses include personnel and related expenses of, and professional fees incurred by our executive, finance, legal, internal audit, corporate development, compliance, and people departments. They also include depreciation, amortization, stock-based compensation, and common expense allocations.
Amortization of acquired intangible assets.    Amortization of acquired intangible assets results primarily from intangible assets acquired in connection with business combinations. The assets include acquired customer
-39-

relationships, acquired developed technology, and acquired trade names and trademarks, which we amortize over the assets' estimated useful lives, estimated to be 7-15 years, 2-5 years, and 3 years, respectively. We also acquired intangible HSA portfolios from third-party custodians. We amortize these assets over the assets’ estimated useful life of 15 years. We evaluate our acquired intangible assets for impairment annually, or at a triggering event.
Merger integration.    Merger integration expenses include personnel and related expenses, including severance, professional fees, legal expenses, and facilities and technology expenses directly related to integration activities to merge operations as a result of acquisitions.
Interest expense
Interest expense consists primarily of accrued interest expense and amortization of deferred financing costs associated with our long-term debt. Interest on our Term Loan Facility changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates.
Other income (expense), net
Other income (expense), net, consists of acquisition costs, interest income earned on corporate cash and other miscellaneous income and expense.
Income tax provision (benefit)
We are subject to federal and state income taxes in the United States based on a January 31 fiscal year end. We use the asset and liability method to account for income taxes, under which current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, net operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. As of January 31, 2024, we have not recorded a valuation allowance on federal deferred tax assets, but we have recorded a valuation allowance on certain state deferred tax assets. We maintain an overall net federal and state deferred tax liability on our consolidated balance sheet.
We evaluate our tax positions in accordance with Accounting Standards Codification (“ASC”) 740-10-25, Accounting for Uncertainty in Income Taxes, which prescribes a recognition threshold and measurement attribute for a tax position taken or expected to be taken in a tax return.
Results of operations
Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The reclassifications relate primarily to recordkeeping and advisory fees associated with HSA investments of $25.6 million, $21.8 million, and $16.7 million for the fiscal years ended January 31, 2024, 2023, and 2022, respectively, which were reclassified from custodial revenue to service revenue to better align our financial statement presentation with the underlying drivers of our revenue streams. We also reclassified certain immaterial personnel-related costs from custodial costs to service costs or general and administrative costs. The reclassifications had no impact on our total revenue, income (loss) from operations, net income (loss), cash flows, or stockholders' equity.
Revenue
The following table sets forth our revenue for the periods indicated:
Year ended January 31,2023 to 20242022 to 2023
(in thousands, except percentages)202420232022$ change% change$ change% change
Service revenue$455,690 $452,026 $443,608 $3,664 %$8,418 %
Custodial revenue386,594 261,282 186,119 125,312 48 %75,163 40 %
Interchange revenue157,303 148,440 126,829 8,863 %21,611 17 %
Total revenue$999,587 $861,748 $756,556 $137,839 16 %$105,192 14 %
-40-

Service revenue. The $3.7 million, or 1%, increase in service revenue from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to an increase in administration fees earned with respect to HSAs and recordkeeping and advisory fees earned with respect to HSA investments, partially offset by lower fees with respect to FSA and COBRA accounts.
The $8.4 million, or 2%, increase in service revenue from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to new revenue from the Further Acquisition and our HSA portfolio acquisitions, an increase in administration fees earned with respect to HSAs and recordkeeping and advisory fees earned with respect to HSA investments, and increased revenue from HRA and commuter benefits administration, partially offset by non-recurring revenue related to COBRA benefits administration during the fiscal year ended January 31, 2022.
We expect service revenue to increase, primarily due to an increase in Total Accounts, partially offset by lower average service fees per account.
Custodial revenue. The $125.3 million, or 48%, increase in custodial revenue from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to an increase in average annualized yield from 1.90% for the fiscal year ended January 31, 2023 to 2.49% for the fiscal year ended January 31, 2024 (due to both higher interest rates overall and increased participation in our Enhanced Rates offering), the $1.0 billion, or 8%, increase in the average daily balance of HSA cash, as described above, and an increase in interest rates on the portion of our Client-held funds held by our Depository Partners in interest-bearing demand deposit accounts that have a floating interest rate.
The $75.2 million, or 40%, increase in custodial revenue from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to the $2.5 billion, or 23%, increase in the average daily balance of HSA cash, as described above, and an increase in average annualized yield from 1.75% for the fiscal year ended January 31, 2022 to 1.90% for the fiscal year ended January 31, 2023 (due to both higher interest rates overall and increased participation in our Enhanced Rates offering).
Assuming the current interest rate environment continues, we expect our average annualized yield on HSA cash to further increase as our existing agreements with our Depository Partners are renewed or replaced with agreements with higher rates, resulting in higher custodial revenue. In addition, we expect an increase in the percentage of HSA cash held in our Enhanced Rates offering to continue to positively impact our average annualized yield and thus our custodial revenue. As Basic Rates contracts mature, we intend to transfer the associated HSA cash into Enhanced Rates contracts unless the HSA member affirmatively opts to remain in the Basic Rates offering.
Interchange revenue. The $8.9 million, or 6%, increase in interchange revenue from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to an increase in Total Accounts.
The $21.6 million, or 17%, increase in interchange revenue from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to increased spend per account and an increase in Total Accounts.
Total revenue. Total revenue increased by $137.8 million, or 16%, from the year ended January 31, 2023 to the year ended January 31, 2024, primarily due to the increase in custodial revenue, as well as the increases in interchange and service revenues, described above.
Total revenue increased by $105.2 million, or 14%, from the year ended January 31, 2022 to the year ended January 31, 2023 due to the increases in custodial, interchange, and service revenues, described above.
Cost of revenue
The following table sets forth our cost of revenue for the periods indicated:
Year ended January 31,2023 to 20242022 to 2023
(in thousands, except percentages)202420232022$ change% change$ change% change
Service costs$317,357 $318,516 $291,618 $(1,159)%$26,898 %
Custodial costs32,502 26,101 19,492 6,401 25 %6,609 34 %
Interchange costs27,091 25,196 20,681 1,895 %4,515 22 %
Total cost of revenue$376,950 $369,813 $331,791 $7,137 %$38,022 11 %
Service costs. The $1.2 million, or less than 1%, decrease in service costs from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to efficiencies resulting from our technology investments and lower amortization expense, largely offset by increases in personnel-related costs to support the increase in average Total Accounts.
-41-

The $26.9 million, or 9%, increase in service costs from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to the inclusion of a full year of Further's results of operations and an increase in personnel-related costs to support the increase in average Total Accounts.
Custodial costs. The $6.4 million, or 25%, increase in custodial costs from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to an increase in the average annualized rate of interest retained by HSA members on HSA cash, which increased from 0.19% for the fiscal year ended January 31, 2023 to 0.22% for the fiscal year ended January 31, 2024, and the $1.0 billion, or 8% increase in the average daily balance of HSA cash, as described above.
The $6.6 million, or 34%, increase in custodial costs from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to an increase in the average daily balance of HSA cash, which increased from $10.6 billion for the fiscal year ended January 31, 2022 to $13.0 billion for the fiscal year ended January 31, 2023, and an increase in the average annualized rate of interest retained by HSA members on HSA cash, which increased from 0.17% for the fiscal year ended January 31, 2022 to 0.19% for the fiscal year ended January 31, 2023.
Assuming the current interest rate environment continues, we expect custodial costs to increase due to an increase in the average annualized rate of interest retained by HSA members on HSA cash and an increase in the year-over-year average daily balance of HSA cash.
Interchange costs. The $1.9 million, or 8%, increase in interchange costs from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to an increase in Total Accounts.
The $4.5 million, or 22%, increase in interchange costs from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to increased spend per account and an increase in Total Accounts.
Total cost of revenue. As we continue to add Total Accounts, we expect that our cost of revenue will increase in dollar amount to support our Network Partners, Clients, and members. However, on an annual basis, relative to the fiscal year ended January 31, 2024, we expect our cost of revenue to decrease as a percentage of our total revenue, primarily due to an increase in custodial revenue, partially offset by increases in stock-based compensation and other personnel costs. Cost of revenue will continue to be affected by a number of different factors, including our ability to scale our service delivery, Network Partner implementation, and account management functions.
Operating expenses
The following table sets forth our operating expenses for the periods indicated:
Year ended January 31,2023 to 20242022 to 2023
(in thousands, except percentages)202420232022$ change% change$ change% change
Sales and marketing$79,273 $68,849 $58,605 $10,424 15 %$10,244 17 %
Technology and development218,811 193,375 157,364 25,436 13 %36,011 23 %
General and administrative103,656 97,472 85,438 6,184 %12,034 14 %
Amortization of acquired intangible assets92,763 94,586 82,791 (1,823)(2)%11,795 14 %
Merger integration10,435 28,596 64,805 (18,161)(64)%(36,209)(56)%
Total operating expenses$504,938 $482,878 $449,003 $22,060 %$33,875 %
Sales and marketing. The $10.4 million, or 15%, increase in sales and marketing expenses from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to an increase in personnel-related expenses and travel costs.
The $10.2 million, or 17%, increase in sales and marketing expenses from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to the inclusion of a full year of Further's results of operations and an increase in personnel-related expenses and travel costs, partially offset by a decrease in advertising expenses.
We expect our sales and marketing expenses to increase for the foreseeable future as we continue to focus on our cross-selling program and marketing campaigns. On an annual basis, we expect our sales and marketing expenses to remain relatively steady as a percentage of our total revenue. However, our sales and marketing expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our sales and marketing expenses.

-42-

Technology and development. The $25.4 million, or 13%, increase in technology and development expenses from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to increases in personnel-related expenses and software costs.
The $36.0 million, or 23%, increase in technology and development expenses from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to the inclusion of a full year of Further's results of operations and increases in amortization and personnel-related expenses.
We expect our technology and development expenses to increase for the foreseeable future as we continue to invest in the development and security of our proprietary technology, including our ongoing modernization project described earlier. On an annual basis, we expect our technology and development expenses to remain relatively steady as a percentage of our total revenue. However, our technology and development expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our technology and development expenses.
General and administrative. The $6.2 million, or 6%, increase in general and administrative expenses from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to increases in professional services expense and personnel-related expenses, partially offset by a decrease in amortization expense.
The $12.0 million, or 14%, increase in general and administrative expenses from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to the inclusion of a full year of Further's results of operations and increases in personnel-related expenses and stock-based compensation.
We expect our general and administrative expenses to increase for the foreseeable future due to the additional demands on our legal, compliance, and finance functions as we continue to grow our business. On an annual basis, we expect our general and administrative expenses to remain relatively steady as a percentage of our total revenue. However, our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our general and administrative expenses.
Amortization of acquired intangible assets. The $1.8 million, or 2%, decrease in amortization of acquired intangible assets from the year ended January 31, 2023 to the year ended January 31, 2024 was due to the smaller carrying amount of intangible assets that have not been fully amortized.
The $11.8 million, or 14%, increase in amortization of acquired intangible assets from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to the inclusion of amortization related to identified intangible assets acquired through the Further Acquisition commencing November 1, 2021. The remainder of the increase was primarily due to amortization of acquired HSA portfolios, including the Fifth Third and HealthSavings HSA portfolios.
Merger integration. The $18.2 million, or 64%, decrease in merger integration expense from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to a decrease in merger integration activities related to the acquisitions of WageWorks and the Further business.
The $10.4 million in merger integration expense for the fiscal year ended January 31, 2024 was primarily due to personnel and related expenses, including expenses incurred in conjunction with the migration of accounts, professional fees, and technology-related expenses directly related to the Further acquisition and certain ongoing merger integration expenses related to the acquisition of WageWorks, including ongoing lease expense related to WageWorks offices that have been permanently closed, less any related sublease income, and professional fees. We expect merger integration expenses attributable to the Further acquisition totaling approximately $55 million to be incurred over a period of approximately five to six years from the date of the acquisition, which occurred in November 2021.
The $36.2 million, or 56%, decrease in merger integration expense from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to a decrease in merger integration activities related to the acquisition of WageWorks.
Interest expense
The $7.0 million increase in interest expense from the year ended January 31, 2023 to the year ended January 31, 2024 was primarily due to the impact of higher interest rates on our Term Loan Facility, which had an effective interest rate of 7.45% as of January 31, 2024, up from 7.14% as of January 31, 2023, and a $1.2 million loss on extinguishment of debt due to the prepayment of $50.0 million under our Term Loan Facility in April 2023, partially offset by a lower average principal balance under our Term Loan Facility. Our Term Loan Facility had an outstanding principal balance of $286.9 million and $341.3 million as of January 31, 2024 and January 31, 2023, respectively.
-43-

The $11.9 million increase in interest expense from the year ended January 31, 2022 to the year ended January 31, 2023 was primarily due to the impact of higher interest rates on our Term Loan Facility, which had an effective interest rate of 7.14% as of January 31, 2023, up from 2.63% as of January 31, 2022. Our Term Loan Facility had an outstanding principal balance of $341.3 million and $350.0 million as of January 31, 2023 and January 31, 2022, respectively.
On an annual basis, we expect our interest expense to increase, primarily due to the impact of borrowings under our Revolving Credit Facility in conjunction with the BenefitWallet HSA portfolio acquisition, which is expected to close in multiple tranches during the first half of fiscal 2025, and increased interest rates on our Term Loan Facility, partially offset by a lower average principal balance under our Term Loan Facility. The interest rate on our Term Loan Facility and Revolving Credit Facility is variable and, accordingly, we may incur additional expense if interest rates continue to increase in future periods.
Other income (expense), net
The $11.5 million increase in other income, net, from $1.3 million during the fiscal year ended January 31, 2023 to $12.8 million during the fiscal year ended January 31, 2024, was primarily due to a $10.4 million increase in interest income on corporate cash and a $1.2 million increase in other miscellaneous income, net.
The change in other income (expense), net, from expense of $5.9 million during the fiscal year ended January 31, 2022 to income of $1.3 million during the fiscal year ended January 31, 2023, was primarily due to a $10.8 million decrease in acquisition costs, partially offset by a $3.6 million decrease in other miscellaneous income, net.
Income tax provision (benefit)
For the fiscal years ended January 31, 2024 and 2023, we recorded an income tax provision of $19.3 million and an income tax benefit of $12.0 million, respectively. The increase in income tax provision was primarily the result of an increase in pre-tax book income, an increase in unrecognized tax benefits, adjustments from settlement of an IRS examination, and a decrease in tax deductible stock-based compensation compared to GAAP stock-based compensation expense, partially offset by an increase in research and development tax credits and a decrease in valuation allowance.
For the fiscal years ended January 31, 2023 and 2022, we recorded an income tax benefit of $12.0 million and $22.5 million, respectively. The decrease in income tax benefit was primarily the result of lower current year pre-tax book loss, a corresponding decrease in benefit for state income taxes, a decrease in research and development tax credits, a decrease in excess tax benefits on stock-based compensation expense, and an increase in nondeductible executive compensation, partially offset by a release of uncertain tax positions and a smaller change in valuation allowance.
Seasonality
Seasonal concentration of our growth combined with our recurring revenue model create seasonal variation in our results of operations. Revenue results are seasonally impacted due to ancillary service fees, timing of HSA contributions, and timing of card spend. Cost of revenue is seasonally impacted as a significant number of new and existing Network Partners bring us new HSAs and CDBs beginning in January of each year concurrent with the start of many employers’ benefit plan years. Before we realize any revenue from these new accounts, we incur costs related to implementing and supporting our new Network Partners and new accounts. These costs of services relate to activating accounts and hiring additional staff, including seasonal help to support our member support center. These expenses begin to ramp up during our third fiscal quarter, with the majority of seasonal expenses incurred in our fourth fiscal quarter.
Liquidity and capital resources
For a discussion related to liquidity and capital resources for fiscal year 2023 compared to fiscal year 2022, refer to Part II, Item 7. Management's discussion and analysis of financial condition and results of operations in our fiscal year 2023 Form 10-K, filed with the SEC on March 30, 2023.
Cash and cash equivalents overview
Our principal sources of liquidity are our current cash and cash equivalents balances, collections from our service, custodial, and interchange revenue activities, and availability under our Revolving Credit Facility. We rely on cash provided by operating activities to meet our short-term liquidity requirements, which primarily relate to the payment of corporate payroll and other operating costs, principal and interest payments on our long-term debt, and capital expenditures.
-44-

As of January 31, 2024 and January 31, 2023, cash and cash equivalents were $404.0 million and $254.3 million, respectively.
Capital resources
We maintain a “shelf” registration statement on Form S-3 on file with the SEC. A shelf registration statement, which includes a base prospectus, allows us at any time to offer any combination of securities described in the prospectus in one or more offerings. Unless otherwise specified in a prospectus supplement accompanying the base prospectus, we would use the net proceeds from the sale of any securities offered pursuant to the shelf registration statement for general corporate purposes, including, but not limited to, working capital, sales and marketing activities, general and administrative matters, capital expenditures, and repayment of indebtedness, and if opportunities arise, for the acquisition of, or investment in, assets, technologies, solutions or businesses that complement our business. Pending such uses, we may invest the net proceeds in interest-bearing securities. In addition, we may conduct concurrent or other financings at any time.
Our Credit Agreement includes a Revolving Credit Facility, in an aggregate principal amount of up to $1.0 billion, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments. For a description of the terms of the Credit Agreement, refer to Note 8—Indebtedness. In connection with the BenefitWallet HSA portfolio acquisition, which is expected to close in multiple tranches during the first half of fiscal 2025, we expect to borrow approximately 50% of the purchase price and related costs using our Revolving Credit Facility with the actual percentages to be determined in connection with the payment for each tranche.
As of January 31, 2024, there were no amounts outstanding under the Revolving Credit Facility. We were in compliance with all covenants under the Credit Agreement as of January 31, 2024, and for the period then ended.
Use of cash
In April 2023, we used $50.0 million of cash to prepay, in direct order of maturity, principal due under our Term Loan Facility.
Capital expenditures for the fiscal years ended January 31, 2024 and 2023 were $42.8 million and $48.5 million, respectively. We expect to continue our current level of capital expenditures during the fiscal year ending January 31, 2025 as we continue to invest in improving the architecture and functionality of our proprietary systems. Capital expenditures to improve the architecture of our proprietary systems include computer hardware, personnel and related costs for software engineering, and outsourced software engineering services.
We believe our existing cash, cash equivalents, and Revolving Credit Facility will be sufficient to meet our operating and capital expenditure requirements for at least the next 12 months. To the extent these current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may need to raise additional funds through public or private equity or debt financing. In the event that additional financing is required, we may not be able to raise it on favorable terms, if at all.
The following table shows our cash flows from operating activities, investing activities, and financing activities for the stated periods:
Year ended January 31,
(in thousands)20242023
 Net cash provided by operating activities$242,826 $150,650 
 Net cash used in investing activities(46,074)(119,127)
 Net cash used in financing activities(47,039)(2,671)
 Increase in cash and cash equivalents149,713 28,852 
Beginning cash and cash equivalents254,266 225,414 
Ending cash and cash equivalents$403,979 $254,266 
Cash flows from operating activities. Net cash provided by operating activities increased by $92.2 million, primarily due to increased cash receipts with respect to our custodial revenue, partially offset by an increase in cash payments for income taxes, personnel-related expenses, and interest expense during the fiscal year ended January 31, 2024.
Cash flows from investing activities. Net cash used in investing activities decreased by $73.1 million, due to a $67.3 million decrease in cash used for HSA portfolio acquisitions, a $4.1 million decrease in cash used for
-45-

purchases of software and capitalized software development costs, and a $1.7 million decrease in cash used for purchases of property and equipment.
Cash flows from financing activities. Net cash used in financing activities increased by $44.4 million, primarily due to a $45.6 million increase in principal payments related to our long-term debt.
Contractual obligations
See Note 7—Commitments and contingencies for information about our contractual obligations.
Off-balance sheet arrangements
As of January 31, 2024, other than outstanding letters of credit issued under our Revolving Credit Facility, we did not have any off-balance sheet arrangements. The standby letters of credit generally expire within one year. However, in the ordinary course of business, we will continue to renew or modify the terms of the letters of credit to support business requirements. The letters of credit are contingent liabilities, supported by our Revolving Credit Facility, and are not reflected on our consolidated balance sheets.
Critical accounting policies and significant management estimates
Our consolidated financial statements are prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances. In many instances, we could have reasonably used different accounting estimates, and in other instances, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ significantly from the estimates made by our management. To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected.
In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application, while in other cases, management’s judgment is required in selecting among available alternative accounting standards that allow different accounting treatment for similar transactions. We believe that there are several accounting policies that are critical to understanding our business and prospects for future performance, as these policies affect the reported amounts of revenue and other significant areas that involve management’s judgment and estimates. These significant policies and our procedures related to these policies are described in detail below.
Capitalized software development costs
We account for the costs of computer software developed or obtained for internal use in accordance with Accounting Standards Codification, or ASC, 350-40, Internal-Use Software. Costs incurred during operation and post-implementation stages are charged to expense. Costs incurred that are directly attributable to developing or obtaining software for internal use incurred in the application development stage are capitalized. Management’s judgment is required in determining the point when various projects enter the stages at which costs may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized.
Valuation of long-lived assets including goodwill and intangible assets
We allocate the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, discount rates and revenue growth rates, net of attrition, related to acquired customer relationships. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Allocation of purchase consideration to identifiable assets and liabilities affects our amortization expense, as acquired finite-lived intangible assets are amortized over the useful life, whereas any indefinite lived intangible assets, including goodwill, are not amortized. During the measurement period, which is not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.
-46-

We review goodwill for impairment at least annually or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. The Company’s annual goodwill impairment test resulted in no impairment charges in any of the periods presented in the accompanying consolidated financial statements.
Long-lived assets, including property and equipment and intangible assets are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such review indicates that the carrying amount of property and equipment and intangible assets is not recoverable, the carrying amount of such assets is reduced to fair value. We have not recorded any significant impairment charges during the years presented.
Recent accounting pronouncements
See Note 1—Summary of business and significant accounting policies within the financial statements included in this Form 10-K for further discussion.
Item 7A. Quantitative and qualitative disclosures about market risk
Market risk
Concentration of market risk. We derive a substantial portion of our revenue from providing services to tax-advantaged healthcare account holders. A significant downturn in this market or changes in state and/or federal laws impacting the preferential tax treatment of healthcare accounts such as HSAs could have a material adverse effect on our results of operations. During the fiscal years ended January 31, 2024, 2023, and 2022, no one customer accounted for greater than 10% of our total revenue. We monitor market and regulatory changes regularly and make adjustments to our business if necessary.
Inflation. Inflationary factors may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, the current high rate of inflation may have an adverse effect on our ability to maintain current levels of expenses as a percentage of revenue if our revenue does not correspondingly increase with inflation.
Concentration of credit risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents. We maintain our cash and cash equivalents in bank and other depository accounts, which frequently may exceed federally insured limits. Our cash and cash equivalents as of January 31, 2024 and 2023 were $404.0 million and $254.3 million, respectively, the vast majority of which was not covered by federal depository insurance. We have not experienced any material losses in such accounts. Our accounts receivable balance as of January 31, 2024 and 2023 was $104.9 million and $96.8 million, respectively. We have not experienced any significant write-offs to our accounts receivable and believe that we are not exposed to significant credit risk with respect to our accounts receivable. We continue to monitor our credit risk and place our cash and cash equivalents with reputable financial institutions.
Interest rate risk
HSA Assets and Client-held funds. HSA Assets consist of custodial HSA funds we hold in custody on behalf of our members. As of January 31, 2024 and 2023, we held in custody HSA Assets of $25.2 billion and $22.1 billion, respectively. As a non-bank custodian, we contract with our Depository Partners and insurance company partners to hold HSA cash on behalf of our members, and we earn a significant portion of our total revenue from interest paid to us by these partners. HSA cash held by our insurance company partners is held in group annuity contracts or similar arrangements. The lengths of our agreements with Depository Partners typically range from three to five years and have either fixed or variable interest rates. As HSA Assets increase and existing contracts with Depository Partners expire, we seek to enter into new contracts with Depository Partners and insurance company partners, the terms of which are impacted by the then-prevailing interest rate environment. We believe that increased participation in our Enhanced Rates offering, diversification of Depository Partners and insurance company partners, and varied contract terms, substantially reduces our exposure to short-term fluctuations in prevailing interest rates and mitigates the short-term impact of a sustained increase or decline in prevailing interest rates on our custodial revenue. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the interest rate yield, or yield, available to us and thus the amount of the custodial revenue we
-47-

can realize. Conversely, a sustained increase in prevailing interest rates can increase our yield. An increase in our yield would increase our custodial revenue as a percentage of total revenue. In addition, if our yield increases, we expect the spread to also increase between the interest offered to us by our Depository Partners and insurance company partners and the interest retained by our members, thus increasing our profitability. However, we may be required to increase the interest retained by our members in a rising prevailing interest rate environment. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control.
Client-held funds are interest earning deposits from which we generate custodial revenue. As of January 31, 2024 and 2023, we held Client-held funds of $842 million and $901 million, respectively. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of our other CDBs. These deposits are held with Depository Partners. We deposit the Client-held funds with our Depository Partners in interest-bearing demand deposit accounts that have a floating interest rate and no set term or duration. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the yield available to us and thus the amount of the custodial revenue we can realize from Client-held funds. Conversely, a sustained increase in prevailing interest rates may increase our yield. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control.
Cash and cash equivalents. We consider all highly liquid investments purchased with an original maturity of three months or less to be unrestricted cash equivalents. Our unrestricted cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market account that is unrestricted as to withdrawal or use. As of January 31, 2024 and 2023, we had unrestricted cash and cash equivalents of $404.0 million and $254.3 million, respectively. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our cash and cash equivalents as a result of changes in interest rates.
Long-term debt. As of January 31, 2024 and 2023, we had $286.9 million and $341.3 million, respectively, outstanding under our Term Loan Facility and no amounts drawn under our Revolving Credit Facility. In connection with the BenefitWallet HSA portfolio acquisition, which is expected to close in multiple tranches during the first half of fiscal 2025, we expect to borrow approximately 50% of the purchase price and related costs using our Revolving Credit Facility with the actual percentages to be determined in connection with the payment for each tranche. Our overall interest rate sensitivity under these credit facilities is primarily influenced by any amounts borrowed and the prevailing interest rates on these instruments. The stated interest rate on our Term Loan Facility and Revolving Credit Facility is variable and was 6.69% and 6.31% at January 31, 2024 and 2023, respectively. Accordingly, we may incur additional expense if interest rates increase in future periods. For example, a one percent increase in the interest rate on the amount outstanding under our credit facilities at January 31, 2024 would result in approximately $2.9 million of additional interest expense over the next 12 months. The interest rate on our $600 million of unsecured Senior Notes due 2029 is fixed at 4.50%.
-48-

Item 8. Financial statements and Supplementary Data

HealthEquity, Inc. and subsidiaries

-49-

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of HealthEquity, Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of HealthEquity, Inc. and its subsidiaries (the “Company”) as of January 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive income (loss), of stockholders’ equity and of cash flows for each of the three years in the period ended January 31, 2024, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of January 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of January 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended January 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of January 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's report on internal control over financial reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may
-50-

become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Service Revenue Recognition
As described in Note 1 to the consolidated financial statements, the Company's primary sources of revenue are service, custodial, and interchange revenue. The Company’s service revenue was $455.7 million for the year ended January 31, 2024. To generate service revenue, the Company administers its platforms, prepares statements, provides a mechanism for spending funds, and provides customer support services. All of these services are consumed as they are received. The Company recognizes service revenue, in an amount that reflects the consideration it expects to be entitled to in exchange for those services, on a monthly basis as it satisfies its performance obligations.
The principal consideration for our determination that performing procedures relating to service revenue recognition is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company’s revenue recognition.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the revenue recognition process for service revenue. These procedures also included, among others, evaluating the recognition of service revenue for a sample of revenue transactions by obtaining confirmation from customers or obtaining and inspecting source documents, including invoices, sales contracts, and cash receipts.

/s/ PricewaterhouseCoopers LLP
Salt Lake City, Utah
March 22, 2024
We have served as the Company’s auditor since 2013.



-51-

HealthEquity, Inc. and subsidiaries
Consolidated balance sheets
(in thousands, except par value)January 31, 2024January 31, 2023
Assets
Current assets
Cash and cash equivalents$403,979 $254,266 
Accounts receivable, net of allowance for doubtful accounts of $3,947 and $4,989 as of January 31, 2024 and 2023, respectively
104,893 96,835 
Other current assets48,564 31,792 
Total current assets557,436 382,893 
Property and equipment, net6,013 12,862 
Operating lease right-of-use assets48,380 56,461 
Intangible assets, net835,948 936,359 
Goodwill1,648,145 1,648,145 
Other assets67,868 52,180 
Total assets$3,163,790 $3,088,900 
Liabilities and stockholders’ equity
Current liabilities
Accounts payable$12,041 $13,899 
Accrued compensation49,608 45,835 
Accrued liabilities46,038 43,668 
Current portion of long-term debt 17,500 
Operating lease liabilities9,404 10,159 
Total current liabilities117,091 131,061 
Long-term liabilities
Long-term debt, net of issuance costs874,972 907,838 
Operating lease liabilities, non-current48,766 58,988 
Other long-term liabilities19,270 12,708 
Deferred tax liability68,670 82,665 
Total long-term liabilities1,011,678 1,062,199 
Total liabilities1,128,769 1,193,260 
Commitments and contingencies (see Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of January 31, 2024 and 2023
  
Common stock, $0.0001 par value, 900,000 shares authorized, 86,127 and 84,758 shares issued and outstanding as of January 31, 2024 and 2023, respectively
9 8 
Additional paid-in capital1,829,384 1,745,716 
Accumulated earnings205,628 149,916 
Total stockholders’ equity2,035,021 1,895,640 
Total liabilities and stockholders’ equity$3,163,790 $3,088,900 
The accompanying notes are an integral part of the consolidated financial statements.
-52-

HealthEquity, Inc. and subsidiaries
Consolidated statements of operations and comprehensive income (loss)
Year ended January 31,
(in thousands, except per share data)202420232022
Revenue
   Service revenue$455,690 $452,026 $443,608 
   Custodial revenue386,594 261,282 186,119 
   Interchange revenue157,303 148,440 126,829 
   Total revenue999,587 861,748 756,556 
 Cost of revenue
   Service costs317,357 318,516 291,618 
   Custodial costs32,502 26,101 19,492 
   Interchange costs27,091 25,196 20,681 
   Total cost of revenue376,950 369,813 331,791 
 Gross profit622,637 491,935 424,765 
 Operating expenses
   Sales and marketing79,273 68,849 58,605 
   Technology and development218,811 193,375 157,364 
   General and administrative103,656 97,472 85,438 
   Amortization of acquired intangible assets92,763 94,586 82,791 
Merger integration10,435 28,596 64,805 
   Total operating expenses504,938 482,878 449,003 
 Income (loss) from operations117,699 9,057 (24,238)
 Other expense
Interest expense(55,455)(48,424)(36,572)
   Other income (expense), net12,796 1,271 (5,931)
 Total other expense(42,659)(47,153)(42,503)
 Income (loss) before income taxes75,040 (38,096)(66,741)
 Income tax provision (benefit)19,328 (11,953)(22,452)
Net income (loss) and comprehensive income (loss)$55,712 $(26,143)$(44,289)
Net income (loss) per share:
 Basic$0.65 $(0.31)$(0.53)
 Diluted$0.64 $(0.31)$(0.53)
Weighted-average number of shares used in computing net income (loss) per share:
 Basic85,564 84,442 83,133 
 Diluted86,957 84,442 83,133 
The accompanying notes are an integral part of the consolidated financial statements.
-53-

HealthEquity, Inc. and subsidiaries
Consolidated statements of stockholders’ equity
Common stockAdditional
paid-in
capital
Accumulated earningsTotal
stockholders'
equity
(in thousands)SharesAmount
Balance as of January 31, 202177,168 $8 $1,158,372 $220,348 $1,378,728 
Issuance of common stock:
Issuance of common stock upon exercise of options, and for restricted stock862 — 8,746 — 8,746 
Other issuance of common stock5,750 — 456,640 — 456,640 
Stock-based compensation— — 52,750 — 52,750 
Net loss— — — (44,289)(44,289)
Balance as of January 31, 202283,780 $8 $1,676,508 $176,059 $1,852,575 
Issuance of common stock:
Issuance of common stock upon exercise of options, and for restricted stock978 — 6,594 — 6,594 
Stock-based compensation— — 62,614 — 62,614 
Net loss— — — (26,143)(26,143)
Balance as of January 31, 202384,758 $8 $1,745,716 $149,916 $1,895,640 
Issuance of common stock:
Issuance of common stock upon exercise of options, and for restricted stock1,369 1 6,517 — 6,518 
Stock-based compensation— — 77,151 — 77,151 
Net income— — — 55,712 55,712 
Balance as of January 31, 202486,127 $9 $1,829,384 $205,628 $2,035,021 
The accompanying notes are an integral part of the consolidated financial statements.
-54-

HealthEquity, Inc. and subsidiaries
Consolidated statements of cash flows
Year ended January 31,
(in thousands)202420232022
 Cash flows from operating activities:
 Net income (loss)$55,712 $(26,143)$(44,289)
 Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization153,078 161,201 137,188 
Stock-based compensation77,151 62,614 52,750 
Impairment of right-of-use assets  11,246 
Amortization of debt issuance costs2,852 3,261 4,448 
Loss on extinguishment of debt1,157  4,049 
Change in fair value of contingent consideration  (2,147)
Gains on equity securities  (1,677)
Other non-cash items 268 1,232 
Deferred taxes(13,995)(17,181)(23,430)
 Changes in operating assets and liabilities:
Accounts receivable(8,058)(9,570)(11,204)
Other assets (32,790)4,620 7,464 
Operating lease right-of-use assets10,190 8,244 15,235 
Accrued compensation2,951 (1,282)(3,657)
Accounts payable, accrued liabilities, and other current liabilities(204)(26,673)(2,178)
Operating lease liabilities, non-current(11,780)(7,232)(9,412)
Other long-term liabilities6,562 (1,477)5,377 
 Net cash provided by operating activities242,826 150,650 140,995 
 Cash flows from investing activities:
Business combinations, net of cash acquired  (504,533)
Purchases of software and capitalized software development costs(41,123)(45,173)(62,708)
Acquisitions of HSA portfolios(3,257)(70,583)(65,465)
Purchases of property and equipment(1,694)(3,371)(8,908)
Proceeds from sale of equity securities  2,367 
 Net cash used in investing activities(46,074)(119,127)(639,247)
 Cash flows from financing activities:
Principal payments on long-term debt(54,375)(8,750)(1,003,125)
Proceeds from long-term debt  950,000 
Payment of debt issuance costs  (11,920)
Proceeds from follow-on equity offering, net of payments for offering costs  456,640 
Settlement of client-held funds obligation, net865 (603)(486)
Proceeds from exercise of common stock options6,471 6,682 9,754 
Payment of contingent consideration  (6,000)
 Net cash provided by (used in) financing activities(47,039)(2,671)394,863 
 Increase (decrease) in cash and cash equivalents149,713 28,852 (103,389)
 Beginning cash and cash equivalents254,266 225,414 328,803 
 Ending cash and cash equivalents$403,979 $254,266 $225,414 
The accompanying notes are an integral part of the consolidated financial statements.

-55-

HealthEquity, Inc. and subsidiaries
Consolidated statements of cash flows (continued)
Year ended January 31,
(in thousands)202420232022
Supplemental cash flow data:
Interest expense paid in cash$49,560 $43,570 $16,107 
Income tax payments (refunds), net35,352 1,526 (5,632)
Supplemental disclosures of non-cash investing and financing activities:
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation3,145 3,595 4,640 
Purchases of property and equipment included in accounts payable or accrued liabilities263 69 1,414 
Acquisitions of HSA portfolios included in accounts payable or accrued liabilities  1,692 
Decrease (increase) in goodwill due to measurement period adjustments, net (2,309)19 
Exercise of common stock options receivable429 382 470 
The accompanying notes are an integral part of the consolidated financial statements.

-56-


HealthEquity, Inc. and subsidiaries
Notes to consolidated financial statements
Note 1. Summary of business and significant accounting policies
Business
HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
In February 2006, HealthEquity received designation by the U.S. Department of Treasury to act as a passive non-bank custodian, which allows HealthEquity to hold custodial assets for individual account holders. On July 24, 2017, HealthEquity received designation by the U.S. Department of Treasury to act as both a passive and non-passive non-bank custodian, which allows HealthEquity to hold custodial assets for individual account holders and use discretion to direct investment of such assets held. As a passive and non-passive non-bank custodian according to Treasury Regulations section 1.408-2(e)(5)(ii)(B), the Company must maintain net worth (assets minus liabilities) greater than the sum of 2% of passive custodial funds held at each fiscal year-end and 4% of the non-passive custodial funds held at each fiscal year-end in order to take on additional custodial assets. As of January 31, 2024, the Company's year-end for trust and tax purposes, the net worth of the Company exceeded the required thresholds.
The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States and have been consistently applied in the preparation of the consolidated financial statements.
Reclassifications
Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The reclassifications relate primarily to recordkeeping and advisory fees associated with HSA investments of $25.6 million, $21.8 million, and $16.7 million for the fiscal years ended January 31, 2024, 2023, and 2022, respectively, which were reclassified from custodial revenue to service revenue to better align the Company's financial statement presentation with the underlying drivers of the Company's revenue streams. The Company also reclassified certain immaterial personnel-related costs from custodial costs to service costs or general and administrative costs. The reclassifications had no impact on the Company's total revenue, income (loss) from operations, net income (loss), cash flows, or stockholders' equity. See Note 13—Selected quarterly financial data for additional information and the impact of the reclassifications by quarter.
Principles of consolidation
The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Segments
The Company operates in one segment, which reflects the way in which its chief operating decision maker, the Chief Executive Officer, reviews the Company's financial performance and makes decisions about resource allocation. All long-lived assets are maintained in the United States of America.
Cash and cash equivalents
The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company’s cash and cash equivalents were held in institutions in the U.S. and include deposits in a money market account that was unrestricted as to withdrawal or use.
Client-held funds
Many of the Company's client services agreements with employers (referred to as "Clients") provide that Clients remit funds to the Company to pre-fund Client and employee participant contributions related to flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs,” respectively) and commuter accounts.
-57-

These Client-held funds remitted to the Company do not represent cash assets of the Company to the extent that they are not combined with corporate cash, and accordingly are not included in cash and cash equivalents on the Company's consolidated balance sheets.
Accounts receivable
Accounts receivable represent monies due to the Company for monthly service revenue, custodial revenue and interchange revenue. The Company maintains an allowance for doubtful accounts to reserve for expected credit losses from trade receivables considering past events, current conditions, and reasonable and supportable forecasts of future economic conditions. In evaluating the Company’s ability to collect outstanding receivable balances, the Company considers various factors including macroeconomic variables, the age of the balance, the creditworthiness of the customer, which is assessed based on ongoing credit evaluations and payment history, and the customer’s current financial condition.
Other assets
Other assets consist primarily of contract costs, prepaid expenditures, debt issuance costs, income tax receivables, and various other assets. Amounts expected to be recouped or recognized over a period of twelve months or less have been classified as current in the accompanying consolidated balance sheets.
Leases
The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices.
Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.
Property and equipment
Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Depreciation is determined using the straight-line method over the estimated useful lives of individual assets. The useful life for leasehold improvements is the shorter of the estimated useful life or the term of the lease ranging from 3-5 years. The useful life used for computing depreciation for all other asset classes is described below:
Computer equipment
3-5 years
Furniture and fixtures5 years
Maintenance and repairs are expensed when incurred, and improvements that extend the economic useful life of an asset are capitalized. Gains and losses on the disposal of property and equipment are reflected in operating expenses.
Intangible assets, net
Intangible assets are carried at cost and amortized, typically, on a straight-line basis over their estimated useful lives. The useful life used for computing amortization for all intangible asset classes is described below:
Software and software development costs3 years
Acquired customer relationships
7-15 years
Acquired developed technology
2-5 years
Acquired trade names and trademarks3 years
Acquired HSA portfolios15 years
-58-

The Company accounts for the costs of computer software developed or obtained for internal use in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software. Costs incurred during operation and post-implementation stages are charged to expense. Costs incurred during the application development stage that are directly attributable to developing or obtaining software for internal use are capitalized. Management’s judgment is required in determining the point when various projects enter the stages at which costs may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized.
Acquired customer relationships, developed technology, and trade names and trademarks are valued utilizing the discounted cash flow method, a form of the income approach. The useful lives of acquired customer relationships were estimated based on discount rates and revenue growth rates, net of attrition. The useful lives of developed technology and trade names were estimated based on expected obsolescence. The Company expenses the assets straight-line over the useful lives and determined that this amortization method is appropriate to reflect the pattern over which the economic benefits of these acquired assets are realized.
Acquired HSA portfolios consist of the contractual rights to administer the activities related to the individual HSAs acquired. The Company used its HSA customer relationship period assumption and the historical attrition rates of member accounts to determine that an average useful life of 15 years and the use of a straight-line amortization method are appropriate to reflect the pattern over which the economic benefits of existing member assets are realized.
The Company reviews identifiable amortizable intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually on January 31 or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company’s impairment tests are based on a single operating segment and reporting unit structure. The goodwill impairment test involves a qualitative assessment to compare a reporting unit's fair value to its carrying value. If it is determined that it is more likely than not that a reporting unit's fair value is less than its carrying value, a quantitative comparison is made between the Company's market capitalization and the carrying value of the reporting unit, including goodwill. If the carrying value of the reporting unit exceeds its fair value, an impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value.
Self-insurance
The Company is self-insured for medical insurance up to certain annual stop-loss limits. The Company establishes a liability as of the balance sheet date for claims, both reported and incurred but not reported, using currently available information as well as historical claims experience, and as determined by an independent third party.
Other long-term liabilities
Other long-term liabilities consists of long-term deferred revenue and other liabilities that the Company does not expect to settle within one year.
Revenue recognition
The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services.
The Company determines revenue recognition through the following steps:
identification of the contract, or contracts, with a customer;
identification of the performance obligations in the contract;
determination of the transaction price;
allocation of the transaction price to the performance obligations in the contract; and
recognition of revenue when, or as, the Company satisfies a performance obligation.
Disaggregation of revenue. The Company's primary sources of revenue are service, custodial, and interchange revenue and are disclosed in the consolidated statements of operations and comprehensive income (loss). All of the
-59-

Company's sources of revenue are deemed to be revenue contracts with customers. Each revenue source is affected differently by economic factors as it relates to the nature, amount, timing and uncertainty.
Costs to obtain a contract. ASC 606, Revenue from contracts with customers, requires capitalizing the costs of obtaining a contract when those costs are expected to be recovered.
In order to determine the amortization period for sales commissions contract costs, the Company applied the portfolio approach. Accordingly, the amortization period of the assets has been determined to be the average economic life of an HSA or other CDB relationship, which is estimated to be 15 years and 7 years, respectively. Amortization of capitalized sales commission contract costs is included in sales and marketing expenses in the consolidated statements of operations and comprehensive income (loss). The Company has applied the practical expedient which allows an entity to account for incremental costs of obtaining a contract at a portfolio level. The Company has also applied the practical expedient to recognize incremental costs of obtaining contracts as an expense when incurred if the amortization period would have been one year or less.
Performance obligations. ASC 606 requires disclosure of the aggregate amount of the transaction price allocated to unsatisfied performance obligations; however, as permitted by ASC 606, the Company has elected to exclude from this disclosure any contracts with an original duration of one year or less and any variable consideration that meets specified criteria.
Service revenue. The Company administers its platforms, prepares statements, provides a mechanism for spending funds, and provides customer support services. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA assets through the Company's investment partner from which the Company earns recordkeeping and advisory fees, calculated as a percentage of the member's HSA investments. All of these services are consumed as they are received. The Company recognizes service revenue, in an amount that reflects the consideration it expects to be entitled to in exchange for those services, on a monthly basis as it satisfies its performance obligations.
Custodial revenue. The Company earns custodial revenue primarily from HSA assets deposited with depository partners or placed in group annuity contracts or similar arrangements with insurance company partners and Client-held funds deposited with depository partners. The placement of funds represents a service that is simultaneously received and consumed by the depository partners and insurance company partners. The Company recognizes custodial revenue each month, in an amount that reflects the consideration it expects to be entitled to in exchange for the service.
Interchange revenue. The Company satisfies its interchange performance obligation each time payments are made with its cards via payment networks. The Company recognizes interchange revenue, in an amount that reflects the consideration it expects to be entitled to in exchange for the service, in the month the payment transaction occurs.
Contract balances. The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied.
Significant judgments. The Company makes no significant judgments in determining the amount or timing of revenue recognition. The Company has estimated the average economic life of an HSA or CDB member relationship, which has been determined to be the amortization period for the capitalized sales commissions contract costs.
Cost of revenue
The Company incurs cost of revenue related to servicing member accounts, managing customer and partner relationships, and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations, new member and participant supplies, and other operating costs of the member account servicing departments. Other components of the Company’s cost of revenue include interest retained by members on custodial assets held and interchange costs incurred in connection with processing card transactions initiated by members.
Stock-based compensation
The Company grants restricted stock units ("RSUs") to certain team members, executive officers, and directors. Historically, the Company also granted stock options and restricted stock awards ("RSAs") under the Incentive Plan. The Company recognizes compensation expense for stock-based awards based on the grant date estimated fair
-60-

value. Expense for stock-based awards is generally recognized on a straight-line basis over the requisite service period and is reversed as pre-vesting forfeitures occur. The fair value of stock options was determined using the Black-Scholes option pricing model. The determination of fair value for stock options on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. The fair value of RSUs is based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate.
For stock-based awards with performance conditions, the Company evaluates the probability of achieving the performance criteria and of the number of shares that are expected to vest, and compensation expense is then adjusted to reflect the number of shares expected to vest and the requisite service period. For awards with performance conditions, compensation expense is recognized using the graded-vesting attribution method in accordance with the provisions of ASC 718, Compensation—Stock Compensation ("Topic 718"). Compensation expense related to stock-based awards with market conditions is recorded on a straight-line basis over the requisite service period regardless of whether the market condition is satisfied.
Upon the exercise of a stock option or release of an RSU, common shares are issued from authorized, but not outstanding, common stock.
Interest expense
Interest expense consists primarily of accrued interest expense and amortization of deferred financing costs associated with long-term debt.
Income tax provision (benefit)
The Company accounts for income taxes and the related accounts under the asset and liability method as set forth in ASC 740, Income Taxes. Under this method, current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, for net operating losses, and for tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. The effect on deferred tax assets and liabilities of changes in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for when it is more likely than not that some or all of the deferred tax assets may not be realized in future years.
The Company recognizes the tax benefit from an uncertain tax position taken or expected to be taken in a tax return using a two-step approach. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authorities, based on the technical merits of the position. For tax positions that are more likely than not to be sustained upon audit, the second step is to measure the tax benefit in the financial statements as the largest benefit that has a greater than 50% likelihood of being sustained upon settlement. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as a component of other income (expense), net in the consolidated statements of operations and comprehensive income (loss). Changes in facts and circumstances could have a material impact on the Company’s effective tax rate and results of operations.
Asset acquisitions
The Company routinely acquires rights to be the custodian of HSA portfolios, in which substantially all of the fair value of the gross portfolio assets acquired is concentrated in a group of similar HSA assets and therefore the acquisitions do not constitute a business. Accordingly, the acquisitions are accounted for under the asset acquisition method of accounting in accordance with ASC 805-50, Business Combinations—Related Issues. Under the asset acquisition method of accounting, the Company is required to fair value the assets transferred. The cost of the assets acquired, including transaction costs incurred in conjunction with an asset acquisition, is allocated to the individual assets acquired based on their relative fair values and does not give rise to goodwill.
Business combinations
Consideration paid for the acquisition of a business as defined by ASC 805-10 is allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date.
Acquisition-related expenses incurred in conjunction with the acquisition of a business are recognized in earnings in the period in which they are incurred and are included in other income (expense), net on the consolidated statements of operations and comprehensive income (loss).
-61-

Use of estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management has made estimates for the allowance for doubtful accounts, capitalized software development costs, evaluating goodwill and long-lived assets for impairment, useful lives of property and equipment and intangible assets, accrued compensation, accrued liabilities, grant date fair value of stock options and performance restricted stock units and restricted stock awards, and income taxes. Actual results could differ from those estimates.
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of other segment items, interim disclosure of a reportable segment’s profit or loss and assets, the title and position of the CODM, and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The ASU requires public companies with a single reportable segment to provide the segment disclosures required by Topic 280 and will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the ASU to determine its impact on our disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for annual periods beginning after December 15, 2024. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. We are currently evaluating the ASU to determine its impact on our income tax disclosures.
Note 2. Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
Year ended January 31,
(in thousands, except per share data)202420232022
Numerator (basic and diluted):
Net income (loss)$55,712 $(26,143)$(44,289)
Denominator (basic):
Weighted-average common shares outstanding85,564 84,442 83,133 
Denominator (diluted):
Weighted-average common shares outstanding85,564 84,442 83,133 
Weighted-average dilutive effect of stock options and restricted stock units1,393   
Diluted weighted-average common shares outstanding86,957 84,442 83,133 
Net income (loss) per share:
Basic $0.65 $(0.31)$(0.53)
Diluted$0.64 $(0.31)$(0.53)
For the fiscal years ended January 31, 2024, 2023 and 2022, 0.6 million, 2.5 million, and 1.8 million shares, respectively, attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted net income (loss) per share as their inclusion would have been anti-dilutive.
-62-

Note 3. Business combinations
Luum acquisition
On March 8, 2021, the Company acquired 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition"). The aggregate purchase price for the acquisition consisted of $56.2 million in cash, which reflects a $2.1 million reduction in the fair value of contingent consideration during the fiscal year ended January 31, 2022.
The Luum Acquisition was accounted for under the acquisition method of accounting for business combinations. The consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and was subject to adjustment during the measurement period (up to one year from the acquisition date). The purchase price allocation was finalized during the three months ended April 30, 2022.
The following table summarizes the Company's allocation of the consideration paid:
(in thousands)Estimated fair valueAdjustmentsUpdated Allocation
Cash and cash equivalents$626 $— $626 
Other current assets1,469 — 1,469 
Intangible assets23,900 — 23,900 
Goodwill36,374 (19)36,355 
Other assets100 — 100 
Current liabilities(597)— (597)
Deferred tax liability(3,566)19 (3,547)
Total consideration paid$58,306 $ $58,306 
The adjustments to the initial allocation were based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters.
Further acquisition
On November 1, 2021, the Company completed its acquisition of the Further business (other than Further's voluntary employee beneficiary association business) for $455 million (the "Further Acquisition").
The Further Acquisition was accounted for under the acquisition method of accounting for business combinations. The consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and was subject to adjustment during the measurement period (up to one year from the acquisition date). The purchase price allocation was finalized during the three months ended January 31, 2023.
The following table summarizes the Company's allocation of the consideration paid:
(in thousands)Estimated fair valueAdjustmentsUpdated Allocation
Current assets$2,667 $(163)$2,504 
Intangible assets172,183 — 172,183 
Goodwill282,287 2,309 284,596 
Current liabilities(2,137)(2,146)(4,283)
Total consideration paid$455,000 $ $455,000 
The adjustments to the initial allocation were based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters.



-63-

Note 4. Supplemental financial statement information
Selected consolidated balance sheet and consolidated statement of operations and comprehensive income (loss) components consisted of the following:
Allowance for doubtful accounts
As of January 31, 2024 and 2023, the Company had an allowance for doubtful accounts of $3.9 million and $5.0 million, respectively. During the fiscal years ended January 31, 2024, 2023, and 2022, the Company recorded credit losses from trade receivables of $1.7 million, $2.1 million, and $3.3 million, respectively.
Prepaid expenses
As of January 31, 2024 and 2023, the Company had prepaid expenses of $31.2 million and $20.1 million, respectively, which are included within other current assets on the Company's consolidated balance sheets.
Costs to obtain a contract
As of January 31, 2024 and 2023, the net amount capitalized as contract costs was $52.1 million and $44.0 million, respectively, which is included in other current assets and other assets. Amortization of capitalized contract costs during the fiscal years ended January 31, 2024, 2023, and 2022 was $5.4 million, $4.4 million, and $4.3 million, respectively.
Property and equipment
Property and equipment consisted of the following as of January 31, 2024 and 2023:
(in thousands)January 31, 2024January 31, 2023
Leasehold improvements$14,455 $18,269 
Furniture and fixtures7,087 8,392 
Computer equipment25,489 28,021 
Property and equipment, gross47,031 54,682 
Accumulated depreciation(41,018)(41,820)
Property and equipment, net$6,013 $12,862 
Depreciation expense for the fiscal years ended January 31, 2024, 2023 and 2022 was $8.8 million, $12.3 million and $14.7 million, respectively.
Contract balances
As of January 31, 2024 and 2023, the balance of deferred revenue was $6.2 million and $8.3 million, respectively. The balances are related to cash received in advance for interchange and custodial revenue arrangements, other up-front fees and other commuter deferred revenue. The Company expects to recognize approximately 77% of its balance of deferred revenue as revenue over the next 12 months and the remainder thereafter. Amounts expected to be recognized as revenue within a period of twelve months or less are classified as accrued liabilities in the Company's consolidated balance sheets, with the remainder included within other long-term liabilities. Revenue recognized during the fiscal year that was included in the beginning balance of deferred revenue was $4.8 million. The Company expects to satisfy its remaining obligations for these arrangements.
Other income (expense), net
Other income (expense), net, consisted of the following:
Year ended January 31,
(in thousands)202420232022
Interest income$12,138 $1,763 $1,501 
Gain on equity securities  1,692 
Acquisition costs (53)(10,832)
Other miscellaneous income (expense)658 (439)1,708 
Total other income (expense), net$12,796 $1,271 $(5,931)


-64-

Interest expense
Based on the application of ASC 470-50, Debt - Modifications and Extinguishments, the Company recorded debt extinguishment losses of $1.2 million and $4.0 million during the fiscal years ended January 31, 2024 and 2022, respectively, which are included within interest expense in the consolidated statements of operations and comprehensive income (loss).
Note 5. Leases
The Company has entered into various non-cancelable operating lease agreements for office space, data storage facilities, and other leases with remaining lease terms of less than 1 year to approximately 7 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 2 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option.
The components of operating lease costs were as follows:
Year ended January 31,
(in thousands)202420232022
Operating lease expense$9,437 $11,371 $14,762 
Sublease income(2,680)(2,187)(1,836)
Net operating lease cost$6,757 $9,184 $12,926 
Weighted average lease term and discount rate were as follows:
January 31, 2024January 31, 2023
Weighted average remaining lease term6.7 years7.5 years
Weighted average discount rate4.3 %4.3 %
Lease liabilities were as follows:
(in thousands)January 31, 2024January 31, 2023
Gross lease liabilities$67,269 $81,313 
Less: imputed interest(9,099)(12,166)
Present value of lease liabilities58,170 69,147 
Less: current portion of lease liabilities(9,404)(10,159)
Lease liabilities, non-current$48,766 $58,988 
As of January 31, 2024, the Company had an additional operating lease for office space that had not yet commenced with aggregate undiscounted lease payments of $1.9 million. The operating lease will commence during fiscal year 2025 and has a lease term of approximately 7 years.
Supplemental cash flow information related to the Company's operating leases was as follows:
Year ended January 31,
(in thousands)20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$10,900 $12,533 
Right-of-use assets obtained in exchange for lease obligations$2,109 $1,092 
During the fiscal year ended January 31, 2022, the Company recorded impairment losses on right-of-use assets of $11.2 million, which are included within merger integration expense in the consolidated statement of operations and comprehensive income (loss). The impairment losses related primarily to a right-of-use asset acquired through the acquisition of the Company's wholly owned subsidiary WageWorks, Inc. ("WageWorks"), which had a carrying value of $14.8 million prior to impairment and no corresponding lease liability. During the fiscal year ended January 31, 2022, the right-of-use asset met the criteria to be classified as held-for-sale and an impairment loss of $10.9 million was recognized. The remaining carrying value of $3.9 million was included within other current assets on the Company's consolidated balance sheet as of January 31, 2022. On March 24, 2022, the Company completed the sale of the asset for $3.9 million.

-65-

Note 6. Intangible assets and goodwill
Intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows:
January 31, 2024
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$267,498 $(197,388)$70,110 
Acquired HSA portfolios264,445 (81,059)183,386 
Acquired customer relationships759,782 (205,127)554,655 
Acquired developed technology132,825 (105,049)27,776 
Acquired trade names12,900 (12,879)21 
Total amortizable intangible assets$1,437,450 $(601,502)$835,948 
January 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$233,194 $(152,178)$81,016 
Acquired HSA portfolios261,188 (63,547)197,641 
Acquired customer relationships759,782 (153,434)606,348 
Acquired developed technology132,825 (81,692)51,133 
Acquired trade names12,900 (12,679)221 
Total amortizable intangible assets$1,399,889 $(463,530)$936,359 
During the fiscal years ended January 31, 2024 and 2023, the Company capitalized $3.3 million and $68.9 million, respectively, to acquire the rights to act as a custodian of HSA portfolios.
Amortization expense for the fiscal years ended January 31, 2024, 2023, and 2022 was $144.3 million, $148.9 million and $122.5 million, respectively. Estimated amortization expense for the fiscal years ending January 31 is as follows:
Year ending January 31, (in thousands)
2025$126,150 
202697,732 
202780,837 
202867,550 
202965,774 
Thereafter397,905 
Total$835,948 
Goodwill
The Company’s annual goodwill impairment test resulted in no impairment charges in any of the periods presented in the accompanying consolidated financial statements. During the fiscal year ended January 31, 2023, goodwill increased by $2.3 million due to measurement period adjustments associated with the Further Acquisition and the Luum Acquisition. There were no changes to the carrying value of goodwill during the fiscal year ended January 31, 2024.


-66-

Note 7. Commitments and contingencies
Commitments
The following table summarizes the payments due by fiscal year for the Company's outstanding contractual obligations as of January 31, 2024:
Payments due by fiscal year
(in thousands)20252026202720282029ThereafterTotal
4.50% Senior Notes due 2029 (1)
$ $ $ $ $ $600,000 $600,000 
Term Loan Facility (1) 6,875 280,000    286,875 
Interest on long-term debt obligations (2)46,502 46,402 39,087 27,000 27,000 18,000 203,991 
Operating lease obligations (3)9,862 10,281 10,165 10,323 10,553 17,952 69,136 
Other contractual obligations (4)23,496 21,487 7,302 6,502   58,787 
BenefitWallet HSA portfolio acquisition (5)445,000      445,000 
Total$524,860 $85,045 $336,554 $43,825 $37,553 $635,952 $1,663,789 
(1)As of January 31, 2024, the outstanding combined principal of $886.9 million is presented net of debt issuance costs on the consolidated balance sheets. The debt issuance costs are not included in the table above.
(2)Estimated interest payments assume the stated interest rates applicable to the Notes and Term Loan Facility as of January 31, 2024, which were 4.50% and 6.69% per annum, respectively.
(3)The Company leases office space and data storage facilities and has other non-cancelable operating leases expiring at various dates through 2030. These amounts exclude contractual sublease income of $16.3 million, which is expected to be received through December 2030.
(4)Other contractual obligations consist of processing services agreements, software subscriptions, and other contractual commitments.
(5)In September 2023, the Company entered into an agreement to acquire the BenefitWallet HSA portfolio from Conduent Business Services, LLC, for a purchase price of $425.0 million and reimbursement of up to $20.0 million of Conduent's transfer-related expenses. In addition, the Company expects to incur approximately $7.0 million of transaction costs associated with the acquisition.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
In April 2021, WageWorks, a wholly owned subsidiary of the Company, exercised its right to terminate a lease for office space in Mesa, Arizona that had not yet commenced, with aggregate lease payments of $63.1 million and a term of approximately 11 years, following the landlord's failure to fulfill its obligations under the lease agreement (the "Lease"). WageWorks' right to terminate the Lease was disputed by the landlord, Union Mesa 1, LLC (“Union Mesa”), which claimed that the Lease had commenced on December 1, 2020. On November 5, 2021, Union Mesa notified WageWorks that it was in default of the Lease for failure to pay rent, which Union Mesa claimed was due beginning in November 2021, after 11 months of abated rent. On November 24, 2021, Union Mesa drew $2.8 million, the full amount under the letter of credit that WageWorks had posted to secure its obligations under the Lease. The Company recorded the $2.8 million draw as merger integration expense in the consolidated statement of operations and comprehensive income (loss). On December 1, 2021, WageWorks filed a lawsuit against Union Mesa in the Maricopa County Superior Court in the State of Arizona. On January 4, 2022, WageWorks filed an amended complaint, seeking a declaratory judgment that the Lease was properly terminated and recourse against Union Mesa for breach of contract, breach of the duty of good faith and fair dealing, and conversion, including return of the funds drawn under the letter of credit. In May and June 2022, Union Mesa filed an answer, counterclaim, and third-party complaint against WageWorks and the Company, denying WageWorks' claims and separately seeking recourse against WageWorks for breach of contract and breach of the implied covenant of good faith and fair dealing as well as against the Company under the terms of its guaranty of WageWorks' obligations under the Lease. On July 21, 2022, WageWorks and the Company filed an answer to the counterclaim and the third-party complaint on its declaratory judgment claim that WageWorks' termination was improper under the Lease. On December 8, 2023, representatives from the parties participated in a court-ordered mediation held in Phoenix, Arizona, which was unsuccessful. On December 29, 2023, the Superior Court issued an order denying Union Mesa’s motion for partial summary judgment after finding that genuine issues of material fact exist. A trial is scheduled to start on December 9, 2024. WageWorks is seeking consequential damages relating to Union Mesa’s breach of the Lease and conversion of the letter of credit, including consequential damages, pre-judgment interest, and its attorneys’ fees.
-67-

Union Mesa has denied liability for these damages. Through its claims, Union Mesa is seeking direct and consequential damages in an amount to be proven at trial and an award of its reasonable attorney fees, plus interest, until any damages or fees that are awarded are paid. According to Union Mesa, these damages include (i) all rent payments due under the Lease accruing from December 2, 2020 (including abated rent), (ii) late charges of 3% on past due amounts, (iii) interest on past due amounts at an interest rate of the prime rate plus 5%, (iv) costs incurred in reletting the premises, (v) attorneys’ fees negotiating the lease and related agreements, and (vi) any other amounts necessary to compensate Union Mesa for the detriment proximately caused by WageWorks’ alleged breach of the Lease. In addition, Union Mesa states that it intends to re-assert periodic actions against WageWorks to seek all amounts due from time to time through the remaining term of the Lease or until the premises are successfully relet.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
Note 8. Indebtedness
Long-term debt consisted of the following:
(in thousands)January 31, 2024January 31, 2023
4.50% Senior Notes due 2029
$600,000 $600,000 
Term Loan Facility286,875 341,250 
Principal amount886,875 941,250 
Less: unamortized discount and issuance costs (1)11,903 15,912 
Total debt, net874,972 925,338 
Less: current portion of long-term debt 17,500 
Long-term debt, net$874,972 $907,838 
(1)In addition to the $11.9 million and $15.9 million of unamortized discount and issuance costs related to long-term debt as of January 31, 2024 and 2023, respectively, $2.5 million and $3.4 million of unamortized issuance costs related to the Revolving Credit Facility (as defined below) are included within other assets on the consolidated balance sheets as of January 31, 2024 and January 31, 2023, respectively.
4.50% Senior Notes due 2029
On October 8, 2021, the Company completed its offering of $600.0 million aggregate principal amount of its 4.50% Senior Notes due 2029 (the “Notes”). The Notes were issued under an indenture (the “Indenture”), dated October 8, 2021, among the Company, the guarantors party thereto, and Wells Fargo Bank, National Association, as trustee.
The Notes are guaranteed by each of the Company’s existing, wholly owned domestic subsidiaries that guarantees its obligations under the Credit Agreement (as defined below) and are required to be guaranteed by any of the Company’s future subsidiaries that guarantee its obligations under the Credit Agreement or certain of its other indebtedness. The Notes will mature on October 1, 2029. Interest on the Notes is payable on April 1 and October 1 of each year. As of January 31, 2024, the balance of accrued interest on the Notes was $9.3 million, which is included within accrued liabilities on the Company's consolidated balance sheets. The effective interest rate on the Notes is 4.72%.
The Notes are unsecured senior obligations of the Company and rank equally in right of payment to all of its existing and future senior unsecured debt and senior in right of payment to all of its future subordinated debt.
The Notes are redeemable at the Company’s option, in whole or in part, at any time on or after October 1, 2024, at a redemption price if redeemed during the 12 months beginning (i) October 1, 2024 of 102.250%, (ii) October 1, 2025 of 101.125%, and (iii) October 1, 2026 and thereafter of 100.000%, in each case of the principal amount of the Notes being redeemed, and together with accrued and unpaid interest, if any, to, but excluding, the date of
-68-

redemption. The Company may also redeem some or all of the Notes before October 1, 2024 at a redemption price equal to 100% of the principal amount of the Notes, plus the applicable “make-whole” premium as of, and accrued and unpaid interest, if any, to, but excluding, the date of redemption. In addition, at any time prior to October 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the Notes issued under the Indenture on one or more occasions in an aggregate amount equal to the net cash proceeds of one or more equity offerings at a redemption price equal to 104.500% of the principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Furthermore, the Company may be required to make an offer to purchase the Notes upon the sale of certain assets or upon specific kinds of changes of control.
The Indenture contains covenants that impose significant operational and financial restrictions on the Company; however, these covenants generally align with the covenants contained in the Credit Agreement. See "Credit Agreement" below for a description of these covenants.
Credit Agreement
On October 8, 2021, the Company entered into a credit agreement (the “Credit Agreement”) among the Company, as borrower, each lender from time to time party thereto (the “Lenders”), JPMorgan Chase Bank, N.A., as administrative agent and the Swing Line Lender (as defined in the Credit Agreement), and each L/C Issuer (as defined therein) party thereto, pursuant to which the Company established:
(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $350 million; and
(ii)     a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $1.0 billion (with a $25 million sub-limit for the issuance of letters of credit), the proceeds of which may be used for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments.
Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company’s pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.
Prior to June 1, 2023, borrowings under the Credit Facilities bore interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement.
On June 1, 2023, the Company entered into an amendment to the Credit Agreement which replaced interest rate provisions based on LIBOR with the forward-looking term rate based on the secured overnight financing rate published by the CME Group Benchmark Administration Limited (“Term SOFR”). As a result, borrowings under the Credit Agreement as so amended bear interest at an annual rate equal to, at the option of the Company, either (i) Term SOFR, plus a 0.10% credit spread adjustment, plus a margin ranging from 1.25% to 2.25%, or (ii) an alternate base rate, plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement (as amended). As of January 31, 2024, the stated interest rate was 6.69% and the effective interest rate was 7.45%.
The Company is also required to pay certain fees to the Lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of January 31, 2024, no amounts have been drawn under the Revolving Credit Facility.
The loans made under the Term Loan Facility amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the Term Loan Facility: (i) 2.5% for the first year after October 8, 2021; (ii) 5.0% for each of the second and third years after October 8, 2021; (iii) 7.5% for the fourth year after October 8, 2021; and (iv) 10.0% for the fifth year after October 8, 2021. In addition, the Term Loan Facility is required to be mandatorily prepaid with 100% of the net cash proceeds of all asset sales, insurance and condemnation recoveries, subject to customary exceptions and thresholds, including to the extent such proceeds are reinvested in assets useful in the business of the Company and its subsidiaries within 450 days following receipt (or committed to be reinvested within such 450-day period and reinvested within 180 days after the end of such 450-day period). The loans under the Credit Facilities may be prepaid, and the commitments thereunder may be reduced, by the Company without penalty or premium, subject to the reimbursement of
-69-

customary “breakage costs.” In April 2023, the Company used $50.0 million of cash to prepay, in direct order of maturity, principal due under its Term Loan Facility.
The Credit Agreement contains significant, customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.00 to 1.00 and (ii) a minimum consolidated interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of January 31, 2024, and for the period then ended.
The repayment obligation under the Credit Agreement may be accelerated upon the occurrence of an event of default thereunder, including, among other things, failure to pay principal, interest or fees on a timely basis, material inaccuracy of any representation or warranty, failure to comply with covenants, cross-default to other material debt, material judgments, change of control and certain insolvency or bankruptcy-related events, in each case, subject to any certain grace and/or cure periods.
The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by each of the Company’s existing or subsequently acquired or organized domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.
Note 9. Income taxes
The income tax provision (benefit) consisted of the following:
Year ended January 31,
(in thousands)202420232022
Current:
Federal$29,376 $3,260 $628 
State3,947 1,968 239 
Total current tax provision$33,323 $5,228 $867 
Deferred:
Federal$(11,004)$(14,382)$(21,197)
State(2,991)(2,799)(2,122)
Total deferred tax benefit$(13,995)$(17,181)$(23,319)
Total income tax provision (benefit)$19,328 $(11,953)$(22,452)
-70-

Total income tax provision (benefit) differed from the amounts computed by applying the U.S. federal statutory income tax rate to income before income taxes as a result of the following:
Year ended January 31,
(in thousands)202420232022
Federal income tax provision (benefit) at the statutory rate$15,759 $(8,000)$(14,016)
State income tax provision (benefit), net of federal tax provision (benefit)5,382 (1,021)(3,733)
Other non-deductible or non-taxable items, net447 225 (165)
Excessive employee remuneration2,939 3,246 1,214 
Excess tax (benefit) shortfall on stock-based compensation expense, net304 (2,479)(5,098)
Federal research and development credits(9,202)(1,341)(4,218)
Change in uncertain tax position reserves, net of indirect benefits6,137 (2,970)836 
Deferred tax rate adjustment due to state apportionment changes(1,039)(30)725 
Adjustment from settlement of IRS examination2,461   
Return-to-provision adjustments(433)(38)(810)
Change in valuation allowance(3,129)733 3,457 
Other items, net(298)(278)(644)
Total income tax provision (benefit)$19,328 $(11,953)$(22,452)
The Company’s effective income tax provision rate for the fiscal year ended January 31, 2024 was 25.8%, and the Company’s effective income tax benefit rate for the fiscal years ended January 31, 2023 and 2022 was 31.4% and 33.6%, respectively. The difference between the effective income tax rate and the U.S. federal statutory income tax rate each period is impacted by a number of factors, including the relative mix of earnings among state jurisdictions, credits, excess tax benefits or shortfalls on stock-based compensation expense, changes in unrecognized tax benefits and valuation allowance, and other items. The increase in the effective tax rate for the fiscal year ended January 31, 2024 compared to the fiscal year ended January 31, 2023 was primarily due to an increase in pre-tax book income, an increase in unrecognized tax benefits, adjustments from settlement of an IRS examination, and a decrease in tax deductible stock-based compensation compared to GAAP stock-based compensation expense, partially offset by an increase in research and development tax credits and a decrease in valuation allowance. The decrease in the effective tax rate for the fiscal year ended January 31, 2023 compared to the fiscal year ended January 31, 2022 was primarily due to a decrease in benefit for state income taxes, a decrease in research and development tax credits, a decrease in excess tax benefits on stock-based compensation expense, and an increase in nondeductible executive compensation relative to pre-tax book loss, partially offset by a release of uncertain tax positions and a smaller change in valuation allowance.
-71-

Deferred tax assets and liabilities consisted of the following:
(in thousands)January 31, 2024January 31, 2023
Deferred tax assets:
Net operating loss carryforward$1,730 $2,646 
Stock compensation14,069 16,217 
Research and development credits3,796 7,147 
Lease liabilities14,371 17,337 
Capitalized research and development33,474 16,419 
Fixed assets939  
Accruals and reserves3,557 4,439 
Other, net1,937 5,643 
Total gross deferred tax assets$73,873 $69,848 
Less valuation allowance(1,164)(4,294)
Deferred tax assets, net of valuation allowance72,709 65,554 
Deferred tax liabilities:
Fixed assets (1,509)
Intangible assets(86,195)(99,471)
Incremental contract costs(12,887)(11,118)
Right-of-use assets(11,949)(14,132)
Goodwill(28,691)(20,271)
Other, net(1,657)(1,718)
Total gross deferred tax liabilities(141,379)(148,219)
Net deferred tax liabilities$(68,670)$(82,665)
Management considered whether it is more likely than not that some portion or all of the deferred tax assets would be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considered the scheduled reversal of deferred tax liabilities in making this assessment and determined that based on the weight of all available evidence, it is more likely than not (i.e., a likelihood of more than 50%) that the Company will be able to realize all of its federal deferred tax assets and the majority if its state deferred tax assets. The Company recorded a valuation allowance of $1.2 million and $4.3 million as of January 31, 2024 and 2023, respectively, related to certain state deferred tax assets. The $3.1 million decrease in valuation allowance recorded is primarily the result of state research and development tax credits that are expected to be utilized before expiration.
As of January 31, 2024, the Company had recorded state net operating loss carryforwards of $27.2 million, which begin to expire at various intervals following the tax year ending January 31, 2032. As of January 31, 2024, the Company also had state research and development credits of $11.9 million, which begin to expire at various intervals following the tax year ending January 31, 2025.
As of January 31, 2024 and 2023, the gross unrecognized tax benefit was $19.2 million and $8.7 million, respectively. If recognized, $16.2 million and $5.4 million of the total unrecognized tax benefits would affect the Company's effective tax rate as of January 31, 2024 and 2023, respectively. Total gross unrecognized tax benefits increased by $10.5 million in the period from January 31, 2023 to January 31, 2024.
A tabular reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
(in thousands)January 31, 2024January 31, 2023
Gross unrecognized tax benefits at beginning of year$8,690 $11,653 
Gross amounts of increases and decreases:
Increases as a result of tax positions taken during a prior period9,325  
Decreases as a result of tax positions taken during a prior period (183)
Increases as a result of tax positions taken during the current period3,386 639 
Decreases as a result of settlement(1,030)
Decreases resulting from the lapse of the applicable statute of limitations(1,158)(3,419)
Gross unrecognized tax benefits at end of year$19,213 $8,690 
-72-

Certain unrecognized tax benefits are required to be netted against their related deferred tax assets as a result of ASU 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The resulting unrecognized tax benefit recorded within the Company's consolidated balance sheet excludes the following amounts that have been netted against the related deferred tax assets accordingly:
(in thousands)January 31, 2024January 31, 2023
Total gross unrecognized tax benefits$19,213 $8,690 
Amounts netted against related deferred tax assets(7,186)(4,337)
Unrecognized tax benefits recorded on the consolidated balance sheet$12,027 $4,353 
The Company’s policy is to recognize interest and penalties related to unrecognized tax benefits as a component of other income (expense), net in the statement of operations and comprehensive income (loss). During the fiscal years ended January 31, 2024, 2023, and 2022, the Company recorded penalties and interest of $0.1 million, $0.4 million, and $0.7 million, respectively, related to unrecognized tax benefits. As of January 31, 2024 and 2023, the Company recorded accrued interest and penalties of $1.4 million and $1.3 million, respectively.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the state of Texas. Such examinations may lead to ordinary course adjustments or proposed adjustments to the Company's taxes, net operating losses, and/or tax credit carryforwards. An IRS examination was settled during the year ended January 31, 2024; adjustments recorded as a result of the examination were not material. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2006.
Note 10. Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's consolidated statements of operations and comprehensive income (loss) during the fiscal years presented:
Year ended January 31,
(in thousands)202420232022
Cost of revenue$16,462 $13,591 $10,684 
Sales and marketing13,182 9,821 7,001 
Technology and development20,891 13,828 13,132 
General and administrative26,616 25,374 21,933 
Other expense, net  342 
Total stock-based compensation expense$77,151 $62,614 $53,092 
The following table shows stock-based compensation by award type:
Year ended January 31,
(in thousands)202420232022
Restricted stock units$60,688 $46,590 $37,693 
Performance restricted stock units16,384 15,120 12,948 
Stock options79 882 1,816 
Restricted stock awards 22 155 
Performance restricted stock awards  138 
Total non-cash stock-based compensation expense77,151 62,614 52,750 
Acquisition awards exchanged for cash  342 
Total stock-based compensation expense$77,151 $62,614 $53,092 
Stock award plans
Incentive Plan. The Company grants RSUs under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provides for the issuance of stock awards to the directors and team members of the Company. Historically, the Company also granted stock options and RSAs under the Incentive Plan. As of January 31, 2024, 11.9 million shares were available for grant under the Incentive Plan.

-73-

Stock options
Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such stock options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance or are forfeited 90 days after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan. No stock options were granted during the fiscal years ended January 31, 2024, 2023, or 2022.
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20231,021 
$14.00 - 82.39
$36.06 3.2$27,293 
Exercised (249)
$14.00 - 66.06
$26.21 
Forfeited (46)
$24.36 - 82.39
$75.08 
Outstanding as of January 31, 2024726 
$14.00 - 73.61
$36.91 2.5$28,067 
Vested and expected to vest as of January 31, 2024726 $36.91 2.5$28,067 
Exercisable as of January 31, 2024726 $36.91 2.5$28,067 
The aggregate intrinsic value in the table above represents the difference between the fair value of common stock and the exercise price of outstanding, in-the-money stock options. The total intrinsic value of options exercised during the fiscal years ended January 31, 2024, 2023 and 2022 was $10.1 million, $7.2 million, and $19.3 million, respectively. As of January 31, 2024, there was no unrecorded stock-based compensation expense associated with stock options, and all outstanding stock options were vested.
Restricted stock units
The Company grants RSUs to certain team members, officers, and directors under the Incentive Plan, which vest upon service-based criteria and performance-based criteria. The weighted-average fair value of RSUs granted during the fiscal years ended January 31, 2024, 2023 and 2022 was $64.16, $75.64 and $64.87 per share, respectively.
Service-based restricted stock units. Generally, service-based RSUs granted prior to March 2022 vest over a four-year period in equal annual installments commencing upon the first anniversary of the grant date. Service-based RSUs granted in March 2022 or later generally vest 25% on the first anniversary of the vesting commencement date, which is generally the first day of the fiscal quarter of the grant date, with the remaining portion vesting ratably over the following 12 calendar quarters. Service-based RSUs are valued based on the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate.
Performance restricted stock units. During the fiscal year ended January 31, 2022, the Company awarded 249,750 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return relative to the Russell 2000 index as measured on January 31, 2024. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $22.4 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Talent, Compensation and Culture Committee of the board of directors.
During the fiscal year ended January 31, 2023, the Company awarded 281,784 PRSUs subject to a market condition based on the Company’s total shareholder return relative to the Russell 2000 index as measured on January 31, 2025. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $32.1 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Talent, Compensation and Culture Committee of the board of directors.
-74-

During the fiscal year ended January 31, 2024, the Company awarded 270,966 PRSUs subject to a market condition based on the Company’s total shareholder return relative to the Russell 2000 index as measured on January 31, 2026. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $23.9 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Talent, Compensation and Culture Committee of the board of directors.
A summary of RSU activity is as follows:
Outstanding RSUs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair value
Outstanding as of January 31, 20233,011 $70.40 
Granted1,929 64.16 
Vested(1,118)65.41 
Forfeited(459)71.56 
Outstanding as of January 31, 20243,363 $67.96 
During the fiscal years ended January 31, 2024, 2023 and 2022, the aggregate intrinsic value of RSUs and RSAs vested was $69.3 million, $50.7 million, and $40.9 million, respectively.
As of January 31, 2024, total unrecorded stock-based compensation expense associated with RSUs was $162.5 million, which was expected to be recognized over a weighted-average period of 2.4 years. As of January 31, 2024, there was no unrecorded stock-based compensation expense associated with RSAs, and there were no RSAs outstanding.
Note 11. Fair value
Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Cash and cash equivalents are considered Level 1 instruments and are valued based on publicly available daily net asset values. The carrying values of cash and cash equivalents approximate fair values due to the short-term nature of these instruments.
The Notes are valued based upon quoted market prices and are considered Level 2 instruments because the markets in which the Notes trade are not considered active markets. As of January 31, 2024, the fair value of the Notes was $560.2 million.
The Term Loan Facility is considered a Level 2 instrument and recorded at book value in the Company's consolidated financial statements. The Term Loan Facility reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, the fair value of the Term Loan Facility approximates carrying value.
Note 12. Employee benefits
The Company has established a 401(k) plan that qualifies as a deferred compensation arrangement under Section 401 of the IRS Code. All non-seasonal team members over the age of 18 are eligible to participate in the plan. The plan provides for Company matching of employee contributions up to 3.5% of eligible earnings. Employer
-75-

matching contribution expense was $8.7 million, $8.0 million and $7.1 million for the fiscal years ended January 31, 2024, 2023 and 2022, respectively.
The Company is self-insured for medical and dental benefits for all qualifying employees. The medical plan carries a stop-loss policy which will protect from individual claims during the plan year exceeding $500,000. The Company records estimates of costs of claims incurred based on an analysis of historical data and independent estimates. The Company's liability for self-insured medical claims is included in accrued compensation in its consolidated balance sheet and was $4.7 million and $5.1 million as of January 31, 2024 and 2023, respectively.
Note 13. Selected quarterly financial data (unaudited)
As described in Note 1—Summary of business and significant accounting policies—Reclassifications, certain reclassifications have been made to prior year amounts to conform to the current year presentation. The following tables present the impact of the reclassifications by quarter:
Three months ended January 31, 2024
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$111,759 $6,816 $118,575 
Custodial revenue112,249 (6,816)105,433 
Interchange revenue38,379  38,379 
Total revenue262,387  262,387 
Total cost of revenue99,939 (872)99,067 
Gross profit162,448 872 163,320 
Total operating expenses123,561 872 124,433 
Total other expense(9,170) (9,170)
Income tax provision3,353  3,353 
Net income$26,364 $ $26,364 
Three months ended October 31, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$107,512 $6,570 $114,082 
Custodial revenue106,575 (6,570)100,005 
Interchange revenue35,132  35,132 
Total revenue249,219  249,219 
Total cost of revenue90,811 (774)90,037 
Gross profit158,408 774 159,182 
Total operating expenses127,517 774 128,291 
Total other expense(9,804) (9,804)
Income tax provision6,414  6,414 
Net income$14,673 $ $14,673 
-76-

Three months ended July 31, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$105,719 $6,241 $111,960 
Custodial revenue98,917 (6,241)92,676 
Interchange revenue38,913  38,913 
Total revenue243,549  243,549 
Total cost of revenue92,619 (735)91,884 
Gross profit150,930 735 151,665 
Total operating expenses126,190 735 126,925 
Total other expense(10,516) (10,516)
Income tax provision3,643  3,643 
Net income$10,581 $ $10,581 
Three months ended April 30, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$105,112 $5,961 $111,073 
Custodial revenue94,441 (5,961)88,480 
Interchange revenue44,879  44,879 
Total revenue244,432  244,432 
Total cost of revenue96,606 (644)95,962 
Gross profit147,826 644 148,470 
Total operating expenses124,645 644 125,289 
Total other expense(13,169) (13,169)
Income tax provision5,918  5,918 
Net income$4,094 $ $4,094 
Three months ended January 31, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$114,234 $5,620 $119,854 
Custodial revenue83,506 (5,620)77,886 
Interchange revenue36,101  36,101 
Total revenue233,841  233,841 
Total cost of revenue99,593 (525)99,068 
Gross profit134,248 525 134,773 
Total operating expenses121,032 525 121,557 
Total other expense(13,208) (13,208)
Income tax provision217  217 
Net loss$(209)$ $(209)
-77-

Three months ended October 31, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$108,580 $5,495 $114,075 
Custodial revenue74,642 (5,495)69,147 
Interchange revenue32,864  32,864 
Total revenue216,086  216,086 
Total cost of revenue89,228 (460)88,768 
Gross profit126,858 460 127,318 
Total operating expenses121,316 460 121,776 
Total other expense(11,722) (11,722)
Income tax benefit(4,539) (4,539)
Net loss$(1,641)$ $(1,641)
Three months ended July 31, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$103,034 $5,508 $108,542 
Custodial revenue65,599 (5,508)60,091 
Interchange revenue37,509  37,509 
Total revenue206,142  206,142 
Total cost of revenue88,330 (436)87,894 
Gross profit117,812 436 118,248 
Total operating expenses120,224 436 120,660 
Total other expense(11,461) (11,461)
Income tax benefit(3,219) (3,219)
Net loss$(10,654)$ $(10,654)
Three months ended April 30, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$104,348 $5,207 $109,555 
Custodial revenue59,365 (5,207)54,158 
Interchange revenue41,966  41,966 
Total revenue205,679  205,679 
Total cost of revenue94,506 (423)94,083 
Gross profit111,173 423 111,596 
Total operating expenses118,462 423 118,885 
Total other expense(10,762) (10,762)
Income tax benefit(4,412) (4,412)
Net loss$(13,639)$ $(13,639)
-78-

Three months ended January 31, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$112,461 $4,924 $117,385 
Custodial revenue58,057 (4,924)53,133 
Interchange revenue32,779  32,779 
Total revenue203,297  203,297 
Total cost of revenue97,998 (315)97,683 
Gross profit105,299 315 105,614 
Total operating expenses132,549 315 132,864 
Total other expense(16,515) (16,515)
Income tax benefit(10,947) (10,947)
Net loss$(32,818)$ $(32,818)
Three months ended October 31, 2021
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$102,733 $4,408 $107,141 
Custodial revenue49,006 (4,408)44,598 
Interchange revenue28,215  28,215 
Total revenue179,954  179,954 
Total cost of revenue76,634 (252)76,382 
Gross profit103,320 252 103,572 
Total operating expenses103,686 252 103,938 
Total other expense(8,759) (8,759)
Income tax benefit(4,087) (4,087)
Net loss$(5,038)$ $(5,038)
Three months ended July 31, 2021
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$109,182 $3,965 $113,147 
Custodial revenue48,776 (3,965)44,811 
Interchange revenue31,145  31,145 
Total revenue189,103  189,103 
Total cost of revenue77,132 (256)76,876 
Gross profit111,971 256 112,227 
Total operating expenses112,846 256 113,102 
Total other expense(6,910) (6,910)
Income tax benefit(3,967) (3,967)
Net loss$(3,818)$ $(3,818)
-79-

Three months ended April 30, 2021
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$102,534 $3,401 $105,935 
Custodial revenue46,978 (3,401)43,577 
Interchange revenue34,690  34,690 
Total revenue184,202  184,202 
Total cost of revenue81,086 (236)80,850 
Gross profit103,116 236 103,352 
Total operating expenses98,863 236 99,099 
Total other expense(10,319) (10,319)
Income tax benefit(3,451) (3,451)
Net loss$(2,615)$ $(2,615)
Note 14. Subsequent events
On March 7, 2024, the first of three HSA asset transfers occurred in connection with HealthEquity's acquisition of the BenefitWallet HSA portfolio, with 266,000 HSAs and $1.1 billion HSA assets transferring to HealthEquity’s custody. In connection with this transfer, HealthEquity paid the applicable purchase price of $163.9 million using cash on hand.
-80-

Item 9. Changes in and disagreements with accountants on accounting and financial disclosure
None.
Item 9A. Controls and Procedures
Evaluation of disclosure controls and procedures
Management, with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of the Company’s disclosure controls and procedures as of January 31, 2024, the end of the period covered by this Annual Report on Form 10-K. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation, our CEO and our CFO have concluded that as of January 31, 2024, the Company's disclosure controls and procedures were effective at the reasonable assurance level.
Management's report on internal control over financial reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.
Management assessed the effectiveness of the Company’s internal control over financial reporting as of January 31, 2024 based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013) (“COSO Framework”).
Based on that assessment, management has concluded that, as of January 31, 2024, the Company’s internal control over financial reporting was effective.
The Company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the Company’s internal control over financial reporting as of January 31, 2024. Its report appears in Part II, Item 8 of this Annual Report on Form 10-K.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended January 31, 2024 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
-81-

Item 9B. Other information
Rule 10b5-1 plan elections
On September 22, 2023, Delano Ladd, our Executive Vice President, General Counsel and Secretary, entered into a Rule 10b5-1 trading arrangement (the “Ladd Arrangement”). The Ladd Arrangement provides for the sale, between December 22, 2023 and August 30, 2024, of up to 7,643 aggregate shares of the Company’s common stock held directly by Mr. Ladd. The Ladd Arrangement was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
On December 08, 2023, Stephen Neeleman, our Founder and Vice Chairman, entered into a Rule 10b5-1 trading arrangement (the “Neeleman Arrangement”). The Neeleman Arrangement provides for the sale, between December 8, 2023 and July 31, 2024, of up to 70,000 aggregate shares of the Company’s common stock held directly by Dr. Neeleman. The Neeleman Arrangement was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
Item 9C. Disclosure regarding foreign jurisdictions that prevent inspections
Not applicable.

-82-

PART III.
Item 10. Directors, executive officers and corporate governance
The information required by this Item 10 of Form 10-K is found in our 2024 Proxy Statement to be filed with the SEC in connection with the solicitation of proxies for the Company's 2024 Annual Meeting of Stockholders is incorporated by reference to our 2024 Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year to which this report relates.
Code of business conduct and ethics
Our board of directors has adopted a Code of Business Conduct and Ethics that applies to all of our team members, officers and directors, including our Chief Executive Officer, Chief Financial Officer, and other executive and senior financial officers. The full text of our Code of Business Conduct and Ethics is posted on our website at www.healthequity.com in the Corporate Governance section of our Investor Relations webpage. We intend to post any amendments to our Code of Business Conduct and Ethics, and any waivers of our Code of Business Conduct and Ethics for directors and executive officers, on the same website.
Item 11. Executive compensation
The information required by this Item 11 of Form 10-K is incorporated by reference in our 2024 Proxy Statement.
Item 12. Security ownership of certain beneficial owners and management and related stockholder matters
The information required by this Item 12 of Form 10-K is incorporated by reference in our 2024 Proxy Statement.
Item 13. Certain relationships and related transactions, and director independence
The information required by this Item 13 of Form 10-K is incorporated by reference in our 2024 Proxy Statement.
Item 14. Principal accounting fees and services
The information required by this Item 14 of Form 10-K is incorporated by reference in our 2024 Proxy Statement.
-83-

Part IV.

Item 15. Exhibits, financial statement schedules

(a) Documents filed as part of this report

(2) Financial statement schedules
All financial statement schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto included in this Form 10-K.



-84-

(3) Exhibits required by Item 601 of Regulation S-K

Exhibit Index
Incorporated by reference
Exhibit
no.
DescriptionFormFile No.ExhibitFiling Date
2.18-K001-365682.1September 19, 2023
3.18-K001-365683.2July 6, 2018
3.28-K001-365683.1February 10, 2023
4.110-K001-365684.1March 31, 2020
4.2S-1/A333-1966454.1July 16, 2014
4.3S-1333-1966454.2June 10, 2014
4.48-K001-365684.1October 12, 2021
10.1S-1/A333-19664510.1July 16, 2014
10.2†S-1333-19664510.2June 10, 2014
10.3†S-1/A333-19664510.3July 16, 2014
10.4†8-K001-3656810.3August 30, 2019
10.5†10-Q001-3656810.4December 6, 2018
10.6†10-K001-3656810.30March 28, 2019
10.7†S-1333-19664510.23June 10, 2014
10.8†S-1333-19664510.24June 10, 2014
10.9†10-Q001-3656810.2June 4, 2020
10.10†S-1333-19664510.25June 10, 2014
10.11†8-K001-3656810.1April 1, 2021
10.12†8-K001-3656810.1July 3, 2023
10.13†10-K001-3656810.17March 31, 2022
10.14†10-K001-3656810.18March 31, 2022
10.15†10-K001-3656810.17March 30, 2023
10.16†10-K001-3656810.18March 30, 2023
10.17†8-K001-3656810.1June 14, 2023
10.1810-Q001-3656810.1June 11, 2015
-85-

Incorporated by reference
Exhibit
no.
DescriptionFormFile No.ExhibitFiling Date
10.1910-Q001-3656810.2June 11, 2015
10.20

10-Q001-3656810.1December 8, 2016
10.21

10-Q001-3656810.1June 8, 2017
10.22

10-Q001-3656810.2December 8, 2016
10.23

10-Q001-3656810.2June 8, 2017
10.2410-K001-3656810.31March 28, 2019
10.2510-Q001-3656810.1December 6, 2018
10.2610-Q001-3656810.2December 6, 2018
10.2710-Q001-3656810.3December 6, 2018
10.288-K001-3656810.1October 12, 2021
10.298-K001-3656810.1June 2, 2023
10.3010-K001-3656810.30March 30, 2023
21.1+
23.1+
24.1+
31.1+
31.2+
32.1*#
32.2*#
97+
101.INS††XBRL Instance document
101.SCH††XBRL Taxonomy schema linkbase document
-86-

Incorporated by reference
Exhibit
no.
DescriptionFormFile No.ExhibitFiling Date
101.CAL††XBRL Taxonomy calculation linkbase document
101.DEF††XBRL Taxonomy definition linkbase document
101.LAB††XBRL Taxonomy labels linkbase document
101.PRE††XBRL Taxonomy presentation linkbase document
104
The cover page from the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2024, formatted in Inline XBRL.
+Filed herewith
*Furnished herewith
#These certifications are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference in any filing the registrant makes under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, irrespective of any general incorporation language in any filings.
Indicates management contract or compensatory plan.
††
In accordance with Rule 406T of Regulation S-T, the information in these exhibits is furnished and deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Exchange Act of 1934, and otherwise is not subject to liability under these sections.
**Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. HealthEquity hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the SEC.

Item 16. Form 10-K Summary
None.
-87-

Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Draper, State of Utah on this 22nd day of March, 2024.
HEALTHEQUITY, INC.
Date: March 22, 2024
By:/s/ Jon Kessler
Name:Jon Kessler
Title:President and Chief Executive Officer

-88-

Power of attorney
KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below hereby constitutes and appoints Jon Kessler and James Lucania, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her or their substitutes, may lawfully do or cause to be done by virtue hereof.
-89-

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Date: March 22, 2024
By:/s/ Robert Selander
Name:Robert Selander
Title:Chairman of the Board, Director
Date: March 22, 2024
By:/s/ Jon Kessler
Name:Jon Kessler
Title:President and Chief Executive Officer (Principal Executive Officer), Director
Date: March 22, 2024
By:/s/ James Lucania
Name:James Lucania
 Title:Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)
Date: March 22, 2024
By:/s/ Paul Black
Name:Paul Black
Title:Director
Date: March 22, 2024
By:/s/ Frank Corvino
Name:Frank Corvino
Title:Director
Date: March 22, 2024
By:/s/ Adrian Dillon
Name:Adrian Dillon
Title:Director
Date: March 22, 2024
By:/s/ Evelyn Dilsaver
Name:Evelyn Dilsaver
Title:Director
Date: March 22, 2024
By:/s/ Debra McCowan
Name:Debra McCowan
Title:Director
Date: March 22, 2024
By:/s/ Rajesh Natarajan
Name:Rajesh Natarajan
Title:Director
Date: March 22, 2024
By:/s/ Stephen Neeleman
Name:Stephen Neeleman, M.D.
Title:Vice Chairman and Director
Date: March 22, 2024
By:/s/ Stuart Parker
Name:Stuart Parker
Title:Director
Date: March 22, 2024
By:/s/ Gayle Wellborn
Name:Gayle Wellborn
Title:Director

-90-
EX-21.1 2 exhibit2112024-1x31.htm EX-21.1 Document

Exhibit 21.1
LIST OF SUBSIDIARIES OF HEALTHEQUITY, INC.

FORT EFFECT CORP., a Washington corporation

FURTHER OPERATIONS, LLC, a Delaware limited liability company

HEALTHEQUITY ADVISORS, LLC, a Utah limited liability company

HEALTHEQUITY COMMUNITY FOUNDATION, a Delaware corporation

HEALTHEQUITY PAYMENTS, LLC, a Delaware limited liability company

HEALTHEQUITY RETIREMENT SERVICES, LLC, a Delaware limited liability company

HEALTHEQUITY TRUST COMPANY, a Wyoming corporation

WAGEWORKS, INC., a Delaware corporation

EX-23.1 3 exhibit2312024-1x31.htm EX-23.1 Document

                                                Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-259417) and Form S-8 (No. 333-272870) of HealthEquity, Inc. of our report dated March 22, 2024 relating to the financial statements, and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.


/s/ PricewaterhouseCoopers LLP
Salt Lake City, UT
March 22, 2024


EX-31.1 4 exhibit3112024-1x31ceo.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Jon Kessler, certify that:
1.I have reviewed this Annual Report on Form 10-K of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: March 22, 2024
 
By:/s/ Jon Kessler
Name:     Jon Kessler
Title:
President and Chief Executive Officer
(Principal Executive Officer)
 

EX-31.2 5 exhibit3122024-1x31cfo.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer
Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, James Lucania, certify that:
1.I have reviewed this Annual Report on Form 10-K of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 22, 2024
By:/s/ James Lucania
Name:James Lucania
Title:Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
 

EX-32.1 6 exhibit3212024-1x31ceo.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jon Kessler, the Chief Executive Officer (Principal Executive Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Annual Report on Form 10-K for the year ended January 31, 2024 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 22, 2024
 
By: /s/ Jon Kessler
Name:Jon Kessler
Title:
President and Chief Executive Officer
(Principal Executive Officer)
 


EX-32.2 7 exhibit3222024-1x31cfo.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, James Lucania, the Executive Vice President and Chief Financial Officer (Principal Financial Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Annual Report on Form 10-K for the year ended January 31, 2024 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 22, 2024
 
By:/s/ James Lucania
Name:James Lucania
Title:
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
 


EX-97 8 exhibit97-clawbackpolicy.htm EX-97 Document


Exhibit 97
HealthEquity, Inc.
Clawback Policy
1INTRODUCTION
The Board of Directors of the Company (the “Board”) believes that it is in the best interests of HealthEquity, Inc., a Delaware corporation (the “Company”) and its stockholders to create and maintain a culture that emphasizes integrity and accountability, that reinforces the Company’s pay-for-performance compensation philosophy and deters wrongdoing. Therefore, and in accordance with Nasdaq Listing Rule 5608(a), which requires recoupment of erroneously award incentive compensation on “no fault” basis, the Board has adopted this HealthEquity, Inc. Clawback Policy (this “Policy”), which provides for the recoupment of Incentive Compensation (as defined below) in the event of an Accounting Restatement (as defined below).
2REQUIREMENTS
2.1Administration
This Policy shall be administered by the Board or, if so designated by the Board, the compensation committee of the Board (the “Compensation Committee”), in which case references herein to the Board shall be deemed references to the Compensation Committee. Any determinations made by the Board shall be final and binding on all affected individuals.
2.2Covered Executives
This Policy applies to any current or former officer of the Company who is (or was) subject to Section 16 of the Securities Exchange Act of 1934, as amended from time to time (each, a “Covered Executive”).
2.3Recoupment; Accounting Restatement
In the event the Company is required to prepare an Accounting Restatement, the Board shall promptly require reimbursement or forfeiture of any excess Incentive Compensation received by any Covered Executive during the three completed fiscal years immediately preceding the Restatement Date (as defined below) and any transition period (that results from a change in the Company’s fiscal year) of less than nine months within or immediately following those three completed fiscal years (the “Covered Period”).

For the purposes of this Policy, “Accounting Restatement” means an accounting restatement (i) due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial restatements that is material to the previously issued financial statements (i.e., a “Big R” restatement) or (ii) that corrects an error that is not material to previously issued financial statements, but would result in a material misstatement if the error were not corrected in the current period or left uncorrected in the current period (i.e., a “little r” restatement).

© 2023 HealthEquity, Inc. Proprietary and confidential, for internal use only.    Page 1 of #NUM_PAGES#

Clawback Policy

For purposes of this Policy, “Incentive Compensation” means any compensation that is granted, earned or vested based wholly or in part on the attainment of a financial reporting measure, such as revenue, net income, earnings before interest, tax, depreciation and amortization, or total custodial assets. For these purposes, “financial reporting measures” are those measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements and any other measures derived wholly or in part from such measures. New HSA sales, stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall for purposes of this Policy be considered financial reporting measures. For the avoidance of doubt, a financial reporting measure need not be presented in the Company’s financial statements or included in a filing with the Securities and Exchange Commission.

Incentive Compensation is deemed “received” in the fiscal period during which the applicable financial reporting measure (as specified in the terms of the award) is attained, even if the payment or grant occurs after the end of that fiscal period. In addition, the date on which the Company is required to prepare an Accounting Restatement is considered the earlier of (A) the date the Board concludes or reasonably should have concluded that the Company is required to prepare an Accounting Restatement and (B) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement (the “Restatement Date”).

For illustrative purposes only, assume that a Covered Executive is granted performance-based restricted stock units (the “PRSUs”) that vest based on the cumulative revenue compound annual growth rate of the Company during the period commencing on February 1, 2023 through January 31, 2026, subject to the Covered Executive’s continued employment with the Company through such date. Assume also that settlement of the shares underlying the PRSUs is deferred to the earlier to occur of (x) January 31, 2031, and (y) the termination of the Covered Executive’s employment. For purposes of this Policy, the PRSUs described above will be deemed received on January 31, 2026 when the applicable financial reporting measure is attained.
2.4Excess Incentive Compensation; Amount Subject to Recovery; No Additional Payments
The amount to be recovered will be the excess of the Incentive Compensation received by the Covered Executive based on the erroneous data over the Incentive Compensation that would have been received by the Covered Executive had it been based on the restated results, computed without regard to any taxes paid, as determined by the Board. For Incentive Compensation based on (or derived from) stock price or total shareholder return where the amount of excess Incentive Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, the amount shall be determined by the Board based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive Compensation was received (in which case, the Company shall maintain documentation of such determination of that reasonable estimate and provide such documentation to Nasdaq).

In the event of an Accounting Restatement, the Board shall promptly (and in all events within ninety (90) days after the Restatement Date) determine the amount of any excess Incentive Compensation for each Covered Executive in connection with such Accounting Restatement and
© 2023 HealthEquity, Inc. Proprietary and confidential, for internal use only.    Page 2 of #NUM_PAGES#

Clawback Policy

shall promptly thereafter provide each Covered Executive with a written notice containing the amount of excess Incentive Compensation and a demand for repayment or return, as applicable.

Notwithstanding anything herein to the contrary, this Policy shall not apply in any situation where a restatement is not an Accounting Restatement, such as, but not limited to, a retrospective: (A) application of a change in accounting principles; (B) revision to reportable segment information due to a change in the structure of the Company’s internal organization; (C) reclassification due to a discontinued operation; (D) application of a change in reporting entity, such as from a reorganization of entities under common control; (E) adjustment to provisional amounts in connection with a prior business combination; and (F) revision for stock splits.

In no event shall the Company be required to award Covered Executives an additional payment if the restated or accurate financial results would have resulted in a higher incentive compensation payment.
2.5Method of Recoupment
If equity compensation is recoverable due to the Covered Executive vesting in such compensation (when the accounting results were the reason the equity compensation vested) in the Covered Period, the Company will recover the excess portion of the equity award that would not have vested based on the restatement, as follows: (A) if the equity award is still outstanding, the Covered Executive will forfeit the excess portion of the award; (B) if the equity award has been exercised or settled into shares (the “Underlying Shares”), and the Covered Executive still holds the Underlying Shares, the Company will recover the number of Underlying Shares relating to the excess portion of the award (less any exercise price, if any, paid for the Underlying Shares); and (C) if the Underlying Shares have been sold by the Covered Executive, the Company will recover the pre-tax portion of the proceeds received by the Covered Executive from the sale of the Underlying Shares relating to the excess portion of the award (less any exercise price, if any, paid for the Underlying Shares).

In addition, the Board may determine, in its sole discretion, any additional method for recouping Incentive Compensation hereunder which may include, without limitation: (A) requiring reimbursement of cash Incentive Compensation previously paid; (B) offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive; or (C) taking any other remedial and recovery action permitted by law, as determined by the Board.

To the extent that a Covered Executive fails to repay all excess Incentive Compensation to the Company when due (as determined in accordance with this Policy), the Company shall take all actions reasonable and appropriate to recover such excess Incentive Compensation from the applicable Covered Executive. The applicable Covered Executive shall be required to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such excess Incentive Compensation in accordance with the immediately preceding sentence.
© 2023 HealthEquity, Inc. Proprietary and confidential, for internal use only.    Page 3 of #NUM_PAGES#

Clawback Policy

2.6No Indemnification
The Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive Compensation that is repaid, returned or recovered pursuant to the terms of this Policy or any claims relating to the Company’s enforcement of its rights under this Policy. Further, the Company shall not enter into any agreement that exempts any Incentive Compensation from the application of this Policy or that waives the Company’s right to recovery any excess Incentive Compensation. This Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).
2.7Reporting and Disclosure
The Company shall file all disclosures with respect to this Policy in accordance with the requirement of the Federal securities laws, including the disclosure requirement by the applicable Securities and Exchange Commission filings.
2.8Other Recoupment Rights; No Additional Payments
The Board intends that this Policy will be applied to the fullest extent of the law. The Board may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.
2.9Impracticability
Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section 2.3 above if the following conditions are met and the Board determines that recovery would be impracticable: (i) the direct expenses paid to a third party to assist in enforcing the Policy against a Covered Executive would exceed the amount to be recovered, after the Company has made a reasonable attempt to recover the applicable excess Incentive Compensation, documented such attempts, and provided such documentation to Nasdaq; (ii) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. § 401(a)(13) and the regulations promulgated thereunder; or (iii) recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable to recover any amount of excess Incentive Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation and a copy of the opinion is provided to Nasdaq.
2.10Successors
This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.
© 2023 HealthEquity, Inc. Proprietary and confidential, for internal use only.    Page 4 of #NUM_PAGES#

Clawback Policy

3INTERPRETATION
The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy.
4AMENDMENT; TERMINATION
The Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary, including as and when it determines that it is legally required by Securities and Exchange Commission rule or the rules of any national securities exchange on which the Company’s securities are listed. The Board may terminate this Policy at any time. Notwithstanding anything in this Section 4 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any Securities and Exchange Commission rule or the rules of any national securities exchange or national securities association on which the Company’s securities are listed.
5EFFECTIVE DATE
This Policy was adopted by the Board on June 22, 2023 and is effective as of October 2, 2023 (the “Effective Date”). This Policy shall apply to Incentive Compensation that is received by the Covered Executives on or after such Effective Date.
6POLICY REVIEW
The policy owner will review this Policy annually.


© 2023 HealthEquity, Inc. Proprietary and confidential, for internal use only.    Page 5 of #NUM_PAGES#
EX-101.SCH 9 hqy-20240131.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated balance sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated balance sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated statements of operations and comprehensive income (loss) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated statements of stockholders' equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated statements of cash flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Summary of business and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Net income (loss) per share link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Business combinations link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Supplemental financial statement information link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Indebtedness link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Fair value link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Employee benefits link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Selected quarterly financial data (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of business and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of business and significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Net income (loss) per share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Business combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Supplemental financial statement information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Commitments and contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Indebtedness (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Income taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Selected quarterly financial data (unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of business and significant accounting policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Summary of business and significant accounting policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Summary of business and significant accounting policies - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Net income (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Business combinations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Business combinations - Preliminary Allocation of Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Supplemental financial statement information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Supplemental financial statement information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Supplemental financial statement information - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Supplemental financial statement information - Other Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases - Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Intangible assets and goodwill - Schedule of Finite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Intangible assets and goodwill - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Intangible assets and goodwill - Schedule for Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Commitments and contingencies - Outstanding Contractual Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Commitments and contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Indebtedness - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Indebtedness - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Indebtedness - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Income taxes - Schedule of Components of Income Tax Provision (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Income taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Income taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Income taxes - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Income taxes - Schedule of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Stock-based compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Stock-based compensation - Schedule of Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Fair value (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Employee benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Selected quarterly financial data (unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 hqy-20240131_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 hqy-20240131_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 hqy-20240131_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Transfer-related expenses Asset Acquisition, Acquisition Related Costs Asset Acquisition, Acquisition Related Costs Deferred taxes Deferred Income Taxes and Tax Credits Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Other long-term liabilities Deferred Charges, Policy [Policy Text Block] Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Accrued liabilities Accrued Liabilities, Current Range [Domain] Statistical Measurement [Domain] Credit facility, amount Line of Credit Facility, Maximum Borrowing Capacity Technology and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expiration period after termination (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Equity Award [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Outstanding (in shares) Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Remaining operating lease terms (in years) Lessee, Operating Lease, Remaining Lease Term Further Acquisition Further Acquisition [Member] Further Acquisition Indebtedness Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cash paid Payments to Acquire Businesses, Gross Schedule of Allocation of Consideration Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Employer matching contribution expense Defined Contribution Plan, Employer Discretionary Contribution Amount Revolving Credit Facility Revolving Credit Facility [Member] Other issuance of common stock Stock Issued During Period, Value, Other Deferred tax liability Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Exercisable, weighted-average contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Computer equipment Computer equipment Computer Equipment [Member] Restatement Determination Date: Restatement Determination Date [Axis] Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Audit Information [Abstract] Audit Information [Abstract] Total other expense Total other expense Nonoperating Income (Expense) Thereafter Interest On Long-Term Debt, To Be Paid, After Year Five Interest On Long-Term Debt, To Be Paid, After Year Five Schedule of Unrecognized Tax Benefit Netted Against Deferred Tax Asset Schedule of Unrecognized Tax Benefits Netted Against Deferred Tax Assets [Table Text Block] Schedule of Unrecognized Tax Benefits Netted Against Deferred Tax Assets [Table Text Block] Commitments and contingencies (see Note 7) Commitments and Contingencies Prior presentation Previously Reported [Member] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Maximum coverage per incident under self-insurance Self Insurance, Maximum Coverage Per Incident Self Insurance, Maximum Coverage Per Incident 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Proceeds from follow-on equity offering, net of payments for offering costs Proceeds from Issuance of Common Stock Income taxes Income Tax Disclosure [Text Block] Leases Lessee, Leases [Policy Text Block] RA Customer Relationship RA Customer Relationship [Member] RA Customer Relationship [Member] Current liabilities Liabilities, Current [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Preferred stock par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of January 31, 2024 and 2023 Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted-average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Payment of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Diluted (in usd per share) Earnings Per Share, Diluted HSAs transferred, value Asset Acquisition, Customer Accounts Transferred, Value Asset Acquisition, Customer Accounts Transferred, Value PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Intangible assets, net Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Accounts receivable, net of allowance for doubtful accounts of $3,947 and $4,989 as of January 31, 2024 and 2023, respectively Accounts Receivable, after Allowance for Credit Loss, Current Luum Acquisition Luum Acquisition [Member] Luum Acquisition Vested and expected to vest, weighted-average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Line of Credit Line of Credit [Member] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Other expense Other Nonoperating Income (Expense) [Abstract] 2027 Interest On Long-Term Debt, To Be Paid, Year Three Interest On Long-Term Debt, To Be Paid, Year Three Debt instrument, amortization of loans, percentage of principal amount (as a percent) Debt Instrument, Periodic Repayments, Percentage Of Principal Amount Debt Instrument, Periodic Repayments, Percentage Of Principal Amount Trading Symbol Trading Symbol Letters of credit outstanding Letters of Credit Outstanding, Amount Current liabilities, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Fair value of the notes Long-Term Debt, Fair Value Net income (loss) Net income (loss) Net Income (Loss) Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Leases Lessee, Operating Leases [Text Block] Accrued interest Interest Payable, Current Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Cost of revenue Cost of Revenue [Abstract] Credit Agreement Credit Agreement [Member] Credit Agreement Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total non-cash stock-based compensation expense Total Non cash Share Based Payment Arrangement Expense [Member] Total Non cash Share Based Payment Arrangement Expense Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Stockholders’ equity Equity, Attributable to Parent [Abstract] Number of transfers Asset Acquisition, Number Of Transfers Asset Acquisition, Number Of Transfers Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Total cost of revenue Cost of Goods and Services Sold Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] 2027 Other Commitment, to be Paid, Year Three New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Name Measure Name Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Name Forgone Recovery, Individual Name Forfeited, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Goodwill Goodwill Goodwill Increases as a result of tax positions taken during a prior period Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Schedule of Estimated Useful Life of Property and Equipment Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Research Research Tax Credit Carryforward [Member] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accounts payable, accrued liabilities, and other current liabilities Increase (Decrease) in Accrued Liabilities Shares available for grant under incentive plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Investment Type [Axis] Investment Type [Axis] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] 2026 Long-Term Debt, Maturity, Year Two Asset Acquisition [Domain] Asset Acquisition [Domain] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Denominator (basic): Weighted Average Number of Shares Outstanding, Basic [Abstract] Accrued Compensation Employee-Related Liabilities, Current [Member] Employee-Related Liabilities, Current [Member] 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Investments [Domain] Investments [Domain] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letter of Credit Letter of Credit [Member] Forfeited, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Operating lease liabilities, non-current Lease liabilities, non-current Operating Lease, Liability, Noncurrent Summary of business and significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Restricted stock units Restricted stock units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Facility term (in years) Debt Instrument, Term Beginning balance, maximum (in usd per share) Ending balance, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation expense Depreciation Exercised, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Retirement Benefits [Abstract] Retirement Benefits [Abstract] Schedule of Payments Due By Fiscal Year For Our Outstanding Contractual Obligations Contractual Obligation, Fiscal Year Maturity [Table Text Block] Payment of debt issuance costs Payments of Debt Issuance Costs Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Less: unamortized discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Reclassifications Revision of Prior Period, Reclassification, Adjustment [Member] Acquired HSA portfolios Acquired HSA Portfolios Acquired HSA Intangible Assets [Member] Acquired HSA Intangible Assets [Member] Operating lease not yet commenced undiscounted amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Defined Contribution Plan [Table] Defined Contribution Plan [Table] Gains on equity securities Gain (Loss) on Sale of Investments Incentive Plan Incentive Plan [Member] Incentive Plan Other issuance of common stock (in shares) Stock Issued During Period, Shares, Other Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Accruals and reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Lease Cost Lease, Cost [Table Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Beginning balance, minimum (in usd per share) Ending balance, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Acquisition costs Business Combination, Acquisition Related Costs Award Type [Axis] Award Type [Axis] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Performance units awards (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Prepayment of debt Payment for Debt Extinguishment or Debt Prepayment Cost First year after the Effective Date Debt Instrument, Amortization Period One [Member] Debt Instrument, Amortization Period One Total Interest On Long-Term Debt, To Be Paid Interest On Long-Term Debt, To Be Paid Supplemental disclosures of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Interest expense Interest Expense Compensation not yet recognized, other than options Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Purchases of property and equipment included in accounts payable or accrued liabilities Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Supplemental financial statement information Additional Financial Information Disclosure [Text Block] Settlement of client-held funds obligation, net Payments For (Proceeds From) Settlement Of Client Held Funds Payments For (Proceeds From) Settlement Of Client Held Funds Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag General and administrative General and Administrative Expense [Member] Finite-lived intangible assets, acquired Finite-Lived Intangible Assets Acquired Property and equipment, gross Property, Plant and Equipment, Gross Selected quarterly financial data (unaudited) Quarterly Financial Information [Text Block] Outstanding stock options, weighted-average contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Reclassification [Line Items] Reclassification [Line Items] Use of estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Deferred tax liability, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Maximum leverage ratio Debt Instrument, Covenant, Net Leverage Ratio Debt Instrument, Covenant, Net Leverage Ratio Maximum borrowing capacity of future commitments Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Schedule of Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Operating lease liabilities Less: current portion of lease liabilities Operating Lease, Liability, Current Debt instrument, number of days to reinvest proceeds from sales of assets (in days) Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales Debt Instrument, Amortization Period [Domain] Debt Instrument, Amortization Period [Domain] Debt Instrument, Amortization Period 2027 Long-Term Debt, Maturity, Year Three Computer software intangible asset Computer Software, Intangible Asset [Member] Decreases as a result of tax positions taken during a prior period Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Restatement Adjustment Revision of Prior Period, Adjustment [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] 2028 Interest On Long-Term Debt, To Be Paid, Year Four Interest On Long-Term Debt, To Be Paid, Year Four Net carrying amount Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Increases as a result of tax positions taken during the current period Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Operating lease not yet commenced term of contract (in years) Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Beginning cash and cash equivalents Ending cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two London Interbank Offered Rate London Interbank Offered Rate [Member] London Interbank Offered Rate Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Technology and development Technology and Development [Member] Technology and Development [Member] Operating lease expense Operating Lease, Cost Common stock, shares issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Aggregate fair value of consideration paid Business Combination, Consideration Transferred Gross profit Gross Profit Commitment fee (as a percent) Line of Credit Facility, Commitment Fee Percentage Other non-deductible or non-taxable items, net Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Security Exchange Name Security Exchange Name Federal research and development credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Total Long-Term Debt Stock-based compensation Share-Based Payment Arrangement [Policy Text Block] 2029 Contractual Obligation, to be Paid, Year Five Thereafter Other Commitment, to be Paid, after Year Five 2028 Long-Term Debt, Maturity, Year Four 2025 Interest On Long-Term Debt, To Be Paid, Year One Interest On Long-Term Debt, To Be Paid, Year One Percentage of options vested (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Stock options Employee Stock Option [Member] Recognition period for stock-based compensation (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Lease liabilities Deferred Tax Assets, Lease Liability Deferred Tax Assets, Lease Liability Maximum Maximum [Member] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] 2028 Other Commitment, to be Paid, Year Four Document Type Document Type Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Change in uncertain tax position reserves, net of indirect benefits Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Fourth year after the Effective Date Debt Instrument, Amortization Period Four [Member] Debt Instrument, Amortization Period Four Tabular List, Table Tabular List [Table Text Block] Sales and marketing Sales and Marketing [Member] Sales and Marketing [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Thereafter Long-Term Debt, Maturity, after Year Five 2026 Interest On Long-Term Debt, To Be Paid, Year Two Interest On Long-Term Debt, To Be Paid, Year Two Subsequent Event [Table] Subsequent Event [Table] Amounts netted against related deferred tax assets Unrecognized Tax Benefits, Amount Netted Against Deferred Tax Assets Unrecognized Tax Benefits, Amount Netted Against Deferred Tax Assets Lessee, operating lease, number of extensions (in years) Lessee, Operating Lease, Number Of Extensions Lessee, Operating Lease, Number Of Extensions Stock-based compensation Share-Based Payment Arrangement [Text Block] Federal Current Federal Tax Expense (Benefit) Capitalized contract cost Capitalized Contract Cost, Net Other non-cash items Other Noncash Income (Expense) Weighted- average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Delano Ladd [Member] Delano Ladd Business Acquisition [Axis] Business Acquisition [Axis] Remaining performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage Accounts receivable, allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Acquired trade names and trademarks Trademarks and Trade Names [Member] Subsequent Event Subsequent Event [Member] Unrecognized tax benefits, income tax penalties and interest accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Operating loss carryforwards Operating Loss Carryforwards Return-to-provision adjustments Effective Income Tax Rate Reconciliation, Return-To-Provision Adjustments Effective Income Tax Rate Reconciliation, Return-To-Provision Adjustments Self-insurance Self Insurance Reserve [Policy Text Block] State Deferred State and Local Income Tax Expense (Benefit) Schedule of Useful Lives of Intangible Assets Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Second and third years after the Effective Date Debt Instrument, Amortization Period Two and Three Period [Member] Debt Instrument, Amortization Period Two and Three Period Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] HSA HSA [Member] HSA Other miscellaneous income (expense) Other Nonoperating Income (Expense), Miscellaneous Other Nonoperating Income (Expense), Miscellaneous Capitalized contract cost, amortization period (in years) Capitalized Contract Cost, Amortization Period Sublease income Sublease Income Business combinations Business Combination Disclosure [Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] 2025 Other Commitment, to be Paid, Year One Outstanding, beginning balance (in usd per share) Outstanding, ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Numerator (basic and diluted): Net Income (Loss) Attributable to Parent [Abstract] Issuance of common stock upon exercise of options, and for restricted stock Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Federal income tax provision (benefit) at the statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Non-passive Custodial Fund Non - Passive Custodial funds [Member] Non - Passive Custodial funds Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number 4.50% Senior Notes due 2029 4.500% Senior Notes due 2029 [Member] 4.500% Senior Notes due 2029 Amortization of capitalized contract costs Capitalized Contract Cost, Amortization Net operating lease cost Lease, Cost Range [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Total consideration paid, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount 2026 Other Commitment, to be Paid, Year Two Right of use asset Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Asset Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Asset Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Purchase price Payments To Acquire Assets Payments To Acquire Assets Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Other Expense, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Interest On Long-Term Debt, Fiscal Year Maturity [Abstract] Interest On Long-Term Debt, Fiscal Year Maturity [Abstract] Interest On Long-Term Debt, Fiscal Year Maturity Amortization of acquired intangible assets Amortization Of Acquired Intangible Amortization of Acquired Intangible Accumulated earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue recognition Revenue from Contract with Customer [Policy Text Block] Principal amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Leases [Abstract] Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Late charge percentage Lessee, Operating Lease, Late Charge, Percentage Lessee, Operating Lease, Late Charge, Percentage Goodwill Deferred Tax Liabilities, Goodwill 2028 Purchase Obligation, to be Paid, Year Four Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] 2025 Purchase Obligation, to be Paid, Year One 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating cash flows from operating leases Operating Lease, Payments Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Liability for self-insured medical claims Self Insurance Reserve, Current Impairment of right-of-use assets Operating Lease, Impairment Loss Net income (loss) per share: Net income (loss) per share: Earnings Per Share, Basic [Abstract] PEO PEO [Member] Auditor Location Auditor Location Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] State income tax provision (benefit), net of federal tax provision (benefit) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Custodial revenue Financial Service, Other [Member] Common stock, par value per share (in usd per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Exercised, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Grant date fair value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Total Lessee, Operating Lease, Liability, To Be Paid, Including Leases Not Yet Commenced Lessee, Operating Lease, Liability, To Be Paid, Including Leases Not Yet Commenced Change in goodwill Goodwill, Period Increase (Decrease) Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax benefit rate Effective Income Tax Rate Reconciliation, Percent Current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Schedule of Quarterly Financial Information Quarterly Financial Information [Table Text Block] Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Operating lease liability Present value of lease liabilities Operating Lease, Liability Vested and expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Service revenue Service [Member] Total current tax provision Current Income Tax Expense (Benefit) Weighted-average number of shares used in computing net income (loss) per share: Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Asset Acquisition [Axis] Asset Acquisition [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] HSA Portfolio HSA Portfolio [Member] HSA Portfolio All Executive Categories All Executive Categories [Member] Long-term liabilities Liabilities, Noncurrent [Abstract] Other items, net Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Unrecognized tax benefits recorded on the consolidated balance sheet Unrecognized Tax Benefit, Net Unrecognized Tax Benefit, Net Plan Name [Axis] Plan Name [Axis] Purchases of software and capitalized software development costs Payments for Software Debt Disclosure [Abstract] Debt Disclosure [Abstract] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Accounts receivable Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Sales and marketing Selling and Marketing Expense Common stock, $0.0001 par value, 900,000 shares authorized, 86,127 and 84,758 shares issued and outstanding as of January 31, 2024 and 2023, respectively Common Stock, Value, Issued Redemption price (as a percent) Debt Instrument, Redemption Price, Percentage General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Acquired trade names Trade Names [Member] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Senior Notes Senior Notes [Member] Segments Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current BenefitWallet HSA Portfolio Acquisition, Fiscal Year Maturity [Abstract] BenefitWallet HSA Portfolio Acquisition, Fiscal Year Maturity [Abstract] BenefitWallet HSA Portfolio Acquisition, Fiscal Year Maturity Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] All Individuals All Individuals [Member] Supplemental cash flow data: Supplemental Cash Flow Information [Abstract] Union Mesa Union Mesa [Member] Union Mesa Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Other income (expense), net Total other income (expense), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Retirement Plan Name [Domain] Retirement Plan Name [Domain] Total Purchase Obligation Passive Custodial Funds Passive Custodial Funds [Member] Passive Custodial Funds Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Range of exercise prices Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract] Gross unrecognized tax benefit Gross unrecognized tax benefits at beginning of year Gross unrecognized tax benefits at end of year Total gross unrecognized tax benefits Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] Excess tax (benefit) shortfall on stock-based compensation expense, net Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount PEO Name PEO Name Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Customary Base Rate Base Rate [Member] 2025 Contractual Obligation, to be Paid, Year One Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] Supplemental Employee Retirement Plan Supplemental Employee Retirement Plan [Member] Weighted-average grant date fair value (in usd per share) Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Stock compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Excessive employee remuneration Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Employee Remuneration Payments, Amount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Employee Remuneration Payments, Amount Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] October 1, 2026 and thereafter Debt Instrument, Redemption, Period Three [Member] Depreciation and amortization Depreciation, Depletion and Amortization Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Furniture and fixtures Furniture and fixtures Furniture and Fixtures [Member] Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Accrued compensation Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Unrecognized tax benefits that would impact the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Goodwill impairment Goodwill, Impairment Loss Purchases of intangible assets Noncash or Part Noncash Acquisition, Intangible Assets Acquired Restricted stock awards Restricted Stock [Member] Deferred tax asset, valuation allowance Less valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Deferred tax rate adjustment due to state apportionment changes Effective Income Tax Rate Reconciliation, Deferred Taxes, State Apportionment Changes Effective Income Tax Rate Reconciliation, Deferred Taxes, State Apportionment Changes Deferred revenue Contract with Customer, Liability, Revenue Recognized Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Restatement [Domain] Revision of Prior Period [Domain] Subsequent Events [Abstract] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Acquisitions of HSA portfolios Payments to Acquire Intangible Assets Long-term Debt, Fiscal Year Maturity [Abstract] Long-Term Debt, Fiscal Year Maturity [Abstract] 2027 Contractual Obligation, to be Paid, Year Three Retirement Plan Name [Axis] Retirement Plan Name [Axis] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Debt issuance costs, net Debt Issuance Costs, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Stephen Neeleman [Member] Stephen Neeleman Total gross deferred tax assets Deferred Tax Assets, Gross 2029 Purchase Obligation, to be Paid, Year Five Effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Number of HSAs transferred Asset Acquisition, Number Of Customer Accounts Transferred Asset Acquisition, Number Of Customer Accounts Transferred Total consideration paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Period increase in unrecognized tax benefit Unrecognized Tax Benefits, Period Increase (Decrease) Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Debt instrument, prepayment covenant, percentage of proceeds from sales to used to prepay (as a percent) Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Useful life of finite-lived intangible asset (in years) Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Opening balance (in usd per share) Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Prior to October 1, 2024, 40% of Principal Debt Instrument, Redemption, Period Five [Member] Common stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net income (loss) per share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Decreases resulting from the lapse of the applicable statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Document Fiscal Year Focus Document Fiscal Year Focus Acquired customer relationships 401(k) Customer Relationships [Member] 401(k) Customer Relationships [Member] Software and software development costs Software and Software Development Costs [Member] Unrecognized tax benefits, income tax penalties and interest expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Minimum Minimum [Member] Denominator (diluted): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Maximum amount of contingent consideration payable Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Proceeds from long-term debt Proceeds from Issuance of Long-Term Debt Other, net Deferred Tax Assets, Other Income tax payments (refunds), net Income Taxes Paid, Net Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Retirement Plan Type [Axis] Retirement Plan Type [Axis] Minimum net worth above custodial assets (as a percent) Minimum Net Worth Above Custodial Assets Minimum Net Worth Above Custodial Assets Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Ownership interest (as a percent) Business Acquisition, Percentage of Voting Interests Acquired Acquired developed technology Developed Technology Rights [Member] Accumulated earnings Retained Earnings [Member] Current portion of long-term debt Less: current portion of long-term debt Long-Term Debt, Current Maturities Schedule of Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic (in usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized stock compensation expense related to options to be recognized in future Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Incremental contract costs Deferred Tax Liabilities, Incremental Contract Costs Deferred Tax Liabilities, Incremental Contract Costs Arrangement Duration Trading Arrangement Duration Acquisition awards exchanged for cash Equity Awards Exchanged For Cash In Business Combination [Member] Equity Awards Exchanged For Cash In Business Combination Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] WageWorks, Inc. Wage Works Inc. [Member] Wage Works Inc. 2026 Purchase Obligation, to be Paid, Year Two Fifth year after the Effective Date Debt Instrument, Amortization Period Five [Member] Debt Instrument, Amortization Period Five Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Principles of consolidation Consolidation, Policy [Policy Text Block] 2027 Purchase Obligation, to be Paid, Year Three Total long-term liabilities Liabilities, Noncurrent Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Goodwill, adjustments Goodwill, Purchase Accounting Adjustments Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Entity Public Float Entity Public Float Gain on equity securities Equity Securities, FV-NI, Gain (Loss) Decrease in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Principal amount Principal amount Long-Term Debt, Gross Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Lessee, operating lease, abated rent, period Lessee, Operating Lease, Abated Rent, Period Lessee, Operating Lease, Abated Rent, Period All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Cash and cash equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] 401(k) 401(k) [Member] 401(k) [Member] Compensation Amount Outstanding Recovery Compensation Amount Credit losses from trade receivables Accounts Receivable, Credit Loss Expense (Reversal) Additional paid-in capital Additional Paid in Capital Reclassification [Table] Reclassification [Table] Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Right-of-use assets Deferred Tax Liabilities, Leasing Arrangements Total deferred tax benefit Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Contractual Obligation, Fiscal Year Maturity [Abstract] Contractual Obligation, Fiscal Year Maturity [Abstract] Income tax provision (benefit) Income Tax, Policy [Policy Text Block] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Percent of employees eligible earnings (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Insider Trading Arrangements [Line Items] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss 2025 Long-Term Debt, Maturity, Year One Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value October 1, 2024 Debt Instrument, Redemption, Period One [Member] Asset acquisition, transferred, transaction cost Asset Acquisition, Consideration Transferred, Transaction Cost Issuance of common stock upon exercise of options, and for restricted stock (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Weighted-average dilutive effect of stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Other assets Increase (Decrease) in Other Operating Assets 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Current assets, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current asset Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current asset Thereafter Contractual Obligation, to be Paid, after Year Five Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of revenue Cost of Sales [Member] Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Exercise of common stock options receivable Exercise of Stock Options Receivable Exercise of Stock Options Receivable WageWorks Inc. WageWorks Inc. [Member] WageWorks Inc. [Member] Auditor Name Auditor Name Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Exercisable, weighted-average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Thereafter Purchase Obligation, to be Paid, after Year Five Proceeds from sale of operating lease Proceeds From Sale Of Operating Lease, Right-Of-Use Asset Proceeds From Sale Of Operating Lease, Right-Of-Use Asset Principal payments on long-term debt Repayments of Long-Term Debt Entity Central Index Key Entity Central Index Key Amortization of debt issuance costs Amortization of Debt Issuance Costs and Discounts Prepaid expense Prepaid Expense Total stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross carrying amount Finite-Lived Intangible Assets, Gross Income tax provision (benefit) Total income tax provision (benefit) Income Tax Expense (Benefit) Income Tax Authority [Domain] Income Tax Authority [Domain] Accrued compensation Employee-related Liabilities, Current Fair value Fair Value Disclosures [Text Block] Operating lease liabilities, non-current Increase (Decrease) In Operating Lease, Liability, Noncurrent Increase (Decrease) In Operating Lease, Liability, Noncurrent Merger integration Business Combination, Integration Related Costs Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Impairment of long-lived assets to be disposed of Impairment of Long-Lived Assets to be Disposed of 2028 Contractual Obligation, to be Paid, Year Four Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Credit spread adjustment on variable rate (as a percent) Debt Instrument, Credit Spread Adjustment On Variable Rate Debt Instrument, Credit Spread Adjustment On Variable Rate Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Interchange revenue Credit and Debit Card [Member] Minimum interest coverage ratio Debt Instrument, Covenant, Minimum Interest Coverage Ratio Debt Instrument, Covenant, Minimum Interest Coverage Ratio Performance restricted stock units Performance restricted stock units Performance Restricted Stock Units [Member] Performance Restricted Stock Units [Member] Decrease (increase) in goodwill due to measurement period adjustments, net Noncash Changes In Goodwill, Measurement Period Adjustments Noncash Changes In Goodwill, Measurement Period Adjustments Credit carryforward Tax Credit Carryforward, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Business combinations, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Performance restricted stock awards Performance Restricted Stock Awards [Member] Performance Restricted Stock Awards [Member] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Interest expense paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Prior to October 1, 2024 Debt Instrument, Redemption, Period Four [Member] Credit Facility [Domain] Credit Facility [Domain] Asset acquisitions and Business combinations Business Combinations Policy [Policy Text Block] Variable rate borrowing spread (as a percent) Debt Instrument, Basis Spread on Variable Rate Useful life of property, plant and equipment (in years) Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt, net of issuance costs Long-term debt, net Long-Term Debt, Excluding Current Maturities Leasehold Improvements Leasehold improvements Leasehold Improvements [Member] Net deferred tax liabilities Deferred Tax Liabilities, Net Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted 2029 Interest On Long-Term Debt, To Be Paid, Year Five Interest On Long-Term Debt, To Be Paid, Year Five Client-held funds Client Held Funds [Policy Text Block] Client Held Funds [Policy Text Block] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Adjustment from settlement of IRS examination Effective Income Tax Rate Reconciliation, Tax Settlement, Amount Total Other Commitment Operating expenses Operating Expenses [Abstract] Decreases as a result of settlement Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Capitalized research and development Deferred Tax Assets, Capitalized Research and Development Costs Deferred Tax Assets, Capitalized Research and Development Costs Additional paid-in capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Proceeds from sale of equity securities Proceeds from Sale of Equity Securities, FV-NI Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Other Commitment, Fiscal Year Maturity [Abstract] Other Commitment, Fiscal Year Maturity [Abstract] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Restatement [Axis] Revision of Prior Period [Axis] Cover [Abstract] Interest income Investment Income, Nonoperating Vested and expected to vest, weighted-average contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Subsequent events Subsequent Events [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 2029 Long-Term Debt, Maturity, Year Five Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Research and development credits Deferred Tax Assets, Tax Credit Carryforwards, Research, Noncurrent Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. Other long-term liabilities Other Liabilities, Noncurrent Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Gross lease liabilities Lessee, Operating Lease, Liability, to be Paid Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Other expense, net Other Nonoperating Income (Expense) [Member] Term Loan Facility Term Loan Facility [Member] Term Loan Facility Employee benefits Compensation and Employee Benefit Plans [Text Block] Interest expense Interest Expense, Policy [Policy Text Block] Total operating expenses Total operating expenses Operating Expenses Prime Rate Prime Rate [Member] Increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Debt Instrument, Amortization Period [Axis] Debt Instrument, Amortization Period [Axis] Debt Instrument, Amortization Period Secured Debt Secured Debt [Member] 2029 Other Commitment, to be Paid, Year Five Non-PEO NEO Non-PEO NEO [Member] Lease renewal terms extension (in years) Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Operating lease right-of-use assets Increase Decrease In Operating Lease Right Of Use Asset Increase Decrease In Operating Lease Right Of Use Asset Adjustment to Compensation: Adjustment to Compensation [Axis] State State and Local Jurisdiction [Member] Total Contractual Obligation Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Other, net Deferred Tax Liabilities, Other Net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Fixed assets Deferred Tax Assets, Property, Plant and Equipment Entity Current Reporting Status Entity Current Reporting Status Luum and Further Luum and Further [Member] Luum and Further Income (loss) from operations Operating Income (Loss) Fixed assets Deferred Tax Liabilities, Property, Plant and Equipment October 1, 2025 Debt Instrument, Redemption, Period Two [Member] Other assets Other Assets [Policy Text Block] Other Assets [Policy Text Block] Revenue Revenues [Abstract] Total gross deferred tax liabilities Deferred Tax Liabilities, Gross 2026 Contractual Obligation, to be Paid, Year Two Percentage of principal amount redeemed (as a percent) Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Sublease income to be received Sublease Income, To Be Received Sublease Income, To Be Received Property and equipment Property, Plant and Equipment, Policy [Policy Text Block] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Intangible assets Deferred Tax Liabilities, Intangible Assets Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Acquired customer relationships Customer Relationships [Member] Expiration period from termination of employment (in days) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period from Termination of Employment Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period from Termination of Employment Debt instrument, number of days to commit to reinvesting proceeds from sales of assets after initial period (in days) Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period Software and software development costs Computer Software And Capitalized Software Development Costs [Member] Computer Software And Capitalized Software Development Costs [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] EX-101.PRE 13 hqy-20240131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 hqy-20240131_g1.jpg begin 644 hqy-20240131_g1.jpg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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover Page - USD ($)
$ in Billions
12 Months Ended
Jan. 31, 2024
Mar. 13, 2024
Jul. 31, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Jan. 31, 2024    
Current Fiscal Year End Date --01-31    
Document Transition Report false    
Entity File Number 001-36568    
Entity Registrant Name HEALTHEQUITY, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 52-2383166    
Entity Address, Address Line One 15 West Scenic Pointe Drive    
Entity Address, Address Line Two Suite 100    
Entity Address, City or Town Draper    
Entity Address, State or Province UT    
Entity Address, Postal Zip Code 84020    
City Area Code 801    
Local Phone Number 727-1000    
Title of 12(b) Security Common stock, par value $0.0001 per share    
Trading Symbol HQY    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 5.1
Entity Common Stock, Shares Outstanding   86,158,631  
Documents Incorporated by Reference
Portions of the Registrant's definitive proxy statement related to its 2024 annual meeting of stockholders (the "2024 Proxy Statement") are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2024 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
   
Entity Central Index Key 0001428336    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Audit Information
12 Months Ended
Jan. 31, 2024
Audit Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Salt Lake City, Utah
Auditor Firm ID 238
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated balance sheets - USD ($)
$ in Thousands
Jan. 31, 2024
Jan. 31, 2023
Current assets    
Cash and cash equivalents $ 403,979 $ 254,266
Accounts receivable, net of allowance for doubtful accounts of $3,947 and $4,989 as of January 31, 2024 and 2023, respectively 104,893 96,835
Other current assets 48,564 31,792
Total current assets 557,436 382,893
Property and equipment, net 6,013 12,862
Operating lease right-of-use assets 48,380 56,461
Intangible assets, net 835,948 936,359
Goodwill 1,648,145 1,648,145
Other assets 67,868 52,180
Total assets 3,163,790 3,088,900
Current liabilities    
Accounts payable 12,041 13,899
Accrued compensation 49,608 45,835
Accrued liabilities 46,038 43,668
Current portion of long-term debt 0 17,500
Operating lease liabilities 9,404 10,159
Total current liabilities 117,091 131,061
Long-term liabilities    
Long-term debt, net of issuance costs 874,972 907,838
Operating lease liabilities, non-current 48,766 58,988
Other long-term liabilities 19,270 12,708
Deferred tax liability 68,670 82,665
Total long-term liabilities 1,011,678 1,062,199
Total liabilities 1,128,769 1,193,260
Commitments and contingencies (see Note 7)
Stockholders’ equity    
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of January 31, 2024 and 2023 0 0
Common stock, $0.0001 par value, 900,000 shares authorized, 86,127 and 84,758 shares issued and outstanding as of January 31, 2024 and 2023, respectively 9 8
Additional paid-in capital 1,829,384 1,745,716
Accumulated earnings 205,628 149,916
Total stockholders’ equity 2,035,021 1,895,640
Total liabilities and stockholders’ equity $ 3,163,790 $ 3,088,900
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated balance sheets (Parenthetical) - USD ($)
$ in Thousands
Jan. 31, 2024
Jan. 31, 2023
Statement of Financial Position [Abstract]    
Accounts receivable, allowance for doubtful accounts $ 3,947 $ 4,989
Preferred stock par value (in usd per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 100,000,000 100,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value per share (in usd per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 900,000,000 900,000,000
Common stock, shares issued (in shares) 86,127,000 84,758,000
Common stock, shares outstanding (in shares) 86,127,000 84,758,000
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated statements of operations and comprehensive income (loss) - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Revenue      
Total revenue $ 999,587 $ 861,748 $ 756,556
Cost of revenue      
Total cost of revenue 376,950 369,813 331,791
Gross profit 622,637 491,935 424,765
Operating expenses      
Sales and marketing 79,273 68,849 58,605
Technology and development 218,811 193,375 157,364
General and administrative 103,656 97,472 85,438
Amortization of acquired intangible assets 92,763 94,586 82,791
Merger integration 10,435 28,596 64,805
Total operating expenses 504,938 482,878 449,003
Income (loss) from operations 117,699 9,057 (24,238)
Other expense      
Interest expense (55,455) (48,424) (36,572)
Other income (expense), net 12,796 1,271 (5,931)
Total other expense (42,659) (47,153) (42,503)
Income (loss) before income taxes 75,040 (38,096) (66,741)
Income tax provision (benefit) 19,328 (11,953) (22,452)
Net income (loss) 55,712 (26,143) (44,289)
Comprehensive income (loss) $ 55,712 $ (26,143) $ (44,289)
Net income (loss) per share:      
Basic (in usd per share) $ 0.65 $ (0.31) $ (0.53)
Diluted (in usd per share) $ 0.64 $ (0.31) $ (0.53)
Weighted-average number of shares used in computing net income (loss) per share:      
Basic (in shares) 85,564 84,442 83,133
Diluted (in shares) 86,957 84,442 83,133
Service revenue      
Revenue      
Total revenue $ 455,690 $ 452,026 $ 443,608
Cost of revenue      
Total cost of revenue 317,357 318,516 291,618
Custodial revenue      
Revenue      
Total revenue 386,594 261,282 186,119
Cost of revenue      
Total cost of revenue 32,502 26,101 19,492
Interchange revenue      
Revenue      
Total revenue 157,303 148,440 126,829
Cost of revenue      
Total cost of revenue $ 27,091 $ 25,196 $ 20,681
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated statements of stockholders' equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated earnings
Beginning balance (in shares) at Jan. 31, 2021   77,168    
Beginning balance at Jan. 31, 2021 $ 1,378,728 $ 8 $ 1,158,372 $ 220,348
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock upon exercise of options, and for restricted stock (in shares)   862    
Issuance of common stock upon exercise of options, and for restricted stock 8,746   8,746  
Other issuance of common stock (in shares)   5,750    
Other issuance of common stock 456,640   456,640  
Stock-based compensation 52,750   52,750  
Net income (loss) (44,289)     (44,289)
Ending balance (in shares) at Jan. 31, 2022   83,780    
Ending balance at Jan. 31, 2022 1,852,575 $ 8 1,676,508 176,059
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock upon exercise of options, and for restricted stock (in shares)   978    
Issuance of common stock upon exercise of options, and for restricted stock 6,594   6,594  
Stock-based compensation 62,614   62,614  
Net income (loss) (26,143)     (26,143)
Ending balance (in shares) at Jan. 31, 2023   84,758    
Ending balance at Jan. 31, 2023 1,895,640 $ 8 1,745,716 149,916
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock upon exercise of options, and for restricted stock (in shares)   1,369    
Issuance of common stock upon exercise of options, and for restricted stock 6,518 $ 1 6,517  
Stock-based compensation 77,151   77,151  
Net income (loss) 55,712     55,712
Ending balance (in shares) at Jan. 31, 2024   86,127    
Ending balance at Jan. 31, 2024 $ 2,035,021 $ 9 $ 1,829,384 $ 205,628
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated statements of cash flows - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Cash flows from operating activities:      
Net income (loss) $ 55,712 $ (26,143) $ (44,289)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Depreciation and amortization 153,078 161,201 137,188
Stock-based compensation 77,151 62,614 52,750
Impairment of right-of-use assets 0 0 11,246
Amortization of debt issuance costs 2,852 3,261 4,448
Loss on extinguishment of debt 1,157 0 4,049
Change in fair value of contingent consideration 0 0 (2,147)
Gains on equity securities 0 0 (1,677)
Other non-cash items 0 268 1,232
Deferred taxes (13,995) (17,181) (23,430)
Changes in operating assets and liabilities:      
Accounts receivable (8,058) (9,570) (11,204)
Other assets (32,790) 4,620 7,464
Operating lease right-of-use assets 10,190 8,244 15,235
Accrued compensation 2,951 (1,282) (3,657)
Accounts payable, accrued liabilities, and other current liabilities (204) (26,673) (2,178)
Operating lease liabilities, non-current (11,780) (7,232) (9,412)
Other long-term liabilities 6,562 (1,477) 5,377
Net cash provided by operating activities 242,826 150,650 140,995
Cash flows from investing activities:      
Business combinations, net of cash acquired 0 0 (504,533)
Purchases of software and capitalized software development costs (41,123) (45,173) (62,708)
Acquisitions of HSA portfolios (3,257) (70,583) (65,465)
Purchases of property and equipment (1,694) (3,371) (8,908)
Proceeds from sale of equity securities 0 0 2,367
Net cash used in investing activities (46,074) (119,127) (639,247)
Cash flows from financing activities:      
Principal payments on long-term debt (54,375) (8,750) (1,003,125)
Proceeds from long-term debt 0 0 950,000
Payment of debt issuance costs 0 0 (11,920)
Proceeds from follow-on equity offering, net of payments for offering costs 0 0 456,640
Settlement of client-held funds obligation, net 865 (603) (486)
Proceeds from exercise of common stock options 6,471 6,682 9,754
Payment of contingent consideration 0 0 (6,000)
Net cash provided by (used in) financing activities (47,039) (2,671) 394,863
Increase (decrease) in cash and cash equivalents 149,713 28,852 (103,389)
Beginning cash and cash equivalents 254,266 225,414 328,803
Ending cash and cash equivalents 403,979 254,266 225,414
Supplemental cash flow data:      
Interest expense paid in cash 49,560 43,570 16,107
Income tax payments (refunds), net 35,352 1,526 (5,632)
Supplemental disclosures of non-cash investing and financing activities:      
Purchases of property and equipment included in accounts payable or accrued liabilities 263 69 1,414
Decrease (increase) in goodwill due to measurement period adjustments, net 0 (2,309) 19
Exercise of common stock options receivable 429 382 470
Computer software intangible asset      
Supplemental disclosures of non-cash investing and financing activities:      
Purchases of intangible assets 3,145 3,595 4,640
Acquired HSA portfolios      
Supplemental disclosures of non-cash investing and financing activities:      
Purchases of intangible assets $ 0 $ 0 $ 1,692
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of business and significant accounting policies
12 Months Ended
Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of business and significant accounting policies Summary of business and significant accounting policies
Business
HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
In February 2006, HealthEquity received designation by the U.S. Department of Treasury to act as a passive non-bank custodian, which allows HealthEquity to hold custodial assets for individual account holders. On July 24, 2017, HealthEquity received designation by the U.S. Department of Treasury to act as both a passive and non-passive non-bank custodian, which allows HealthEquity to hold custodial assets for individual account holders and use discretion to direct investment of such assets held. As a passive and non-passive non-bank custodian according to Treasury Regulations section 1.408-2(e)(5)(ii)(B), the Company must maintain net worth (assets minus liabilities) greater than the sum of 2% of passive custodial funds held at each fiscal year-end and 4% of the non-passive custodial funds held at each fiscal year-end in order to take on additional custodial assets. As of January 31, 2024, the Company's year-end for trust and tax purposes, the net worth of the Company exceeded the required thresholds.
The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP. The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States and have been consistently applied in the preparation of the consolidated financial statements.
Reclassifications
Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The reclassifications relate primarily to recordkeeping and advisory fees associated with HSA investments of $25.6 million, $21.8 million, and $16.7 million for the fiscal years ended January 31, 2024, 2023, and 2022, respectively, which were reclassified from custodial revenue to service revenue to better align the Company's financial statement presentation with the underlying drivers of the Company's revenue streams. The Company also reclassified certain immaterial personnel-related costs from custodial costs to service costs or general and administrative costs. The reclassifications had no impact on the Company's total revenue, income (loss) from operations, net income (loss), cash flows, or stockholders' equity. See Note 13—Selected quarterly financial data for additional information and the impact of the reclassifications by quarter.
Principles of consolidation
The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Segments
The Company operates in one segment, which reflects the way in which its chief operating decision maker, the Chief Executive Officer, reviews the Company's financial performance and makes decisions about resource allocation. All long-lived assets are maintained in the United States of America.
Cash and cash equivalents
The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company’s cash and cash equivalents were held in institutions in the U.S. and include deposits in a money market account that was unrestricted as to withdrawal or use.
Client-held funds
Many of the Company's client services agreements with employers (referred to as "Clients") provide that Clients remit funds to the Company to pre-fund Client and employee participant contributions related to flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs,” respectively) and commuter accounts.
These Client-held funds remitted to the Company do not represent cash assets of the Company to the extent that they are not combined with corporate cash, and accordingly are not included in cash and cash equivalents on the Company's consolidated balance sheets.
Accounts receivable
Accounts receivable represent monies due to the Company for monthly service revenue, custodial revenue and interchange revenue. The Company maintains an allowance for doubtful accounts to reserve for expected credit losses from trade receivables considering past events, current conditions, and reasonable and supportable forecasts of future economic conditions. In evaluating the Company’s ability to collect outstanding receivable balances, the Company considers various factors including macroeconomic variables, the age of the balance, the creditworthiness of the customer, which is assessed based on ongoing credit evaluations and payment history, and the customer’s current financial condition.
Other assets
Other assets consist primarily of contract costs, prepaid expenditures, debt issuance costs, income tax receivables, and various other assets. Amounts expected to be recouped or recognized over a period of twelve months or less have been classified as current in the accompanying consolidated balance sheets.
Leases
The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices.
Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.
Property and equipment
Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Depreciation is determined using the straight-line method over the estimated useful lives of individual assets. The useful life for leasehold improvements is the shorter of the estimated useful life or the term of the lease ranging from 3-5 years. The useful life used for computing depreciation for all other asset classes is described below:
Computer equipment
3-5 years
Furniture and fixtures5 years
Maintenance and repairs are expensed when incurred, and improvements that extend the economic useful life of an asset are capitalized. Gains and losses on the disposal of property and equipment are reflected in operating expenses.
Intangible assets, net
Intangible assets are carried at cost and amortized, typically, on a straight-line basis over their estimated useful lives. The useful life used for computing amortization for all intangible asset classes is described below:
Software and software development costs3 years
Acquired customer relationships
7-15 years
Acquired developed technology
2-5 years
Acquired trade names and trademarks3 years
Acquired HSA portfolios15 years
The Company accounts for the costs of computer software developed or obtained for internal use in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software. Costs incurred during operation and post-implementation stages are charged to expense. Costs incurred during the application development stage that are directly attributable to developing or obtaining software for internal use are capitalized. Management’s judgment is required in determining the point when various projects enter the stages at which costs may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized.
Acquired customer relationships, developed technology, and trade names and trademarks are valued utilizing the discounted cash flow method, a form of the income approach. The useful lives of acquired customer relationships were estimated based on discount rates and revenue growth rates, net of attrition. The useful lives of developed technology and trade names were estimated based on expected obsolescence. The Company expenses the assets straight-line over the useful lives and determined that this amortization method is appropriate to reflect the pattern over which the economic benefits of these acquired assets are realized.
Acquired HSA portfolios consist of the contractual rights to administer the activities related to the individual HSAs acquired. The Company used its HSA customer relationship period assumption and the historical attrition rates of member accounts to determine that an average useful life of 15 years and the use of a straight-line amortization method are appropriate to reflect the pattern over which the economic benefits of existing member assets are realized.
The Company reviews identifiable amortizable intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually on January 31 or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company’s impairment tests are based on a single operating segment and reporting unit structure. The goodwill impairment test involves a qualitative assessment to compare a reporting unit's fair value to its carrying value. If it is determined that it is more likely than not that a reporting unit's fair value is less than its carrying value, a quantitative comparison is made between the Company's market capitalization and the carrying value of the reporting unit, including goodwill. If the carrying value of the reporting unit exceeds its fair value, an impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value.
Self-insurance
The Company is self-insured for medical insurance up to certain annual stop-loss limits. The Company establishes a liability as of the balance sheet date for claims, both reported and incurred but not reported, using currently available information as well as historical claims experience, and as determined by an independent third party.
Other long-term liabilities
Other long-term liabilities consists of long-term deferred revenue and other liabilities that the Company does not expect to settle within one year.
Revenue recognition
The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services.
The Company determines revenue recognition through the following steps:
identification of the contract, or contracts, with a customer;
identification of the performance obligations in the contract;
determination of the transaction price;
allocation of the transaction price to the performance obligations in the contract; and
recognition of revenue when, or as, the Company satisfies a performance obligation.
Disaggregation of revenue. The Company's primary sources of revenue are service, custodial, and interchange revenue and are disclosed in the consolidated statements of operations and comprehensive income (loss). All of the
Company's sources of revenue are deemed to be revenue contracts with customers. Each revenue source is affected differently by economic factors as it relates to the nature, amount, timing and uncertainty.
Costs to obtain a contract. ASC 606, Revenue from contracts with customers, requires capitalizing the costs of obtaining a contract when those costs are expected to be recovered.
In order to determine the amortization period for sales commissions contract costs, the Company applied the portfolio approach. Accordingly, the amortization period of the assets has been determined to be the average economic life of an HSA or other CDB relationship, which is estimated to be 15 years and 7 years, respectively. Amortization of capitalized sales commission contract costs is included in sales and marketing expenses in the consolidated statements of operations and comprehensive income (loss). The Company has applied the practical expedient which allows an entity to account for incremental costs of obtaining a contract at a portfolio level. The Company has also applied the practical expedient to recognize incremental costs of obtaining contracts as an expense when incurred if the amortization period would have been one year or less.
Performance obligations. ASC 606 requires disclosure of the aggregate amount of the transaction price allocated to unsatisfied performance obligations; however, as permitted by ASC 606, the Company has elected to exclude from this disclosure any contracts with an original duration of one year or less and any variable consideration that meets specified criteria.
Service revenue. The Company administers its platforms, prepares statements, provides a mechanism for spending funds, and provides customer support services. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA assets through the Company's investment partner from which the Company earns recordkeeping and advisory fees, calculated as a percentage of the member's HSA investments. All of these services are consumed as they are received. The Company recognizes service revenue, in an amount that reflects the consideration it expects to be entitled to in exchange for those services, on a monthly basis as it satisfies its performance obligations.
Custodial revenue. The Company earns custodial revenue primarily from HSA assets deposited with depository partners or placed in group annuity contracts or similar arrangements with insurance company partners and Client-held funds deposited with depository partners. The placement of funds represents a service that is simultaneously received and consumed by the depository partners and insurance company partners. The Company recognizes custodial revenue each month, in an amount that reflects the consideration it expects to be entitled to in exchange for the service.
Interchange revenue. The Company satisfies its interchange performance obligation each time payments are made with its cards via payment networks. The Company recognizes interchange revenue, in an amount that reflects the consideration it expects to be entitled to in exchange for the service, in the month the payment transaction occurs.
Contract balances. The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied.
Significant judgments. The Company makes no significant judgments in determining the amount or timing of revenue recognition. The Company has estimated the average economic life of an HSA or CDB member relationship, which has been determined to be the amortization period for the capitalized sales commissions contract costs.
Cost of revenue
The Company incurs cost of revenue related to servicing member accounts, managing customer and partner relationships, and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations, new member and participant supplies, and other operating costs of the member account servicing departments. Other components of the Company’s cost of revenue include interest retained by members on custodial assets held and interchange costs incurred in connection with processing card transactions initiated by members.
Stock-based compensation
The Company grants restricted stock units ("RSUs") to certain team members, executive officers, and directors. Historically, the Company also granted stock options and restricted stock awards ("RSAs") under the Incentive Plan. The Company recognizes compensation expense for stock-based awards based on the grant date estimated fair
value. Expense for stock-based awards is generally recognized on a straight-line basis over the requisite service period and is reversed as pre-vesting forfeitures occur. The fair value of stock options was determined using the Black-Scholes option pricing model. The determination of fair value for stock options on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. The fair value of RSUs is based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate.
For stock-based awards with performance conditions, the Company evaluates the probability of achieving the performance criteria and of the number of shares that are expected to vest, and compensation expense is then adjusted to reflect the number of shares expected to vest and the requisite service period. For awards with performance conditions, compensation expense is recognized using the graded-vesting attribution method in accordance with the provisions of ASC 718, Compensation—Stock Compensation ("Topic 718"). Compensation expense related to stock-based awards with market conditions is recorded on a straight-line basis over the requisite service period regardless of whether the market condition is satisfied.
Upon the exercise of a stock option or release of an RSU, common shares are issued from authorized, but not outstanding, common stock.
Interest expense
Interest expense consists primarily of accrued interest expense and amortization of deferred financing costs associated with long-term debt.
Income tax provision (benefit)
The Company accounts for income taxes and the related accounts under the asset and liability method as set forth in ASC 740, Income Taxes. Under this method, current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, for net operating losses, and for tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. The effect on deferred tax assets and liabilities of changes in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for when it is more likely than not that some or all of the deferred tax assets may not be realized in future years.
The Company recognizes the tax benefit from an uncertain tax position taken or expected to be taken in a tax return using a two-step approach. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authorities, based on the technical merits of the position. For tax positions that are more likely than not to be sustained upon audit, the second step is to measure the tax benefit in the financial statements as the largest benefit that has a greater than 50% likelihood of being sustained upon settlement. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as a component of other income (expense), net in the consolidated statements of operations and comprehensive income (loss). Changes in facts and circumstances could have a material impact on the Company’s effective tax rate and results of operations.
Asset acquisitions
The Company routinely acquires rights to be the custodian of HSA portfolios, in which substantially all of the fair value of the gross portfolio assets acquired is concentrated in a group of similar HSA assets and therefore the acquisitions do not constitute a business. Accordingly, the acquisitions are accounted for under the asset acquisition method of accounting in accordance with ASC 805-50, Business Combinations—Related Issues. Under the asset acquisition method of accounting, the Company is required to fair value the assets transferred. The cost of the assets acquired, including transaction costs incurred in conjunction with an asset acquisition, is allocated to the individual assets acquired based on their relative fair values and does not give rise to goodwill.
Business combinations
Consideration paid for the acquisition of a business as defined by ASC 805-10 is allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date.
Acquisition-related expenses incurred in conjunction with the acquisition of a business are recognized in earnings in the period in which they are incurred and are included in other income (expense), net on the consolidated statements of operations and comprehensive income (loss).
Use of estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management has made estimates for the allowance for doubtful accounts, capitalized software development costs, evaluating goodwill and long-lived assets for impairment, useful lives of property and equipment and intangible assets, accrued compensation, accrued liabilities, grant date fair value of stock options and performance restricted stock units and restricted stock awards, and income taxes. Actual results could differ from those estimates.
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of other segment items, interim disclosure of a reportable segment’s profit or loss and assets, the title and position of the CODM, and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The ASU requires public companies with a single reportable segment to provide the segment disclosures required by Topic 280 and will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the ASU to determine its impact on our disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for annual periods beginning after December 15, 2024. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. We are currently evaluating the ASU to determine its impact on our income tax disclosures.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Net income (loss) per share
12 Months Ended
Jan. 31, 2024
Earnings Per Share [Abstract]  
Net income (loss) per share Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
Year ended January 31,
(in thousands, except per share data)202420232022
Numerator (basic and diluted):
Net income (loss)$55,712 $(26,143)$(44,289)
Denominator (basic):
Weighted-average common shares outstanding85,564 84,442 83,133 
Denominator (diluted):
Weighted-average common shares outstanding85,564 84,442 83,133 
Weighted-average dilutive effect of stock options and restricted stock units1,393 — — 
Diluted weighted-average common shares outstanding86,957 84,442 83,133 
Net income (loss) per share:
Basic $0.65 $(0.31)$(0.53)
Diluted$0.64 $(0.31)$(0.53)
For the fiscal years ended January 31, 2024, 2023 and 2022, 0.6 million, 2.5 million, and 1.8 million shares, respectively, attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted net income (loss) per share as their inclusion would have been anti-dilutive.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Business combinations
12 Months Ended
Jan. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Business combinations Business combinations
Luum acquisition
On March 8, 2021, the Company acquired 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition"). The aggregate purchase price for the acquisition consisted of $56.2 million in cash, which reflects a $2.1 million reduction in the fair value of contingent consideration during the fiscal year ended January 31, 2022.
The Luum Acquisition was accounted for under the acquisition method of accounting for business combinations. The consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and was subject to adjustment during the measurement period (up to one year from the acquisition date). The purchase price allocation was finalized during the three months ended April 30, 2022.
The following table summarizes the Company's allocation of the consideration paid:
(in thousands)Estimated fair valueAdjustmentsUpdated Allocation
Cash and cash equivalents$626 $— $626 
Other current assets1,469 — 1,469 
Intangible assets23,900 — 23,900 
Goodwill36,374 (19)36,355 
Other assets100 — 100 
Current liabilities(597)— (597)
Deferred tax liability(3,566)19 (3,547)
Total consideration paid$58,306 $— $58,306 
The adjustments to the initial allocation were based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters.
Further acquisition
On November 1, 2021, the Company completed its acquisition of the Further business (other than Further's voluntary employee beneficiary association business) for $455 million (the "Further Acquisition").
The Further Acquisition was accounted for under the acquisition method of accounting for business combinations. The consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and was subject to adjustment during the measurement period (up to one year from the acquisition date). The purchase price allocation was finalized during the three months ended January 31, 2023.
The following table summarizes the Company's allocation of the consideration paid:
(in thousands)Estimated fair valueAdjustmentsUpdated Allocation
Current assets$2,667 $(163)$2,504 
Intangible assets172,183 — 172,183 
Goodwill282,287 2,309 284,596 
Current liabilities(2,137)(2,146)(4,283)
Total consideration paid$455,000 $— $455,000 
The adjustments to the initial allocation were based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Supplemental financial statement information
12 Months Ended
Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental financial statement information Supplemental financial statement information
Selected consolidated balance sheet and consolidated statement of operations and comprehensive income (loss) components consisted of the following:
Allowance for doubtful accounts
As of January 31, 2024 and 2023, the Company had an allowance for doubtful accounts of $3.9 million and $5.0 million, respectively. During the fiscal years ended January 31, 2024, 2023, and 2022, the Company recorded credit losses from trade receivables of $1.7 million, $2.1 million, and $3.3 million, respectively.
Prepaid expenses
As of January 31, 2024 and 2023, the Company had prepaid expenses of $31.2 million and $20.1 million, respectively, which are included within other current assets on the Company's consolidated balance sheets.
Costs to obtain a contract
As of January 31, 2024 and 2023, the net amount capitalized as contract costs was $52.1 million and $44.0 million, respectively, which is included in other current assets and other assets. Amortization of capitalized contract costs during the fiscal years ended January 31, 2024, 2023, and 2022 was $5.4 million, $4.4 million, and $4.3 million, respectively.
Property and equipment
Property and equipment consisted of the following as of January 31, 2024 and 2023:
(in thousands)January 31, 2024January 31, 2023
Leasehold improvements$14,455 $18,269 
Furniture and fixtures7,087 8,392 
Computer equipment25,489 28,021 
Property and equipment, gross47,031 54,682 
Accumulated depreciation(41,018)(41,820)
Property and equipment, net$6,013 $12,862 
Depreciation expense for the fiscal years ended January 31, 2024, 2023 and 2022 was $8.8 million, $12.3 million and $14.7 million, respectively.
Contract balances
As of January 31, 2024 and 2023, the balance of deferred revenue was $6.2 million and $8.3 million, respectively. The balances are related to cash received in advance for interchange and custodial revenue arrangements, other up-front fees and other commuter deferred revenue. The Company expects to recognize approximately 77% of its balance of deferred revenue as revenue over the next 12 months and the remainder thereafter. Amounts expected to be recognized as revenue within a period of twelve months or less are classified as accrued liabilities in the Company's consolidated balance sheets, with the remainder included within other long-term liabilities. Revenue recognized during the fiscal year that was included in the beginning balance of deferred revenue was $4.8 million. The Company expects to satisfy its remaining obligations for these arrangements.
Other income (expense), net
Other income (expense), net, consisted of the following:
Year ended January 31,
(in thousands)202420232022
Interest income$12,138 $1,763 $1,501 
Gain on equity securities— — 1,692 
Acquisition costs— (53)(10,832)
Other miscellaneous income (expense)658 (439)1,708 
Total other income (expense), net$12,796 $1,271 $(5,931)
Interest expense
Based on the application of ASC 470-50, Debt - Modifications and Extinguishments, the Company recorded debt extinguishment losses of $1.2 million and $4.0 million during the fiscal years ended January 31, 2024 and 2022, respectively, which are included within interest expense in the consolidated statements of operations and comprehensive income (loss).
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Leases
12 Months Ended
Jan. 31, 2024
Leases [Abstract]  
Leases Leases
The Company has entered into various non-cancelable operating lease agreements for office space, data storage facilities, and other leases with remaining lease terms of less than 1 year to approximately 7 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 2 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option.
The components of operating lease costs were as follows:
Year ended January 31,
(in thousands)202420232022
Operating lease expense$9,437 $11,371 $14,762 
Sublease income(2,680)(2,187)(1,836)
Net operating lease cost$6,757 $9,184 $12,926 
Weighted average lease term and discount rate were as follows:
January 31, 2024January 31, 2023
Weighted average remaining lease term6.7 years7.5 years
Weighted average discount rate4.3 %4.3 %
Lease liabilities were as follows:
(in thousands)January 31, 2024January 31, 2023
Gross lease liabilities$67,269 $81,313 
Less: imputed interest(9,099)(12,166)
Present value of lease liabilities58,170 69,147 
Less: current portion of lease liabilities(9,404)(10,159)
Lease liabilities, non-current$48,766 $58,988 
As of January 31, 2024, the Company had an additional operating lease for office space that had not yet commenced with aggregate undiscounted lease payments of $1.9 million. The operating lease will commence during fiscal year 2025 and has a lease term of approximately 7 years.
Supplemental cash flow information related to the Company's operating leases was as follows:
Year ended January 31,
(in thousands)20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$10,900 $12,533 
Right-of-use assets obtained in exchange for lease obligations$2,109 $1,092 
During the fiscal year ended January 31, 2022, the Company recorded impairment losses on right-of-use assets of $11.2 million, which are included within merger integration expense in the consolidated statement of operations and comprehensive income (loss). The impairment losses related primarily to a right-of-use asset acquired through the acquisition of the Company's wholly owned subsidiary WageWorks, Inc. ("WageWorks"), which had a carrying value of $14.8 million prior to impairment and no corresponding lease liability. During the fiscal year ended January 31, 2022, the right-of-use asset met the criteria to be classified as held-for-sale and an impairment loss of $10.9 million was recognized. The remaining carrying value of $3.9 million was included within other current assets on the Company's consolidated balance sheet as of January 31, 2022. On March 24, 2022, the Company completed the sale of the asset for $3.9 million.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible assets and goodwill
12 Months Ended
Jan. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets and goodwill Intangible assets and goodwill
Intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows:
January 31, 2024
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$267,498 $(197,388)$70,110 
Acquired HSA portfolios264,445 (81,059)183,386 
Acquired customer relationships759,782 (205,127)554,655 
Acquired developed technology132,825 (105,049)27,776 
Acquired trade names12,900 (12,879)21 
Total amortizable intangible assets$1,437,450 $(601,502)$835,948 
January 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$233,194 $(152,178)$81,016 
Acquired HSA portfolios261,188 (63,547)197,641 
Acquired customer relationships759,782 (153,434)606,348 
Acquired developed technology132,825 (81,692)51,133 
Acquired trade names12,900 (12,679)221 
Total amortizable intangible assets$1,399,889 $(463,530)$936,359 
During the fiscal years ended January 31, 2024 and 2023, the Company capitalized $3.3 million and $68.9 million, respectively, to acquire the rights to act as a custodian of HSA portfolios.
Amortization expense for the fiscal years ended January 31, 2024, 2023, and 2022 was $144.3 million, $148.9 million and $122.5 million, respectively. Estimated amortization expense for the fiscal years ending January 31 is as follows:
Year ending January 31, (in thousands)
2025$126,150 
202697,732 
202780,837 
202867,550 
202965,774 
Thereafter397,905 
Total$835,948 
Goodwill
The Company’s annual goodwill impairment test resulted in no impairment charges in any of the periods presented in the accompanying consolidated financial statements. During the fiscal year ended January 31, 2023, goodwill increased by $2.3 million due to measurement period adjustments associated with the Further Acquisition and the Luum Acquisition. There were no changes to the carrying value of goodwill during the fiscal year ended January 31, 2024.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and contingencies
12 Months Ended
Jan. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Commitments
The following table summarizes the payments due by fiscal year for the Company's outstanding contractual obligations as of January 31, 2024:
Payments due by fiscal year
(in thousands)20252026202720282029ThereafterTotal
4.50% Senior Notes due 2029 (1)
$— $— $— $— $— $600,000 $600,000 
Term Loan Facility (1)— 6,875 280,000 — — — 286,875 
Interest on long-term debt obligations (2)46,502 46,402 39,087 27,000 27,000 18,000 203,991 
Operating lease obligations (3)9,862 10,281 10,165 10,323 10,553 17,952 69,136 
Other contractual obligations (4)23,496 21,487 7,302 6,502 — — 58,787 
BenefitWallet HSA portfolio acquisition (5)445,000 — — — — — 445,000 
Total$524,860 $85,045 $336,554 $43,825 $37,553 $635,952 $1,663,789 
(1)As of January 31, 2024, the outstanding combined principal of $886.9 million is presented net of debt issuance costs on the consolidated balance sheets. The debt issuance costs are not included in the table above.
(2)Estimated interest payments assume the stated interest rates applicable to the Notes and Term Loan Facility as of January 31, 2024, which were 4.50% and 6.69% per annum, respectively.
(3)The Company leases office space and data storage facilities and has other non-cancelable operating leases expiring at various dates through 2030. These amounts exclude contractual sublease income of $16.3 million, which is expected to be received through December 2030.
(4)Other contractual obligations consist of processing services agreements, software subscriptions, and other contractual commitments.
(5)In September 2023, the Company entered into an agreement to acquire the BenefitWallet HSA portfolio from Conduent Business Services, LLC, for a purchase price of $425.0 million and reimbursement of up to $20.0 million of Conduent's transfer-related expenses. In addition, the Company expects to incur approximately $7.0 million of transaction costs associated with the acquisition.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
In April 2021, WageWorks, a wholly owned subsidiary of the Company, exercised its right to terminate a lease for office space in Mesa, Arizona that had not yet commenced, with aggregate lease payments of $63.1 million and a term of approximately 11 years, following the landlord's failure to fulfill its obligations under the lease agreement (the "Lease"). WageWorks' right to terminate the Lease was disputed by the landlord, Union Mesa 1, LLC (“Union Mesa”), which claimed that the Lease had commenced on December 1, 2020. On November 5, 2021, Union Mesa notified WageWorks that it was in default of the Lease for failure to pay rent, which Union Mesa claimed was due beginning in November 2021, after 11 months of abated rent. On November 24, 2021, Union Mesa drew $2.8 million, the full amount under the letter of credit that WageWorks had posted to secure its obligations under the Lease. The Company recorded the $2.8 million draw as merger integration expense in the consolidated statement of operations and comprehensive income (loss). On December 1, 2021, WageWorks filed a lawsuit against Union Mesa in the Maricopa County Superior Court in the State of Arizona. On January 4, 2022, WageWorks filed an amended complaint, seeking a declaratory judgment that the Lease was properly terminated and recourse against Union Mesa for breach of contract, breach of the duty of good faith and fair dealing, and conversion, including return of the funds drawn under the letter of credit. In May and June 2022, Union Mesa filed an answer, counterclaim, and third-party complaint against WageWorks and the Company, denying WageWorks' claims and separately seeking recourse against WageWorks for breach of contract and breach of the implied covenant of good faith and fair dealing as well as against the Company under the terms of its guaranty of WageWorks' obligations under the Lease. On July 21, 2022, WageWorks and the Company filed an answer to the counterclaim and the third-party complaint on its declaratory judgment claim that WageWorks' termination was improper under the Lease. On December 8, 2023, representatives from the parties participated in a court-ordered mediation held in Phoenix, Arizona, which was unsuccessful. On December 29, 2023, the Superior Court issued an order denying Union Mesa’s motion for partial summary judgment after finding that genuine issues of material fact exist. A trial is scheduled to start on December 9, 2024. WageWorks is seeking consequential damages relating to Union Mesa’s breach of the Lease and conversion of the letter of credit, including consequential damages, pre-judgment interest, and its attorneys’ fees.
Union Mesa has denied liability for these damages. Through its claims, Union Mesa is seeking direct and consequential damages in an amount to be proven at trial and an award of its reasonable attorney fees, plus interest, until any damages or fees that are awarded are paid. According to Union Mesa, these damages include (i) all rent payments due under the Lease accruing from December 2, 2020 (including abated rent), (ii) late charges of 3% on past due amounts, (iii) interest on past due amounts at an interest rate of the prime rate plus 5%, (iv) costs incurred in reletting the premises, (v) attorneys’ fees negotiating the lease and related agreements, and (vi) any other amounts necessary to compensate Union Mesa for the detriment proximately caused by WageWorks’ alleged breach of the Lease. In addition, Union Mesa states that it intends to re-assert periodic actions against WageWorks to seek all amounts due from time to time through the remaining term of the Lease or until the premises are successfully relet.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Indebtedness
12 Months Ended
Jan. 31, 2024
Debt Disclosure [Abstract]  
Indebtedness Indebtedness
Long-term debt consisted of the following:
(in thousands)January 31, 2024January 31, 2023
4.50% Senior Notes due 2029
$600,000 $600,000 
Term Loan Facility286,875 341,250 
Principal amount886,875 941,250 
Less: unamortized discount and issuance costs (1)11,903 15,912 
Total debt, net874,972 925,338 
Less: current portion of long-term debt— 17,500 
Long-term debt, net$874,972 $907,838 
(1)In addition to the $11.9 million and $15.9 million of unamortized discount and issuance costs related to long-term debt as of January 31, 2024 and 2023, respectively, $2.5 million and $3.4 million of unamortized issuance costs related to the Revolving Credit Facility (as defined below) are included within other assets on the consolidated balance sheets as of January 31, 2024 and January 31, 2023, respectively.
4.50% Senior Notes due 2029
On October 8, 2021, the Company completed its offering of $600.0 million aggregate principal amount of its 4.50% Senior Notes due 2029 (the “Notes”). The Notes were issued under an indenture (the “Indenture”), dated October 8, 2021, among the Company, the guarantors party thereto, and Wells Fargo Bank, National Association, as trustee.
The Notes are guaranteed by each of the Company’s existing, wholly owned domestic subsidiaries that guarantees its obligations under the Credit Agreement (as defined below) and are required to be guaranteed by any of the Company’s future subsidiaries that guarantee its obligations under the Credit Agreement or certain of its other indebtedness. The Notes will mature on October 1, 2029. Interest on the Notes is payable on April 1 and October 1 of each year. As of January 31, 2024, the balance of accrued interest on the Notes was $9.3 million, which is included within accrued liabilities on the Company's consolidated balance sheets. The effective interest rate on the Notes is 4.72%.
The Notes are unsecured senior obligations of the Company and rank equally in right of payment to all of its existing and future senior unsecured debt and senior in right of payment to all of its future subordinated debt.
The Notes are redeemable at the Company’s option, in whole or in part, at any time on or after October 1, 2024, at a redemption price if redeemed during the 12 months beginning (i) October 1, 2024 of 102.250%, (ii) October 1, 2025 of 101.125%, and (iii) October 1, 2026 and thereafter of 100.000%, in each case of the principal amount of the Notes being redeemed, and together with accrued and unpaid interest, if any, to, but excluding, the date of
redemption. The Company may also redeem some or all of the Notes before October 1, 2024 at a redemption price equal to 100% of the principal amount of the Notes, plus the applicable “make-whole” premium as of, and accrued and unpaid interest, if any, to, but excluding, the date of redemption. In addition, at any time prior to October 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the Notes issued under the Indenture on one or more occasions in an aggregate amount equal to the net cash proceeds of one or more equity offerings at a redemption price equal to 104.500% of the principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Furthermore, the Company may be required to make an offer to purchase the Notes upon the sale of certain assets or upon specific kinds of changes of control.
The Indenture contains covenants that impose significant operational and financial restrictions on the Company; however, these covenants generally align with the covenants contained in the Credit Agreement. See "Credit Agreement" below for a description of these covenants.
Credit Agreement
On October 8, 2021, the Company entered into a credit agreement (the “Credit Agreement”) among the Company, as borrower, each lender from time to time party thereto (the “Lenders”), JPMorgan Chase Bank, N.A., as administrative agent and the Swing Line Lender (as defined in the Credit Agreement), and each L/C Issuer (as defined therein) party thereto, pursuant to which the Company established:
(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $350 million; and
(ii)     a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $1.0 billion (with a $25 million sub-limit for the issuance of letters of credit), the proceeds of which may be used for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments.
Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company’s pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.
Prior to June 1, 2023, borrowings under the Credit Facilities bore interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement.
On June 1, 2023, the Company entered into an amendment to the Credit Agreement which replaced interest rate provisions based on LIBOR with the forward-looking term rate based on the secured overnight financing rate published by the CME Group Benchmark Administration Limited (“Term SOFR”). As a result, borrowings under the Credit Agreement as so amended bear interest at an annual rate equal to, at the option of the Company, either (i) Term SOFR, plus a 0.10% credit spread adjustment, plus a margin ranging from 1.25% to 2.25%, or (ii) an alternate base rate, plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement (as amended). As of January 31, 2024, the stated interest rate was 6.69% and the effective interest rate was 7.45%.
The Company is also required to pay certain fees to the Lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of January 31, 2024, no amounts have been drawn under the Revolving Credit Facility.
The loans made under the Term Loan Facility amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the Term Loan Facility: (i) 2.5% for the first year after October 8, 2021; (ii) 5.0% for each of the second and third years after October 8, 2021; (iii) 7.5% for the fourth year after October 8, 2021; and (iv) 10.0% for the fifth year after October 8, 2021. In addition, the Term Loan Facility is required to be mandatorily prepaid with 100% of the net cash proceeds of all asset sales, insurance and condemnation recoveries, subject to customary exceptions and thresholds, including to the extent such proceeds are reinvested in assets useful in the business of the Company and its subsidiaries within 450 days following receipt (or committed to be reinvested within such 450-day period and reinvested within 180 days after the end of such 450-day period). The loans under the Credit Facilities may be prepaid, and the commitments thereunder may be reduced, by the Company without penalty or premium, subject to the reimbursement of
customary “breakage costs.” In April 2023, the Company used $50.0 million of cash to prepay, in direct order of maturity, principal due under its Term Loan Facility.
The Credit Agreement contains significant, customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.00 to 1.00 and (ii) a minimum consolidated interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of January 31, 2024, and for the period then ended.
The repayment obligation under the Credit Agreement may be accelerated upon the occurrence of an event of default thereunder, including, among other things, failure to pay principal, interest or fees on a timely basis, material inaccuracy of any representation or warranty, failure to comply with covenants, cross-default to other material debt, material judgments, change of control and certain insolvency or bankruptcy-related events, in each case, subject to any certain grace and/or cure periods.
The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by each of the Company’s existing or subsequently acquired or organized domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Income taxes
12 Months Ended
Jan. 31, 2024
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The income tax provision (benefit) consisted of the following:
Year ended January 31,
(in thousands)202420232022
Current:
Federal$29,376 $3,260 $628 
State3,947 1,968 239 
Total current tax provision$33,323 $5,228 $867 
Deferred:
Federal$(11,004)$(14,382)$(21,197)
State(2,991)(2,799)(2,122)
Total deferred tax benefit$(13,995)$(17,181)$(23,319)
Total income tax provision (benefit)$19,328 $(11,953)$(22,452)
Total income tax provision (benefit) differed from the amounts computed by applying the U.S. federal statutory income tax rate to income before income taxes as a result of the following:
Year ended January 31,
(in thousands)202420232022
Federal income tax provision (benefit) at the statutory rate$15,759 $(8,000)$(14,016)
State income tax provision (benefit), net of federal tax provision (benefit)5,382 (1,021)(3,733)
Other non-deductible or non-taxable items, net447 225 (165)
Excessive employee remuneration2,939 3,246 1,214 
Excess tax (benefit) shortfall on stock-based compensation expense, net304 (2,479)(5,098)
Federal research and development credits(9,202)(1,341)(4,218)
Change in uncertain tax position reserves, net of indirect benefits6,137 (2,970)836 
Deferred tax rate adjustment due to state apportionment changes(1,039)(30)725 
Adjustment from settlement of IRS examination2,461 — — 
Return-to-provision adjustments(433)(38)(810)
Change in valuation allowance(3,129)733 3,457 
Other items, net(298)(278)(644)
Total income tax provision (benefit)$19,328 $(11,953)$(22,452)
The Company’s effective income tax provision rate for the fiscal year ended January 31, 2024 was 25.8%, and the Company’s effective income tax benefit rate for the fiscal years ended January 31, 2023 and 2022 was 31.4% and 33.6%, respectively. The difference between the effective income tax rate and the U.S. federal statutory income tax rate each period is impacted by a number of factors, including the relative mix of earnings among state jurisdictions, credits, excess tax benefits or shortfalls on stock-based compensation expense, changes in unrecognized tax benefits and valuation allowance, and other items. The increase in the effective tax rate for the fiscal year ended January 31, 2024 compared to the fiscal year ended January 31, 2023 was primarily due to an increase in pre-tax book income, an increase in unrecognized tax benefits, adjustments from settlement of an IRS examination, and a decrease in tax deductible stock-based compensation compared to GAAP stock-based compensation expense, partially offset by an increase in research and development tax credits and a decrease in valuation allowance. The decrease in the effective tax rate for the fiscal year ended January 31, 2023 compared to the fiscal year ended January 31, 2022 was primarily due to a decrease in benefit for state income taxes, a decrease in research and development tax credits, a decrease in excess tax benefits on stock-based compensation expense, and an increase in nondeductible executive compensation relative to pre-tax book loss, partially offset by a release of uncertain tax positions and a smaller change in valuation allowance.
Deferred tax assets and liabilities consisted of the following:
(in thousands)January 31, 2024January 31, 2023
Deferred tax assets:
Net operating loss carryforward$1,730 $2,646 
Stock compensation14,069 16,217 
Research and development credits3,796 7,147 
Lease liabilities14,371 17,337 
Capitalized research and development33,474 16,419 
Fixed assets939 — 
Accruals and reserves3,557 4,439 
Other, net1,937 5,643 
Total gross deferred tax assets$73,873 $69,848 
Less valuation allowance(1,164)(4,294)
Deferred tax assets, net of valuation allowance72,709 65,554 
Deferred tax liabilities:
Fixed assets— (1,509)
Intangible assets(86,195)(99,471)
Incremental contract costs(12,887)(11,118)
Right-of-use assets(11,949)(14,132)
Goodwill(28,691)(20,271)
Other, net(1,657)(1,718)
Total gross deferred tax liabilities(141,379)(148,219)
Net deferred tax liabilities$(68,670)$(82,665)
Management considered whether it is more likely than not that some portion or all of the deferred tax assets would be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considered the scheduled reversal of deferred tax liabilities in making this assessment and determined that based on the weight of all available evidence, it is more likely than not (i.e., a likelihood of more than 50%) that the Company will be able to realize all of its federal deferred tax assets and the majority if its state deferred tax assets. The Company recorded a valuation allowance of $1.2 million and $4.3 million as of January 31, 2024 and 2023, respectively, related to certain state deferred tax assets. The $3.1 million decrease in valuation allowance recorded is primarily the result of state research and development tax credits that are expected to be utilized before expiration.
As of January 31, 2024, the Company had recorded state net operating loss carryforwards of $27.2 million, which begin to expire at various intervals following the tax year ending January 31, 2032. As of January 31, 2024, the Company also had state research and development credits of $11.9 million, which begin to expire at various intervals following the tax year ending January 31, 2025.
As of January 31, 2024 and 2023, the gross unrecognized tax benefit was $19.2 million and $8.7 million, respectively. If recognized, $16.2 million and $5.4 million of the total unrecognized tax benefits would affect the Company's effective tax rate as of January 31, 2024 and 2023, respectively. Total gross unrecognized tax benefits increased by $10.5 million in the period from January 31, 2023 to January 31, 2024.
A tabular reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
(in thousands)January 31, 2024January 31, 2023
Gross unrecognized tax benefits at beginning of year$8,690 $11,653 
Gross amounts of increases and decreases:
Increases as a result of tax positions taken during a prior period9,325 — 
Decreases as a result of tax positions taken during a prior period— (183)
Increases as a result of tax positions taken during the current period3,386 639 
Decreases as a result of settlement(1,030)
Decreases resulting from the lapse of the applicable statute of limitations(1,158)(3,419)
Gross unrecognized tax benefits at end of year$19,213 $8,690 
Certain unrecognized tax benefits are required to be netted against their related deferred tax assets as a result of ASU 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The resulting unrecognized tax benefit recorded within the Company's consolidated balance sheet excludes the following amounts that have been netted against the related deferred tax assets accordingly:
(in thousands)January 31, 2024January 31, 2023
Total gross unrecognized tax benefits$19,213 $8,690 
Amounts netted against related deferred tax assets(7,186)(4,337)
Unrecognized tax benefits recorded on the consolidated balance sheet$12,027 $4,353 
The Company’s policy is to recognize interest and penalties related to unrecognized tax benefits as a component of other income (expense), net in the statement of operations and comprehensive income (loss). During the fiscal years ended January 31, 2024, 2023, and 2022, the Company recorded penalties and interest of $0.1 million, $0.4 million, and $0.7 million, respectively, related to unrecognized tax benefits. As of January 31, 2024 and 2023, the Company recorded accrued interest and penalties of $1.4 million and $1.3 million, respectively.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the state of Texas. Such examinations may lead to ordinary course adjustments or proposed adjustments to the Company's taxes, net operating losses, and/or tax credit carryforwards. An IRS examination was settled during the year ended January 31, 2024; adjustments recorded as a result of the examination were not material. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2006.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-based compensation
12 Months Ended
Jan. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's consolidated statements of operations and comprehensive income (loss) during the fiscal years presented:
Year ended January 31,
(in thousands)202420232022
Cost of revenue$16,462 $13,591 $10,684 
Sales and marketing13,182 9,821 7,001 
Technology and development20,891 13,828 13,132 
General and administrative26,616 25,374 21,933 
Other expense, net— — 342 
Total stock-based compensation expense$77,151 $62,614 $53,092 
The following table shows stock-based compensation by award type:
Year ended January 31,
(in thousands)202420232022
Restricted stock units$60,688 $46,590 $37,693 
Performance restricted stock units16,384 15,120 12,948 
Stock options79 882 1,816 
Restricted stock awards— 22 155 
Performance restricted stock awards— — 138 
Total non-cash stock-based compensation expense77,151 62,614 52,750 
Acquisition awards exchanged for cash— — 342 
Total stock-based compensation expense$77,151 $62,614 $53,092 
Stock award plans
Incentive Plan. The Company grants RSUs under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provides for the issuance of stock awards to the directors and team members of the Company. Historically, the Company also granted stock options and RSAs under the Incentive Plan. As of January 31, 2024, 11.9 million shares were available for grant under the Incentive Plan.
Stock options
Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such stock options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance or are forfeited 90 days after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan. No stock options were granted during the fiscal years ended January 31, 2024, 2023, or 2022.
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20231,021 
$14.00 - 82.39
$36.06 3.2$27,293 
Exercised (249)
$14.00 - 66.06
$26.21 
Forfeited (46)
$24.36 - 82.39
$75.08 
Outstanding as of January 31, 2024726 
$14.00 - 73.61
$36.91 2.5$28,067 
Vested and expected to vest as of January 31, 2024726 $36.91 2.5$28,067 
Exercisable as of January 31, 2024726 $36.91 2.5$28,067 
The aggregate intrinsic value in the table above represents the difference between the fair value of common stock and the exercise price of outstanding, in-the-money stock options. The total intrinsic value of options exercised during the fiscal years ended January 31, 2024, 2023 and 2022 was $10.1 million, $7.2 million, and $19.3 million, respectively. As of January 31, 2024, there was no unrecorded stock-based compensation expense associated with stock options, and all outstanding stock options were vested.
Restricted stock units
The Company grants RSUs to certain team members, officers, and directors under the Incentive Plan, which vest upon service-based criteria and performance-based criteria. The weighted-average fair value of RSUs granted during the fiscal years ended January 31, 2024, 2023 and 2022 was $64.16, $75.64 and $64.87 per share, respectively.
Service-based restricted stock units. Generally, service-based RSUs granted prior to March 2022 vest over a four-year period in equal annual installments commencing upon the first anniversary of the grant date. Service-based RSUs granted in March 2022 or later generally vest 25% on the first anniversary of the vesting commencement date, which is generally the first day of the fiscal quarter of the grant date, with the remaining portion vesting ratably over the following 12 calendar quarters. Service-based RSUs are valued based on the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate.
Performance restricted stock units. During the fiscal year ended January 31, 2022, the Company awarded 249,750 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return relative to the Russell 2000 index as measured on January 31, 2024. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $22.4 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Talent, Compensation and Culture Committee of the board of directors.
During the fiscal year ended January 31, 2023, the Company awarded 281,784 PRSUs subject to a market condition based on the Company’s total shareholder return relative to the Russell 2000 index as measured on January 31, 2025. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $32.1 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Talent, Compensation and Culture Committee of the board of directors.
During the fiscal year ended January 31, 2024, the Company awarded 270,966 PRSUs subject to a market condition based on the Company’s total shareholder return relative to the Russell 2000 index as measured on January 31, 2026. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $23.9 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Talent, Compensation and Culture Committee of the board of directors.
A summary of RSU activity is as follows:
Outstanding RSUs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair value
Outstanding as of January 31, 20233,011 $70.40 
Granted1,929 64.16 
Vested(1,118)65.41 
Forfeited(459)71.56 
Outstanding as of January 31, 20243,363 $67.96 
During the fiscal years ended January 31, 2024, 2023 and 2022, the aggregate intrinsic value of RSUs and RSAs vested was $69.3 million, $50.7 million, and $40.9 million, respectively.
As of January 31, 2024, total unrecorded stock-based compensation expense associated with RSUs was $162.5 million, which was expected to be recognized over a weighted-average period of 2.4 years. As of January 31, 2024, there was no unrecorded stock-based compensation expense associated with RSAs, and there were no RSAs outstanding.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Fair value
12 Months Ended
Jan. 31, 2024
Fair Value Disclosures [Abstract]  
Fair value Fair value
Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Cash and cash equivalents are considered Level 1 instruments and are valued based on publicly available daily net asset values. The carrying values of cash and cash equivalents approximate fair values due to the short-term nature of these instruments.
The Notes are valued based upon quoted market prices and are considered Level 2 instruments because the markets in which the Notes trade are not considered active markets. As of January 31, 2024, the fair value of the Notes was $560.2 million.
The Term Loan Facility is considered a Level 2 instrument and recorded at book value in the Company's consolidated financial statements. The Term Loan Facility reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, the fair value of the Term Loan Facility approximates carrying value.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Employee benefits
12 Months Ended
Jan. 31, 2024
Retirement Benefits [Abstract]  
Employee benefits Employee benefits
The Company has established a 401(k) plan that qualifies as a deferred compensation arrangement under Section 401 of the IRS Code. All non-seasonal team members over the age of 18 are eligible to participate in the plan. The plan provides for Company matching of employee contributions up to 3.5% of eligible earnings. Employer
matching contribution expense was $8.7 million, $8.0 million and $7.1 million for the fiscal years ended January 31, 2024, 2023 and 2022, respectively.
The Company is self-insured for medical and dental benefits for all qualifying employees. The medical plan carries a stop-loss policy which will protect from individual claims during the plan year exceeding $500,000. The Company records estimates of costs of claims incurred based on an analysis of historical data and independent estimates. The Company's liability for self-insured medical claims is included in accrued compensation in its consolidated balance sheet and was $4.7 million and $5.1 million as of January 31, 2024 and 2023, respectively.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Selected quarterly financial data (unaudited)
12 Months Ended
Jan. 31, 2024
Quarterly Financial Information Disclosure [Abstract]  
Selected quarterly financial data (unaudited) Selected quarterly financial data (unaudited)
As described in Note 1—Summary of business and significant accounting policies—Reclassifications, certain reclassifications have been made to prior year amounts to conform to the current year presentation. The following tables present the impact of the reclassifications by quarter:
Three months ended January 31, 2024
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$111,759 $6,816 $118,575 
Custodial revenue112,249 (6,816)105,433 
Interchange revenue38,379 — 38,379 
Total revenue262,387 — 262,387 
Total cost of revenue99,939 (872)99,067 
Gross profit162,448 872 163,320 
Total operating expenses123,561 872 124,433 
Total other expense(9,170)— (9,170)
Income tax provision3,353 — 3,353 
Net income$26,364 $— $26,364 
Three months ended October 31, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$107,512 $6,570 $114,082 
Custodial revenue106,575 (6,570)100,005 
Interchange revenue35,132 — 35,132 
Total revenue249,219 — 249,219 
Total cost of revenue90,811 (774)90,037 
Gross profit158,408 774 159,182 
Total operating expenses127,517 774 128,291 
Total other expense(9,804)— (9,804)
Income tax provision6,414 — 6,414 
Net income$14,673 $— $14,673 
Three months ended July 31, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$105,719 $6,241 $111,960 
Custodial revenue98,917 (6,241)92,676 
Interchange revenue38,913 — 38,913 
Total revenue243,549 — 243,549 
Total cost of revenue92,619 (735)91,884 
Gross profit150,930 735 151,665 
Total operating expenses126,190 735 126,925 
Total other expense(10,516)— (10,516)
Income tax provision3,643 — 3,643 
Net income$10,581 $— $10,581 
Three months ended April 30, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$105,112 $5,961 $111,073 
Custodial revenue94,441 (5,961)88,480 
Interchange revenue44,879 — 44,879 
Total revenue244,432 — 244,432 
Total cost of revenue96,606 (644)95,962 
Gross profit147,826 644 148,470 
Total operating expenses124,645 644 125,289 
Total other expense(13,169)— (13,169)
Income tax provision5,918 — 5,918 
Net income$4,094 $— $4,094 
Three months ended January 31, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$114,234 $5,620 $119,854 
Custodial revenue83,506 (5,620)77,886 
Interchange revenue36,101 — 36,101 
Total revenue233,841 — 233,841 
Total cost of revenue99,593 (525)99,068 
Gross profit134,248 525 134,773 
Total operating expenses121,032 525 121,557 
Total other expense(13,208)— (13,208)
Income tax provision217 — 217 
Net loss$(209)$— $(209)
Three months ended October 31, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$108,580 $5,495 $114,075 
Custodial revenue74,642 (5,495)69,147 
Interchange revenue32,864 — 32,864 
Total revenue216,086 — 216,086 
Total cost of revenue89,228 (460)88,768 
Gross profit126,858 460 127,318 
Total operating expenses121,316 460 121,776 
Total other expense(11,722)— (11,722)
Income tax benefit(4,539)— (4,539)
Net loss$(1,641)$— $(1,641)
Three months ended July 31, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$103,034 $5,508 $108,542 
Custodial revenue65,599 (5,508)60,091 
Interchange revenue37,509 — 37,509 
Total revenue206,142 — 206,142 
Total cost of revenue88,330 (436)87,894 
Gross profit117,812 436 118,248 
Total operating expenses120,224 436 120,660 
Total other expense(11,461)— (11,461)
Income tax benefit(3,219)— (3,219)
Net loss$(10,654)$— $(10,654)
Three months ended April 30, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$104,348 $5,207 $109,555 
Custodial revenue59,365 (5,207)54,158 
Interchange revenue41,966 — 41,966 
Total revenue205,679 — 205,679 
Total cost of revenue94,506 (423)94,083 
Gross profit111,173 423 111,596 
Total operating expenses118,462 423 118,885 
Total other expense(10,762)— (10,762)
Income tax benefit(4,412)— (4,412)
Net loss$(13,639)$— $(13,639)
Three months ended January 31, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$112,461 $4,924 $117,385 
Custodial revenue58,057 (4,924)53,133 
Interchange revenue32,779 — 32,779 
Total revenue203,297 — 203,297 
Total cost of revenue97,998 (315)97,683 
Gross profit105,299 315 105,614 
Total operating expenses132,549 315 132,864 
Total other expense(16,515)— (16,515)
Income tax benefit(10,947)— (10,947)
Net loss$(32,818)$— $(32,818)
Three months ended October 31, 2021
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$102,733 $4,408 $107,141 
Custodial revenue49,006 (4,408)44,598 
Interchange revenue28,215 — 28,215 
Total revenue179,954 — 179,954 
Total cost of revenue76,634 (252)76,382 
Gross profit103,320 252 103,572 
Total operating expenses103,686 252 103,938 
Total other expense(8,759)— (8,759)
Income tax benefit(4,087)— (4,087)
Net loss$(5,038)$— $(5,038)
Three months ended July 31, 2021
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$109,182 $3,965 $113,147 
Custodial revenue48,776 (3,965)44,811 
Interchange revenue31,145 — 31,145 
Total revenue189,103 — 189,103 
Total cost of revenue77,132 (256)76,876 
Gross profit111,971 256 112,227 
Total operating expenses112,846 256 113,102 
Total other expense(6,910)— (6,910)
Income tax benefit(3,967)— (3,967)
Net loss$(3,818)$— $(3,818)
Three months ended April 30, 2021
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$102,534 $3,401 $105,935 
Custodial revenue46,978 (3,401)43,577 
Interchange revenue34,690 — 34,690 
Total revenue184,202 — 184,202 
Total cost of revenue81,086 (236)80,850 
Gross profit103,116 236 103,352 
Total operating expenses98,863 236 99,099 
Total other expense(10,319)— (10,319)
Income tax benefit(3,451)— (3,451)
Net loss$(2,615)$— $(2,615)
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Subsequent events
12 Months Ended
Jan. 31, 2024
Subsequent Events [Abstract]  
Subsequent events Subsequent events
On March 7, 2024, the first of three HSA asset transfers occurred in connection with HealthEquity's acquisition of the BenefitWallet HSA portfolio, with 266,000 HSAs and $1.1 billion HSA assets transferring to HealthEquity’s custody. In connection with this transfer, HealthEquity paid the applicable purchase price of $163.9 million using cash on hand.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jan. 31, 2024
Oct. 31, 2023
Jul. 31, 2023
Apr. 30, 2023
Jan. 31, 2023
Oct. 31, 2022
Jul. 31, 2022
Apr. 30, 2022
Jan. 31, 2022
Oct. 31, 2021
Jul. 31, 2021
Apr. 30, 2021
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Pay vs Performance Disclosure                              
Net income (loss) $ 26,364 $ 14,673 $ 10,581 $ 4,094 $ (209) $ (1,641) $ (10,654) $ (13,639) $ (32,818) $ (5,038) $ (3,818) $ (2,615) $ 55,712 $ (26,143) $ (44,289)
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements
3 Months Ended 12 Months Ended
Jan. 31, 2024
shares
Jan. 31, 2024
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Delano Ladd [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On September 22, 2023, Delano Ladd, our Executive Vice President, General Counsel and Secretary, entered into a Rule 10b5-1 trading arrangement (the “Ladd Arrangement”). The Ladd Arrangement provides for the sale, between December 22, 2023 and August 30, 2024, of up to 7,643 aggregate shares of the Company’s common stock held directly by Mr. Ladd. The Ladd Arrangement was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
Name Delano Ladd  
Title Executive Vice President, General Counsel and Secretary  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date September 22, 2023  
Arrangement Duration 252 days  
Aggregate Available 7,643 7,643
Stephen Neeleman [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
On December 08, 2023, Stephen Neeleman, our Founder and Vice Chairman, entered into a Rule 10b5-1 trading arrangement (the “Neeleman Arrangement”). The Neeleman Arrangement provides for the sale, between December 8, 2023 and July 31, 2024, of up to 70,000 aggregate shares of the Company’s common stock held directly by Dr. Neeleman. The Neeleman Arrangement was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
Name Stephen Neeleman  
Title Founder and Vice Chairman  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date December 08, 2023  
Arrangement Duration 236 days  
Aggregate Available 70,000 70,000
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of business and significant accounting policies (Policies)
12 Months Ended
Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of consolidation
Principles of consolidation
The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Segments
Segments
The Company operates in one segment, which reflects the way in which its chief operating decision maker, the Chief Executive Officer, reviews the Company's financial performance and makes decisions about resource allocation. All long-lived assets are maintained in the United States of America.
Cash and cash equivalents
Cash and cash equivalents
The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company’s cash and cash equivalents were held in institutions in the U.S. and include deposits in a money market account that was unrestricted as to withdrawal or use.
Client-held funds
Client-held funds
Many of the Company's client services agreements with employers (referred to as "Clients") provide that Clients remit funds to the Company to pre-fund Client and employee participant contributions related to flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs,” respectively) and commuter accounts.
These Client-held funds remitted to the Company do not represent cash assets of the Company to the extent that they are not combined with corporate cash, and accordingly are not included in cash and cash equivalents on the Company's consolidated balance sheets.
Accounts receivable
Accounts receivable
Accounts receivable represent monies due to the Company for monthly service revenue, custodial revenue and interchange revenue. The Company maintains an allowance for doubtful accounts to reserve for expected credit losses from trade receivables considering past events, current conditions, and reasonable and supportable forecasts of future economic conditions. In evaluating the Company’s ability to collect outstanding receivable balances, the Company considers various factors including macroeconomic variables, the age of the balance, the creditworthiness of the customer, which is assessed based on ongoing credit evaluations and payment history, and the customer’s current financial condition.
Other assets
Other assets
Other assets consist primarily of contract costs, prepaid expenditures, debt issuance costs, income tax receivables, and various other assets. Amounts expected to be recouped or recognized over a period of twelve months or less have been classified as current in the accompanying consolidated balance sheets.
Leases
Leases
The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices.
Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.
Property and equipment
Property and equipment
Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation. Depreciation is determined using the straight-line method over the estimated useful lives of individual assets. The useful life for leasehold improvements is the shorter of the estimated useful life or the term of the lease ranging from 3-5 years. The useful life used for computing depreciation for all other asset classes is described below:
Computer equipment
3-5 years
Furniture and fixtures5 years
Maintenance and repairs are expensed when incurred, and improvements that extend the economic useful life of an asset are capitalized. Gains and losses on the disposal of property and equipment are reflected in operating expenses.
Intangible assets, net
Intangible assets, net
Intangible assets are carried at cost and amortized, typically, on a straight-line basis over their estimated useful lives. The useful life used for computing amortization for all intangible asset classes is described below:
Software and software development costs3 years
Acquired customer relationships
7-15 years
Acquired developed technology
2-5 years
Acquired trade names and trademarks3 years
Acquired HSA portfolios15 years
The Company accounts for the costs of computer software developed or obtained for internal use in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software. Costs incurred during operation and post-implementation stages are charged to expense. Costs incurred during the application development stage that are directly attributable to developing or obtaining software for internal use are capitalized. Management’s judgment is required in determining the point when various projects enter the stages at which costs may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized.
Acquired customer relationships, developed technology, and trade names and trademarks are valued utilizing the discounted cash flow method, a form of the income approach. The useful lives of acquired customer relationships were estimated based on discount rates and revenue growth rates, net of attrition. The useful lives of developed technology and trade names were estimated based on expected obsolescence. The Company expenses the assets straight-line over the useful lives and determined that this amortization method is appropriate to reflect the pattern over which the economic benefits of these acquired assets are realized.
Acquired HSA portfolios consist of the contractual rights to administer the activities related to the individual HSAs acquired. The Company used its HSA customer relationship period assumption and the historical attrition rates of member accounts to determine that an average useful life of 15 years and the use of a straight-line amortization method are appropriate to reflect the pattern over which the economic benefits of existing member assets are realized.
The Company reviews identifiable amortizable intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value.
Goodwill
Goodwill
Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually on January 31 or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company’s impairment tests are based on a single operating segment and reporting unit structure. The goodwill impairment test involves a qualitative assessment to compare a reporting unit's fair value to its carrying value. If it is determined that it is more likely than not that a reporting unit's fair value is less than its carrying value, a quantitative comparison is made between the Company's market capitalization and the carrying value of the reporting unit, including goodwill. If the carrying value of the reporting unit exceeds its fair value, an impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value.
Self-insurance
Self-insurance
The Company is self-insured for medical insurance up to certain annual stop-loss limits. The Company establishes a liability as of the balance sheet date for claims, both reported and incurred but not reported, using currently available information as well as historical claims experience, and as determined by an independent third party.
Other long-term liabilities
Other long-term liabilities
Other long-term liabilities consists of long-term deferred revenue and other liabilities that the Company does not expect to settle within one year.
Revenue recognition
Revenue recognition
The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services.
The Company determines revenue recognition through the following steps:
identification of the contract, or contracts, with a customer;
identification of the performance obligations in the contract;
determination of the transaction price;
allocation of the transaction price to the performance obligations in the contract; and
recognition of revenue when, or as, the Company satisfies a performance obligation.
Disaggregation of revenue. The Company's primary sources of revenue are service, custodial, and interchange revenue and are disclosed in the consolidated statements of operations and comprehensive income (loss). All of the
Company's sources of revenue are deemed to be revenue contracts with customers. Each revenue source is affected differently by economic factors as it relates to the nature, amount, timing and uncertainty.
Costs to obtain a contract. ASC 606, Revenue from contracts with customers, requires capitalizing the costs of obtaining a contract when those costs are expected to be recovered.
In order to determine the amortization period for sales commissions contract costs, the Company applied the portfolio approach. Accordingly, the amortization period of the assets has been determined to be the average economic life of an HSA or other CDB relationship, which is estimated to be 15 years and 7 years, respectively. Amortization of capitalized sales commission contract costs is included in sales and marketing expenses in the consolidated statements of operations and comprehensive income (loss). The Company has applied the practical expedient which allows an entity to account for incremental costs of obtaining a contract at a portfolio level. The Company has also applied the practical expedient to recognize incremental costs of obtaining contracts as an expense when incurred if the amortization period would have been one year or less.
Performance obligations. ASC 606 requires disclosure of the aggregate amount of the transaction price allocated to unsatisfied performance obligations; however, as permitted by ASC 606, the Company has elected to exclude from this disclosure any contracts with an original duration of one year or less and any variable consideration that meets specified criteria.
Service revenue. The Company administers its platforms, prepares statements, provides a mechanism for spending funds, and provides customer support services. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA assets through the Company's investment partner from which the Company earns recordkeeping and advisory fees, calculated as a percentage of the member's HSA investments. All of these services are consumed as they are received. The Company recognizes service revenue, in an amount that reflects the consideration it expects to be entitled to in exchange for those services, on a monthly basis as it satisfies its performance obligations.
Custodial revenue. The Company earns custodial revenue primarily from HSA assets deposited with depository partners or placed in group annuity contracts or similar arrangements with insurance company partners and Client-held funds deposited with depository partners. The placement of funds represents a service that is simultaneously received and consumed by the depository partners and insurance company partners. The Company recognizes custodial revenue each month, in an amount that reflects the consideration it expects to be entitled to in exchange for the service.
Interchange revenue. The Company satisfies its interchange performance obligation each time payments are made with its cards via payment networks. The Company recognizes interchange revenue, in an amount that reflects the consideration it expects to be entitled to in exchange for the service, in the month the payment transaction occurs.
Contract balances. The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied.
Significant judgments. The Company makes no significant judgments in determining the amount or timing of revenue recognition. The Company has estimated the average economic life of an HSA or CDB member relationship, which has been determined to be the amortization period for the capitalized sales commissions contract costs.
Cost of revenue
The Company incurs cost of revenue related to servicing member accounts, managing customer and partner relationships, and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations, new member and participant supplies, and other operating costs of the member account servicing departments. Other components of the Company’s cost of revenue include interest retained by members on custodial assets held and interchange costs incurred in connection with processing card transactions initiated by members.
Stock-based compensation
Stock-based compensation
The Company grants restricted stock units ("RSUs") to certain team members, executive officers, and directors. Historically, the Company also granted stock options and restricted stock awards ("RSAs") under the Incentive Plan. The Company recognizes compensation expense for stock-based awards based on the grant date estimated fair
value. Expense for stock-based awards is generally recognized on a straight-line basis over the requisite service period and is reversed as pre-vesting forfeitures occur. The fair value of stock options was determined using the Black-Scholes option pricing model. The determination of fair value for stock options on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. The fair value of RSUs is based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate.
For stock-based awards with performance conditions, the Company evaluates the probability of achieving the performance criteria and of the number of shares that are expected to vest, and compensation expense is then adjusted to reflect the number of shares expected to vest and the requisite service period. For awards with performance conditions, compensation expense is recognized using the graded-vesting attribution method in accordance with the provisions of ASC 718, Compensation—Stock Compensation ("Topic 718"). Compensation expense related to stock-based awards with market conditions is recorded on a straight-line basis over the requisite service period regardless of whether the market condition is satisfied.
Upon the exercise of a stock option or release of an RSU, common shares are issued from authorized, but not outstanding, common stock.
Interest expense
Interest expense
Interest expense consists primarily of accrued interest expense and amortization of deferred financing costs associated with long-term debt.
Income tax provision (benefit)
Income tax provision (benefit)
The Company accounts for income taxes and the related accounts under the asset and liability method as set forth in ASC 740, Income Taxes. Under this method, current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, for net operating losses, and for tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. The effect on deferred tax assets and liabilities of changes in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for when it is more likely than not that some or all of the deferred tax assets may not be realized in future years.
The Company recognizes the tax benefit from an uncertain tax position taken or expected to be taken in a tax return using a two-step approach. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authorities, based on the technical merits of the position. For tax positions that are more likely than not to be sustained upon audit, the second step is to measure the tax benefit in the financial statements as the largest benefit that has a greater than 50% likelihood of being sustained upon settlement. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as a component of other income (expense), net in the consolidated statements of operations and comprehensive income (loss). Changes in facts and circumstances could have a material impact on the Company’s effective tax rate and results of operations.
Asset acquisitions and Business combinations
Asset acquisitions
The Company routinely acquires rights to be the custodian of HSA portfolios, in which substantially all of the fair value of the gross portfolio assets acquired is concentrated in a group of similar HSA assets and therefore the acquisitions do not constitute a business. Accordingly, the acquisitions are accounted for under the asset acquisition method of accounting in accordance with ASC 805-50, Business Combinations—Related Issues. Under the asset acquisition method of accounting, the Company is required to fair value the assets transferred. The cost of the assets acquired, including transaction costs incurred in conjunction with an asset acquisition, is allocated to the individual assets acquired based on their relative fair values and does not give rise to goodwill.
Business combinations
Consideration paid for the acquisition of a business as defined by ASC 805-10 is allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date.
Acquisition-related expenses incurred in conjunction with the acquisition of a business are recognized in earnings in the period in which they are incurred and are included in other income (expense), net on the consolidated statements of operations and comprehensive income (loss).
Use of estimates
Use of estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management has made estimates for the allowance for doubtful accounts, capitalized software development costs, evaluating goodwill and long-lived assets for impairment, useful lives of property and equipment and intangible assets, accrued compensation, accrued liabilities, grant date fair value of stock options and performance restricted stock units and restricted stock awards, and income taxes. Actual results could differ from those estimates.
Recently adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of other segment items, interim disclosure of a reportable segment’s profit or loss and assets, the title and position of the CODM, and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The ASU requires public companies with a single reportable segment to provide the segment disclosures required by Topic 280 and will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the ASU to determine its impact on our disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for annual periods beginning after December 15, 2024. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. We are currently evaluating the ASU to determine its impact on our income tax disclosures.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of business and significant accounting policies (Tables)
12 Months Ended
Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Estimated Useful Life of Property and Equipment The useful life used for computing depreciation for all other asset classes is described below:
Computer equipment
3-5 years
Furniture and fixtures5 years
Property and equipment consisted of the following as of January 31, 2024 and 2023:
(in thousands)January 31, 2024January 31, 2023
Leasehold improvements$14,455 $18,269 
Furniture and fixtures7,087 8,392 
Computer equipment25,489 28,021 
Property and equipment, gross47,031 54,682 
Accumulated depreciation(41,018)(41,820)
Property and equipment, net$6,013 $12,862 
Schedule of Useful Lives of Intangible Assets The useful life used for computing amortization for all intangible asset classes is described below:
Software and software development costs3 years
Acquired customer relationships
7-15 years
Acquired developed technology
2-5 years
Acquired trade names and trademarks3 years
Acquired HSA portfolios15 years
The gross carrying amount and associated accumulated amortization of intangible assets were as follows:
January 31, 2024
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$267,498 $(197,388)$70,110 
Acquired HSA portfolios264,445 (81,059)183,386 
Acquired customer relationships759,782 (205,127)554,655 
Acquired developed technology132,825 (105,049)27,776 
Acquired trade names12,900 (12,879)21 
Total amortizable intangible assets$1,437,450 $(601,502)$835,948 
January 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$233,194 $(152,178)$81,016 
Acquired HSA portfolios261,188 (63,547)197,641 
Acquired customer relationships759,782 (153,434)606,348 
Acquired developed technology132,825 (81,692)51,133 
Acquired trade names12,900 (12,679)221 
Total amortizable intangible assets$1,399,889 $(463,530)$936,359 
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Net income (loss) per share (Tables)
12 Months Ended
Jan. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of basic and diluted net income (loss) per share:
Year ended January 31,
(in thousands, except per share data)202420232022
Numerator (basic and diluted):
Net income (loss)$55,712 $(26,143)$(44,289)
Denominator (basic):
Weighted-average common shares outstanding85,564 84,442 83,133 
Denominator (diluted):
Weighted-average common shares outstanding85,564 84,442 83,133 
Weighted-average dilutive effect of stock options and restricted stock units1,393 — — 
Diluted weighted-average common shares outstanding86,957 84,442 83,133 
Net income (loss) per share:
Basic $0.65 $(0.31)$(0.53)
Diluted$0.64 $(0.31)$(0.53)
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Business combinations (Tables)
12 Months Ended
Jan. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Schedule of Allocation of Consideration
The following table summarizes the Company's allocation of the consideration paid:
(in thousands)Estimated fair valueAdjustmentsUpdated Allocation
Cash and cash equivalents$626 $— $626 
Other current assets1,469 — 1,469 
Intangible assets23,900 — 23,900 
Goodwill36,374 (19)36,355 
Other assets100 — 100 
Current liabilities(597)— (597)
Deferred tax liability(3,566)19 (3,547)
Total consideration paid$58,306 $— $58,306 
The following table summarizes the Company's allocation of the consideration paid:
(in thousands)Estimated fair valueAdjustmentsUpdated Allocation
Current assets$2,667 $(163)$2,504 
Intangible assets172,183 — 172,183 
Goodwill282,287 2,309 284,596 
Current liabilities(2,137)(2,146)(4,283)
Total consideration paid$455,000 $— $455,000 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Supplemental financial statement information (Tables)
12 Months Ended
Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Property and Equipment The useful life used for computing depreciation for all other asset classes is described below:
Computer equipment
3-5 years
Furniture and fixtures5 years
Property and equipment consisted of the following as of January 31, 2024 and 2023:
(in thousands)January 31, 2024January 31, 2023
Leasehold improvements$14,455 $18,269 
Furniture and fixtures7,087 8,392 
Computer equipment25,489 28,021 
Property and equipment, gross47,031 54,682 
Accumulated depreciation(41,018)(41,820)
Property and equipment, net$6,013 $12,862 
Schedule of Other Expense, Net
Other income (expense), net, consisted of the following:
Year ended January 31,
(in thousands)202420232022
Interest income$12,138 $1,763 $1,501 
Gain on equity securities— — 1,692 
Acquisition costs— (53)(10,832)
Other miscellaneous income (expense)658 (439)1,708 
Total other income (expense), net$12,796 $1,271 $(5,931)
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Leases (Tables)
12 Months Ended
Jan. 31, 2024
Leases [Abstract]  
Schedule of Lease Cost
The components of operating lease costs were as follows:
Year ended January 31,
(in thousands)202420232022
Operating lease expense$9,437 $11,371 $14,762 
Sublease income(2,680)(2,187)(1,836)
Net operating lease cost$6,757 $9,184 $12,926 
Weighted average lease term and discount rate were as follows:
January 31, 2024January 31, 2023
Weighted average remaining lease term6.7 years7.5 years
Weighted average discount rate4.3 %4.3 %
Lease liabilities were as follows:
(in thousands)January 31, 2024January 31, 2023
Gross lease liabilities$67,269 $81,313 
Less: imputed interest(9,099)(12,166)
Present value of lease liabilities58,170 69,147 
Less: current portion of lease liabilities(9,404)(10,159)
Lease liabilities, non-current$48,766 $58,988 
Supplemental cash flow information related to the Company's operating leases was as follows:
Year ended January 31,
(in thousands)20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$10,900 $12,533 
Right-of-use assets obtained in exchange for lease obligations$2,109 $1,092 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible assets and goodwill (Tables)
12 Months Ended
Jan. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets The useful life used for computing amortization for all intangible asset classes is described below:
Software and software development costs3 years
Acquired customer relationships
7-15 years
Acquired developed technology
2-5 years
Acquired trade names and trademarks3 years
Acquired HSA portfolios15 years
The gross carrying amount and associated accumulated amortization of intangible assets were as follows:
January 31, 2024
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$267,498 $(197,388)$70,110 
Acquired HSA portfolios264,445 (81,059)183,386 
Acquired customer relationships759,782 (205,127)554,655 
Acquired developed technology132,825 (105,049)27,776 
Acquired trade names12,900 (12,879)21 
Total amortizable intangible assets$1,437,450 $(601,502)$835,948 
January 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$233,194 $(152,178)$81,016 
Acquired HSA portfolios261,188 (63,547)197,641 
Acquired customer relationships759,782 (153,434)606,348 
Acquired developed technology132,825 (81,692)51,133 
Acquired trade names12,900 (12,679)221 
Total amortizable intangible assets$1,399,889 $(463,530)$936,359 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Estimated amortization expense for the fiscal years ending January 31 is as follows:
Year ending January 31, (in thousands)
2025$126,150 
202697,732 
202780,837 
202867,550 
202965,774 
Thereafter397,905 
Total$835,948 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and contingencies (Tables)
12 Months Ended
Jan. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Payments Due By Fiscal Year For Our Outstanding Contractual Obligations
The following table summarizes the payments due by fiscal year for the Company's outstanding contractual obligations as of January 31, 2024:
Payments due by fiscal year
(in thousands)20252026202720282029ThereafterTotal
4.50% Senior Notes due 2029 (1)
$— $— $— $— $— $600,000 $600,000 
Term Loan Facility (1)— 6,875 280,000 — — — 286,875 
Interest on long-term debt obligations (2)46,502 46,402 39,087 27,000 27,000 18,000 203,991 
Operating lease obligations (3)9,862 10,281 10,165 10,323 10,553 17,952 69,136 
Other contractual obligations (4)23,496 21,487 7,302 6,502 — — 58,787 
BenefitWallet HSA portfolio acquisition (5)445,000 — — — — — 445,000 
Total$524,860 $85,045 $336,554 $43,825 $37,553 $635,952 $1,663,789 
(1)As of January 31, 2024, the outstanding combined principal of $886.9 million is presented net of debt issuance costs on the consolidated balance sheets. The debt issuance costs are not included in the table above.
(2)Estimated interest payments assume the stated interest rates applicable to the Notes and Term Loan Facility as of January 31, 2024, which were 4.50% and 6.69% per annum, respectively.
(3)The Company leases office space and data storage facilities and has other non-cancelable operating leases expiring at various dates through 2030. These amounts exclude contractual sublease income of $16.3 million, which is expected to be received through December 2030.
(4)Other contractual obligations consist of processing services agreements, software subscriptions, and other contractual commitments.
(5)In September 2023, the Company entered into an agreement to acquire the BenefitWallet HSA portfolio from Conduent Business Services, LLC, for a purchase price of $425.0 million and reimbursement of up to $20.0 million of Conduent's transfer-related expenses. In addition, the Company expects to incur approximately $7.0 million of transaction costs associated with the acquisition.
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Indebtedness (Tables)
12 Months Ended
Jan. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Long-term debt consisted of the following:
(in thousands)January 31, 2024January 31, 2023
4.50% Senior Notes due 2029
$600,000 $600,000 
Term Loan Facility286,875 341,250 
Principal amount886,875 941,250 
Less: unamortized discount and issuance costs (1)11,903 15,912 
Total debt, net874,972 925,338 
Less: current portion of long-term debt— 17,500 
Long-term debt, net$874,972 $907,838 
(1)In addition to the $11.9 million and $15.9 million of unamortized discount and issuance costs related to long-term debt as of January 31, 2024 and 2023, respectively, $2.5 million and $3.4 million of unamortized issuance costs related to the Revolving Credit Facility (as defined below) are included within other assets on the consolidated balance sheets as of January 31, 2024 and January 31, 2023, respectively.
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Income taxes (Tables)
12 Months Ended
Jan. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Expense (Benefit)
The income tax provision (benefit) consisted of the following:
Year ended January 31,
(in thousands)202420232022
Current:
Federal$29,376 $3,260 $628 
State3,947 1,968 239 
Total current tax provision$33,323 $5,228 $867 
Deferred:
Federal$(11,004)$(14,382)$(21,197)
State(2,991)(2,799)(2,122)
Total deferred tax benefit$(13,995)$(17,181)$(23,319)
Total income tax provision (benefit)$19,328 $(11,953)$(22,452)
Schedule of Effective Income Tax Rate Reconciliation
Total income tax provision (benefit) differed from the amounts computed by applying the U.S. federal statutory income tax rate to income before income taxes as a result of the following:
Year ended January 31,
(in thousands)202420232022
Federal income tax provision (benefit) at the statutory rate$15,759 $(8,000)$(14,016)
State income tax provision (benefit), net of federal tax provision (benefit)5,382 (1,021)(3,733)
Other non-deductible or non-taxable items, net447 225 (165)
Excessive employee remuneration2,939 3,246 1,214 
Excess tax (benefit) shortfall on stock-based compensation expense, net304 (2,479)(5,098)
Federal research and development credits(9,202)(1,341)(4,218)
Change in uncertain tax position reserves, net of indirect benefits6,137 (2,970)836 
Deferred tax rate adjustment due to state apportionment changes(1,039)(30)725 
Adjustment from settlement of IRS examination2,461 — — 
Return-to-provision adjustments(433)(38)(810)
Change in valuation allowance(3,129)733 3,457 
Other items, net(298)(278)(644)
Total income tax provision (benefit)$19,328 $(11,953)$(22,452)
Schedule of Deferred Tax Assets and Liabilities
Deferred tax assets and liabilities consisted of the following:
(in thousands)January 31, 2024January 31, 2023
Deferred tax assets:
Net operating loss carryforward$1,730 $2,646 
Stock compensation14,069 16,217 
Research and development credits3,796 7,147 
Lease liabilities14,371 17,337 
Capitalized research and development33,474 16,419 
Fixed assets939 — 
Accruals and reserves3,557 4,439 
Other, net1,937 5,643 
Total gross deferred tax assets$73,873 $69,848 
Less valuation allowance(1,164)(4,294)
Deferred tax assets, net of valuation allowance72,709 65,554 
Deferred tax liabilities:
Fixed assets— (1,509)
Intangible assets(86,195)(99,471)
Incremental contract costs(12,887)(11,118)
Right-of-use assets(11,949)(14,132)
Goodwill(28,691)(20,271)
Other, net(1,657)(1,718)
Total gross deferred tax liabilities(141,379)(148,219)
Net deferred tax liabilities$(68,670)$(82,665)
Schedule of Unrecognized Tax Benefits Roll Forward
A tabular reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
(in thousands)January 31, 2024January 31, 2023
Gross unrecognized tax benefits at beginning of year$8,690 $11,653 
Gross amounts of increases and decreases:
Increases as a result of tax positions taken during a prior period9,325 — 
Decreases as a result of tax positions taken during a prior period— (183)
Increases as a result of tax positions taken during the current period3,386 639 
Decreases as a result of settlement(1,030)
Decreases resulting from the lapse of the applicable statute of limitations(1,158)(3,419)
Gross unrecognized tax benefits at end of year$19,213 $8,690 
Schedule of Unrecognized Tax Benefit Netted Against Deferred Tax Asset The resulting unrecognized tax benefit recorded within the Company's consolidated balance sheet excludes the following amounts that have been netted against the related deferred tax assets accordingly:
(in thousands)January 31, 2024January 31, 2023
Total gross unrecognized tax benefits$19,213 $8,690 
Amounts netted against related deferred tax assets(7,186)(4,337)
Unrecognized tax benefits recorded on the consolidated balance sheet$12,027 $4,353 
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-based compensation (Tables)
12 Months Ended
Jan. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation
The following table shows a summary of stock-based compensation in the Company's consolidated statements of operations and comprehensive income (loss) during the fiscal years presented:
Year ended January 31,
(in thousands)202420232022
Cost of revenue$16,462 $13,591 $10,684 
Sales and marketing13,182 9,821 7,001 
Technology and development20,891 13,828 13,132 
General and administrative26,616 25,374 21,933 
Other expense, net— — 342 
Total stock-based compensation expense$77,151 $62,614 $53,092 
The following table shows stock-based compensation by award type:
Year ended January 31,
(in thousands)202420232022
Restricted stock units$60,688 $46,590 $37,693 
Performance restricted stock units16,384 15,120 12,948 
Stock options79 882 1,816 
Restricted stock awards— 22 155 
Performance restricted stock awards— — 138 
Total non-cash stock-based compensation expense77,151 62,614 52,750 
Acquisition awards exchanged for cash— — 342 
Total stock-based compensation expense$77,151 $62,614 $53,092 
Schedule of Stock Option Activity
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20231,021 
$14.00 - 82.39
$36.06 3.2$27,293 
Exercised (249)
$14.00 - 66.06
$26.21 
Forfeited (46)
$24.36 - 82.39
$75.08 
Outstanding as of January 31, 2024726 
$14.00 - 73.61
$36.91 2.5$28,067 
Vested and expected to vest as of January 31, 2024726 $36.91 2.5$28,067 
Exercisable as of January 31, 2024726 $36.91 2.5$28,067 
Schedule of Restricted Stock Unit Activity
A summary of RSU activity is as follows:
Outstanding RSUs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair value
Outstanding as of January 31, 20233,011 $70.40 
Granted1,929 64.16 
Vested(1,118)65.41 
Forfeited(459)71.56 
Outstanding as of January 31, 20243,363 $67.96 
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Selected quarterly financial data (unaudited) (Tables)
12 Months Ended
Jan. 31, 2024
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information The following tables present the impact of the reclassifications by quarter:
Three months ended January 31, 2024
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$111,759 $6,816 $118,575 
Custodial revenue112,249 (6,816)105,433 
Interchange revenue38,379 — 38,379 
Total revenue262,387 — 262,387 
Total cost of revenue99,939 (872)99,067 
Gross profit162,448 872 163,320 
Total operating expenses123,561 872 124,433 
Total other expense(9,170)— (9,170)
Income tax provision3,353 — 3,353 
Net income$26,364 $— $26,364 
Three months ended October 31, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$107,512 $6,570 $114,082 
Custodial revenue106,575 (6,570)100,005 
Interchange revenue35,132 — 35,132 
Total revenue249,219 — 249,219 
Total cost of revenue90,811 (774)90,037 
Gross profit158,408 774 159,182 
Total operating expenses127,517 774 128,291 
Total other expense(9,804)— (9,804)
Income tax provision6,414 — 6,414 
Net income$14,673 $— $14,673 
Three months ended July 31, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$105,719 $6,241 $111,960 
Custodial revenue98,917 (6,241)92,676 
Interchange revenue38,913 — 38,913 
Total revenue243,549 — 243,549 
Total cost of revenue92,619 (735)91,884 
Gross profit150,930 735 151,665 
Total operating expenses126,190 735 126,925 
Total other expense(10,516)— (10,516)
Income tax provision3,643 — 3,643 
Net income$10,581 $— $10,581 
Three months ended April 30, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$105,112 $5,961 $111,073 
Custodial revenue94,441 (5,961)88,480 
Interchange revenue44,879 — 44,879 
Total revenue244,432 — 244,432 
Total cost of revenue96,606 (644)95,962 
Gross profit147,826 644 148,470 
Total operating expenses124,645 644 125,289 
Total other expense(13,169)— (13,169)
Income tax provision5,918 — 5,918 
Net income$4,094 $— $4,094 
Three months ended January 31, 2023
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$114,234 $5,620 $119,854 
Custodial revenue83,506 (5,620)77,886 
Interchange revenue36,101 — 36,101 
Total revenue233,841 — 233,841 
Total cost of revenue99,593 (525)99,068 
Gross profit134,248 525 134,773 
Total operating expenses121,032 525 121,557 
Total other expense(13,208)— (13,208)
Income tax provision217 — 217 
Net loss$(209)$— $(209)
Three months ended October 31, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$108,580 $5,495 $114,075 
Custodial revenue74,642 (5,495)69,147 
Interchange revenue32,864 — 32,864 
Total revenue216,086 — 216,086 
Total cost of revenue89,228 (460)88,768 
Gross profit126,858 460 127,318 
Total operating expenses121,316 460 121,776 
Total other expense(11,722)— (11,722)
Income tax benefit(4,539)— (4,539)
Net loss$(1,641)$— $(1,641)
Three months ended July 31, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$103,034 $5,508 $108,542 
Custodial revenue65,599 (5,508)60,091 
Interchange revenue37,509 — 37,509 
Total revenue206,142 — 206,142 
Total cost of revenue88,330 (436)87,894 
Gross profit117,812 436 118,248 
Total operating expenses120,224 436 120,660 
Total other expense(11,461)— (11,461)
Income tax benefit(3,219)— (3,219)
Net loss$(10,654)$— $(10,654)
Three months ended April 30, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$104,348 $5,207 $109,555 
Custodial revenue59,365 (5,207)54,158 
Interchange revenue41,966 — 41,966 
Total revenue205,679 — 205,679 
Total cost of revenue94,506 (423)94,083 
Gross profit111,173 423 111,596 
Total operating expenses118,462 423 118,885 
Total other expense(10,762)— (10,762)
Income tax benefit(4,412)— (4,412)
Net loss$(13,639)$— $(13,639)
Three months ended January 31, 2022
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$112,461 $4,924 $117,385 
Custodial revenue58,057 (4,924)53,133 
Interchange revenue32,779 — 32,779 
Total revenue203,297 — 203,297 
Total cost of revenue97,998 (315)97,683 
Gross profit105,299 315 105,614 
Total operating expenses132,549 315 132,864 
Total other expense(16,515)— (16,515)
Income tax benefit(10,947)— (10,947)
Net loss$(32,818)$— $(32,818)
Three months ended October 31, 2021
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$102,733 $4,408 $107,141 
Custodial revenue49,006 (4,408)44,598 
Interchange revenue28,215 — 28,215 
Total revenue179,954 — 179,954 
Total cost of revenue76,634 (252)76,382 
Gross profit103,320 252 103,572 
Total operating expenses103,686 252 103,938 
Total other expense(8,759)— (8,759)
Income tax benefit(4,087)— (4,087)
Net loss$(5,038)$— $(5,038)
Three months ended July 31, 2021
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$109,182 $3,965 $113,147 
Custodial revenue48,776 (3,965)44,811 
Interchange revenue31,145 — 31,145 
Total revenue189,103 — 189,103 
Total cost of revenue77,132 (256)76,876 
Gross profit111,971 256 112,227 
Total operating expenses112,846 256 113,102 
Total other expense(6,910)— (6,910)
Income tax benefit(3,967)— (3,967)
Net loss$(3,818)$— $(3,818)
Three months ended April 30, 2021
(in thousands)Prior presentationReclassificationsCurrent presentation
Service revenue$102,534 $3,401 $105,935 
Custodial revenue46,978 (3,401)43,577 
Interchange revenue34,690 — 34,690 
Total revenue184,202 — 184,202 
Total cost of revenue81,086 (236)80,850 
Gross profit103,116 236 103,352 
Total operating expenses98,863 236 99,099 
Total other expense(10,319)— (10,319)
Income tax benefit(3,451)— (3,451)
Net loss$(2,615)$— $(2,615)
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of business and significant accounting policies - Narrative (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Jan. 31, 2024
USD ($)
Oct. 31, 2023
USD ($)
Jul. 31, 2023
USD ($)
Apr. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Oct. 31, 2022
USD ($)
Jul. 31, 2022
USD ($)
Apr. 30, 2022
USD ($)
Jan. 31, 2022
USD ($)
Oct. 31, 2021
USD ($)
Jul. 31, 2021
USD ($)
Apr. 30, 2021
USD ($)
Jan. 31, 2024
USD ($)
segment
Jan. 31, 2023
USD ($)
Jan. 31, 2022
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Total revenue $ 262,387 $ 249,219 $ 243,549 $ 244,432 $ 233,841 $ 216,086 $ 206,142 $ 205,679 $ 203,297 $ 179,954 $ 189,103 $ 184,202 $ 999,587 $ 861,748 $ 756,556
Number of operating segments | segment                         1    
Leasehold Improvements | Minimum                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Useful life of property, plant and equipment (in years) 3 years                       3 years    
Leasehold Improvements | Maximum                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Useful life of property, plant and equipment (in years) 5 years                       5 years    
Acquired HSA Portfolios                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Useful life of finite-lived intangible asset (in years) 15 years                       15 years    
Custodial revenue                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Total revenue $ 105,433 100,005 92,676 88,480 77,886 69,147 60,091 54,158 53,133 44,598 44,811 43,577 $ 386,594 261,282 186,119
Custodial revenue | Restatement Adjustment                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Total revenue                         (25,600) (21,800) (16,700)
Service revenue                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Total revenue $ 118,575 $ 114,082 $ 111,960 $ 111,073 $ 119,854 $ 114,075 $ 108,542 $ 109,555 $ 117,385 $ 107,141 $ 113,147 $ 105,935 455,690 452,026 443,608
Service revenue | Restatement Adjustment                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Total revenue                         $ 25,600 $ 21,800 $ 16,700
HSA                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Capitalized contract cost, amortization period (in years) 15 years                       15 years    
RA Customer Relationship                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Capitalized contract cost, amortization period (in years) 7 years                       7 years    
Passive Custodial Funds                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Minimum net worth above custodial assets (as a percent) 2.00%                       2.00%    
Non-passive Custodial Fund                              
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                              
Minimum net worth above custodial assets (as a percent) 4.00%                       4.00%    
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of business and significant accounting policies - Property and Equipment (Details)
Jan. 31, 2024
Computer equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Useful life of property, plant and equipment (in years) 3 years
Computer equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Useful life of property, plant and equipment (in years) 5 years
Furniture and fixtures  
Property, Plant and Equipment [Line Items]  
Useful life of property, plant and equipment (in years) 5 years
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of business and significant accounting policies - Intangible Assets (Details)
Jan. 31, 2024
Software and software development costs  
Acquired Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, useful life 3 years
Acquired customer relationships | Minimum  
Acquired Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, useful life 7 years
Acquired customer relationships | Maximum  
Acquired Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, useful life 15 years
Acquired developed technology | Minimum  
Acquired Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, useful life 2 years
Acquired developed technology | Maximum  
Acquired Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, useful life 5 years
Acquired trade names and trademarks  
Acquired Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, useful life 3 years
Acquired HSA portfolios  
Acquired Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible asset, useful life 15 years
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Net income (loss) per share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 12 Months Ended
Jan. 31, 2024
Oct. 31, 2023
Jul. 31, 2023
Apr. 30, 2023
Jan. 31, 2023
Oct. 31, 2022
Jul. 31, 2022
Apr. 30, 2022
Jan. 31, 2022
Oct. 31, 2021
Jul. 31, 2021
Apr. 30, 2021
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Numerator (basic and diluted):                              
Net income (loss) $ 26,364 $ 14,673 $ 10,581 $ 4,094 $ (209) $ (1,641) $ (10,654) $ (13,639) $ (32,818) $ (5,038) $ (3,818) $ (2,615) $ 55,712 $ (26,143) $ (44,289)
Denominator (basic):                              
Weighted-average common shares outstanding (in shares)                         85,564 84,442 83,133
Denominator (diluted):                              
Weighted-average common shares outstanding (in shares)                         85,564 84,442 83,133
Weighted-average dilutive effect of stock options and restricted stock units (in shares)                         1,393 0 0
Diluted weighted-average common shares outstanding (in shares)                         86,957 84,442 83,133
Net income (loss) per share:                              
Basic (in usd per share)                         $ 0.65 $ (0.31) $ (0.53)
Diluted (in usd per share)                         $ 0.64 $ (0.31) $ (0.53)
Antidilutive securities excluded from computation of earnings per share (in shares)                         600 2,500 1,800
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Business combinations - Narrative (Details) - USD ($)
$ in Millions
Nov. 01, 2021
Mar. 08, 2021
Luum Acquisition    
Business Acquisition [Line Items]    
Ownership interest (as a percent)   100.00%
Cash paid   $ 56.2
Maximum amount of contingent consideration payable   $ 2.1
Further Acquisition    
Business Acquisition [Line Items]    
Aggregate fair value of consideration paid $ 455.0  
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Business combinations - Preliminary Allocation of Consideration (Details) - USD ($)
$ in Thousands
14 Months Ended 15 Months Ended
Apr. 30, 2022
Jan. 31, 2023
Jan. 31, 2024
Nov. 01, 2021
Mar. 08, 2021
Business Acquisition [Line Items]          
Goodwill   $ 1,648,145 $ 1,648,145    
Luum Acquisition          
Business Acquisition [Line Items]          
Cash and cash equivalents $ 626       $ 626
Other current assets 1,469       1,469
Intangible assets 23,900       23,900
Goodwill 36,355       36,374
Goodwill, adjustments (19)        
Other assets 100       100
Current liabilities (597)       (597)
Deferred tax liability (3,547)       (3,566)
Deferred tax liability, adjustments 19        
Total consideration paid 58,306       $ 58,306
Total consideration paid, adjustments $ 0        
Further Acquisition          
Business Acquisition [Line Items]          
Current assets   2,504   $ 2,667  
Current assets, adjustments   (163)      
Intangible assets   172,183   172,183  
Goodwill   284,596   282,287  
Goodwill, adjustments   2,309      
Current liabilities   (4,283)   (2,137)  
Current liabilities, adjustments   (2,146)      
Total consideration paid   455,000   $ 455,000  
Total consideration paid, adjustments   $ 0      
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Supplemental financial statement information - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Allowance for doubtful accounts $ 3,900 $ 5,000  
Credit losses from trade receivables 1,700 2,100 $ 3,300
Prepaid expense 31,200 20,100  
Capitalized contract cost 52,100 44,000  
Amortization of capitalized contract costs 5,400 4,400 4,300
Depreciation expense 8,800 12,300 14,700
Remaining performance obligation 6,200 8,300  
Deferred revenue 4,800    
Loss on extinguishment of debt $ 1,157 $ 0 $ 4,049
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-02-01      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Remaining performance obligation, percentage 77.00%    
Revenue, remaining performance obligation, expected timing of satisfaction, period 12 months    
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Supplemental financial statement information - Property and Equipment (Details) - USD ($)
$ in Thousands
Jan. 31, 2024
Jan. 31, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 47,031 $ 54,682
Accumulated depreciation (41,018) (41,820)
Property and equipment, net 6,013 12,862
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 14,455 18,269
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 7,087 8,392
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 25,489 $ 28,021
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Supplemental financial statement information - Other Expense, Net (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Interest income $ 12,138 $ 1,763 $ 1,501
Gain on equity securities 0 0 1,692
Acquisition costs 0 (53) (10,832)
Other miscellaneous income (expense) 658 (439) 1,708
Total other income (expense), net $ 12,796 $ 1,271 $ (5,931)
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Leases - Narrative (Details)
12 Months Ended
Mar. 24, 2022
USD ($)
Jan. 31, 2024
USD ($)
extension
Jan. 31, 2023
USD ($)
Jan. 31, 2022
USD ($)
Lessee, Lease, Description [Line Items]        
Lessee, operating lease, number of extensions (in years) | extension   1    
Operating lease not yet commenced undiscounted amount   $ 1,900,000    
Operating lease not yet commenced term of contract (in years)   7 years    
Impairment of right-of-use assets   $ 0 $ 0 $ 11,246,000
Operating lease right-of-use assets   48,380,000 56,461,000  
Operating lease liability   $ 58,170,000 $ 69,147,000  
Right of use asset       3,900,000
Proceeds from sale of operating lease $ 3,900,000      
WageWorks, Inc.        
Lessee, Lease, Description [Line Items]        
Operating lease right-of-use assets       14,800,000
Operating lease liability       0
Impairment of long-lived assets to be disposed of       $ 10,900,000
Minimum        
Lessee, Lease, Description [Line Items]        
Remaining operating lease terms (in years)   1 year    
Lease renewal terms extension (in years)   2 years    
Maximum        
Lessee, Lease, Description [Line Items]        
Remaining operating lease terms (in years)   7 years    
Lease renewal terms extension (in years)   10 years    
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Leases - Lease Cost (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Leases [Abstract]      
Operating lease expense $ 9,437 $ 11,371 $ 14,762
Sublease income (2,680) (2,187) (1,836)
Net operating lease cost $ 6,757 $ 9,184 $ 12,926
Weighted average remaining lease term 6 years 8 months 12 days 7 years 6 months  
Weighted average discount rate 4.30% 4.30%  
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Leases - Lease Liabilities (Details) - USD ($)
$ in Thousands
Jan. 31, 2024
Jan. 31, 2023
Leases [Abstract]    
Gross lease liabilities $ 67,269 $ 81,313
Less: imputed interest (9,099) (12,166)
Present value of lease liabilities 58,170 69,147
Less: current portion of lease liabilities (9,404) (10,159)
Lease liabilities, non-current $ 48,766 $ 58,988
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Leases - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 10,900 $ 12,533
Right-of-use assets obtained in exchange for lease obligations $ 2,109 $ 1,092
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible assets and goodwill - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Jan. 31, 2024
Jan. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 1,437,450 $ 1,399,889
Accumulated amortization (601,502) (463,530)
Net carrying amount 835,948 936,359
Software and software development costs    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 267,498 233,194
Accumulated amortization (197,388) (152,178)
Net carrying amount 70,110 81,016
Acquired HSA portfolios    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 264,445 261,188
Accumulated amortization (81,059) (63,547)
Net carrying amount 183,386 197,641
Acquired customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 759,782 759,782
Accumulated amortization (205,127) (153,434)
Net carrying amount 554,655 606,348
Acquired developed technology    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 132,825 132,825
Accumulated amortization (105,049) (81,692)
Net carrying amount 27,776 51,133
Acquired trade names    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 12,900 12,900
Accumulated amortization (12,879) (12,679)
Net carrying amount $ 21 $ 221
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible assets and goodwill - Narrative (Details) - USD ($)
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Finite-Lived Intangible Assets [Line Items]      
Amortization expense $ 144,300,000 $ 148,900,000 $ 122,500,000
Goodwill impairment 0 0 $ 0
Change in goodwill 0    
Luum and Further      
Finite-Lived Intangible Assets [Line Items]      
Goodwill, adjustments   2,300,000  
Acquired HSA Portfolios      
Finite-Lived Intangible Assets [Line Items]      
Finite-lived intangible assets, acquired $ 3,300,000 $ 68,900,000  
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible assets and goodwill - Schedule for Future Amortization Expense (Details) - USD ($)
$ in Thousands
Jan. 31, 2024
Jan. 31, 2023
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]    
2025 $ 126,150  
2026 97,732  
2027 80,837  
2028 67,550  
2029 65,774  
Thereafter 397,905  
Net carrying amount $ 835,948 $ 936,359
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and contingencies - Outstanding Contractual Obligations (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Sep. 30, 2023
Jan. 31, 2024
Jan. 31, 2023
Long-term Debt, Fiscal Year Maturity [Abstract]      
Total   $ 874,972 $ 925,338
Interest On Long-Term Debt, Fiscal Year Maturity [Abstract]      
2025   46,502  
2026   46,402  
2027   39,087  
2028   27,000  
2029   27,000  
Thereafter   18,000  
Total   203,991  
Lessee, Operating Lease, Liability, Payment, Due [Abstract]      
2025   9,862  
2026   10,281  
2027   10,165  
2028   10,323  
2029   10,553  
Thereafter   17,952  
Total   69,136  
Other Commitment, Fiscal Year Maturity [Abstract]      
2025   23,496  
2026   21,487  
2027   7,302  
2028   6,502  
2029   0  
Thereafter   0  
Total   58,787  
Contractual Obligation, Fiscal Year Maturity [Abstract]      
2025   524,860  
2026   85,045  
2027   336,554  
2028   43,825  
2029   37,553  
Thereafter   635,952  
Total   1,663,789  
Principal amount   886,875 941,250
Sublease income to be received   16,300  
HSA Portfolio      
BenefitWallet HSA Portfolio Acquisition, Fiscal Year Maturity [Abstract]      
2025   445,000  
2026   0  
2027   0  
2028   0  
2029   0  
Thereafter   0  
Total   445,000  
Contractual Obligation, Fiscal Year Maturity [Abstract]      
Purchase price $ 425,000    
Transfer-related expenses 20,000    
Asset acquisition, transferred, transaction cost $ 7,000    
4.50% Senior Notes due 2029      
Long-term Debt, Fiscal Year Maturity [Abstract]      
2025   0  
2026   0  
2027   0  
2028   0  
2029   0  
Thereafter   600,000  
Total   600,000  
Contractual Obligation, Fiscal Year Maturity [Abstract]      
Principal amount   $ 600,000 600,000
Stated interest rate (as a percent)   4.50%  
Credit Agreement      
Contractual Obligation, Fiscal Year Maturity [Abstract]      
Stated interest rate (as a percent)   6.69%  
Credit Agreement | Term Loan Facility      
Long-term Debt, Fiscal Year Maturity [Abstract]      
2025   $ 0  
2026   6,875  
2027   280,000  
2028   0  
2029   0  
Thereafter   0  
Total   286,875  
Contractual Obligation, Fiscal Year Maturity [Abstract]      
Principal amount   $ 286,875 $ 341,250
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and contingencies - Narrative (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Nov. 05, 2021
Jan. 31, 2024
Nov. 24, 2021
Apr. 30, 2021
Loss Contingencies [Line Items]          
Operating lease not yet commenced undiscounted amount     $ 1.9    
Operating lease not yet commenced term of contract (in years)     7 years    
WageWorks Inc.          
Loss Contingencies [Line Items]          
Operating lease not yet commenced undiscounted amount         $ 63.1
Operating lease not yet commenced term of contract (in years)         11 years
WageWorks Inc. | Union Mesa          
Loss Contingencies [Line Items]          
Lessee, operating lease, abated rent, period   11 months      
Letters of credit outstanding       $ 2.8  
Late charge percentage 3.00%        
WageWorks Inc. | Union Mesa | Prime Rate          
Loss Contingencies [Line Items]          
Variable rate borrowing spread (as a percent) 5.00%        
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.24.1
Indebtedness - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Jan. 31, 2024
Jan. 31, 2023
Debt Instrument [Line Items]    
Principal amount $ 886,875 $ 941,250
Less: unamortized discount and issuance costs 11,903 15,912
Total 874,972 925,338
Less: current portion of long-term debt 0 17,500
Long-term debt, net 874,972 907,838
Revolving Credit Facility    
Debt Instrument [Line Items]    
Debt issuance costs, net 2,500 3,400
4.50% Senior Notes due 2029    
Debt Instrument [Line Items]    
Principal amount 600,000 600,000
Total $ 600,000  
Stated interest rate (as a percent) 4.50%  
Credit Agreement    
Debt Instrument [Line Items]    
Stated interest rate (as a percent) 6.69%  
Credit Agreement | Term Loan Facility    
Debt Instrument [Line Items]    
Principal amount $ 286,875 $ 341,250
Total $ 286,875  
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Indebtedness - Narrative (Details) - USD ($)
1 Months Ended 12 Months Ended
Jun. 01, 2023
May 31, 2023
Oct. 08, 2021
Apr. 30, 2023
Jan. 31, 2024
Line of Credit | Revolving Credit Facility | Minimum          
Debt Instrument [Line Items]          
Commitment fee (as a percent)         0.20%
Line of Credit | Revolving Credit Facility | Maximum          
Debt Instrument [Line Items]          
Commitment fee (as a percent)         0.40%
4.50% Senior Notes due 2029          
Debt Instrument [Line Items]          
Stated interest rate (as a percent)         4.50%
4.50% Senior Notes due 2029 | Senior Notes          
Debt Instrument [Line Items]          
Stated interest rate (as a percent)     4.50%    
Principal amount     $ 600,000,000    
Accrued interest         $ 9,300,000
Effective interest rate (as a percent)         4.72%
4.50% Senior Notes due 2029 | Senior Notes | October 1, 2024          
Debt Instrument [Line Items]          
Redemption price (as a percent)     102.25%    
4.50% Senior Notes due 2029 | Senior Notes | October 1, 2025          
Debt Instrument [Line Items]          
Redemption price (as a percent)     101.125%    
4.50% Senior Notes due 2029 | Senior Notes | October 1, 2026 and thereafter          
Debt Instrument [Line Items]          
Redemption price (as a percent)     100.00%    
4.50% Senior Notes due 2029 | Senior Notes | Prior to October 1, 2024          
Debt Instrument [Line Items]          
Redemption price (as a percent)     100.00%    
4.50% Senior Notes due 2029 | Senior Notes | Prior to October 1, 2024, 40% of Principal          
Debt Instrument [Line Items]          
Redemption price (as a percent)     104.50%    
Percentage of principal amount redeemed (as a percent)     40.00%    
Credit Agreement          
Debt Instrument [Line Items]          
Stated interest rate (as a percent)         6.69%
Effective interest rate (as a percent)         7.45%
Maximum borrowing capacity of future commitments     $ 300,000,000    
Maximum leverage ratio     3.85   5.00
Minimum interest coverage ratio         3.00
Credit Agreement | Secured Overnight Financing Rate (SOFR)          
Debt Instrument [Line Items]          
Credit spread adjustment on variable rate (as a percent) 0.10%        
Credit Agreement | Minimum | London Interbank Offered Rate          
Debt Instrument [Line Items]          
Variable rate borrowing spread (as a percent)   1.25%      
Credit Agreement | Minimum | Customary Base Rate          
Debt Instrument [Line Items]          
Variable rate borrowing spread (as a percent) 0.25% 0.25%      
Credit Agreement | Minimum | Secured Overnight Financing Rate (SOFR)          
Debt Instrument [Line Items]          
Variable rate borrowing spread (as a percent) 1.25%        
Credit Agreement | Maximum | London Interbank Offered Rate          
Debt Instrument [Line Items]          
Variable rate borrowing spread (as a percent)   2.25%      
Credit Agreement | Maximum | Customary Base Rate          
Debt Instrument [Line Items]          
Variable rate borrowing spread (as a percent) 1.25% 1.25%      
Credit Agreement | Maximum | Secured Overnight Financing Rate (SOFR)          
Debt Instrument [Line Items]          
Variable rate borrowing spread (as a percent) 2.25%        
Credit Agreement | Secured Debt | Term Loan Facility          
Debt Instrument [Line Items]          
Facility term (in years)     5 years    
Credit facility, amount     $ 350,000,000    
Credit Agreement | Line of Credit | Term Loan Facility          
Debt Instrument [Line Items]          
Debt instrument, prepayment covenant, percentage of proceeds from sales to used to prepay (as a percent)         100.00%
Debt instrument, number of days to reinvest proceeds from sales of assets (in days)         450 days
Debt instrument, number of days to commit to reinvesting proceeds from sales of assets after initial period (in days)         180 days
Prepayment of debt       $ 50,000,000  
Credit Agreement | Line of Credit | Term Loan Facility | First year after the Effective Date          
Debt Instrument [Line Items]          
Debt instrument, amortization of loans, percentage of principal amount (as a percent)         2.50%
Credit Agreement | Line of Credit | Term Loan Facility | Second and third years after the Effective Date          
Debt Instrument [Line Items]          
Debt instrument, amortization of loans, percentage of principal amount (as a percent)         5.00%
Credit Agreement | Line of Credit | Term Loan Facility | Fourth year after the Effective Date          
Debt Instrument [Line Items]          
Debt instrument, amortization of loans, percentage of principal amount (as a percent)         7.50%
Credit Agreement | Line of Credit | Term Loan Facility | Fifth year after the Effective Date          
Debt Instrument [Line Items]          
Debt instrument, amortization of loans, percentage of principal amount (as a percent)         10.00%
Credit Agreement | Line of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Facility term (in years)     5 years    
Credit facility, amount     $ 1,000,000,000    
Credit Agreement | Letter of Credit | Revolving Credit Facility          
Debt Instrument [Line Items]          
Credit facility, amount     $ 25,000,000    
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Income taxes - Schedule of Components of Income Tax Provision (Benefit) (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jan. 31, 2024
Oct. 31, 2023
Jul. 31, 2023
Apr. 30, 2023
Jan. 31, 2023
Oct. 31, 2022
Jul. 31, 2022
Apr. 30, 2022
Jan. 31, 2022
Oct. 31, 2021
Jul. 31, 2021
Apr. 30, 2021
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Current:                              
Federal                         $ 29,376 $ 3,260 $ 628
State                         3,947 1,968 239
Total current tax provision                         33,323 5,228 867
Deferred:                              
Federal                         (11,004) (14,382) (21,197)
State                         (2,991) (2,799) (2,122)
Total deferred tax benefit                         (13,995) (17,181) (23,319)
Total income tax provision (benefit) $ 3,353 $ 6,414 $ 3,643 $ 5,918 $ 217 $ (4,539) $ (3,219) $ (4,412) $ (10,947) $ (4,087) $ (3,967) $ (3,451) $ 19,328 $ (11,953) $ (22,452)
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.24.1
Income taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jan. 31, 2024
Oct. 31, 2023
Jul. 31, 2023
Apr. 30, 2023
Jan. 31, 2023
Oct. 31, 2022
Jul. 31, 2022
Apr. 30, 2022
Jan. 31, 2022
Oct. 31, 2021
Jul. 31, 2021
Apr. 30, 2021
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Income Tax Disclosure [Abstract]                              
Federal income tax provision (benefit) at the statutory rate                         $ 15,759 $ (8,000) $ (14,016)
State income tax provision (benefit), net of federal tax provision (benefit)                         5,382 (1,021) (3,733)
Other non-deductible or non-taxable items, net                         447 225 (165)
Excessive employee remuneration                         2,939 3,246 1,214
Excess tax (benefit) shortfall on stock-based compensation expense, net                         304 (2,479) (5,098)
Federal research and development credits                         (9,202) (1,341) (4,218)
Change in uncertain tax position reserves, net of indirect benefits                         6,137 (2,970) 836
Deferred tax rate adjustment due to state apportionment changes                         (1,039) (30) 725
Adjustment from settlement of IRS examination                         2,461 0 0
Return-to-provision adjustments                         (433) (38) (810)
Change in valuation allowance                         (3,129) 733 3,457
Other items, net                         (298) (278) (644)
Total income tax provision (benefit) $ 3,353 $ 6,414 $ 3,643 $ 5,918 $ 217 $ (4,539) $ (3,219) $ (4,412) $ (10,947) $ (4,087) $ (3,967) $ (3,451) $ 19,328 $ (11,953) $ (22,452)
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.24.1
Income taxes - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Operating Loss Carryforwards [Line Items]      
Effective income tax benefit rate 25.80% 31.40% 33.60%
Deferred tax asset, valuation allowance $ 1,164 $ 4,294  
Decrease in valuation allowance 3,100    
Gross unrecognized tax benefit 19,213 8,690 $ 11,653
Unrecognized tax benefits that would impact the effective tax rate 16,200 5,400  
Period increase in unrecognized tax benefit 10,500    
Unrecognized tax benefits, income tax penalties and interest expense 100 400 $ 700
Unrecognized tax benefits, income tax penalties and interest accrued 1,400 $ 1,300  
State      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforwards 27,200    
State | Research      
Operating Loss Carryforwards [Line Items]      
Credit carryforward $ 11,900    
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.24.1
Income taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jan. 31, 2024
Jan. 31, 2023
Deferred tax assets:    
Net operating loss carryforward $ 1,730 $ 2,646
Stock compensation 14,069 16,217
Research and development credits 3,796 7,147
Lease liabilities 14,371 17,337
Capitalized research and development 33,474 16,419
Fixed assets 939 0
Accruals and reserves 3,557 4,439
Other, net 1,937 5,643
Total gross deferred tax assets 73,873 69,848
Less valuation allowance (1,164) (4,294)
Deferred tax assets, net of valuation allowance 72,709 65,554
Deferred tax liabilities:    
Fixed assets 0 (1,509)
Intangible assets (86,195) (99,471)
Incremental contract costs (12,887) (11,118)
Right-of-use assets (11,949) (14,132)
Goodwill (28,691) (20,271)
Other, net (1,657) (1,718)
Total gross deferred tax liabilities (141,379) (148,219)
Net deferred tax liabilities $ (68,670) $ (82,665)
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.24.1
Income taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]    
Gross unrecognized tax benefits at beginning of year $ 8,690 $ 11,653
Increases as a result of tax positions taken during a prior period 9,325 0
Decreases as a result of tax positions taken during a prior period 0 (183)
Increases as a result of tax positions taken during the current period 3,386 639
Decreases as a result of settlement (1,030)
Decreases resulting from the lapse of the applicable statute of limitations (1,158) (3,419)
Gross unrecognized tax benefits at end of year 19,213 8,690
Total gross unrecognized tax benefits 19,213 8,690
Amounts netted against related deferred tax assets (7,186) (4,337)
Unrecognized tax benefits recorded on the consolidated balance sheet $ 12,027 $ 4,353
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-based compensation - Schedule of Stock-Based Compensation (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 77,151 $ 62,614 $ 53,092
Restricted stock units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 60,688 46,590 37,693
Performance restricted stock units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 16,384 15,120 12,948
Stock options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 79 882 1,816
Restricted stock awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 0 22 155
Performance restricted stock awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 0 0 138
Total non-cash stock-based compensation expense      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 77,151 62,614 52,750
Acquisition awards exchanged for cash      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 0 0 342
Cost of revenue      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 16,462 13,591 10,684
Sales and marketing      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 13,182 9,821 7,001
Technology and development      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 20,891 13,828 13,132
General and administrative      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense 26,616 25,374 21,933
Other expense, net      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total stock-based compensation expense $ 0 $ 0 $ 342
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-based compensation - Narrative (Details) - USD ($)
1 Months Ended 12 Months Ended
Mar. 31, 2022
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)   0 0 0
Aggregate intrinsic value   $ 10,100,000 $ 7,200,000 $ 19,300,000
Unrecognized stock compensation expense related to options to be recognized in future   $ 0    
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expiration period after termination (in years)   10 years    
Expiration period from termination of employment (in days)   90 days    
Restricted stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Weighted-average grant date fair value (in usd per share)   $ 64.16 $ 75.64 $ 64.87
Award vesting period (in years)   4 years    
Percentage of options vested (as a percent) 25.00%      
Performance units awards (in shares)   1,929,000    
Aggregate intrinsic value   $ 69,300,000 $ 50,700,000 $ 40,900,000
Compensation not yet recognized, other than options   $ 162,500,000    
Recognition period for stock-based compensation (in years)   2 years 4 months 24 days    
Outstanding (in shares)   3,363,000 3,011,000  
Performance restricted stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Performance units awards (in shares)   270,966 281,784 249,750
Grant date fair value   $ 23,900,000 $ 32,100,000 $ 22,400,000
Performance restricted stock units | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Percentage of options vested (as a percent)   0.00% 0.00% 0.00%
Performance restricted stock units | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Percentage of options vested (as a percent)   200.00% 200.00% 200.00%
Restricted stock awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Compensation not yet recognized, other than options   $ 0    
Outstanding (in shares)   0    
Incentive Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares available for grant under incentive plan (in shares)   11,900,000    
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-based compensation - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Number of options    
Outstanding, beginning balance (in shares) 1,021  
Exercised (in shares) (249)  
Forfeited (in shares) (46)  
Outstanding, ending balance (in shares) 726 1,021
Vested and expected to vest (in shares) 726  
Exercisable (in shares) 726  
Range of exercise prices    
Beginning balance, minimum (in usd per share) $ 14.00  
Beginning balance, maximum (in usd per share) 82.39  
Exercised, minimum (in usd per share) 14.00  
Exercised, maximum (in usd per share) 66.06  
Forfeited, minimum (in usd per share) 24.36  
Forfeited, maximum (in usd per share) 82.39  
Ending balance, minimum (in usd per share) 14.00 $ 14.00
Ending balance, maximum (in usd per share) 73.61 82.39
Weighted- average exercise price    
Opening balance (in usd per share) 36.06  
Exercised (in usd per share) 26.21  
Forfeited (in usd per share) 75.08  
Ending balance (in usd per share) 36.91 $ 36.06
Vested and expected to vest, weighted-average exercise price (in usd per share) 36.91  
Exercisable, weighted-average exercise price (in usd per share) $ 36.91  
Outstanding stock options, weighted-average contractual term (in years) 2 years 6 months 3 years 2 months 12 days
Vested and expected to vest, weighted-average contractual term (in years) 2 years 6 months  
Exercisable, weighted-average contractual term (in years) 2 years 6 months  
Aggregate intrinsic value $ 28,067 $ 27,293
Vested and expected to vest, aggregate intrinsic value 28,067  
Exercisable, aggregate intrinsic value $ 28,067  
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-based compensation - Schedule of Restricted Stock Unit Activity (Details) - Restricted stock units - $ / shares
shares in Thousands
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Shares      
Outstanding, beginning balance (in shares) 3,011    
Granted (in shares) 1,929    
Vested (in shares) (1,118)    
Forfeited (in shares) (459)    
Outstanding, ending balance (in shares) 3,363 3,011  
Weighted-average grant date fair value      
Outstanding, beginning balance (in usd per share) $ 70.40    
Granted (in usd per share) 64.16 $ 75.64 $ 64.87
Vested (in usd per share) 65.41    
Forfeited (in usd per share) 71.56    
Outstanding, ending balance (in usd per share) $ 67.96 $ 70.40  
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.24.1
Fair value (Details)
$ in Millions
Jan. 31, 2024
USD ($)
Level 2 | 4.50% Senior Notes due 2029  
Defined Benefit Plan Disclosure [Line Items]  
Fair value of the notes $ 560.2
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.24.1
Employee benefits (Details) - USD ($)
12 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Defined Contribution Plan Disclosure [Line Items]      
Maximum coverage per incident under self-insurance $ 500,000    
Accrued Compensation      
Defined Contribution Plan Disclosure [Line Items]      
Liability for self-insured medical claims $ 4,700,000 $ 5,100,000  
Supplemental Employee Retirement Plan | 401(k)      
Defined Contribution Plan Disclosure [Line Items]      
Percent of employees eligible earnings (as a percent) 3.50%    
Employer matching contribution expense $ 8,700,000 $ 8,000,000 $ 7,100,000
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.24.1
Selected quarterly financial data (unaudited) (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jan. 31, 2024
Oct. 31, 2023
Jul. 31, 2023
Apr. 30, 2023
Jan. 31, 2023
Oct. 31, 2022
Jul. 31, 2022
Apr. 30, 2022
Jan. 31, 2022
Oct. 31, 2021
Jul. 31, 2021
Apr. 30, 2021
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2022
Reclassification [Line Items]                              
Total revenue $ 262,387 $ 249,219 $ 243,549 $ 244,432 $ 233,841 $ 216,086 $ 206,142 $ 205,679 $ 203,297 $ 179,954 $ 189,103 $ 184,202 $ 999,587 $ 861,748 $ 756,556
Total cost of revenue 99,067 90,037 91,884 95,962 99,068 88,768 87,894 94,083 97,683 76,382 76,876 80,850 376,950 369,813 331,791
Gross profit 163,320 159,182 151,665 148,470 134,773 127,318 118,248 111,596 105,614 103,572 112,227 103,352 622,637 491,935 424,765
Total operating expenses 124,433 128,291 126,925 125,289 121,557 121,776 120,660 118,885 132,864 103,938 113,102 99,099 504,938 482,878 449,003
Total other expense (9,170) (9,804) (10,516) (13,169) (13,208) (11,722) (11,461) (10,762) (16,515) (8,759) (6,910) (10,319) (42,659) (47,153) (42,503)
Income tax provision (benefit) 3,353 6,414 3,643 5,918 217 (4,539) (3,219) (4,412) (10,947) (4,087) (3,967) (3,451) 19,328 (11,953) (22,452)
Net income (loss) 26,364 14,673 10,581 4,094 (209) (1,641) (10,654) (13,639) (32,818) (5,038) (3,818) (2,615) 55,712 (26,143) (44,289)
Prior presentation                              
Reclassification [Line Items]                              
Total revenue 262,387 249,219 243,549 244,432 233,841 216,086 206,142 205,679 203,297 179,954 189,103 184,202      
Total cost of revenue 99,939 90,811 92,619 96,606 99,593 89,228 88,330 94,506 97,998 76,634 77,132 81,086      
Gross profit 162,448 158,408 150,930 147,826 134,248 126,858 117,812 111,173 105,299 103,320 111,971 103,116      
Total operating expenses 123,561 127,517 126,190 124,645 121,032 121,316 120,224 118,462 132,549 103,686 112,846 98,863      
Total other expense (9,170) (9,804) (10,516) (13,169) (13,208) (11,722) (11,461) (10,762) (16,515) (8,759) (6,910) (10,319)      
Income tax provision (benefit) 3,353 6,414 3,643 5,918 217 (4,539) (3,219) (4,412) (10,947) (4,087) (3,967) (3,451)      
Net income (loss) 26,364 14,673 10,581 4,094 (209) (1,641) (10,654) (13,639) (32,818) (5,038) (3,818) (2,615)      
Reclassifications                              
Reclassification [Line Items]                              
Total revenue 0 0 0 0 0 0 0 0 0 0 0 0      
Total cost of revenue (872) (774) (735) (644) (525) (460) (436) (423) (315) (252) (256) (236)      
Gross profit 872 774 735 644 525 460 436 423 315 252 256 236      
Total operating expenses 872 774 735 644 525 460 436 423 315 252 256 236      
Total other expense 0 0 0 0 0 0 0 0 0 0 0 0      
Income tax provision (benefit) 0 0 0 0 0 0 0 0 0 0 0 0      
Net income (loss) 0 0 0 0 0 0 0 0 0 0 0 0      
Service revenue                              
Reclassification [Line Items]                              
Total revenue 118,575 114,082 111,960 111,073 119,854 114,075 108,542 109,555 117,385 107,141 113,147 105,935 455,690 452,026 443,608
Total cost of revenue                         317,357 318,516 291,618
Service revenue | Prior presentation                              
Reclassification [Line Items]                              
Total revenue 111,759 107,512 105,719 105,112 114,234 108,580 103,034 104,348 112,461 102,733 109,182 102,534      
Service revenue | Reclassifications                              
Reclassification [Line Items]                              
Total revenue 6,816 6,570 6,241 5,961 5,620 5,495 5,508 5,207 4,924 4,408 3,965 3,401      
Custodial revenue                              
Reclassification [Line Items]                              
Total revenue 105,433 100,005 92,676 88,480 77,886 69,147 60,091 54,158 53,133 44,598 44,811 43,577 386,594 261,282 186,119
Total cost of revenue                         32,502 26,101 19,492
Custodial revenue | Prior presentation                              
Reclassification [Line Items]                              
Total revenue 112,249 106,575 98,917 94,441 83,506 74,642 65,599 59,365 58,057 49,006 48,776 46,978      
Custodial revenue | Reclassifications                              
Reclassification [Line Items]                              
Total revenue (6,816) (6,570) (6,241) (5,961) (5,620) (5,495) (5,508) (5,207) (4,924) (4,408) (3,965) (3,401)      
Interchange revenue                              
Reclassification [Line Items]                              
Total revenue 38,379 35,132 38,913 44,879 36,101 32,864 37,509 41,966 32,779 28,215 31,145 34,690 157,303 148,440 126,829
Total cost of revenue                         $ 27,091 $ 25,196 $ 20,681
Interchange revenue | Prior presentation                              
Reclassification [Line Items]                              
Total revenue 38,379 35,132 38,913 44,879 36,101 32,864 37,509 41,966 32,779 28,215 31,145 34,690      
Interchange revenue | Reclassifications                              
Reclassification [Line Items]                              
Total revenue $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0      
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.24.1
Subsequent events (Details) - HSA Portfolio
$ in Millions
1 Months Ended
Mar. 07, 2024
USD ($)
account
transfer
Sep. 30, 2023
USD ($)
Subsequent Event [Line Items]    
Purchase price   $ 425.0
Subsequent Event    
Subsequent Event [Line Items]    
Number of transfers | transfer 3  
Number of HSAs transferred | account 266,000  
HSAs transferred, value $ 1,100.0  
Purchase price $ 163.9  
EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 352 450 1 false 78 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.healthequity.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.healthequity.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated balance sheets Sheet http://www.healthequity.com/role/Consolidatedbalancesheets Consolidated balance sheets Statements 3 false false R4.htm 0000004 - Statement - Consolidated balance sheets (Parenthetical) Sheet http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical Consolidated balance sheets (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated statements of operations and comprehensive income (loss) Sheet http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss Consolidated statements of operations and comprehensive income (loss) Statements 5 false false R6.htm 0000006 - Statement - Consolidated statements of stockholders' equity Sheet http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity Consolidated statements of stockholders' equity Statements 6 false false R7.htm 0000007 - Statement - Consolidated statements of cash flows Sheet http://www.healthequity.com/role/Consolidatedstatementsofcashflows Consolidated statements of cash flows Statements 7 false false R8.htm 0000008 - Disclosure - Summary of business and significant accounting policies Sheet http://www.healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies Summary of business and significant accounting policies Notes 8 false false R9.htm 0000009 - Disclosure - Net income (loss) per share Sheet http://www.healthequity.com/role/Netincomelosspershare Net income (loss) per share Notes 9 false false R10.htm 0000010 - Disclosure - Business combinations Sheet http://www.healthequity.com/role/Businesscombinations Business combinations Notes 10 false false R11.htm 0000011 - Disclosure - Supplemental financial statement information Sheet http://www.healthequity.com/role/Supplementalfinancialstatementinformation Supplemental financial statement information Notes 11 false false R12.htm 0000012 - Disclosure - Leases Sheet http://www.healthequity.com/role/Leases Leases Notes 12 false false R13.htm 0000013 - Disclosure - Intangible assets and goodwill Sheet http://www.healthequity.com/role/Intangibleassetsandgoodwill Intangible assets and goodwill Notes 13 false false R14.htm 0000014 - Disclosure - Commitments and contingencies Sheet http://www.healthequity.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 14 false false R15.htm 0000015 - Disclosure - Indebtedness Sheet http://www.healthequity.com/role/Indebtedness Indebtedness Notes 15 false false R16.htm 0000016 - Disclosure - Income taxes Sheet http://www.healthequity.com/role/Incometaxes Income taxes Notes 16 false false R17.htm 0000017 - Disclosure - Stock-based compensation Sheet http://www.healthequity.com/role/Stockbasedcompensation Stock-based compensation Notes 17 false false R18.htm 0000018 - Disclosure - Fair value Sheet http://www.healthequity.com/role/Fairvalue Fair value Notes 18 false false R19.htm 0000019 - Disclosure - Employee benefits Sheet http://www.healthequity.com/role/Employeebenefits Employee benefits Notes 19 false false R20.htm 0000020 - Disclosure - Selected quarterly financial data (unaudited) Sheet http://www.healthequity.com/role/Selectedquarterlyfinancialdataunaudited Selected quarterly financial data (unaudited) Notes 20 false false R21.htm 0000021 - Disclosure - Subsequent events Sheet http://www.healthequity.com/role/Subsequentevents Subsequent events Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Summary of business and significant accounting policies (Policies) Sheet http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies Summary of business and significant accounting policies (Policies) Policies 24 false false R25.htm 9954472 - Disclosure - Summary of business and significant accounting policies (Tables) Sheet http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesTables Summary of business and significant accounting policies (Tables) Tables http://www.healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies 25 false false R26.htm 9954473 - Disclosure - Net income (loss) per share (Tables) Sheet http://www.healthequity.com/role/NetincomelosspershareTables Net income (loss) per share (Tables) Tables http://www.healthequity.com/role/Netincomelosspershare 26 false false R27.htm 9954474 - Disclosure - Business combinations (Tables) Sheet http://www.healthequity.com/role/BusinesscombinationsTables Business combinations (Tables) Tables http://www.healthequity.com/role/Businesscombinations 27 false false R28.htm 9954475 - Disclosure - Supplemental financial statement information (Tables) Sheet http://www.healthequity.com/role/SupplementalfinancialstatementinformationTables Supplemental financial statement information (Tables) Tables http://www.healthequity.com/role/Supplementalfinancialstatementinformation 28 false false R29.htm 9954476 - Disclosure - Leases (Tables) Sheet http://www.healthequity.com/role/LeasesTables Leases (Tables) Tables http://www.healthequity.com/role/Leases 29 false false R30.htm 9954477 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://www.healthequity.com/role/IntangibleassetsandgoodwillTables Intangible assets and goodwill (Tables) Tables http://www.healthequity.com/role/Intangibleassetsandgoodwill 30 false false R31.htm 9954478 - Disclosure - Commitments and contingencies (Tables) Sheet http://www.healthequity.com/role/CommitmentsandcontingenciesTables Commitments and contingencies (Tables) Tables http://www.healthequity.com/role/Commitmentsandcontingencies 31 false false R32.htm 9954479 - Disclosure - Indebtedness (Tables) Sheet http://www.healthequity.com/role/IndebtednessTables Indebtedness (Tables) Tables http://www.healthequity.com/role/Indebtedness 32 false false R33.htm 9954480 - Disclosure - Income taxes (Tables) Sheet http://www.healthequity.com/role/IncometaxesTables Income taxes (Tables) Tables http://www.healthequity.com/role/Incometaxes 33 false false R34.htm 9954481 - Disclosure - Stock-based compensation (Tables) Sheet http://www.healthequity.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://www.healthequity.com/role/Stockbasedcompensation 34 false false R35.htm 9954482 - Disclosure - Selected quarterly financial data (unaudited) (Tables) Sheet http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedTables Selected quarterly financial data (unaudited) (Tables) Tables http://www.healthequity.com/role/Selectedquarterlyfinancialdataunaudited 35 false false R36.htm 9954483 - Disclosure - Summary of business and significant accounting policies - Narrative (Details) Sheet http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails Summary of business and significant accounting policies - Narrative (Details) Details http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesTables 36 false false R37.htm 9954484 - Disclosure - Summary of business and significant accounting policies - Property and Equipment (Details) Sheet http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails Summary of business and significant accounting policies - Property and Equipment (Details) Details 37 false false R38.htm 9954485 - Disclosure - Summary of business and significant accounting policies - Intangible Assets (Details) Sheet http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails Summary of business and significant accounting policies - Intangible Assets (Details) Details 38 false false R39.htm 9954486 - Disclosure - Net income (loss) per share (Details) Sheet http://www.healthequity.com/role/NetincomelosspershareDetails Net income (loss) per share (Details) Details http://www.healthequity.com/role/NetincomelosspershareTables 39 false false R40.htm 9954487 - Disclosure - Business combinations - Narrative (Details) Sheet http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails Business combinations - Narrative (Details) Details 40 false false R41.htm 9954488 - Disclosure - Business combinations - Preliminary Allocation of Consideration (Details) Sheet http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails Business combinations - Preliminary Allocation of Consideration (Details) Details 41 false false R42.htm 9954489 - Disclosure - Supplemental financial statement information - Narrative (Details) Sheet http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails Supplemental financial statement information - Narrative (Details) Details 42 false false R43.htm 9954490 - Disclosure - Supplemental financial statement information - Property and Equipment (Details) Sheet http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails Supplemental financial statement information - Property and Equipment (Details) Details 43 false false R44.htm 9954491 - Disclosure - Supplemental financial statement information - Other Expense, Net (Details) Sheet http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails Supplemental financial statement information - Other Expense, Net (Details) Details 44 false false R45.htm 9954492 - Disclosure - Leases - Narrative (Details) Sheet http://www.healthequity.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 45 false false R46.htm 9954493 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.healthequity.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 46 false false R47.htm 9954494 - Disclosure - Leases - Lease Liabilities (Details) Sheet http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails Leases - Lease Liabilities (Details) Details 47 false false R48.htm 9954495 - Disclosure - Leases - Supplemental Cash Flow Information (Details) Sheet http://www.healthequity.com/role/LeasesSupplementalCashFlowInformationDetails Leases - Supplemental Cash Flow Information (Details) Details 48 false false R49.htm 9954496 - Disclosure - Intangible assets and goodwill - Schedule of Finite-Lived Intangible Assets (Details) Sheet http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails Intangible assets and goodwill - Schedule of Finite-Lived Intangible Assets (Details) Details 49 false false R50.htm 9954497 - Disclosure - Intangible assets and goodwill - Narrative (Details) Sheet http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails Intangible assets and goodwill - Narrative (Details) Details 50 false false R51.htm 9954498 - Disclosure - Intangible assets and goodwill - Schedule for Future Amortization Expense (Details) Sheet http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails Intangible assets and goodwill - Schedule for Future Amortization Expense (Details) Details 51 false false R52.htm 9954499 - Disclosure - Commitments and contingencies - Outstanding Contractual Obligations (Details) Sheet http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails Commitments and contingencies - Outstanding Contractual Obligations (Details) Details 52 false false R53.htm 9954500 - Disclosure - Commitments and contingencies - Narrative (Details) Sheet http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails Commitments and contingencies - Narrative (Details) Details 53 false false R54.htm 9954501 - Disclosure - Indebtedness - Schedule of Long-term Debt (Details) Sheet http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails Indebtedness - Schedule of Long-term Debt (Details) Details 54 false false R55.htm 9954502 - Disclosure - Indebtedness - Narrative (Details) Sheet http://www.healthequity.com/role/IndebtednessNarrativeDetails Indebtedness - Narrative (Details) Details 55 false false R56.htm 9954503 - Disclosure - Income taxes - Schedule of Components of Income Tax Provision (Benefit) (Details) Sheet http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails Income taxes - Schedule of Components of Income Tax Provision (Benefit) (Details) Details 56 false false R57.htm 9954504 - Disclosure - Income taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails Income taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Details 57 false false R58.htm 9954505 - Disclosure - Income taxes - Narrative (Details) Sheet http://www.healthequity.com/role/IncometaxesNarrativeDetails Income taxes - Narrative (Details) Details 58 false false R59.htm 9954506 - Disclosure - Income taxes - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails Income taxes - Schedule of Deferred Tax Assets and Liabilities (Details) Details 59 false false R60.htm 9954507 - Disclosure - Income taxes - Schedule of Unrecognized Tax Benefits (Details) Sheet http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails Income taxes - Schedule of Unrecognized Tax Benefits (Details) Details 60 false false R61.htm 9954508 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation (Details) Sheet http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails Stock-based compensation - Schedule of Stock-Based Compensation (Details) Details 61 false false R62.htm 9954509 - Disclosure - Stock-based compensation - Narrative (Details) Sheet http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails Stock-based compensation - Narrative (Details) Details 62 false false R63.htm 9954510 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details) Sheet http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails Stock-based compensation - Schedule of Stock Option Activity (Details) Details 63 false false R64.htm 9954511 - Disclosure - Stock-based compensation - Schedule of Restricted Stock Unit Activity (Details) Sheet http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails Stock-based compensation - Schedule of Restricted Stock Unit Activity (Details) Details 64 false false R65.htm 9954512 - Disclosure - Fair value (Details) Sheet http://www.healthequity.com/role/FairvalueDetails Fair value (Details) Details http://www.healthequity.com/role/Fairvalue 65 false false R66.htm 9954513 - Disclosure - Employee benefits (Details) Sheet http://www.healthequity.com/role/EmployeebenefitsDetails Employee benefits (Details) Details http://www.healthequity.com/role/Employeebenefits 66 false false R67.htm 9954514 - Disclosure - Selected quarterly financial data (unaudited) (Details) Sheet http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails Selected quarterly financial data (unaudited) (Details) Details http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedTables 67 false false R68.htm 9954515 - Disclosure - Subsequent events (Details) Sheet http://www.healthequity.com/role/SubsequenteventsDetails Subsequent events (Details) Details http://www.healthequity.com/role/Subsequentevents 68 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration - hqy-20240131.htm 4 [DQC.US.0076.7653] The filer has reported a value for us-gaap:RevenueRemainingPerformanceObligationPercentage with a value of 0.770000 using the dimension member (none) The filer has not reported a duration value for the corresponding elements of RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1. The properties of this us-gaap:RevenueRemainingPerformanceObligationPercentage fact are: Context: c-81 Unit: number. - hqy-20240131.htm 4 - hqy-20240131.htm 4 hqy-20240131.htm hqy-20240131.xsd hqy-20240131_cal.xml hqy-20240131_def.xml hqy-20240131_lab.xml hqy-20240131_pre.xml hqy-20240131_g1.jpg http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hqy-20240131.htm": { "nsprefix": "hqy", "nsuri": "http://www.healthequity.com/20240131", "dts": { "inline": { "local": [ "hqy-20240131.htm" ] }, "schema": { "local": [ "hqy-20240131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "hqy-20240131_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20240131_def.xml" ] }, "labelLink": { "local": [ "hqy-20240131_lab.xml" ] }, "presentationLink": { "local": [ "hqy-20240131_pre.xml" ] } }, "keyStandard": 390, "keyCustom": 60, "axisStandard": 28, "axisCustom": 1, "memberStandard": 44, "memberCustom": 34, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 4, "http://xbrl.sec.gov/ecd/2023": 2 }, "contextCount": 352, "entityCount": 1, "segmentCount": 78, "elementCount": 753, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1254, "http://xbrl.sec.gov/dei/2023": 39, "http://xbrl.sec.gov/ecd/2023": 17, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://www.healthequity.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.healthequity.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.healthequity.com/role/Consolidatedbalancesheets", "longName": "0000003 - Statement - Consolidated balance sheets", "shortName": "Consolidated balance sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical", "longName": "0000004 - Statement - Consolidated balance sheets (Parenthetical)", "shortName": "Consolidated balance sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "longName": "0000005 - Statement - Consolidated statements of operations and comprehensive income (loss)", "shortName": "Consolidated statements of operations and comprehensive income (loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingAndMarketingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R6": { "role": "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity", "longName": "0000006 - Statement - Consolidated statements of stockholders' equity", "shortName": "Consolidated statements of stockholders' equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-17", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-17", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.healthequity.com/role/Consolidatedstatementsofcashflows", "longName": "0000007 - Statement - Consolidated statements of cash flows", "shortName": "Consolidated statements of cash flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R8": { "role": "http://www.healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies", "longName": "0000008 - Disclosure - Summary of business and significant accounting policies", "shortName": "Summary of business and significant accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.healthequity.com/role/Netincomelosspershare", "longName": "0000009 - Disclosure - Net income (loss) per share", "shortName": "Net income (loss) per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.healthequity.com/role/Businesscombinations", "longName": "0000010 - Disclosure - Business combinations", "shortName": "Business combinations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.healthequity.com/role/Supplementalfinancialstatementinformation", "longName": "0000011 - Disclosure - Supplemental financial statement information", "shortName": "Supplemental financial statement information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.healthequity.com/role/Leases", "longName": "0000012 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.healthequity.com/role/Intangibleassetsandgoodwill", "longName": "0000013 - Disclosure - Intangible assets and goodwill", "shortName": "Intangible assets and goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.healthequity.com/role/Commitmentsandcontingencies", "longName": "0000014 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.healthequity.com/role/Indebtedness", "longName": "0000015 - Disclosure - Indebtedness", "shortName": "Indebtedness", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.healthequity.com/role/Incometaxes", "longName": "0000016 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.healthequity.com/role/Stockbasedcompensation", "longName": "0000017 - Disclosure - Stock-based compensation", "shortName": "Stock-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.healthequity.com/role/Fairvalue", "longName": "0000018 - Disclosure - Fair value", "shortName": "Fair value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.healthequity.com/role/Employeebenefits", "longName": "0000019 - Disclosure - Employee benefits", "shortName": "Employee benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.healthequity.com/role/Selectedquarterlyfinancialdataunaudited", "longName": "0000020 - Disclosure - Selected quarterly financial data (unaudited)", "shortName": "Selected quarterly financial data (unaudited)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.healthequity.com/role/Subsequentevents", "longName": "0000021 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-212", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-212", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-212", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies", "longName": "9954471 - Disclosure - Summary of business and significant accounting policies (Policies)", "shortName": "Summary of business and significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesTables", "longName": "9954472 - Disclosure - Summary of business and significant accounting policies (Tables)", "shortName": "Summary of business and significant accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://www.healthequity.com/role/NetincomelosspershareTables", "longName": "9954473 - Disclosure - Net income (loss) per share (Tables)", "shortName": "Net income (loss) per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.healthequity.com/role/BusinesscombinationsTables", "longName": "9954474 - Disclosure - Business combinations (Tables)", "shortName": "Business combinations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.healthequity.com/role/SupplementalfinancialstatementinformationTables", "longName": "9954475 - Disclosure - Supplemental financial statement information (Tables)", "shortName": "Supplemental financial statement information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R29": { "role": "http://www.healthequity.com/role/LeasesTables", "longName": "9954476 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.healthequity.com/role/IntangibleassetsandgoodwillTables", "longName": "9954477 - Disclosure - Intangible assets and goodwill (Tables)", "shortName": "Intangible assets and goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R31": { "role": "http://www.healthequity.com/role/CommitmentsandcontingenciesTables", "longName": "9954478 - Disclosure - Commitments and contingencies (Tables)", "shortName": "Commitments and contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.healthequity.com/role/IndebtednessTables", "longName": "9954479 - Disclosure - Indebtedness (Tables)", "shortName": "Indebtedness (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.healthequity.com/role/IncometaxesTables", "longName": "9954480 - Disclosure - Income taxes (Tables)", "shortName": "Income taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.healthequity.com/role/StockbasedcompensationTables", "longName": "9954481 - Disclosure - Stock-based compensation (Tables)", "shortName": "Stock-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedTables", "longName": "9954482 - Disclosure - Selected quarterly financial data (unaudited) (Tables)", "shortName": "Selected quarterly financial data (unaudited) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails", "longName": "9954483 - Disclosure - Summary of business and significant accounting policies - Narrative (Details)", "shortName": "Summary of business and significant accounting policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-212", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R37": { "role": "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails", "longName": "9954484 - Disclosure - Summary of business and significant accounting policies - Property and Equipment (Details)", "shortName": "Summary of business and significant accounting policies - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-56", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-56", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails", "longName": "9954485 - Disclosure - Summary of business and significant accounting policies - Intangible Assets (Details)", "shortName": "Summary of business and significant accounting policies - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-59", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-59", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.healthequity.com/role/NetincomelosspershareDetails", "longName": "9954486 - Disclosure - Net income (loss) per share (Details)", "shortName": "Net income (loss) per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-212", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R40": { "role": "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails", "longName": "9954487 - Disclosure - Business combinations - Narrative (Details)", "shortName": "Business combinations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-68", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-68", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails", "longName": "9954488 - Disclosure - Business combinations - Preliminary Allocation of Consideration (Details)", "shortName": "Business combinations - Preliminary Allocation of Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R42": { "role": "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails", "longName": "9954489 - Disclosure - Supplemental financial statement information - Narrative (Details)", "shortName": "Supplemental financial statement information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails", "longName": "9954490 - Disclosure - Supplemental financial statement information - Property and Equipment (Details)", "shortName": "Supplemental financial statement information - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails", "longName": "9954491 - Disclosure - Supplemental financial statement information - Other Expense, Net (Details)", "shortName": "Supplemental financial statement information - Other Expense, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentIncomeNonoperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentIncomeNonoperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.healthequity.com/role/LeasesNarrativeDetails", "longName": "9954492 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "hqy:LesseeOperatingLeaseNumberOfExtensions", "unitRef": "extension", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hqy:LesseeOperatingLeaseNumberOfExtensions", "unitRef": "extension", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.healthequity.com/role/LeasesLeaseCostDetails", "longName": "9954493 - Disclosure - Leases - Lease Cost (Details)", "shortName": "Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails", "longName": "9954494 - Disclosure - Leases - Lease Liabilities (Details)", "shortName": "Leases - Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.healthequity.com/role/LeasesSupplementalCashFlowInformationDetails", "longName": "9954495 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails", "longName": "9954496 - Disclosure - Intangible assets and goodwill - Schedule of Finite-Lived Intangible Assets (Details)", "shortName": "Intangible assets and goodwill - Schedule of Finite-Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "longName": "9954497 - Disclosure - Intangible assets and goodwill - Narrative (Details)", "shortName": "Intangible assets and goodwill - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails", "longName": "9954498 - Disclosure - Intangible assets and goodwill - Schedule for Future Amortization Expense (Details)", "shortName": "Intangible assets and goodwill - Schedule for Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "longName": "9954499 - Disclosure - Commitments and contingencies - Outstanding Contractual Obligations (Details)", "shortName": "Commitments and contingencies - Outstanding Contractual Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "hqy:InterestOnLongTermDebtToBePaidYearOne", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R53": { "role": "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "longName": "9954500 - Disclosure - Commitments and contingencies - Narrative (Details)", "shortName": "Commitments and contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-4", "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-102", "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R54": { "role": "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails", "longName": "9954501 - Disclosure - Indebtedness - Schedule of Long-term Debt (Details)", "shortName": "Indebtedness - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R55": { "role": "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "longName": "9954502 - Disclosure - Indebtedness - Narrative (Details)", "shortName": "Indebtedness - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-133", "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-133", "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails", "longName": "9954503 - Disclosure - Income taxes - Schedule of Components of Income Tax Provision (Benefit) (Details)", "shortName": "Income taxes - Schedule of Components of Income Tax Provision (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails", "longName": "9954504 - Disclosure - Income taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "shortName": "Income taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.healthequity.com/role/IncometaxesNarrativeDetails", "longName": "9954505 - Disclosure - Income taxes - Narrative (Details)", "shortName": "Income taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails", "longName": "9954506 - Disclosure - Income taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "shortName": "Income taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails", "longName": "9954507 - Disclosure - Income taxes - Schedule of Unrecognized Tax Benefits (Details)", "shortName": "Income taxes - Schedule of Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R61": { "role": "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "longName": "9954508 - Disclosure - Stock-based compensation - Schedule of Stock-Based Compensation (Details)", "shortName": "Stock-based compensation - Schedule of Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "longName": "9954509 - Disclosure - Stock-based compensation - Narrative (Details)", "shortName": "Stock-based compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails", "longName": "9954510 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details)", "shortName": "Stock-based compensation - Schedule of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R64": { "role": "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails", "longName": "9954511 - Disclosure - Stock-based compensation - Schedule of Restricted Stock Unit Activity (Details)", "shortName": "Stock-based compensation - Schedule of Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-191", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R65": { "role": "http://www.healthequity.com/role/FairvalueDetails", "longName": "9954512 - Disclosure - Fair value (Details)", "shortName": "Fair value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-195", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-195", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.healthequity.com/role/EmployeebenefitsDetails", "longName": "9954513 - Disclosure - Employee benefits (Details)", "shortName": "Employee benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "hqy:SelfInsuranceMaximumCoveragePerIncident", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hqy:SelfInsuranceMaximumCoveragePerIncident", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails", "longName": "9954514 - Disclosure - Selected quarterly financial data (unaudited) (Details)", "shortName": "Selected quarterly financial data (unaudited) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-212", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-212", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } }, "R68": { "role": "http://www.healthequity.com/role/SubsequenteventsDetails", "longName": "9954515 - Disclosure - Subsequent events (Details)", "shortName": "Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-101", "name": "hqy:PaymentsToAcquireAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-345", "name": "hqy:AssetAcquisitionNumberOfTransfers", "unitRef": "transfer", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240131.htm", "unique": true } } }, "tag": { "hqy_A401kCustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "A401kCustomerRelationshipsMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired customer relationships", "label": "401(k) Customer Relationships [Member]", "documentation": "401(k) Customer Relationships [Member]" } } }, "auth_ref": [] }, "hqy_A401kMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "A401kMember", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "401(k)", "label": "401(k) [Member]", "documentation": "401(k) [Member]" } } }, "auth_ref": [] }, "hqy_A4500SeniorNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "A4500SeniorNotesDue2029Member", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/FairvalueDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.50% Senior Notes due 2029", "label": "4.500% Senior Notes due 2029 [Member]", "documentation": "4.500% Senior Notes due 2029" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r798" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $3,947 and $4,989 as of January 31, 2024 and 2023, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r285", "r286" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r56", "r190", "r647" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "hqy_AcquiredHSAIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "AcquiredHSAIntangibleAssetsMember", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows", "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired HSA portfolios", "verboseLabel": "Acquired HSA Portfolios", "label": "Acquired HSA Intangible Assets [Member]", "documentation": "Acquired HSA Intangible Assets [Member]" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r851" ] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [ "http://www.healthequity.com/role/Supplementalfinancialstatementinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental financial statement information", "label": "Additional Financial Information Disclosure [Text Block]", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r111", "r798", "r1066" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r494", "r495", "r496", "r681", "r915", "r916", "r917", "r1042", "r1068" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r857" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r857" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r857" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r857" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r70", "r71", "r456" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r821", "r833", "r843", "r869" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r824", "r836", "r846", "r872" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r857" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r864" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r828", "r837", "r847", "r864", "r873", "r877", "r885" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r883" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r489", "r501" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r197", "r287", "r301", "r302", "r304", "r1063" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r197", "r287", "r301" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "hqy_AmortizationOfAcquiredIntangible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "AmortizationOfAcquiredIntangible", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "label": "Amortization Of Acquired Intangible", "documentation": "Amortization of Acquired Intangible" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r359", "r594", "r778", "r779", "r908" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r10", "r50", "r54" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r255" ] }, "hqy_AssetAcquisitionAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "AssetAcquisitionAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer-related expenses", "label": "Asset Acquisition, Acquisition Related Costs", "documentation": "Asset Acquisition, Acquisition Related Costs" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r1038" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, transferred, transaction cost", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r796", "r1039", "r1040", "r1041" ] }, "hqy_AssetAcquisitionCustomerAccountsTransferredValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "AssetAcquisitionCustomerAccountsTransferredValue", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HSAs transferred, value", "label": "Asset Acquisition, Customer Accounts Transferred, Value", "documentation": "Asset Acquisition, Customer Accounts Transferred, Value" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r1038" ] }, "hqy_AssetAcquisitionNumberOfCustomerAccountsTransferred": { "xbrltype": "integerItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "AssetAcquisitionNumberOfCustomerAccountsTransferred", "presentation": [ "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of HSAs transferred", "label": "Asset Acquisition, Number Of Customer Accounts Transferred", "documentation": "Asset Acquisition, Number Of Customer Accounts Transferred" } } }, "auth_ref": [] }, "hqy_AssetAcquisitionNumberOfTransfers": { "xbrltype": "integerItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "AssetAcquisitionNumberOfTransfers", "presentation": [ "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of transfers", "label": "Asset Acquisition, Number Of Transfers", "documentation": "Asset Acquisition, Number Of Transfers" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r156", "r194", "r220", "r261", "r275", "r279", "r290", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r548", "r550", "r579", "r639", "r711", "r798", "r810", "r937", "r938", "r1052" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r186", "r200", "r220", "r290", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r548", "r550", "r579", "r798", "r937", "r938", "r1052" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "hqy_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information [Abstract]" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.healthequity.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r815", "r816", "r829" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.healthequity.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r815", "r816", "r829" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.healthequity.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r815", "r816", "r829" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r880" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r881" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r876" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r876" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r484", "r485", "r486", "r487", "r488" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r879" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r878" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r877" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r877" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r90", "r91" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customary Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "hqy_BenefitWalletHSAPortfolioAcquisitionFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "BenefitWalletHSAPortfolioAcquisitionFiscalYearMaturityAbstract", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BenefitWallet HSA Portfolio Acquisition, Fiscal Year Maturity [Abstract]", "label": "BenefitWallet HSA Portfolio Acquisition, Fiscal Year Maturity [Abstract]", "documentation": "BenefitWallet HSA Portfolio Acquisition, Fiscal Year Maturity" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails", "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails", "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r541", "r786", "r789" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails", "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails", "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r78", "r80", "r541", "r786", "r789" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails", "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r541" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest (as a percent)", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r79" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r77" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of consideration paid", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r3", "r4", "r15" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r547", "r907" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount of contingent consideration payable", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r86" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.healthequity.com/role/Businesscombinations" ], "lang": { "en-us": { "role": { "terseLabel": "Business combinations", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r151", "r542" ] }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationIntegrationRelatedCosts", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Merger integration", "label": "Business Combination, Integration Related Costs", "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total consideration paid, adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r83" ] }, "hqy_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAsset", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets, adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current asset", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current asset" } } }, "auth_ref": [] }, "hqy_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Current liabilities, adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current Liabilities" } } }, "auth_ref": [] }, "hqy_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxes", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred tax liability, adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r82" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r82" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r82" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r82" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred tax liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r82" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r82" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total consideration paid", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r81", "r82" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r82" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisitions and Business combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r76" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of property and equipment included in accounts payable or accrued liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r41", "r42", "r43" ] }, "us-gaap_CapitalizedContractCostAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostAmortization", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of capitalized contract costs", "label": "Capitalized Contract Cost, Amortization", "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r306" ] }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostAmortizationPeriod", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized contract cost, amortization period (in years)", "label": "Capitalized Contract Cost, Amortization Period", "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r899" ] }, "us-gaap_CapitalizedContractCostNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostNet", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized contract cost", "label": "Capitalized Contract Cost, Net", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r305" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r188", "r764" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r39", "r155" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning cash and cash equivalents", "periodEndLabel": "Ending cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r125", "r218" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r5", "r125" ] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": [ "http://www.healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r855" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "hqy_ClientHeldFundsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ClientHeldFundsPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Client-held funds", "label": "Client Held Funds [Policy Text Block]", "documentation": "Client Held Funds [Policy Text Block]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r856" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r856" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (see Note 7)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r31", "r97", "r641", "r697" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.healthequity.com/role/Commitmentsandcontingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r137", "r320", "r321", "r758", "r932" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r801", "r802", "r803", "r805", "r806", "r807", "r808", "r915", "r916", "r1042", "r1065", "r1068" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value per share (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r110" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r110", "r698" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r110" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r17", "r110", "r698", "r717", "r1068", "r1069" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value, 900,000 shares authorized, 86,127 and 84,758 shares issued and outstanding as of January 31, 2024 and 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r110", "r643", "r798" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r861" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r860" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r862" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r859" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.healthequity.com/role/Employeebenefits" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r142", "r143", "r144", "r145" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r33", "r202", "r204", "r210", "r635", "r651" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Computer equipment", "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "hqy_ComputerSoftwareAndCapitalizedSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ComputerSoftwareAndCapitalizedSoftwareDevelopmentCostsMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software and software development costs", "label": "Computer Software And Capitalized Software Development Costs [Member]", "documentation": "Computer Software And Capitalized Software Development Costs [Member]" } } }, "auth_ref": [] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "verboseLabel": "Computer software intangible asset", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r763", "r929", "r930" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r89", "r768" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r381" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligation", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Contractual Obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r912" ] }, "us-gaap_ContractualObligationDueAfterFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueAfterFifthYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Contractual Obligation, to be Paid, after Year Five", "documentation": "Amount of contractual obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInFifthYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Contractual Obligation, to be Paid, Year Five", "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInFourthYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Contractual Obligation, to be Paid, Year Four", "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Contractual Obligation, to be Paid, Year One", "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInSecondYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Contractual Obligation, to be Paid, Year Two", "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInThirdYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Contractual Obligation, to be Paid, Year Three", "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationFiscalYearMaturityAbstract", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Obligation, Fiscal Year Maturity [Abstract]", "label": "Contractual Obligation, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Payments Due By Fiscal Year For Our Outstanding Contractual Obligations", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r913" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cost of revenue", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r120", "r628" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenueAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r178", "r222", "r223", "r341", "r369", "r619", "r765", "r767" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "hqy_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "CreditAgreementMember", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Agreement", "label": "Credit Agreement [Member]", "documentation": "Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_CreditAndDebitCardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditAndDebitCardMember", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interchange revenue", "label": "Credit and Debit Card [Member]", "documentation": "Card issued to user to facilitate payment for purchase of product and service paid directly to merchant by issuer, or from user's checking account." } } }, "auth_ref": [ "r943" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r906", "r911", "r1037" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current tax provision", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r150", "r529", "r537", "r911" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current:", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r906", "r911", "r1037" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r85" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.healthequity.com/role/Indebtedness" ], "lang": { "en-us": { "role": { "terseLabel": "Indebtedness", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r138", "r219", "r337", "r343", "r344", "r345", "r346", "r347", "r348", "r353", "r360", "r361", "r363" ] }, "hqy_DebtInstrumentAmortizationPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentAmortizationPeriodAxis", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Amortization Period [Axis]", "label": "Debt Instrument, Amortization Period [Axis]", "documentation": "Debt Instrument, Amortization Period" } } }, "auth_ref": [] }, "hqy_DebtInstrumentAmortizationPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentAmortizationPeriodDomain", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Amortization Period [Domain]", "label": "Debt Instrument, Amortization Period [Domain]", "documentation": "Debt Instrument, Amortization Period" } } }, "auth_ref": [] }, "hqy_DebtInstrumentAmortizationPeriodFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentAmortizationPeriodFiveMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fifth year after the Effective Date", "label": "Debt Instrument, Amortization Period Five [Member]", "documentation": "Debt Instrument, Amortization Period Five" } } }, "auth_ref": [] }, "hqy_DebtInstrumentAmortizationPeriodFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentAmortizationPeriodFourMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fourth year after the Effective Date", "label": "Debt Instrument, Amortization Period Four [Member]", "documentation": "Debt Instrument, Amortization Period Four" } } }, "auth_ref": [] }, "hqy_DebtInstrumentAmortizationPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentAmortizationPeriodOneMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First year after the Effective Date", "label": "Debt Instrument, Amortization Period One [Member]", "documentation": "Debt Instrument, Amortization Period One" } } }, "auth_ref": [] }, "hqy_DebtInstrumentAmortizationPeriodTwoAndThreePeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentAmortizationPeriodTwoAndThreePeriodMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second and third years after the Effective Date", "label": "Debt Instrument, Amortization Period Two and Three Period [Member]", "documentation": "Debt Instrument, Amortization Period Two and Three Period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/FairvalueDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r22", "r104", "r105", "r157", "r159", "r224", "r338", "r339", "r340", "r341", "r342", "r344", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r595", "r775", "r776", "r777", "r778", "r779", "r909" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable rate borrowing spread (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal amount", "terseLabel": "Principal amount", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r22", "r159", "r364" ] }, "hqy_DebtInstrumentCovenantMinimumInterestCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentCovenantMinimumInterestCoverageRatio", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum interest coverage ratio", "label": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio", "documentation": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio" } } }, "auth_ref": [] }, "hqy_DebtInstrumentCovenantNetLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentCovenantNetLeverageRatio", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum leverage ratio", "label": "Debt Instrument, Covenant, Net Leverage Ratio", "documentation": "Debt Instrument, Covenant, Net Leverage Ratio" } } }, "auth_ref": [] }, "hqy_DebtInstrumentCreditSpreadAdjustmentOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentCreditSpreadAdjustmentOnVariableRate", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit spread adjustment on variable rate (as a percent)", "label": "Debt Instrument, Credit Spread Adjustment On Variable Rate", "documentation": "Debt Instrument, Credit Spread Adjustment On Variable Rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r93", "r95", "r338", "r595", "r776", "r777" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r28", "r93", "r367", "r595" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r28", "r339" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r338", "r339", "r340", "r341", "r342", "r344", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r595", "r775", "r776", "r777", "r778", "r779", "r909" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/FairvalueDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r29", "r224", "r338", "r339", "r340", "r341", "r342", "r344", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r595", "r775", "r776", "r777", "r778", "r779", "r909" ] }, "hqy_DebtInstrumentPeriodicRepaymentsPercentageOfPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentPeriodicRepaymentsPercentageOfPrincipalAmount", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, amortization of loans, percentage of principal amount (as a percent)", "label": "Debt Instrument, Periodic Repayments, Percentage Of Principal Amount", "documentation": "Debt Instrument, Periodic Repayments, Percentage Of Principal Amount" } } }, "auth_ref": [] }, "hqy_DebtInstrumentPrepaymentCovenantPercentageOfProceedsFromSales": { "xbrltype": "percentItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentPrepaymentCovenantPercentageOfProceedsFromSales", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, prepayment covenant, percentage of proceeds from sales to used to prepay (as a percent)", "label": "Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales", "documentation": "Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales" } } }, "auth_ref": [] }, "hqy_DebtInstrumentPrepaymentCovenantPeriodToCommitToReinvestAfterInitialPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentPrepaymentCovenantPeriodToCommitToReinvestAfterInitialPeriod", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, number of days to commit to reinvesting proceeds from sales of assets after initial period (in days)", "label": "Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period", "documentation": "Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period" } } }, "auth_ref": [] }, "hqy_DebtInstrumentPrepaymentCovenantPeriodToReinvestProceedsFromSales": { "xbrltype": "durationItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DebtInstrumentPrepaymentCovenantPeriodToReinvestProceedsFromSales", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, number of days to reinvest proceeds from sales of assets (in days)", "label": "Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales", "documentation": "Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information about timing of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodFiveMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior to October 1, 2024, 40% of Principal", "label": "Debt Instrument, Redemption, Period Five [Member]", "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentRedemptionPeriodFourMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodFourMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior to October 1, 2024", "label": "Debt Instrument, Redemption, Period Four [Member]", "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 1, 2024", "label": "Debt Instrument, Redemption, Period One [Member]", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodThreeMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 1, 2026 and thereafter", "label": "Debt Instrument, Redemption, Period Three [Member]", "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 1, 2025", "label": "Debt Instrument, Redemption, Period Two [Member]", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price (as a percent)", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of principal amount redeemed (as a percent)", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "documentation": "Percentage of principal amount of debt redeemed." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r29", "r60", "r61", "r92", "r93", "r95", "r98", "r139", "r140", "r224", "r338", "r339", "r340", "r341", "r342", "r344", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r595", "r775", "r776", "r777", "r778", "r779", "r909" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility term (in years)", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: unamortized discount and issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r94", "r349", "r365", "r776", "r777" ] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r193" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r911", "r1036", "r1037" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, net", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r94", "r940" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax benefit", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r10", "r150", "r175", "r536", "r537", "r911" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred:", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total gross deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r107", "r108", "r158", "r523" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r508", "r509", "r640" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r127" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r911", "r1036", "r1037" ] }, "hqy_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research and development", "label": "Deferred Tax Assets, Capitalized Research and Development Costs", "documentation": "Deferred Tax Assets, Capitalized Research and Development Costs" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total gross deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r524" ] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Deferred Tax Assets, Gross [Abstract]" } } }, "auth_ref": [] }, "hqy_DeferredTaxAssetsLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DeferredTaxAssetsLeaseLiability", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Deferred Tax Assets, Lease Liability", "documentation": "Deferred Tax Assets, Lease Liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets, net of valuation allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1034" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforward", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r75", "r1035" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r75", "r1035" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed assets", "label": "Deferred Tax Assets, Property, Plant and Equipment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [] }, "hqy_DeferredTaxAssetsTaxCreditCarryforwardsResearchNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchNoncurrent", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development credits", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research, Noncurrent", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r75", "r1035" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals and reserves", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r75", "r1035" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails", "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset, valuation allowance", "negatedTerseLabel": "Less valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r525" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net deferred tax liabilities", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r72", "r1034" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities:", "label": "Deferred Tax Liabilities, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Goodwill", "label": "Deferred Tax Liabilities, Goodwill", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill." } } }, "auth_ref": [ "r75", "r87", "r88", "r1035" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Intangible assets", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r75", "r1035" ] }, "hqy_DeferredTaxLiabilitiesIncrementalContractCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DeferredTaxLiabilitiesIncrementalContractCosts", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Incremental contract costs", "label": "Deferred Tax Liabilities, Incremental Contract Costs", "documentation": "Deferred Tax Liabilities, Incremental Contract Costs" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Right-of-use assets", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r75", "r1035" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r75", "r1035" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Fixed assets", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r75", "r1035" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.healthequity.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanDisclosureLineItems", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan Disclosure [Line Items]", "label": "Defined Contribution Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r441" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer matching contribution expense", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of employees eligible earnings (as a percent)", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanTable", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan [Table]", "label": "Defined Contribution Plan [Table]", "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans." } } }, "auth_ref": [ "r441" ] }, "hqy_DelanoLaddMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DelanoLaddMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Delano Ladd [Member]", "documentation": "Delano Ladd" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r10", "r55" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r10", "r265" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired developed technology", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r153" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.healthequity.com/role/Stockbasedcompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r454", "r459", "r490", "r491", "r493", "r793" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "hqy_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Asset", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Asset" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r815", "r816", "r829" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r815", "r816", "r829", "r865" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r850" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r813" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r211", "r233", "r234", "r236", "r237", "r239", "r245", "r247", "r252", "r253", "r254", "r258", "r572", "r573", "r636", "r652", "r769" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share:", "verboseLabel": "Net income (loss) per share:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r211", "r233", "r234", "r236", "r237", "r239", "r247", "r252", "r253", "r254", "r258", "r572", "r573", "r636", "r652", "r769" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.healthequity.com/role/Netincomelosspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r244", "r255", "r256", "r257" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax benefit rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r511" ] }, "hqy_EffectiveIncomeTaxRateReconciliationDeferredTaxesStateApportionmentChanges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxesStateApportionmentChanges", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax rate adjustment due to state apportionment changes", "label": "Effective Income Tax Rate Reconciliation, Deferred Taxes, State Apportionment Changes", "documentation": "Effective Income Tax Rate Reconciliation, Deferred Taxes, State Apportionment Changes" } } }, "auth_ref": [] }, "hqy_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Return-to-provision adjustments", "label": "Effective Income Tax Rate Reconciliation, Return-To-Provision Adjustments", "documentation": "Effective Income Tax Rate Reconciliation, Return-To-Provision Adjustments" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess tax (benefit) shortfall on stock-based compensation expense, net", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r892", "r1031" ] }, "hqy_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitEmployeeRemunerationPaymentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitEmployeeRemunerationPaymentsAmount", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excessive employee remuneration", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Employee Remuneration Payments, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Employee Remuneration Payments, Amount" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "hqy_EmployeeRelatedLiabilitiesCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "EmployeeRelatedLiabilitiesCurrentMember", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Compensation", "label": "Employee-Related Liabilities, Current [Member]", "documentation": "Employee-Related Liabilities, Current [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognition period for stock-based compensation (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r492" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation not yet recognized, other than options", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1030" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock compensation expense related to options to be recognized in future", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1030" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r812" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r812" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r812" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r890" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r812" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r812" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r812" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r812" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r891" ] }, "hqy_EquityAwardsExchangedForCashInBusinessCombinationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "EquityAwardsExchangedForCashInBusinessCombinationMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition awards exchanged for cash", "label": "Equity Awards Exchanged For Cash In Business Combination [Member]", "documentation": "Equity Awards Exchanged For Cash In Business Combination" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r181", "r206", "r207", "r208", "r225", "r226", "r227", "r230", "r240", "r242", "r260", "r294", "r300", "r370", "r494", "r495", "r496", "r532", "r533", "r555", "r557", "r558", "r559", "r560", "r562", "r571", "r584", "r585", "r586", "r587", "r588", "r589", "r618", "r664", "r665", "r666", "r681", "r738" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on equity securities", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r653", "r921" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r858" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r821", "r833", "r843", "r869" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r818", "r830", "r840", "r866" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r864" ] }, "hqy_ExerciseOfStockOptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ExerciseOfStockOptionsReceivable", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock options receivable", "label": "Exercise of Stock Options Receivable", "documentation": "Exercise of Stock Options Receivable" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.healthequity.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r351", "r406", "r407", "r408", "r409", "r410", "r411", "r576", "r623", "r624", "r625", "r776", "r777", "r782", "r783", "r784" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.healthequity.com/role/Fairvalue" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r575" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.healthequity.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r351", "r406", "r411", "r576", "r624", "r776", "r777", "r782", "r783", "r784" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.healthequity.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r351", "r406", "r407", "r408", "r409", "r410", "r411", "r623", "r624", "r625", "r776", "r777", "r782", "r783", "r784" ] }, "us-gaap_FinancialServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialServiceOtherMember", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Custodial revenue", "label": "Financial Service, Other [Member]", "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance, classified as other." } } }, "auth_ref": [ "r943" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Useful life of finite-lived intangible asset (in years)", "netLabel": "Finite-lived intangible asset, useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r192", "r315" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows", "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r312", "r314", "r315", "r316", "r629", "r633" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r133", "r633" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r629" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows", "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r51", "r53" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleforFutureAmortizationExpenseDetails", "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net carrying amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r133", "r629" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets, acquired", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r313" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r825", "r837", "r847", "r873" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r825", "r837", "r847", "r873" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r825", "r837", "r847", "r873" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r825", "r837", "r847", "r873" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r825", "r837", "r847", "r873" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Furniture and fixtures", "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "hqy_FurtherAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "FurtherAcquisitionMember", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails", "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Further Acquisition", "label": "Further Acquisition [Member]", "documentation": "Further Acquisition" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfInvestments", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Gains on equity securities", "label": "Gain (Loss) on Sale of Investments", "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r10", "r58", "r59" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r121", "r721" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r118" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails", "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r191", "r308", "r634", "r774", "r798", "r926", "r928" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.healthequity.com/role/Intangibleassetsandgoodwill" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets and goodwill", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r132" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r307", "r311", "r774" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r14" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r10", "r309", "r310", "r311", "r774" ] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in goodwill", "label": "Goodwill, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r925" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails", "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, adjustments", "label": "Goodwill, Purchase Accounting Adjustments", "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r2", "r927" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r119", "r220", "r261", "r274", "r278", "r280", "r290", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r579", "r771", "r937" ] }, "hqy_HSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "HSAMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HSA", "label": "HSA [Member]", "documentation": "HSA" } } }, "auth_ref": [] }, "hqy_HSAPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "HSAPortfolioMember", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HSA Portfolio", "label": "HSA Portfolio [Member]", "documentation": "HSA Portfolio" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r815", "r816", "r829" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets to be disposed of", "label": "Impairment of Long-Lived Assets to be Disposed of", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r10", "r135" ] }, "hqy_IncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "IncentivePlanMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive Plan", "label": "Incentive Plan [Member]", "documentation": "Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r116", "r161", "r261", "r274", "r278", "r280", "r637", "r649", "r771" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r317", "r319", "r722" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r319", "r722" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.healthequity.com/role/Incometaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r221", "r503", "r512", "r520", "r527", "r534", "r538", "r539", "r540", "r680" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/IncometaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails", "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax provision (benefit)", "totalLabel": "Total income tax provision (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r165", "r176", "r241", "r242", "r266", "r510", "r535", "r654" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax provision (benefit)", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r205", "r506", "r507", "r520", "r521", "r526", "r528", "r676" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r505", "r511" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal income tax provision (benefit) at the statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r511" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-deductible or non-taxable items, net", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other items, net", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income tax provision (benefit), net of federal tax provision (benefit)", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxContingencies", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in uncertain tax position reserves, net of indirect benefits", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Federal research and development credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_IncomeTaxReconciliationTaxSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxSettlements", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment from settlement of IRS examination", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax payments (refunds), net", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r40" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued liabilities, and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "hqy_IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, non-current", "label": "Increase (Decrease) In Operating Lease, Liability, Noncurrent", "documentation": "Increase (Decrease) In Operating Lease, Liability, Noncurrent" } } }, "auth_ref": [] }, "hqy_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating lease right-of-use assets", "label": "Increase Decrease In Operating Lease Right Of Use Asset", "documentation": "Increase Decrease In Operating Lease Right Of Use Asset" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.healthequity.com/role/NetincomelosspershareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average dilutive effect of stock options and restricted stock units (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r248", "r249", "r250", "r254", "r458" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r828", "r837", "r847", "r864", "r873", "r877", "r885" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r883" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r817", "r889" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r817", "r889" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r817", "r889" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r49", "r52" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r94", "r163", "r209", "r264", "r593", "r723", "r809", "r1067" ] }, "us-gaap_InterestExpensePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpensePolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs." } } }, "auth_ref": [ "r0" ] }, "hqy_InterestOnLongTermDebtFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "InterestOnLongTermDebtFiscalYearMaturityAbstract", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest On Long-Term Debt, Fiscal Year Maturity [Abstract]", "label": "Interest On Long-Term Debt, Fiscal Year Maturity [Abstract]", "documentation": "Interest On Long-Term Debt, Fiscal Year Maturity" } } }, "auth_ref": [] }, "hqy_InterestOnLongTermDebtToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "InterestOnLongTermDebtToBePaid", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Interest On Long-Term Debt, To Be Paid", "documentation": "Interest On Long-Term Debt, To Be Paid" } } }, "auth_ref": [] }, "hqy_InterestOnLongTermDebtToBePaidAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "InterestOnLongTermDebtToBePaidAfterYearFive", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Interest On Long-Term Debt, To Be Paid, After Year Five", "documentation": "Interest On Long-Term Debt, To Be Paid, After Year Five" } } }, "auth_ref": [] }, "hqy_InterestOnLongTermDebtToBePaidYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "InterestOnLongTermDebtToBePaidYearFive", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Interest On Long-Term Debt, To Be Paid, Year Five", "documentation": "Interest On Long-Term Debt, To Be Paid, Year Five" } } }, "auth_ref": [] }, "hqy_InterestOnLongTermDebtToBePaidYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "InterestOnLongTermDebtToBePaidYearFour", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Interest On Long-Term Debt, To Be Paid, Year Four", "documentation": "Interest On Long-Term Debt, To Be Paid, Year Four" } } }, "auth_ref": [] }, "hqy_InterestOnLongTermDebtToBePaidYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "InterestOnLongTermDebtToBePaidYearOne", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Interest On Long-Term Debt, To Be Paid, Year One", "documentation": "Interest On Long-Term Debt, To Be Paid, Year One" } } }, "auth_ref": [] }, "hqy_InterestOnLongTermDebtToBePaidYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "InterestOnLongTermDebtToBePaidYearThree", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Interest On Long-Term Debt, To Be Paid, Year Three", "documentation": "Interest On Long-Term Debt, To Be Paid, Year Three" } } }, "auth_ref": [] }, "hqy_InterestOnLongTermDebtToBePaidYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "InterestOnLongTermDebtToBePaidYearTwo", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_InterestOnLongTermDebtToBePaid", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Interest On Long-Term Debt, To Be Paid, Year Two", "documentation": "Interest On Long-Term Debt, To Be Paid, Year Two" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense paid in cash", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r213", "r216", "r217" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_InvestmentIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNonoperating", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Nonoperating", "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations." } } }, "auth_ref": [ "r122" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r683", "r684", "r685", "r686", "r687", "r741", "r743", "r745", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r803" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r683", "r684", "r685", "r686", "r687", "r741", "r743", "r745", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r803" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/LeasesLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net operating lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r606", "r797" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.healthequity.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1049" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Leasehold Improvements", "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r136" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r605" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r605" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r604" ] }, "hqy_LesseeOperatingLeaseAbatedRentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "LesseeOperatingLeaseAbatedRentPeriod", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, abated rent, period", "label": "Lessee, Operating Lease, Abated Rent, Period", "documentation": "Lessee, Operating Lease, Abated Rent, Period" } } }, "auth_ref": [] }, "hqy_LesseeOperatingLeaseLateChargePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "LesseeOperatingLeaseLateChargePercentage", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Late charge percentage", "label": "Lessee, Operating Lease, Late Charge, Percentage", "documentation": "Lessee, Operating Lease, Late Charge, Percentage" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease not yet commenced term of contract (in years)", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1048" ] }, "hqy_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease not yet commenced undiscounted amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross lease liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r613" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r613" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r613" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r613" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r613" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r613" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r613" ] }, "hqy_LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "LesseeOperatingLeaseLiabilityToBePaidIncludingLeasesNotYetCommenced", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, To Be Paid, Including Leases Not Yet Commenced", "documentation": "Lessee, Operating Lease, Liability, To Be Paid, Including Leases Not Yet Commenced" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r613" ] }, "hqy_LesseeOperatingLeaseNumberOfExtensions": { "xbrltype": "integerItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "LesseeOperatingLeaseNumberOfExtensions", "presentation": [ "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, number of extensions (in years)", "label": "Lessee, Operating Lease, Number Of Extensions", "documentation": "Lessee, Operating Lease, Number Of Extensions" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining operating lease terms (in years)", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1046" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease renewal terms extension (in years)", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1047" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.healthequity.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r600" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r25", "r220", "r290", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r549", "r550", "r551", "r579", "r696", "r770", "r810", "r937", "r1052", "r1053" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r115", "r160", "r645", "r798", "r910", "r922", "r1044" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r27", "r187", "r220", "r290", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r549", "r550", "r551", "r579", "r798", "r937", "r1052", "r1053" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r22", "r101", "r102", "r103", "r106", "r220", "r290", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r549", "r550", "r551", "r579", "r937", "r1052", "r1053" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee (as a percent)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility, amount", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r24" ] }, "hqy_LineOfCreditFacilityMaximumBorrowingCapacityOfFutureCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "LineOfCreditFacilityMaximumBorrowingCapacityOfFutureCommitments", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity of future commitments", "label": "Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments", "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "hqy_LondonInterbankOfferedRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "LondonInterbankOfferedRateMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "London Interbank Offered Rate", "label": "London Interbank Offered Rate [Member]", "documentation": "London Interbank Offered Rate" } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r22", "r159", "r350", "r366", "r776", "r777", "r1062" ] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtByMaturityAbstract", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]", "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "verboseLabel": "Less: current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r195" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of the notes", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r224", "r941" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r224", "r355" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r224", "r355" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r224", "r355" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r224", "r355" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r224", "r355" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 }, "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of issuance costs", "verboseLabel": "Long-term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r196" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r29" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r29", "r57" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r322", "r323", "r324", "r327", "r933", "r934" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r322", "r323", "r324", "r327", "r933", "r934" ] }, "hqy_LuumAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "LuumAcquisitionMember", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails", "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Luum Acquisition", "label": "Luum Acquisition [Member]", "documentation": "Luum Acquisition" } } }, "auth_ref": [] }, "hqy_LuumAndFurtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "LuumAndFurtherMember", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Luum and Further", "label": "Luum and Further [Member]", "documentation": "Luum and Further" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/LeasesNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r323", "r324", "r325", "r326", "r447", "r627", "r661", "r688", "r689", "r742", "r744", "r746", "r747", "r752", "r759", "r760", "r773", "r780", "r792", "r800", "r939", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r856" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r856" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/LeasesNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r323", "r324", "r325", "r326", "r447", "r627", "r661", "r688", "r689", "r742", "r744", "r746", "r747", "r752", "r759", "r760", "r773", "r780", "r792", "r800", "r939", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059" ] }, "hqy_MinimumNetWorthAboveCustodialAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "MinimumNetWorthAboveCustodialAssets", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum net worth above custodial assets (as a percent)", "label": "Minimum Net Worth Above Custodial Assets", "documentation": "Minimum Net Worth Above Custodial Assets" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r876" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r884" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r857" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r215" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r215" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r125", "r126", "r127" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 }, "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows", "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity", "http://www.healthequity.com/role/NetincomelosspershareDetails", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r117", "r127", "r162", "r185", "r201", "r203", "r208", "r220", "r229", "r233", "r234", "r236", "r237", "r241", "r242", "r251", "r261", "r274", "r278", "r280", "r290", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r573", "r579", "r650", "r719", "r736", "r737", "r771", "r809", "r937" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator (basic and diluted):", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r179", "r180", "r181", "r182", "r183", "r228", "r229", "r230", "r231", "r232", "r236", "r243", "r258", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r318", "r494", "r495", "r496", "r530", "r531", "r532", "r533", "r543", "r544", "r545", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r577", "r578", "r580", "r581", "r582", "r583", "r591", "r592", "r596", "r597", "r598", "r599", "r614", "r615", "r616", "r617", "r618", "r630", "r631", "r632", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items." } } }, "auth_ref": [ "r44", "r179", "r180", "r181", "r182", "r183", "r228", "r229", "r230", "r231", "r232", "r236", "r243", "r258", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r318", "r494", "r495", "r496", "r530", "r531", "r532", "r533", "r543", "r544", "r545", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r577", "r578", "r580", "r581", "r582", "r583", "r591", "r592", "r596", "r597", "r598", "r599", "r614", "r615", "r616", "r617", "r618", "r630", "r631", "r632", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r856" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r825", "r837", "r847", "r864", "r873" ] }, "hqy_NonPassiveCustodialFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "NonPassiveCustodialFundsMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-passive Custodial Fund", "label": "Non - Passive Custodial funds [Member]", "documentation": "Non - Passive Custodial funds" } } }, "auth_ref": [] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r854" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r853" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r864" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r884" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r884" ] }, "hqy_NoncashChangesInGoodwillMeasurementPeriodAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "NoncashChangesInGoodwillMeasurementPeriodAdjustments", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (increase) in goodwill due to measurement period adjustments, net", "label": "Noncash Changes In Goodwill, Measurement Period Adjustments", "documentation": "Noncash Changes In Goodwill, Measurement Period Adjustments" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchases of intangible assets", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r41", "r42", "r43" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "terseLabel": "Total other expense", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r122" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r920" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "terseLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r261", "r274", "r278", "r280", "r771" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r607", "r797" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows", "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of right-of-use assets", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1045" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails", "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "totalLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r602" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets", "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "negatedTerseLabel": "Less: current portion of lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r602" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets", "http://www.healthequity.com/role/LeasesLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, non-current", "verboseLabel": "Lease liabilities, non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r602" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r603", "r609" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets", "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r601" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.healthequity.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r612", "r797" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.healthequity.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r611", "r797" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r74" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r73" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of business and significant accounting policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r100", "r128", "r130", "r154" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r199", "r798" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r193" ] }, "hqy_OtherAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "OtherAssetsPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets [Policy Text Block]", "documentation": "Other Assets [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitment", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Other Commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentDueAfterFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentDueAfterFifthYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_OtherCommitment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Other Commitment, to be Paid, after Year Five", "documentation": "Amount of commitment classified as other to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentDueInFifthYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_OtherCommitment", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Other Commitment, to be Paid, Year Five", "documentation": "Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentDueInFourthYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_OtherCommitment", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Other Commitment, to be Paid, Year Four", "documentation": "Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentDueInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_OtherCommitment", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Other Commitment, to be Paid, Year One", "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentDueInSecondYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_OtherCommitment", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Other Commitment, to be Paid, Year Two", "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentDueInThirdYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_OtherCommitment", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Other Commitment, to be Paid, Year Three", "documentation": "Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentFiscalYearMaturityAbstract", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitment, Fiscal Year Maturity [Abstract]", "label": "Other Commitment, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r30" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-cash items", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r127" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other income (expense), net", "totalLabel": "Total other income (expense), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r123" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "hqy_OtherNonoperatingIncomeExpenseMiscellaneous": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "OtherNonoperatingIncomeExpenseMiscellaneous", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationOtherExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other miscellaneous income (expense)", "label": "Other Nonoperating Income (Expense), Miscellaneous", "documentation": "Other Nonoperating Income (Expense), Miscellaneous" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r856" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r823", "r835", "r845", "r871" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r826", "r838", "r848", "r874" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r826", "r838", "r848", "r874" ] }, "hqy_PassiveCustodialFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "PassiveCustodialFundsMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Passive Custodial Funds", "label": "Passive Custodial Funds [Member]", "documentation": "Passive Custodial Funds" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r852" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r7" ] }, "hqy_PaymentsForProceedsFromSettlementOfClientHeldFunds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "PaymentsForProceedsFromSettlementOfClientHeldFunds", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlement of client-held funds obligation, net", "label": "Payments For (Proceeds From) Settlement Of Client Held Funds", "documentation": "Payments For (Proceeds From) Settlement Of Client Held Funds" } } }, "auth_ref": [] }, "us-gaap_PaymentsForSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForSoftware", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of software and capitalized software development costs", "label": "Payments for Software", "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization." } } }, "auth_ref": [ "r124" ] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment of debt", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r37" ] }, "hqy_PaymentsToAcquireAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "PaymentsToAcquireAssets", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price", "label": "Payments To Acquire Assets", "documentation": "Payments To Acquire Assets" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r34", "r546" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Business combinations, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r34" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of HSA portfolios", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r124" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r124" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r855" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r855" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r854" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r864" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r857" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r853" ] }, "hqy_PerformanceRestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "PerformanceRestrictedStockAwardsMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance restricted stock awards", "label": "Performance Restricted Stock Awards [Member]", "documentation": "Performance Restricted Stock Awards [Member]" } } }, "auth_ref": [] }, "hqy_PerformanceRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "PerformanceRestrictedStockUnitsMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance restricted stock units", "verboseLabel": "Performance restricted stock units", "label": "Performance Restricted Stock Units [Member]", "documentation": "Performance Restricted Stock Units [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock par value (in usd per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r109", "r368" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r109", "r698" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r109", "r368" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.healthequity.com/role/ConsolidatedbalancesheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r109", "r698", "r717", "r1068", "r1069" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of January 31, 2024 and 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r109", "r642", "r798" ] }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expense", "label": "Prepaid Expense", "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs." } } }, "auth_ref": [ "r96", "r198", "r710", "r1061" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from follow-on equity offering, net of payments for offering costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from long-term debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r35", "r677" ] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of equity securities", "label": "Proceeds from Sale of Equity Securities, FV-NI", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r164", "r214" ] }, "hqy_ProceedsFromSaleOfOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ProceedsFromSaleOfOperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of operating lease", "label": "Proceeds From Sale Of Operating Lease, Right-Of-Use Asset", "documentation": "Proceeds From Sale Of Operating Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r20" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r281", "r628", "r655", "r656", "r657", "r658", "r659", "r660", "r762", "r781", "r799", "r901", "r935", "r936", "r942", "r1064" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r281", "r628", "r655", "r656", "r657", "r658", "r659", "r660", "r762", "r781", "r799", "r901", "r935", "r936", "r942", "r1064" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r136", "r189", "r648" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r638", "r648", "r798" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r11", "r169", "r174", "r646" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesTables", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Estimated Useful Life of Property and Equipment", "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r136" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life of property, plant and equipment (in years)", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit losses from trade receivables", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r212", "r303" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligation", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueAfterFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueAfterFifthYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Purchase Obligation, to be Paid, after Year Five", "documentation": "Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInFifthYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Purchase Obligation, to be Paid, Year Five", "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInFourthYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Purchase Obligation, to be Paid, Year Four", "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInSecondYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Purchase Obligation, to be Paid, Year Two", "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInThirdYear", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails": { "parentTag": "us-gaap_PurchaseObligation", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Purchase Obligation, to be Paid, Year Three", "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r852" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r852" ] }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "QuarterlyFinancialInformationDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Quarterly Financial Information Disclosure [Abstract]", "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "QuarterlyFinancialInformationTextBlock", "presentation": [ "http://www.healthequity.com/role/Selectedquarterlyfinancialdataunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selected quarterly financial data (unaudited)", "label": "Quarterly Financial Information [Text Block]", "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information." } } }, "auth_ref": [ "r129", "r259" ] }, "hqy_RACustomerRelationshipMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "RACustomerRelationshipMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RA Customer Relationship", "label": "RA Customer Relationship [Member]", "documentation": "RA Customer Relationship [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/LeasesNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r323", "r324", "r325", "r326", "r404", "r447", "r485", "r486", "r487", "r626", "r627", "r661", "r688", "r689", "r742", "r744", "r746", "r747", "r752", "r759", "r760", "r773", "r780", "r792", "r800", "r803", "r931", "r939", "r1055", "r1056", "r1057", "r1058", "r1059" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/LeasesNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r323", "r324", "r325", "r326", "r404", "r447", "r485", "r486", "r487", "r626", "r627", "r661", "r688", "r689", "r742", "r744", "r746", "r747", "r752", "r759", "r760", "r773", "r780", "r792", "r800", "r803", "r931", "r939", "r1055", "r1056", "r1057", "r1058", "r1059" ] }, "us-gaap_ReclassificationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationLineItems", "presentation": [ "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification [Line Items]", "label": "Reclassification [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r184" ] }, "us-gaap_ReclassificationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationTable", "presentation": [ "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification [Table]", "label": "Reclassification [Table]", "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r184" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r818", "r830", "r840", "r866" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments on long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r36", "r678" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r222", "r223", "r341", "r369", "r619", "r766", "r767" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Technology and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r99", "r502", "r1060" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research", "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r73" ] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAdjustmentMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Adjustment", "label": "Revision of Prior Period, Adjustment [Member]", "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r225", "r226", "r227", "r239", "r240", "r258", "r571", "r572", "r893", "r894", "r896", "r897", "r900", "r904", "r905" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement [Axis]", "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r182", "r225", "r226", "r227", "r229", "r230", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r258", "r295", "r296", "r533", "r567", "r571", "r572", "r573", "r599", "r617", "r618", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r819", "r831", "r841", "r867" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r820", "r832", "r842", "r868" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r827", "r839", "r849", "r875" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement [Domain]", "label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r182", "r225", "r226", "r227", "r229", "r230", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r258", "r295", "r296", "r533", "r567", "r571", "r572", "r573", "r599", "r617", "r618", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r45" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "verboseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r112", "r141", "r644", "r668", "r673", "r679", "r699", "r798" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r181", "r225", "r226", "r227", "r230", "r240", "r242", "r294", "r300", "r494", "r495", "r496", "r532", "r533", "r555", "r558", "r559", "r562", "r571", "r664", "r666", "r681", "r1068" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanNameAxis", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name [Axis]", "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r792", "r895", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanNameDomain", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Name [Domain]", "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r792", "r895", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r453", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r453", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r262", "r263", "r273", "r276", "r277", "r281", "r282", "r283", "r379", "r380", "r628" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r177", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r761" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligation", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r172" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r173" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r173" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligation, percentage", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": [ "r898" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "presentation": [ "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Revision of Prior Period, Reclassification, Adjustment [Member]", "documentation": "Cumulative increase (decrease) to previously issued financial statements for reclassification. Excludes adjustment for reclassification from amendment to accounting standards." } } }, "auth_ref": [ "r184" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r610", "r797" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r884" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r884" ] }, "hqy_SalesandMarketingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "SalesandMarketingMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Sales and Marketing [Member]", "documentation": "Sales and Marketing [Member]" } } }, "auth_ref": [] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior presentation", "label": "Previously Reported [Member]", "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r182", "r225", "r227", "r229", "r230", "r233", "r234", "r242", "r258", "r533", "r567", "r571", "r572", "r599", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r900", "r902", "r903", "r904", "r918", "r923", "r924", "r1043", "r1050", "r1051" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsNarrativeDetails", "http://www.healthequity.com/role/BusinesscombinationsPreliminaryAllocationofConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r78", "r80", "r541" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.healthequity.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r149" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.healthequity.com/role/IndebtednessTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r29", "r60", "r61", "r92", "r93", "r95", "r98", "r139", "r140", "r776", "r778", "r914" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.healthequity.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r148" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.healthequity.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r13", "r62", "r63", "r64", "r65" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.healthequity.com/role/NetincomelosspershareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r919" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.healthequity.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r147" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r51", "r53", "r629" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillTables", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Useful Lives of Intangible Assets", "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r51", "r53" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Expense, Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPropertyandEquipmentDetails", "http://www.healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "presentation": [ "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Quarterly Financial Information", "label": "Quarterly Financial Information [Table Text Block]", "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data." } } }, "auth_ref": [ "r166" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.healthequity.com/role/BusinesscombinationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allocation of Consideration", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r152" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r455", "r457", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r484", "r485", "r486", "r487", "r488" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Unit Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r67" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r18", "r19", "r67" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.healthequity.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r795", "r1032" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r53" ] }, "hqy_ScheduleofUnrecognizedTaxBenefitsNettedAgainstDeferredTaxAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ScheduleofUnrecognizedTaxBenefitsNettedAgainstDeferredTaxAssetsTableTextBlock", "presentation": [ "http://www.healthequity.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrecognized Tax Benefit Netted Against Deferred Tax Asset", "label": "Schedule of Unrecognized Tax Benefits Netted Against Deferred Tax Assets [Table Text Block]", "documentation": "Schedule of Unrecognized Tax Benefits Netted Against Deferred Tax Assets [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "hqy_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r811" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r814" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r267", "r268", "r269", "r270", "r271", "r272", "r282", "r772" ] }, "hqy_SelfInsuranceMaximumCoveragePerIncident": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "SelfInsuranceMaximumCoveragePerIncident", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum coverage per incident under self-insurance", "label": "Self Insurance, Maximum Coverage Per Incident", "documentation": "Self Insurance, Maximum Coverage Per Incident" } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReserveCurrent", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for self-insured medical claims", "label": "Self Insurance Reserve, Current", "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReservePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SelfInsuranceReservePolicyTextBlock", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Self-insurance", "label": "Self Insurance Reserve [Policy Text Block]", "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR)." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/SelectedquarterlyfinancialdataunauditedDetails", "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service revenue", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r781" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/Consolidatedstatementsofcashflows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r793" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r477" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r477" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance units awards (in shares)", "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r475" ] }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average grant date fair value (in usd per share)", "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r475" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r472", "r473" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in usd per share)", "periodEndLabel": "Outstanding, ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r472", "r473" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r476" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r476" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r455", "r457", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r484", "r485", "r486", "r487", "r488" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for grant under incentive plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r66" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, weighted-average exercise price (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r466" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r479" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r470" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r468" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r66" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r464", "r465" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Opening balance (in usd per share)", "periodEndLabel": "Ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r464", "r465" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r481" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r481" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r480" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r480" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, weighted-average exercise price (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r480" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofRestrictedStockUnitActivityDetails", "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Award [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r484", "r485", "r486", "r487", "r488" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r469" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r470" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r454", "r463", "r482", "r483", "r484", "r485", "r488", "r497", "r498", "r499", "r500" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range of exercise prices", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract]" } } }, "auth_ref": [] }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, minimum (in usd per share)", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised" } } }, "auth_ref": [] }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited": { "xbrltype": "perShareItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, minimum (in usd per share)", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited", "documentation": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited" } } }, "auth_ref": [] }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, minimum (in usd per share)", "periodEndLabel": "Ending balance, minimum (in usd per share)", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding" } } }, "auth_ref": [] }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, maximum (in usd per share)", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised" } } }, "auth_ref": [] }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited": { "xbrltype": "perShareItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited, maximum (in usd per share)", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited", "documentation": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited" } } }, "auth_ref": [] }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, maximum (in usd per share)", "periodEndLabel": "Ending balance, maximum (in usd per share)", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of options vested (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1004" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period after termination (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r794" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r66" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, weighted-average contractual term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r66" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding stock options, weighted-average contractual term (in\u00a0years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r146" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, weighted-average contractual term (in\u00a0years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r481" ] }, "hqy_SharebasedCompensationArrangementbySharebasedPaymentAwardExpirationPeriodfromTerminationofEmployment": { "xbrltype": "durationItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardExpirationPeriodfromTerminationofEmployment", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period from termination of employment (in days)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period from Termination of Employment", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period from Termination of Employment" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software and software development costs", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r32", "r181", "r206", "r207", "r208", "r225", "r226", "r227", "r230", "r240", "r242", "r260", "r294", "r300", "r370", "r494", "r495", "r496", "r532", "r533", "r555", "r557", "r558", "r559", "r560", "r562", "r571", "r584", "r585", "r586", "r587", "r588", "r589", "r618", "r664", "r665", "r666", "r681", "r738" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows", "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r225", "r226", "r227", "r260", "r628", "r675", "r682", "r690", "r691", "r692", "r693", "r694", "r695", "r698", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r713", "r714", "r715", "r716", "r718", "r720", "r721", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r738", "r804" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows", "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r225", "r226", "r227", "r260", "r628", "r675", "r682", "r690", "r691", "r692", "r693", "r694", "r695", "r698", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r713", "r714", "r715", "r716", "r718", "r720", "r721", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r738", "r804" ] }, "hqy_StephenNeelemanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "StephenNeelemanMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Stephen Neeleman [Member]", "documentation": "Stephen Neeleman" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r822", "r834", "r844", "r870" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Other issuance of common stock (in shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock upon exercise of options, and for restricted stock (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r17", "r109", "r110", "r141" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r17", "r109", "r110", "r141", "r469" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Other issuance of common stock", "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of options, and for restricted stock", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r68", "r109", "r110", "r141" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/Consolidatedbalancesheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets", "http://www.healthequity.com/role/Consolidatedstatementsofstockholdersequity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r110", "r113", "r114", "r131", "r700", "r717", "r739", "r740", "r798", "r810", "r910", "r922", "r1044", "r1068" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedbalancesheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r608", "r797" ] }, "hqy_SubleaseIncomeToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "SubleaseIncomeToBeReceived", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease income to be received", "label": "Sublease Income, To Be Received", "documentation": "Sublease Income, To Be Received" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r590", "r621" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r590", "r621" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r590", "r621" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r590", "r621" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.healthequity.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r590", "r621" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.healthequity.com/role/Subsequentevents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r620", "r622" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow data:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalEmployeeRetirementPlanDefinedBenefitMember", "presentation": [ "http://www.healthequity.com/role/EmployeebenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Employee Retirement Plan", "label": "Supplemental Employee Retirement Plan [Member]", "documentation": "Plan designed to provide limited group of employees with supplemental retirement benefits, in addition to other pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r863" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit carryforward", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r74" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r73" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r73" ] }, "hqy_TechnologyandDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "TechnologyandDevelopmentMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology and development", "label": "Technology and Development [Member]", "documentation": "Technology and Development [Member]" } } }, "auth_ref": [] }, "hqy_TermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "TermLoanFacilityMember", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesOutstandingContractualObligationsDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails", "http://www.healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facility", "label": "Term Loan Facility [Member]", "documentation": "Term Loan Facility" } } }, "auth_ref": [] }, "hqy_TotalNonCashShareBasedPaymentArrangementExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "TotalNonCashShareBasedPaymentArrangementExpenseMember", "presentation": [ "http://www.healthequity.com/role/StockbasedcompensationScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total non-cash stock-based compensation expense", "label": "Total Non cash Share Based Payment Arrangement Expense [Member]", "documentation": "Total Non cash Share Based Payment Arrangement Expense" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r855" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r862" ] }, "us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date." } } }, "auth_ref": [ "r284" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.healthequity.com/role/IntangibleassetsandgoodwillScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired trade names", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r84" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired trade names and trademarks", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r84" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r883" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r885" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r886" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r887" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r885" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r885" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r888" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r886" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r882" ] }, "hqy_UnionMesaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "UnionMesaMember", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Union Mesa", "label": "Union Mesa [Member]", "documentation": "Union Mesa" } } }, "auth_ref": [] }, "hqy_UnrecognizedTaxBenefitNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "UnrecognizedTaxBenefitNet", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Unrecognized tax benefits recorded on the consolidated balance sheet", "label": "Unrecognized Tax Benefit, Net", "documentation": "Unrecognized Tax Benefit, Net" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails": { "parentTag": "hqy_UnrecognizedTaxBenefitNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails", "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross unrecognized tax benefit", "periodStartLabel": "Gross unrecognized tax benefits at beginning of year", "periodEndLabel": "Gross unrecognized tax benefits at end of year", "terseLabel": "Total gross unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r504", "r514" ] }, "hqy_UnrecognizedTaxBenefitsAmountNettedAgainstDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "UnrecognizedTaxBenefitsAmountNettedAgainstDeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails": { "parentTag": "hqy_UnrecognizedTaxBenefitNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts netted against related deferred tax assets", "label": "Unrecognized Tax Benefits, Amount Netted Against Deferred Tax Assets", "documentation": "Unrecognized Tax Benefits, Amount Netted Against Deferred Tax Assets" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decreases as a result of tax positions taken during a prior period", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r515" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decreases as a result of settlement", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r517" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r513" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, income tax penalties and interest expense", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r513" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases as a result of tax positions taken during the current period", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r516" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases as a result of tax positions taken during a prior period", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r515" ] }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period increase in unrecognized tax benefit", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns." } } }, "auth_ref": [ "r1033" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.healthequity.com/role/IncometaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decreases resulting from the lapse of the applicable statute of limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r518" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits that would impact the effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r519" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r46", "r47", "r48", "r167", "r168", "r170", "r171" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.healthequity.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r522" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://www.healthequity.com/role/IndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "hqy_WageWorksInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "WageWorksInc.Member", "presentation": [ "http://www.healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WageWorks Inc.", "label": "WageWorks Inc. [Member]", "documentation": "WageWorks Inc. [Member]" } } }, "auth_ref": [] }, "hqy_WageWorksIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "WageWorksIncMember", "presentation": [ "http://www.healthequity.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WageWorks, Inc.", "label": "Wage Works Inc. [Member]", "documentation": "Wage Works Inc." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.healthequity.com/role/NetincomelosspershareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r246", "r254" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator (diluted):", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.healthequity.com/role/NetincomelosspershareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss", "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r245", "r254" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.healthequity.com/role/NetincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator (basic):", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] }, "hqy_WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthequity.com/20240131", "localname": "WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract", "presentation": [ "http://www.healthequity.com/role/Consolidatedstatementsofoperationsandcomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of shares used in computing net income (loss) per share:", "label": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "documentation": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "SubTopic": "10", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482914/835-10-05-3" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-4A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479692/805-740-25-8" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479692/805-740-25-9" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "270", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//270/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "(m)", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310/tableOfContent" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "340", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 92 0001428336-24-000016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-24-000016-xbrl.zip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